AU2002334733A1 - MCH receptors antagonists - Google Patents
MCH receptors antagonistsInfo
- Publication number
- AU2002334733A1 AU2002334733A1 AU2002334733A AU2002334733A AU2002334733A1 AU 2002334733 A1 AU2002334733 A1 AU 2002334733A1 AU 2002334733 A AU2002334733 A AU 2002334733A AU 2002334733 A AU2002334733 A AU 2002334733A AU 2002334733 A1 AU2002334733 A1 AU 2002334733A1
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- carbocyclic
- carbocyclic aryl
- alkyl
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
MCH RECEPTOR ANTAGONISTS
Field of the Invention
The present invention relates to compounds which act as antagonists for MCH receptors and to the use of these compounds in pharmaceutical compositions.
Background of the Invention
Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/neuromodulator to alter a number of behavioral responses such as feeding habits. For example, injection of MCH into rats has been reported to increase their consumption of food. Reports indicate that genetically engineered mice which lack MCH show lower body weight and increased metabolism. See Saito et al., TEM, vol. 11, 299 (2000). As such, the literature suggests that discovery of MCH antagonists that interact with SCL-1 expressing cells will be useful in developing obesity treatments. See Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999).
G protein-coupled receptors (GPCRs) share a common structural motif. All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane. The fourth and fifth transmembrane helices are joined on the extracellular side of the membrane by a strand of amino acids that forms a relatively large loop. Another larger loop, composed primarily of hydrophilic amino acids, joins transmembrane helices five and six on the intracellular side of the membrane. The carboxy terminus of the receptor lies intracellularly, and the amino terminus lies in the extracellular space. It is thought that the loop joining helices five and six,
as well as the carboxy terminus, interact with the G protein. Currently, Gq, Gs, Gi, and Go are G proteins that have been identified as possible proteins that interact with the receptor.
Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between two different states or conformations: an "inactive" state and an "active" state. A receptor in an inactive state is unable to link to the intracellular transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway and produces a biological response.
A receptor may be stabilized in an active state by an endogenous ligand or an exogenous agonist ligand. Recent discoveries, including but not exclusively limited to, modifications to the amino acid sequence of the receptor, provide alternative mechanisms other than ligands to stabilize the active state conformation. These approaches effectively stabilize the receptor in an active state by simulating the effect of a ligand binding to the receptor. Stabilization by such ligand-independent approaches is termed "constitutive receptor activation." In contrast, antagonists can competitively bind to the receptor at the same site as agonists, but do not activate the intracellular response initiated by the active form of the receptor, and therefore inhibit the intracellular responses by agonists.
Certain 2-aminoquinazoline derivatives have been reported to be NPY antagonists which are said to be effective in the treatment of disorders and diseases associated with the NPY receptor subtype Y5. See PCT Patent Application 97/20823. Quinazoline derivatives have also been found to be useful by enhancing antitumor activity. See PCT Patent Application 92/07844.
Recently, our current knowledge of human obesity has advanced dramatically. Previously, obesity was viewed as an oppugnant behavior of inappropriate eating in the setting of appealing foods. Studies of animal models of obesity, biochemical alterations in both humans and animals, and the complex interactions of psychosocial and cultural factors that create receptiveness to human obesity indicate that this disease in humans is multifaceted and deeply entrenched in biologic systems. Thus, it is almost certain that obesity has multiple causes and that there are different types of obesity. Not only does MCHR1 antagonist have potent and durable anti-obesity effects in rodents, it has surprising antidepressant and anxiolytic properties as well (Borowsky et al, Nature Medicine, 8, 825- 830, 2002). MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models such as social interaction, forced swimming test and ultrasonic
vocalization. These findings indicate that MCHRl antagonists could be useful for treatment of obesity patients with multiple causes. Moreover, MCHRl antagonists could be used to treat subjects not only with obesity, but also those with depression and anxiety. These advantages make it different from NPY receptor antagonists, with which anxiogenic-like activity may be expected, as NPY itself has anxiolytic-like effect.
Obesity is also regarded as a chronic disease and the possibly of long-term treatment is a concept that is receiving more attention. In this context, it is noteworthy that the depletion of MCH leads to hypophagia as well as leanness (Shimada et al., Nature, 396, 670-674, 1998). By contrast, NPY (Erickson et al., Nature, 381, 415-418, 1996), as well as the Yl (Pedrazzini et al., Nature Medicine, 4, 722-726, 1998) and Y5 receptors (Marsh et al, Nature Medicine, 4, 718-721, 1998), disrupted mice maintained a stable body weight or rather became obese. Considering the above reports, MCHRl antagonists may be more attractive than Yl or Y5 receptor antagonists in terms of long-term treatment of obese patients.
An increasing number of children and adolescents are overweight. Although not all overweight children will necessarily become overweight adults, the growing occurrence of obesity in childhood is likely to be reflected in increasing obesity in adult years. The high prevalence of obesity in our adult population and the likelihood that the nation of the future will be even more obese demands a re-examination of the health implications of this disease. See, Health Implications of Obesity. NIH Consens. Statement Online 1985 Feb ll-13; 5(9):l-7.
"Clinical obesity" is a measurement of the excess body fat relative to lean body mass and is defined as a body weight more than 20% above the ideal body weight. Recent estimates suggest that 1 in 2 adults in the United States is clinically obese, an increase of more than 25% over the past decades. Flegal M.D. et al., 22 Int. J Obes. Relat. Metab. Disor. 39 (1998). Both overweight conditions and clinical obesity are a major health concerns worldwide, in particular because clinical obesity is often accompanied by numerous complications, i.e., hypertension and Type II diabetes, which in turn can cause coronary artery disease, stroke, late-stage complications of diabetes and premature death. (See, e.g., Nishina P.M. et al., 43 Metab. 554 (1994)).
Although the etiologic mechanisms underlying obesity require further clarification, the net effect of such mechanisms leads to an imbalance between energy intake and
expenditure. Both genetic and environmental factors are likely to be involved in the pathogenesis of obesity. These include excess caloric intake, decreased physical activity, and metabolic and endocrine abnormalities.
Treatment of overweight conditions and clinical obesity via pharmaceutical agents are not only of importance with respect to the conditions themselves, but also with respect to the possibility of preventing other diseases that are associated with, e.g., clinical obesity, as well as enhancement of the positive feeling of "self that often accompanies those who are overweight or clinically obese and who encounter a significant reduction in body weight. Given the foregoing discussion, it is apparent that compounds which help in the treatment of such disorders would be useful and would provide an advance in both research and clinical medicine. The present invention is directed to these, as well as other, important ends.
Summary of the Invention
The present invention, in one aspect, relates to compounds represented by Formula I:
Q. -Y
R
or a pharmaceutically acceptable salt or prodrug thereof, wherein Q is
II III
Ri represents (i) C1-C16 alkyl,
Cι-C16 alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•Cι-C3 alkoxy,
•Cι-C alkoxy substituted by substituent(s) independently selected from
••carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by Ci-C3 alkyl,
•Cι-C3 alkylcarbonyloxy,
•carbocyclyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••nitro,
••carbocyclic aryl,
••carbocyclic aryl substituted by Ci-C3 alkoxy,
••C1-C4 alkyl,
••Ci-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••mono- or di-d-C alkylamino,
•••mono- or di-Cj-C alkylamino substituted by carbocyclic aryl,
•••mono- or di-Ci-C3 alkylamino substituted by halogenated carbocyclic aryl,
•••carbocyclic arylcarbonylamino,
•••halogenated carbocyclic arylcarbonylamino,
•heterocyclyloxy,
•heterocyclyloxy substituted by Ci-C3 alkyl,
•substituted heterocyclyl-ethylideneaminooxy,
•Cι-C3 alkoxycarbonyl,
•Cι-C3 alkoxycarbonyl substituted by carbocyclic aryl,
•mono- or di-Cι-C3 alkylaminocarbonyl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-CrC3 alkylamino substituted by substituent(s) independently selected from
••cyano,
••carbocyclic aryl,
••heterocyclyl,
•mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
••hydroxy,
••C1-C3 alkyl,
•C C3 alkylcalbonylamino,
•Cι-C3 alkylcalbonylamino substituted by substituent(s) independently selected from
••Ci-C3 alkylcalbonylamino,
••carbocyclic arylcalbonylamino,
••heterocyclyl,
•C1-C4 alkoxycalbonylamino,
•heterocyclyl calbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-Cι-C3 alkylamino,
•Ci- s alkylthio,
•C1-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylaminocarbonyl,
••halogenated mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••Cι-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•heterocyclylthio substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
•C3-C6 cycloalkyl,
•C3-C6 cycloalkyl substituted by Cι-C3 alkyl,
•C3-C6 cycloalkenyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C1-C3 alkoxy,
••C2-C3 alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted C1-C3 alkylsulfmyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C4 alkyl,
••C1-C alkyl substituted by substituent(s) independently selected from
•••halogen,
•••hydroxy,
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
•••mono- or di-carbocyclic arylamino,
•••mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
••••halogen,
nitro, ••C1-C3 alkyl, ••Ci-C alkoxy, ••halogenated C1-C3 alkoxy, C1-C4 alkoxy,
C1-C4 alkoxy substituted by substituent(s) independently selected from •halogen, •carbocyclic aryl, carbocyclic aryloxy, Ci-C3 alkoxycarbonyl, C1-C3 alkylcarbonyloxy, mono- or di-C1-C3 alkylamino, mono- or di-carbocyclic arylamino, halogenated mono- or di-carbocyclic arylamino, mono- or di-carbocyclic arylaminocarbonyl, mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from halogen, nitro,
C1-C3 alkyl,
C C3 alkoxy, halogenated Ci-C3 alkoxy, mercapto, C1-C3 alkylthio, halogenated C1-C3 alkylthio, C1-C3 alkylsulfonyl, C3-C6 cycloalkyl, carbocyclic aryl, heterocyclyl, heterocyclyl, heterocyclyl substituted by substituent(s) independently selected from hydroxy,
••C1-C3 alkyl,
••C1-C3 alkyl substituted by carbocyclic aryl,
••C1-C3 alkoxy,
•• -C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C8 alkenyl,
C2-C8 alkenyl substituted by substituent(s) independently selected from
•halogen,
•oxo,
•CrC alkoxy,
•Ci-C3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C3 alkyl,
••halogenated C C3 alkyl,
••C1-C3 alkoxy,
••halogenated Ci-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••nitro,
••C1-C3 alkyl,
••C1-C3 alkoxy,
(iii) C2-C4 alkynyl,
C2-C4 alkynyl substituted by carbocyclic aryl,
(iv) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•Cι-C3 alkyl substituted by substituent(s) independently selected from
••hydroxy,
••oxo,
••carbocyclic aryl,
•mono- or di-CpC3 alkylamino,
•mono- or di-C!-C3 alkylamino substituted by carbocyclic aryl,
•carbocyclic arylcarbonylamino,
•carbocyclic aryl,
(v) C3-C6 cycloalkeyl,
C3-C6 cycloalkeyl substituted by Ci-C3 alkyl,
(vi) carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from
•hydroxy,
•nitro,
(vii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•Ci-C9 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••Ci-C3 alkoxy,
••carbocyclic aryloxy,
••mono- or di-CrC3 alkylamino-N-oxy,
••mono- or di-Cι-C alkylamino,
••mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
• •carbocyclylimino,
••carbocyclylimino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylamino substituted by C alkoxy,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by -C3 alkoxy,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
—Ci-C3 alkyl,
•••halogenated Cι-C3 alkyl,
••heterocyclyl,
••heterocyclyl substituted by C1-C3 alkyl,
•C2-C3 alkenyl,
•C2-C3 alkenyl substituted by carbocyclic aryl,
•Ci-C9 alkoxy,
•C^Cg alkoxy substituted by substituent(s) independently selected from
••hydroxy,
••halogen,
••carboxy,
••mono- or di-CrC3 alkylamino,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••heterocyclyl,
•••heterocyclyl substituted by substituent(s) independently selected from
••••halogen,
••••C1-C3 alkyl,
••••halogenated Cι-C3 alkyl,
•C2-C3 alkenyloxy,
•C1-C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) mdependently selected from
••halogen,
••nitro,
••C1-C4 alkyl,
••halogenated -C4 alkyl,
••C1-C3 alkoxy,
•heterocyclyloxy,
•heterocyclyloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated C!-C3 alkyl,
•(carbocyclic aryl)S(O) O,
•carboxy,
•Cι-C3 alkoxycarbonyl,
•mono- or di-Cι-C3 alkylaminocarbonyl,
•mono- or di-Cι-C3 alkylaminocarbonyl substituted by carbocyclic aryl,
•mono- or di-carbocyclic arylaminocarbonyl,
•mono- or di-carbocyclic arylaminocarbonyl substituted by Cι-C3 alkyl,
•amino,
•mono- or di-Ci-C4 alkylamino,
•mono- or di-Cι-C4 alkylamino substituted by cyano,
•mono- or di-carbocyclic arylamino,
•Cι-C3 alkynylcarbonylamino,
•C1-C3 alkynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by Cι-C alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by C1-C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated C1-C3 alkoxy,
•carbocyclic aryl diazo,
•carbocyclic aryl diazo substituted by mono- or di- C C3 alkylamino,
C C3 alkylthio, halogenated C1-C3 alkylthio, carbocyclic arylthio, carbocyclic arylthio substituted by substituent(s) independently selected from
•halogen,
•cyano,
•C C3 alkyl, heterocyclylthio,
C C3 alkylsulfonyl, mono- or di-Ci-C3 alkylaminosulfonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•C1-C7 alkyl,
•halogenated Ci-C7 alkyl, heterocyclyl, heterocyclyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl, (viii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •cyano, •nitro,
•C1-C4 alkyl,
•Ci-C4 alkyl substituted by substituent(s) independently selected from ••halogen, ••hydroxy, ••oxo,
••C1-C3 alkylcarbonyloxy, ••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino,
••C1-C3 alkoxycarbonyl,
••C1-C3 alkylthio,
••C Cs alkylthio substituted by carbocyclic aryl,
••C1-C3 alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C C3 alkyl,
•••halogenated CpC3 alkyl,
•C C3 alkoxy,
•C1-C3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•mono- or di-Cι-C3 alkylamino,
•C1-C4 alkylcarbonylamino,
•C C3 alkylthio,
•CrC3 alkenylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by 0^03 alkoxycarbonyl,
•heterocyclylthio,
•heterocyclylthio substituted by Ci-Cs alkyl,
•Ci-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by Cι-C4 alkyl,
•C1-C3 alkoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••halogenated CrC3 alkyl,
••Ci-Cs alkoxy,
••halogenated Cι-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated C C3 alkyl,
•• -C3 alkoxy,
••C1-C3 alkoxycarbonyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or -C3 alkyl;
R2b is C1-C4 alkyl, C1-C4 alkyl substituted by substituent(s) independently selected from •hydroxy, •C1-C3 alkoxy, •amino, •-NHBoc, •C3-C6 cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••C1-C3 alkyl, ••C1-C3 alkoxy, ••-SO2NH2,
•heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•Ci-C3 alkoxy, or a group of Formula IN;
wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C1-C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by C C3 alkoxy;
L is selected from Formula V - XLX;
VI Via Vlb
R4 R4 R4 IX IXa IXb
XIV XV XVI
XVII XVIII XIX*
wherein R4 is H or C1-C3 alkyl;
R5 is H, C1-C3 alkyl, or Cι-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -S(O)2-, -C(O)-, or -(CH2)m; m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, biphenyl, or phenanthryl; carbocyclyl is 10,l l-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7-
dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2. ljhepteny; heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1H- indolyl, lH-pyrrolo[2,3-c]pyridyl, lH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,2',5',2"- terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro- benzo[l,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H- benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 3,4-dihydro-2H-benzo[b][l,4]dioxepinyl, 4H-benzo[l,3]dioxinyl, 4H-benzopyranyl, 4- oxo-l,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,l-b]thiazolyl, imidazolyl, isoxazolyl, mo holino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3- dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl; halogen is fluoro, chloro, bromo, or iodo.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) d-Cio alkyl,
C do alkyl substituted by substituent(s) mdependently selected from •halogen, •oxo,
•C1-C3 alkoxy,
•Cι-C3 alkoxy substituted by carbocyclic aryl, •C d alkylcarbonyloxy, •carbocyclyloxy, •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected from
halogen,
•nitro,
•C1-C4 alkyl,
•CrC4 alkyl substituted by substituent(s) independently selected from
••oxo,
••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino, heterocyclyloxy, heterocyclyloxy substituted by C C3 alkyl, substituted heterocyclyl-ethylideneaminooxy,
Cι-C3 alkoxycarbonyl,
Ci-C3 alkoxycarbonyl substituted by carbocyclic aryl, mono- or di-CrC3 alkylaminocarbonyl, mono- or di-carbocyclic arylamino, mono- or di-carbocyclic arylamino substituted by hydroxy,
C C3 alkylcalbonylamino,
C C3 alkylcalbonylamino substituted by substituent(s) independently selected from
•C Cs alkylcalbonylamino,
•carbocyclic arylcalbonylamino,
•heterocyclyl,
Ci-C alkoxycalbonylamino, heterocyclyl calbonylamino, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
•nitro,
•C1-C3 alkyl,
•mono- or di-Ci-03 alkylamino,
C1-C3 alkylthio,
C1-C3 alkylthio substituted by substituent(s) independently selected from
•mono- or di-carbocyclic arylaminocarbonyl,
•halogenated mono- or di-carbocyclic arylaminocarbonyl,
•carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•heterocyclylthio substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
•C3-C6 cycloalkyl,
•C3-C6 cycloalkyl substituted by Cι-C3 alkyl,
•C3-C6 cycloalkenyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C1-C3 alkoxy,
••C2-C3 alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted Ci-C3 alkylsulfinyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••Cι-C4 alkyl,
••Cι-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••C1-C4 alkoxy,
••C1-C4 alkoxy substituted by substituent(s) independently selected from
•••halogen,
•••carbocyclic aryl,
••carbocyclic aryloxy,
••C1-C3 alkylcarbonyloxy,
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
•••C1-C3 alkyl,
•••C1-C3 alkoxy,
•••halogenated -C3 alkoxy,
••mercapto,
••C1-C3 alkylthio,
••halogenated C C3 alkylthio,
••C1-C3 alkylsulfonyl,
••C3-C6 cycloalkyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••C C3 alkyl,
••C1-C3 alkyl substituted by carbocyclic aryl,
••C1-C3 alkoxy,
••C C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C6 alkenyl,
C2-C6 alkenyl substituted by substituent(s) independently selected from
•oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••CrC3 alkyl,
••halogenated CrC3 alkyl,
••C1-C3 alkoxy,
••halogenated C C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••C C3 alkyl,
••C C3 alkoxy,
(iii) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
C1-C3 alkyl,
C1-C3 alkyl substituted by substituent(s) independently selected from
•oxo,
•carbocyclic aryl, carbocyclic arylcarbonylamino, carbocyclic aryl, (iv) carbocyclyl, carbocyclyl substituted by nitro, (v) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•Cι-C9 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryloxy,
••carbocyclylimino,
••carbocyclylimino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by Cι-C3 alkoxy,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
—C1-C3 alkyl,
•••halogenated C C3 alkyl,
••heterocyclyl,
••heterocyclyl substituted by C1-C3 alkyl,
•CrC7 alkoxy,
*C C7 alkoxy substituted by substituent(s) independently selected from
••halogen,
••carbocyclic aryl,
•C C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by Ci-C3 alkoxy,
•Cι-C3 alkoxycarbonyl,
•mono- or di-CrC3 alkylaminocarbonyl,
•mono- or di-Ci-C3 alkylaminocarbonyl substituted by carbocyclic aryl,
•mono- or di-carbocyclic arylaminocarbonyl,
•mono- or di-carbocyclic arylaminocarbonyl substituted by C C3 alkyl,
•amino,
•mono- or di-Cι-C3 alkylamino,
•Cι-C3 alkynylcarbonylamino,
•Cι-C3 alkynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by C1-C3 alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by C C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated C1-C3 alkoxy,
•C1-C3 alkylthio,
•halogenated Ci-C alkylthio,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by cyano,
•Cι-C3 alkylsulfonyl,
•mono- or di-Cι-C3 alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••C1-C7 alkyl,
••halogenated -C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(vi) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••C1-C3 alkylthio,
••C1-C3 alkylthio substituted by carbocyclic aryl,
••Cι-C3 alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•Cι-C3 alkoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•C1-C3 alkylthio,
•C1-C3 alkenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by Cι-C alkyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••C1-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••halogenated Ci-C3 alkyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or C1-C3 alkyl;
R2b is C1-C4 alkyl, C C4 alkyl substituted by substituent(s) independently selected from •hydroxy, •C1-C3 alkoxy,
•amino,
•-NHBoc,
•C3-C6 cycloalkyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C1-C3 alkoxy,
••-SO2NH2,
•heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•d-C3 alkyl,
•C1-C3 alkoxy, or a group of Formula IV; wherein Boc is carbamic acid tert-butyl ester and R3 is C C3 alkyl or d-Cs alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by C1-C3 alkoxy;
L is selected from Formula N - XIX; wherein R4 is H or Ci-C3 alkyl;
R5 is H, C1-C3 alkyl, or C C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; carbocyclyl is 10,l l-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 9H- fiuorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxo-isoindolyl, IH-indolyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,3-dihydro- benzo[l,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-
benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H- benzo[b][l,4]dioxepinyl, 4-oxo-l,5,6,7-tetrahydro-indolyl3 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[bjthienyl, cinnolyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Other preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Kι represents (i) Cι-C10 alkyl,
Ci-do alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl, •methoxy substituted by carbocyclic aryl, •rnethylcarbonyloxy, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •carbocyclic aryloxy substituted by nitro, •heterocyclyloxy substituted by methyl, •substituted heterocyclyl-ethylideneaminooxy, •tert-butoxycarbonylamino, •carbocyclic arylcarbonylamino, •C1-C2 alkylthio,
•C1-C2 alkylthio substituted by substituent(s) independently selected from ••halogenated carbocyclic aryl, ••carbocyclic aryl substituted by methoxy, •carbocyclic arylthio, •hetrocyclylthio substituted by nitro,
•hetrocyclylthio substituted by methyl,
•C5-C6 cycloalkyl,
•C5-C6 cycloalkenyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••methyl,
••methoxy,
••ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C4 alkyl,
••C C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••Cι-C4 alkoxy,
••halogenated Cι-C alkoxy,
••0^04 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C2 alkyl,
•• C C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•CrC9 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryl,
••carbocyclic aryl substituted by methyl,
••carbocyclic aryloxy,
•Ci-C7 alkoxy,
•halogenated C1-C7 alkoxy,
•C1-C7 alkoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methoxy,
•amino,
•di-methylamino,
•propargynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino substituted by methyl,
•(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
•halogenated methylthio,
•carbocyclic arylthio substituted by cyano,
•di-propylamino sulfonyl,
•mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•Ci-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••methylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•C1-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl substituted by Ci-C4 alkyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro, •heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula Na, Villa, or FXa; wherein R4 and R5 are independently selected from H or C1-C3 alkyl;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren- 9-ylidene, 1,2,3,4-tetrahydro-naphfhyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxo-isoindolyl, IH-indolyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,3-dihydro- benzo[l,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3 ,4-dihydro-2H-benzo [b] [ 1 ,4] dioxepinyl, 4-oxo-3 ,4-dihydro-phthalazinyl, 4-oxo- benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]fhienyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3- dihydro-benzofuryl, 2-oxo-pyrrolidinyl, 4-oxo-l,5,6,7-tetrahydro-indolyl, cinnolyl, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Cι-Cj.0 alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl, •methoxy substituted by carbocyclic aryl, •mefhylcarbonyloxy, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy,
•carbocyclic aryloxy substituted by nitro,
•heterocyclyloxy substituted by methyl,
•tert-butoxycarbonylamino,
•carbocyclic arylcarbonylamino,
•Cι-C2 alkylthio,
•Cι-C2 alkylthio substituted by substituent(s) independently selected from
••halogenated carbocyclic aryl,
••carbocyclic aryl substituted by methoxy,
•carbocyclic arylthio,
•hetrocyclylthio substituted by nitro,
•hetrocyclylthio substituted by methyl,
•C5-C6 cycloalkenyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••methyl,
••methoxy,
••ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••C1-C4 alkoxy,
••halogenated C1-C4 alkoxy,
••Cι-C4 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C2 alkyl,
•• C1-C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, cyano, nitro,
C1-C9 alkyl,
Cι-C9 alkyl substituted by substituent(s) independently selected from
•halogen,
•oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryloxy,
C1-C7 alkoxy, halogenated C1-C7 alkoxy,
C1-C7 alkoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methoxy,
•amino,
•di-methylamino,
•propargynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino substituted by methyl,
•(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
•halogenated methylthio,
•carbocyclic arylthio substituted by cyano,
•di-propylamino sulfonyl,
•mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••methylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•C1-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•Cι-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by C1-C4 alkyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren- 9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, IH- indolyl, IH-pyrrolyl, 2,4-dihydro-3-oxo-pyrazoιyl, 2H-benzopyranyl, 4-oxo-benzopyranyl, azetidinyl, benzo[b]thienyl, furyl, isoxazolyl, morpholinyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-l,5,6,7-tetrahydro- indolyl, 9H-xanthenyl, cinnolyl, imidazolyl, morpholino, pyrimidyl, pyrrolidyl, tetrahydro- thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Further other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II; Ri represents
(i) Q-Cs alkyl substituted by substituent(s) independently selected from
•oxo,
•di-propylaminocarbonyl,
•methoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•halogenated carbocyclic aryloxy,
•carbocyclic aryloxy substituted by nitro,
•heterocyclyloxy substituted by methyl,
•substituted heterocyclyl-ethylideneaminooxy,
•tert-butoxycarbonylamino,
•carbocyclic arylcarbonylamino,
•C1-C2 alkylthio,
•C1-C2 alkylthio substituted by substituent(s) independently selected from
••halogenated carbocyclic aryl,
••carbocyclic aryl substituted by methoxy,
•carbocyclic arylthio,
•hetrocyclylthio substituted by nitro,
•hetrocyclylthio substituted by methyl,
•cyclohexenyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••methyl,
••methoxy,
••ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
•• C1-C4 alkyl,
••C C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••C1-C2 alkoxy,
••halogenated Cι-C2 alkoxy,
••Cι-C2 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
»d-C2 alkyl,
•• d-C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C4 alkyl,
•d-C2 alkyl substituted by substituent(s) independently selected from
•halogen,
•oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryloxy, d-C2 alkoxy, halogenated Cι-C2 alkoxy,
Cι-C2 alkoxy substituted by carbocyclic aryl, methylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by methoxy, amino, di-methylamino, propargvnylcarbonylamino substituted by carbocyclic aryl, carbocyclic arylsulfonylamino substituted by methyl,
(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy, halogenated methylthio, carbocyclic arylthio substituted by cyano, di-propylamino sulfonyl, mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl, carbocyclic aryl, heterocyclyl substituted by methyl, heterocyclyl substituted by halogenated carbocyclic aryl, vi) or heterocyclyl substituted by substituent(s) independently selected from halogen, nitro,
C1-C4 alkyl, d-C4 alkyl substituted by substituent(s) independently selected from
•halogen,
•methylthio substituted by halogenated carbocyclic aryl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•d-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
• -d alkylsulfonyl,
•carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by methyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl , naphthyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, indenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is IH-indolyl, 2,4-dihydro-3-oxo-pyrazolyl, furyl, pyrazolyl, pyridyl, thienyl, 1,2,3-triazolyl, IH-pyrrolyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-l,5,6,7-tetrahydro-indolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, pyrazolyl, pyrimidyl, quinolyl, thiazolyl, tetrahydro- thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
cώ rjo
o
cά π Br
Xi r'X
cώ Λ
&x H xx
or, in case of, a salt thereof.
Other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) d-Cio alkyl,
Ci-Cio alkyl substituted by substituent(s) independently selected from •C5-C6 cycloalkyl, •carbocyclic aryl, •heterocyclyl, (ii) C3-C6 cycloalkyl, (iii) carbocyclic aryl, (iv) or heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; heterocyclyl is 1,3-dioxo-isoindolyl, IH-indolyl, l-oxo-3H-isobenzofuranyl, 2,3- dihydro-benzo [1,4] dioxinyl, 3 ,4-dihydro-2H-benzo [b] [ 1 ,4] dioxepinyl, 4-oxo-3 ,4-dihydro- phthalazinyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, oxolanyl, piperidyl, pyridyl, quinoxalyl, thienyl, quinolyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Further other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Ci-C alkyl,
C1-C4 alkyl substituted by substituent(s) independently selected from •cyclopentyl, •carbocyclic aryl, •heterocyclyl,
(ii) carbocyclic aryl, (iii) or heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; heterocyclyl is 9H-xanthenyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, thienyl, IH-indolyl, quinoxalyl, quinolyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
or, in case of, a salt thereof.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Ci-Cio alkyl,
Ci-Cio alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•CrC3 alkoxy,
•Ci-C3 alkoxy substituted by substituent(s) independently selected from ••carbocyclic aryl, ••heterocyclyl,
••heterocyclyl substituted by Cι-C3 alkyl, •carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from ••halogen, ••nitro,
••carbocyclic aryl,
••carbocyclic aryl substituted by Cι-C3 alkoxy, ••C1-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from •••mono- or di-Cι-C3 alkylamino,
•••mono- or di-Ci-C3 alkylamino substituted by carbocyclic aryl, •••mono- or di-Cι-C3 alkylamino substituted by halogenated carbocyclic aryl, •mono- or di-Cι-C3 alkylamino,
•mono- or di-C C3 alkylamino substituted by substituent(s) independently selected from ••cyano,
••carbocyclic aryl, ••heterocyclyl,
•mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by Cι-C3 alkyl, •CrC3 alkylcalbonylamino,
•Cι-C4 alkoxycalbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-Ci-C3 alkylamino,
•C1-C3 alkylthio,
•Cι-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••Cι-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•C3-C6 cycloalkyl,
•C3-C15 cycloalkyl substituted by Cι-C3 alkyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C2-C3 alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted C C3 alkylsulfmyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
•halogen, •hydroxy, •nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from ••halogen, ••hydroxy, ••carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
•••halogen, •••nitro, •••C1-C3 alkyl, •••Ci-C3 alkoxy, •••halogenated C C3 alkoxy, •CrC3 alkoxy,
•Cι-C3 alkoxy substituted by substituent(s) independently selected from ••halogen, ••carbocyclic aryl, •carbocyclic aryloxy, •Ci-C3 alkoxycarbonyl, •mono- or di-Cι-C3 alkylamino, •C1-C3 alkylthio, •halogenated Cι-C3 alkylthio, •Ci-C3 alkylsulfonyl, •C3-C6 cycloalkyl, •carbocyclic aryl, •heterocyclyl, heterocyclyl, heterocyclyl substituted by substituent(s) independently selected from C1-C3 alkyl,
••CX3 alkoxy,
••Cι-C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C8 alkenyl,
C2-C8 alkenyl substituted by substituent(s) independently selected from
•halogen,
•Cι-C3 alkoxy,
•CX3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••C1-C3 alkoxy,
••halogenated Ci-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by nitro,
(iii) C2-C4 alkynyl,
C2-C4 alkynyl substituted by carbocyclic aryl,
(iv) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•C1-C3 alkyl substituted by substituent(s) independently selected from
••hydroxy,
••oxo,
••carbocyclic aryl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl,
•carbocyclic aryl,
(v) C3-C6 cycloalkeyl,
C3-C6 cycloalkeyl substituted by C1-C3 alkyl,
(vi) carbocyclyl,
carbocyclyl substituted by substituent(s) independently selected from
•hydroxy,
•nitro,
(vii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•CrC9 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••C1-C3 alkoxy,
••carbocyclic aryloxy,
••mono- or di-Cι-C3 alkylamino-N-oxy,
••mono- or di- -Cs alkylamino,
••mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylamino substituted by C1-C3 alkoxy,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by C1-C3 alkyl,
•C -C3 alkenyl,
•C2-C3 alkenyl substituted by carbocyclic aryl,
•CrC9 alkoxy,
•Ci-C9 alkoxy substituted by substituent(s) independently selected from
••hydroxy,
••halogen,
••carboxy,
•mono- or di-Cι-C3 alkylamino,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkyl,
•••halogenated Cι-C3 alkyl,
C2-C3 alkenyloxy,
Cι-C3 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from
•halogen,
•C1-C4 alkyl,
•halogenated C1-C4 alkyl,
•C1-C3 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•halogenated d-C3 alkyl,
(carbocyclic aryl)S(O)2O, carboxy,
C1-C3 alkoxycarbonyl, mono- or di-Ci-C3 alkylaminocarbonyl,
'mono- or di-Cι-C3 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono- or di-Cι-C4 alkylamino, mono- or di-Cι-C4 alkylamino substituted by cyano, mono- or di-carbocyclic arylamino,
•C1-C3 alkylcarbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by C1-C3 alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by C1-C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated -C3 alkoxy,
•Cι-C3 alkylthio,
•halogenated Cι-C3 alkylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by C C3 alkyl,
•heterocyclylthio,
•Cι-C3 alkylsulfonyl,
•mono- or di-C]-C3 alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••C1-C7 alkyl,
••halogenated C1-C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(viii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
•hydroxy,
•oxo,
•Cι-C3 alkylcarbonyloxy,
•Cι-C3 alkoxycarbonyl,
•C1-C3 alkylthio,
•CrC-3 alkylthio substituted by carbocyclic aryl,
•Cι-C3 alkylthio substituted by halogenated carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
•heterocyclyl,
Cι-C3 alkoxy,
CrC3 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-C3 alkyl, mono- or di-Ci-C3 alkylamino,
Cι-C4 alkylcarbonylamino,
C1-C3 alkylthio, carbocyclic arylthio, halogenated carbocyclic arylthio, carbocyclic arylthio substituted by C C3 alkoxycarbonyl, heterocyclylthio, heterocyclylthio substituted by C1-C3 alkyl,
C]i-C3 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-C4 alkyl,
CrC3 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from halogen, nitro,
••C1-C3 alkyl,
••halogenated C1-C3 alkyl,
••C1-C3 alkoxy,
••halogenated Cι-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••halogenated C C3 alkyl,
••C1-C3 alkoxy,
••Cι-C3 alkoxycarbonyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or -C3 alkyl;
R2b is C1-C4 alkyl, Cι-C alkyl substituted by substituent(s) independently selected from •hydroxy, •Ci-C3 alkoxy, •amino, •-NHBoc, •C3-C6 cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••C1-C3 alkyl, ••C1-C3 alkoxy, ••-SO2NH2, •heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •C1-C3 alkyl, •C1-C3 alkoxy, or a group of Formula IN;
wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C^Cs alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by C1-C3 alkoxy;
L is selected from Formula N - XIX; wherein R4 is H or Cι-C3 alkyl;
R5 is H, CX3 alkyl, or C1-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -(CH2)m, m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl; carbocyclyl is 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, indanyl, or indenyl; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, IH-indolyl, lH-pyrrolo[2,3- c]pyridyl, IH-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-l-oxo- isoindolyl, 2,3-dihydro-benzo[l,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo- pyrazolyl, 2H-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 3,4- dihydro-2H-benzo[b][l,4]dioxepinyl, 4H-benzo[l,3]dioxinyl, 4H-benzopyranyl, 4-oxo- 1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,l-b]τhiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperazyl, piperidyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, or thiolanyl; halogen is fluoro, chloro, bromo, or iodo.
Other preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Cι-C10 alkyl substituted by substituent(s) independently selected from •methoxy, •methoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•halogenated carbocyclic aryloxy,
•mono-C C2 alkylamino substituted by cyano,
•mono- or di-Cι-C2 alkylamino substituted by carbocyclic aryl,
•mono-carbocyclic arylamino,
•mono-carbocyclic arylamino substituted by methyl,
•carbocyclic arylsulfonylamino substituted by methyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C4 alkyl,
••C1-C alkyl substituted by carbocyclic aryl,
••C].-C4 alkyl substituted by hydroxy,
••C1-C2 alkoxy,
••halogenated Cι-C2 alkoxy,
•heterocyclyl substituted by carbocyclic aryl,
(ii) C2-C8 alkenyl substituted by substituent(s) independently selected from
•methoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by methoxy,
(iii) C2-C alkynyl substituted by carbocyclic aryl,
(iv) cyclohexyl substituted by carbocyclic arylmethyl,
(v) carbocyclyl,
(vi) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•amino,
•C1-C9 alkyl,
•halogenated C1-C9 alkyl,
•Cι-C9 alkoxy,
•C1-C9 alkoxy substituted by substituent(s) independently selected from
••halogen,
••halogenated carbocyclic aryl,
•propenyloxy,
•methylamino,
•di-Cι-C2 alkylamino,
•di-Cι-C2 alkylamino substituted by cyano,
•methylthio,
•halogenated methylthio,
(vii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C4 alkyl,
•CrC4 alkyl substituted by hydroxy,
•0^04 alkyl substituted by carbocyclic aryl,
•methoxy,
•Ci-C2 alkoxycarbonyl,
•carbocyclic arylthio substituted by methoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••halogenated methyl,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula Na, Nffla, or IXa; wherein R4 and R5 are independently selected from H or C1-C3 alkyl;
Y is -(CH2)m, m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl; carbocyclyl is 9H-fluorenyl, acenaphthyl, or anthraquinonyl; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxolanyl, IH-indolyl, IH-pyrrolyl, 2,2',5,,2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-
dihydro-benzo[l,4]dioxinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 4-oxo-benzopyranyl, 9H- carbazolyl, 9H-xanthenyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, oxolanyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, 2H-benzopyranyl, 4H-benzo[l,3]dioxinyl, azetidinyl, imidazo[2,l-b]thiazolyl, morpholinyl, or 2,3-dihydro- benzofuryl; halogen is fluoro, chloro, bromo, or iodo.
Other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Kι represents (i) C1-C7 alkyl substituted by substituent(s) independently selected from •methoxy,
•methoxy substituted by carbocyclic aryl, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •mono-efhylamino substituted by cyano, •di-methylamino substituted by carbocyclic aryl, •mono-carbocyclic arylamino, •mono-carbocyclic arylamino substituted by methyl, •carbocyclic arylsulfonylamino substituted by methyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro, ••C1-C4 alkyl,
••C1-C4 alkyl substituted by carbocyclic aryl, ••C1-C4 alkyl substituted by hydroxy, ••metoxy,
••halogenated methoxy, •heterocyclyl substituted by carbocyclic aryl,
(ii) C2-C alkenyl substituted by substituent(s) independently selected from
•methoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by methoxy,
(iii) butynyl substituted by carbocyclic aryl,
(iv) cyclohexyl substituted by carbocyclic arylmethyl,
(v) carbocyclyl,
(vi) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•amino,
•C1-C2 alkyl,
•halogenated methyl,
•C C3 alkoxy,
•C1-C3 alkoxy substituted by substituent(s) independently selected from
••halogen,
••halogenated carbocyclic aryl,
•propenyloxy,
•di-Cι-C2 alkylamino,
•di-Ci-C2 alkylamino substituted by cyano,
•methylthio,
•halogenated methylthio,
(vii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•C1-C3 alkyl substituted by hydroxy,
•Ci-C3 alkyl substituted by carbocyclic aryl,
•methoxy,
•ethoxycarbonyl,
•carbocyclic arylthio substituted by methoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••halogenated methyl,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -(CH2)m, m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is acenaphthyl; heterocyclyl is IH-indolyl, IH-pyrrolyl, 2,3-dihydro-benzo[l,4]dioxinyl, 9H- carbazolyl, benzo[l,3]dioxolyl, furyl, pyrazolyl, thienyl, 4-oxo-benzopyranyl, azetidinyl, imidazo[2,l-b]thiazolyl, pyridyl, imidazolyl, 2,3-dihydro-benzofuryl, or benzo[b]thienyl;; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
?0
; or, in case of, a salt thereof.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Ci-Ci6 alkyl,
Cι-C16 alkyl substituted by substituent(s) independently selected from •halogen, •carbocyclyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro, ■•C1-C3 alkyl, ••halogenated -C3 alkyl, (ii) C2-C3 alkenyl,
C2-C3 alkenyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •cyano, •nitro,
•C1-C5 alkyl,
•CXs alkyl substituted by substituent(s) independently selected from ••halogen, ••oxo,
•Q2-C3 alkenyl, •Ci-C4 alkoxy,
•CX4 alkoxy substituted by substituent(s) independently selected from ••halogen, ••heterocyclyl, ••halogenated heterocyclyl, •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••nitro,
•heterocyclyloxy,
•heterocyclyloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated CX3 alkyl,
•C1-C3 alkoxycarbonyl,
•mono- or di-Cι-C4 alkylamino,
•CX3 alkylcarbonylamino,
•carbocyclic aryl diazo,
•carbocyclic aryl diazo substituted by mono- or di- C1-C3 alkylamino,
•Cι-C3 alkylsulfonyl,
•carbocyclic aryl,
(iv) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
• C1-C3 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkyl,
•••halogenated C1-C3 alkyl,
•C1-C3 alkoxy,
•CX3 alkylcarbonylamino,
•carbocyclic arylsulfonyl,
•C1-C3 alkoxycarbonyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated C C3 alkyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or CrC3 alkyl;
R2b is C1-C4 alkyl, C C4 alkyl substituted by substituent(s) independently selected from •hydroxy, •C1-C3 alkoxy, •amino, •-NHBoc, •C3-C6 cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••C1-C3 alkyl, •• -C3 alkoxy, ••-SO2NH2, •heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •C1-C3 alkyl, •CX3 alkoxy, or a group of Formula IV; wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by CX3 alkoxy;
L is selected from Formula V - XIX; wherein R4 is H or CX3 alkyl;
R5 is H, -C3 alkyl, or C1-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -S(O)2-; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl; heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, IH-pyrrolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, quinolyl, thiazolyl, or thienyl; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
or, in case of, a salt thereof.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Fomura II;
Rt is selected from H, -CO2'Bu, or -CO Bn (Bn is a benzyl group);
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is a single bond; or a salt thereof.
Also provided in accordance with the present invention are methods of modulating G-protein receptor SLC-1 comprising contacting the SLC-1 receptor with a compound of the invention.
The present invention further provides pharmaceutical compositions containing MCH receptor antagonists of the invention.
Brief Description of the Figures
Figure 1 provides an illustration of IP3 production from several non-endogenous, constitutively activated version of MCH receptor as compared with the endogenous version of this receptor.
Detailed Description
The present invention relates to MCH receptor antagonist compounds, and methods of modulating MCH receptors by contacting the receptors with one or more compounds of the invention.
The term "antagonist" is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist. As used herein, the term "agonist" is intended to mean moieties that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes. In the context of the present invention, a pharmaceutical composition comprising a MCH receptor antagonist of the invention can be utilized for modulating the activity of the MCH receptor,
decreasing body weight and/or affecting metabolism such that the recipient loses weight and/or maintains weight. Such pharmaceutical compositions can be used in the context of disorders and/or diseases where weight gain is a component of the disease and/or disorder such as, for example, obesity.
As used herein, the term "contact" or "contacting"shall mean bringing the indicated moieties together, whether in an in vitro system or an in vivo system. Thus, "contacting" an MCH receptor with a compound of the invention includes the administration of a compound of the invention to an animal having an MCH receptor, as well as, for example, introducing a compound of the invention into a sample containing a cellular or more purified preparation containing an MCH receptor.
Compounds of the invention include those having Formula I, shown below:
wherein Q can be either Foemura II or 111:
II III
Ri represents (i) d-Ciβ alkyl,
C Cι6 alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•C C3 alkoxy,
•CrC3 alkoxy substituted by substituent(s) independently selected from ••carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by C1-C3 alkyl,
•C1-C3 alkylcarbonyloxy,
•carbocyclyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••nitro,
••carbocyclic aryl,
••carbocyclic aryl substituted by CX3 alkoxy,
••C1-C4 alkyl,
••CrC4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••mono- or di-Cι-C3 alkylamino,
•••mono- or di-CXs alkylamino substituted by carbocyclic aryl,
•••mono- or di-Cι-C3 alkylamino substituted by halogenated carbocyclic aryl,
•••carbocyclic arylcarbonylamino,
•••halogenated carbocyclic arylcarbonylamino,
•heterocyclyloxy,
•heterocyclyloxy substituted by CX3 alkyl,
•substituted heterocyclyl-ethylideneaminooxy,
•Cι-C3 alkoxycarbonyl,
•Cι-C3 alkoxycarbonyl substituted by carbocyclic aryl,
•mono- or di-C!-C3 alkylaminocarbonyl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-CXs alkylamino substituted by substituent(s) independently selected from
••cyano,
••carbocyclic aryl,
••heterocyclyl,
•mono- or di-carbocyclic arylamino, .
•mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
••hydroxy,
••C1-C3 alkyl,
•C1-C3 alkylcalbonylamino,
•CX3 alkylcalbonylamino substituted by substituent(s) independently selected from
••C1-C3 alkylcalbonylamino,
••carbocyclic arylcalbonylamino,
••heterocyclyl,
•Q-C4 alkoxycalbonylamino,
•heterocyclyl calbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-Cι-C3 alkylamino,
•C1-C3 aikylthio,
•CX3 aikylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylaminocarbonyl,
••halogenated mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•heterocyclylthio substituted by substituent(s) independently selected from
•nitro,
•C1-C3 alkyl, C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by C1-C3 alkyl, C -C6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from •halogen, •C1-C3 alkyl, •C1-C3 alkoxy, •C2-C3 alkenyl,
•C2-C alkenyl substituted by carbocyclic aryl,
•C2-C3 alkenyl substituted by carbocyclic aryl substituted Cι-C3 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •hydroxy, •nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from ••halogen, ••hydroxy, ••oxo,
••carbocyclic aryl, ••heterocyclyl,
••mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C3 alkyl,
•Ci-C3 alkoxy,
•••halogenated C1-C3 alkoxy, •C1-C4 alkoxy,
•C1-C4 alkoxy substituted by substituent(s) independently selected from '•halogen, ••carbocyclic aryl, 'carbocyclic aryloxy, •0X3 alkoxycarbonyl, •Cι-C3 alkylcarbonyloxy, •mono- or di-Cι-C3 alkylamino, •mono- or di-carbocyclic arylamino, -halogenated mono- or di-carbocyclic arylamino, •mono- or di-carbocyclic arylaminocarbonyl,
•mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from ••halogen, ••nitro, ••C1-C3 alkyl, ••C1-C3 alkoxy, ••halogenated Cι-C3 alkoxy, •mercapto, •CrC3 alkylthio, •halogenated C1-C3 alkylthio, •CX3 alkylsulfonyl, •C3-C6 cycloalkyl, •carbocyclic aryl, •heterocyclyl, heterocyclyl, heterocyclyl substituted by substituent(s) independently selected from hydroxy, C1-C3 alkyl,
C C3 alkyl substituted by carbocyclic aryl, C1-C3 alkoxy,
••C1-C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C» alkenyl,
C2-C8 alkenyl substituted by substituent(s) independently selected from
•halogen,
•oxo,
•CrC3 alkoxy,
•C1-C3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C3 alkyl,
••halogenated CX3 alkyl,
••C1-C3 alkoxy,
••halogenated C C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••nitro,
••C1-C3 alkyl,
••C1-C3 alkoxy,
(iii) C2-C4 alkynyl,
C2-C4 alkynyl substituted by carbocyclic aryl,
(iv) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•d-C3 alkyl,
•Cι-C3 alkyl substituted by substituent(s) independently selected from
••hydroxy,
••oxo,
••carbocyclic aryl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-C C3 alkylamino substituted by carbocyclic aryl,
•carbocyclic arylcarbonylamino,
•carbocyclic aryl,
(v) C3-C6 cycloalkeyl,
C3-C6 cycloalkeyl substituted by C1-C3 alkyl,
(vi) carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from
•hydroxy,
•nitro,
(vii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•C1-C9 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••C1-C3 alkoxy,
••carbocyclic aryloxy,
••mono- or di-Cι-C3 alkylamino-N-oxy,
••mono- or di-Cι-C3 alkylamino,
••mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
••carbocyclylimino,
••carbocyclylimino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylamino substituted by CX3 alkoxy,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by Cι-C3 alkoxy,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
— C1-C3 alkyl,
•••halogenated C C3 alkyl,
••heterocyclyl,
••heterocyclyl substituted by CX3 alkyl,
•Q2-C3 alkenyl,
•C2-C3 alkenyl substituted by carbocyclic aryl,
•C1-C9 alkoxy,
•C1-C9 alkoxy substituted by substituent(s) independently selected from
••hydroxy,
••halogen,
••carboxy,
••mono- or di-Cι-C3 alkylamino,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••heterocyclyl,
•••heterocyclyl substituted by substituent(s) independently selected from
••••halogen,
••••C1-C3 alkyl,
••••halogenated 0X3 alkyl,
•C2-C3 alkenyloxy,
•C1-C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
nitro,
C1-C4 alkyl, halogenated Cι-C4 alkyl,
CpC3 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by substituent(s) independently selected from halogen,
€ι-C3 alkyl, halogenated Q-C3 alkyl, (carbocyclic aryl)S(O)2O, carboxy,
C C3 alkoxycarbonyl, mono- or di-C C3 alkylaminocarbonyl, mono- or di-Cι-C3 alkylaminocarbonyl substituted by carbocyclic aryl, mono- or di-carbocyclic arylaminocarbonyl, mono- or di-carbocyclic arylaminocarbonyl substituted by CX3 alkyl, amino, mono- or di-Cι-C4 alkylamino, mono- or di-Cι-C4 alkylamino substituted by cyano, mono- or di-carbocyclic arylamino, C1-C3 alkynylcarbonylamino,
C1-C3 alkynylcarbonylamino substituted by carbocyclic aryl, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by C C3 alkyl, (carbocyclic aryl)NHC(O)NH,
(carbocyclic aryl)NHC(O)NH substituted by Cι-C3 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-C3 alkoxy, carbocyclic aryl diazo, carbocyclic aryl diazo substituted by mono- or di- Cι-C3 alkylamino, C1-C3 alkylthio, halogenated C1-C3 alkylthio, carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••cyano,
••C1-C3 alkyl,
•heterocyclylthio,
•C1-C3 alkylsulfonyl,
•mono- or di-Cι-C3 alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••C1-C7 alkyl,
••halogenated C1-C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(viii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C4 alkyl,
•C C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••C1-C3 alkylcarbonyloxy,
••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino,
••C1-C3 alkoxycarbonyl,
••C1-C3 alkylthio,
••C1-C3 alkylthio substituted by carbocyclic aryl,
••C1-C3 alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkyl,
•••halogenated 0X3 alkyl,
•C1-C3 alkoxy,
•C1-C3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••Ci-C3 alkyl,
•mono- or di-Ci-C3 alkylamino,
•Cι-C4 alkylcarbonylamino,
•C C3 alkylthio,
•CX3 alkenylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by C1-C3 alkoxycarbonyl,
•heterocyclylthio,
•heterocyclylthio substituted by CX3 alkyl,
•CX3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by Cι-C alkyl,
•CrC3 alkoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
-C1-C3 alkyl,
••halogenated CX3 alkyl,
••C1-C3 alkoxy,
••halogenated CX3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated CX3 alkyl,
••C C3 alkoxy,
••CX3 alkoxycarbonyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or C1-C3 alkyl;
R2b is C1-C4 alkyl, C1-C4 alkyl substituted by substituent(s) independently selected from •hydroxy, •C1-C3 alkoxy, •amino, •-NHBoc, •C3-Q cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••C1-C3 alkyl, ••C1-C3 alkoxy, ••-SO2NH2, •heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•Cι-C3 alkoxy, or a group of Formula IV;
wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C1-C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by C1-C3 alkoxy;
L is selected from Formula V - XTX;
VI Via Vlb
R5 R5 R5
VII Vila Vllb
R4 K R4
VIII Villa Vlllb
XIV XV XVI
XVII XVIII XIX
wherein R4 is H or C1-C3 alkyl;
R5 is H, CX3 alkyl, or C1-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -S(0)2-, -C(O)-, or -(CH2)m; m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, biphenyl, or phenanthryl; carbocyclyl is 10,l l-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7- dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2. l]hepteny; heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl,
l,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, IH- indolyl, lH-pyrrolo[2,3-c]pyridyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,2',5',2"- terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro- benzo[ 1,4] dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H- benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 3,4-dihydro-2H-benzo[b][l,4]dioxepinyl, 4H-benzo[l,3]dioxinyl, 4H-benzopyranyl, 4- oxo-l,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,l-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, fhiolanyl, 2,3- dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl; halogen is fluoro, chloro, bromo, or iodo.
Preferred compounds of this invention are those compounds of Formula I wherein, Q is Formula II; Ri represents (i) d-do alkyl, -do alkyl substituted by substituent(s) independently selected from halogen, oxo, - alkoxy, d-d alkoxy substituted by carbocyclic aryl, d-d alkylcarbonyloxy, carbocyclyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from
•halogen,
•nitro,
•Cι-C4 alkyl,
•d-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic arylcarbonylamino,
•••halogenated carbocyclic arylcarbonylamino,
•heterocyclyloxy,
•heterocyclyloxy substituted by d-d alkyl,
•substituted heterocyclyl-ethylideneaminooxy,
•Cι-C3 alkoxycarbonyl,
•Cι-C3 alkoxycarbonyl substituted by carbocyclic aryl,
•mono- or di-d-C alkylaminocarbonyl,
•mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by hydroxy,
•Cι-C3 alkylcalbonylamino,
•Cι-C3 alkylcalbonylamino substituted by substituent(s) independently selected from
••d-C3 alkylcalbonylamino,
••carbocyclic arylcalbonylamino,
••heterocyclyl,
•Cι-C4 alkoxycalbonylamino,
•heterocyclyl calbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-d-C3 alkylamino,
•C1-C3 alkylthio,
•C1-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylaminocarbonyl,
••halogenated mono- or di-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•"d-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
"halogen,
"d-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•heterocyclylthio substituted by substituent(s) independently selected from
••nitro,
-d-d alkyl,
•d-C6 cycloalkyl,
•d-C6 cycloalkyl substituted by d-d alkyl,
•d-C6 cycloalkenyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
-d-d alkyl,
"C1-C3 alkoxy,
"C2-C3 alkenyl,
"C2-d alkenyl substituted by carbocyclic aryl,
"d-d aikenyl substituted by carbocyclic aryl substituted C1-C3 alkylsulfinyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••d-C4 alkyl,
"Cι-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
"Cι-C4 alkoxy,
"C1-C4 alkoxy substituted by substituent(s) independently selected from
•••halogen,
•••carbocyclic aryl,
"carbocyclic aryloxy,
"C1-C3 alkylcarbonyloxy,
••mono- or di-carbocyclic arylamino,
"halogenated mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
— C1-C3 alkyl,
•••C1-C3 alkoxy,
•••halogenated C1-C3 alkoxy,
••mercapto,
••d-d alkylthio,
••halogenated d-d alkylthio,
"d-d alkylsulfonyl,
"d-C6 cycloalkyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
"d-C3 alkyl,
"d-d alkyl substituted by carbocyclic aryl,
"d-C3 alkoxy,
"d-d alkoxy substituted by carbocyclic aryl,
"carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C6 alkenyl,
C2-C6 alkenyl substituted by substituent(s) independently selected from
•oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••halogenated C1-C3 alkyl,
"d-C3 alkoxy,
••halogenated d-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
"d-C3 alkyl,
"d-d alkoxy,
(iii) C3-C6 cycloalkyl, d-d cycloalkyl substituted by substituent(s) independently selected from
•Ci-d alkyl,
•d-C3 alkyl substituted by substituent(s) independently selected from
••oxo,
"carbocyclic aryl,
•carbocyclic arylcarbonylamino,
•carbocyclic aryl,
(iv) carbocyclyl, carbocyclyl substituted by nitro,
(v) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•d-C9 alkyl,
•C1-C9 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryloxy,
••carbocyclylimino,
••carbocyclylimino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by d-C3 alkoxy,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••d-d alkyl,
•••halogenated d-C3 alkyl,
••heterocyclyl,
••heterocyclyl substituted by Cι-C3 alkyl,
•d-C7 alkoxy,
•d-C7 alkoxy substituted by substituent(s) independently selected from
••halogen,
••carbocyclic aryl,
•d-C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by d-C3 alkoxy,
•C1-C3 alkoxycarbonyl,
•mono- or di-Ci-d alkylaminocarbonyl,
•mono- or di-Ci-d alkylaminocarbonyl substituted by carbocyclic aryl,
•mono- or di-carbocyclic arylaminocarbonyl,
•mono- or di-carbocyclic arylaminocarbonyl substituted by d-d alkyl,
•amino,
•mono- or di-d-d alkylamino,
•d-d alkynylcarbonylamino,
•d-C3 alkynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by d-C3 alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by C1-C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated C1-C3 alkoxy,
•C1-C3 alkylthio,
•halogenated C1-C3 alkylthio,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by cyano,
•d-d alkylsulfonyl,
•mono- or di-Ci-d alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••d-d alkyl,
••halogenated d-C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••d-d alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(vi) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•d-C alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
"C1-C3 alkylthio,
"d-C3 alkylthio substituted by carbocyclic aryl,
••d-d alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•C1-C3 alkoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•d-d alkylthio,
•d-d alkenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by Cι-C4 alkyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••d-d alkyl,
"d-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••d-d alkyl,
••halogenated C1-C3 alkyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or C1-C3 alkyl;
R2b is Cι-C4 alkyl, Cι-C alkyl substituted by substituent(s) independently selected from •hydroxy, •d-d alkoxy, •amino, •-NHBoc, •d-C6 cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
"halogen,
-d-d alkyl,
"C1-C3 alkoxy,
••-SO2NH2,
•heterocyclyl, d-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•d-d alkyl,
•d-d alkoxy, or a group of Formula IN; wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C1-C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by C1-C3 alkoxy;
L is selected from Formula N - XIX; wherein R4 is H or d-d alkyl;
R5 is H, d-d alkyl, or d-d alkyl substituted by a substituted carbocyclic aryl;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; carbocyclyl is 10,l l-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 9H- fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxo-isoindolyl, IH-indolyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,3-dihydro- benzo[l,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H- benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H- benzo[b] [1 ,4]dioxepinyl, 4-oxo-l ,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phfhalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, cinnolyl,
furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Other preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Cι-Cιo alkyl, d-Cio alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl, •methoxy substituted by carbocyclic aryl, •methylcarbonyloxy, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •carbocyclic aryloxy substituted by nitro, •heterocyclyloxy substituted by methyl, •substituted heterocyclyl-ethylideneaminooxy, •tert-butoxycarbonylamino, •carbocyclic arylcarbonylamino, •d-d alkylthio,
•Cι-C2 alkylthio substituted by substituent(s) independently selected from "halogenated carbocyclic aryl, ••carbocyclic aryl substituted by methoxy, •carbocyclic arylthio, •hetrocyclylthio substituted by nitro, •hetrocyclylthio substituted by methyl, •d-C6 cycloalkyl, •C5-C6 cycloalkenyl, •carbocyclyl substituted by substituent(s) independently selected from
'•halogen,
'•methyl,
'•methoxy,
'•ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
'carbocyclic aryl,
■carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, nitro, d-C4 alkyl, d-C4 alkyl substituted by substituent(s) independently selected from
•oxo,
•carbocyclic aryl,
•heterocyclyl,
Cι-C4 alkoxy, halogenated d-C4 alkoxy, d-C4 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, halogenated mono-carbocyclic arylaminocarbonyl, carbocyclic aryl, heterocyclyl, •heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from ••d-d alkyl,
•• d-d substituted by carbocyclic aryl, ••methoxy,
••methoxy substituted by carbocyclic aryl, ••carbocyclic aryl, ••halogenated carbocyclic aryl,
(ii) C2-d alkenyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) C -C6 cycloalkyl, d-d cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•d-C alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryl,
••carbocyclic aryl substituted by methyl,
••carbocyclic aryloxy,
•Ci-C7 alkoxy,
•halogenated C1-C7 alkoxy,
•d-C7 alkoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methoxy,
•amino,
•di-methylamino,
•propargynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino substituted by methyl,
•(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
•halogenated methylthio,
•carbocyclic arylthio substituted by cyano,
•di-propylamino sulfonyl,
•mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••methylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•d-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl substituted by - alkyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula Na, Villa, or IXa;
wherein R4 and R5 are independently selected from H or d-d alkyl;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren- 9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxo-isoindolyl, IH-indolyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,3-dihydro- benzo[ 1,4] dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3 ,4-dihydro-2H-benzo [b] [1,4] dioxepinyl, 4-oxo-3 ,4-dihydro-phthalazinyl, 4-oxo- benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3- dihydro-benzofuryl, 2-oxo-pyrrolidinyl, 4-oxo-l, 5,6,7-tetrahydro-indolyl, cinnolyl, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Kι represents (i) C1-C10 alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl, •methoxy substituted by carbocyclic aryl, •methylcarbonyloxy, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •carbocyclic aryloxy substituted by nitro, •heterocyclyloxy substituted by methyl, •substituted heterocyclyl-ethylideneaminooxy, •tert-butoxycarbonylamino,
carbocyclic arylcarbonylamino,
Ci-d alkylthio,
Cι-C2 alkylthio substituted by substituent(s) independently selected from
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methoxy, carbocyclic arylthio, hetrocyclylthio substituted by nitro, hetrocyclylthio substituted by methyl,
C5-C6 cycloalkenyl, carbocyclyl substituted by substituent(s) independently selected from
•halogen,
•methyl,
•methoxy,
•ethenyl substituted by carbocyclic aryl substituted methylsulfinyl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•nitro,
•d-d alkyl,
•d-C4 alkyl substituted by substituent(s) independently selected from
••oxo,
••carbocyclic aryl,
"heterocyclyl,
•Cι-C4 alkoxy,
•halogenated d-C4 alkoxy,
•Cι-C alkoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•halogenated mono-carbocyclic arylaminocarbonyl,
•carbocyclic aryl,
•heterocyclyl, heterocyclyl substituted by substituent(s) independently selected from
•Ci-d alkyl,
•• d-C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) d-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, cyano, nitro,
C1-C9 alkyl,
C1-C9 alkyl substituted by substituent(s) independently selected from
•halogen,
•oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryloxy, d-d alkoxy, halogenated d-C7 alkoxy,
C1-C7 alkoxy substituted by carbocyclic aryl, methylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by methoxy,
amino, di-mefhylamino, propargynylcarbonylamino substituted by carbocyclic aryl, carbocyclic arylsulfonylamino substituted by methyl,
(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy, halogenated methylthio, carbocyclic arylthio substituted by cyano, di-propylamino sulfonyl, mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl, carbocyclic aryl, heterocyclyl substituted by methyl, heterocyclyl substituted by halogenated carbocyclic aryl, vi) or heterocyclyl substituted by substituent(s) independently selected from halogen, nitro, d-d alkyl,
C1-C4 alkyl substituted by substituent(s) independently selected from
•halogen,
•methylthio substituted by halogenated carbocyclic aryl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•heterocyclyl, methoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by methyl,
C1-C3 alkylthio, propenylthio, carbocyclic arylthio, d-d alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by Cι-C alkyl, carbocyclic aryl,
•halogenated carbocyclic aryl, •carbocyclic aryl substituted by methyl, •carbocyclic aryl substituted by nitro, •heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is l-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren- 9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, IH- indolyl, IH-pyrrolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 4-oxo-benzopyranyl, azetidinyl, benzo[b]thienyl, furyl, isoxazolyl, mo holinyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-l, 5,6,7-tetrahydro- indolyl, 9H-xanthenyl, cinnolyl, imidazolyl, morpholino, pyrimidyl, pyrrolidyl, tetrahydro- thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Further other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Cι-C5 alkyl substituted by substituent(s) independently selected from •oxo, •di-propylaminocarbonyl,
methoxy substituted by carbocyclic aryl, methylcarbonyloxy, carbocyclic aryloxy, halogenated carbocyclic aryloxy, carbocyclic aryloxy substituted by nitro, heterocyclyloxy substituted by methyl, substituted heterocyclyl-ethylideneaminooxy, tert-butoxycarbonylamino, carbocyclic arylcarbonylamino, d-d alkylthio,
Cι-C2 alkylthio substituted by substituent(s) independently selected from
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methoxy, carbocyclic arylthio, hetrocyclylthio substituted by nitro, hetrocyclylthio substituted by methyl, cyclohexenyl, carbocyclyl substituted by substituent(s) independently selected from
•halogen, .
•methyl,
•methoxy,
•ethenyl substituted by carbocyclic aryl substituted methylsulfinyl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•nitro,
• d-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••oxo,
••carbocyclic aryl,
••heterocyclyl,
•CrC2 alkoxy,
••halogenated Cι-C2 alkoxy,
"Cι-C2 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••Ci-d alkyl,
•• Cι-C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-d alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) d-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•d-d alkyl,
•d-C2 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryl,
••carbocyclic aryl substituted by methyl,
••carbocyclic aryloxy,
•d-d alkoxy,
•halogenated d-C2 alkoxy,
•d-C alkoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methoxy,
•amino,
•di-methylamino,
•propargynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino substituted by methyl,
•(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
•halogenated methylthio,
•carbocyclic arylthio substituted by cyano,
•di-propylamino sulfonyl,
•mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•d-C4 alkyl,
•d-C alkyl substituted by substituent(s) independently selected from
••halogen,
"methylthio substituted by halogenated carbocyclic aryl,
"carbocyclic aryl,
"halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•C1-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by methyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl , naphthyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, indenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is IH-indolyl, 2,4-dihydro-3-oxo-pyrazolyl, furyl, pyrazolyl, pyridyl, thienyl, 1,2,3-triazolyl, IH-pyrrolyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-l,5,6,7-tetrahydro-indolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, pyrazolyl, pyrimidyl, quinolyl, thiazolyl, tetrahydro- thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
eά Nx α
oό ύ
c£x„ HcrXύr
c N rκ rl
c Cl
N' "
ciχ
OOXXY
or, in case of. a salt thereof.
Other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Ci-Cio alkyl, d-Cio alkyl substituted by substituent(s) independently selected from •C5-C6 cycloalkyl, •carbocyclic aryl, •heterocyclyl, (ii) C3-C6 cycloalkyl, (iii) carbocyclic aryl, (iv) or heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; heterocyclyl is 1,3-dioxo-isoindolyl, IH-indolyl, l-oxo-3H-isobenzofuranyl, 2,3- dihydro-benzo [ 1 ,4] dioxinyl, 3 ,4-dihydro-2H-benzo [b] [ 1 ,4] dioxepinyl, 4-oxo-3 ,4-dihydro- phthalazinyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, oxolanyl, piperidyl, pyridyl, quinoxalyl, thienyl, quinolyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
Further other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) C C4 alkyl,
Cι-C4 alkyl substituted by substituent(s) independently selected from •cyclopentyl, •carbocyclic aryl, •heterocyclyl,
(ii) carbocyclic aryl, (iii) or heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; heterocyclyl is 9H-xanthenyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, thienyl, IH-indolyl, quinoxalyl, quinolyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
or, in case of, a salt thereof.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) Ci-Cio alkyl,
Cι-C10 alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•Ci-C alkoxy,
•CrC alkoxy substituted by substituent(s) independently selected from ••carbocyclic aryl, ••heterocyclyl,
••heterocyclyl substituted by C C3 alkyl, •carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from ••halogen, ••nitro,
••carbocyclic aryl,
••carbocyclic aryl substituted by CpC3 alkoxy, ••Cι-C4 alkyl,
••Cι-C4 alkyl substituted by substituent(s) mdependently selected from •••mono- or di-CrC3 alkylamino,
•••mono- or di-CrC3 alkylamino substituted by carbocyclic aryl, •••mono- or di-Ci-C3 alkylamino substituted by halogenated carbocyclic aryl, •mono- or di-C^ alkylamino,
•mono- or di-Ci-C3 alkylamino substituted by substituent(s) independently selected from ••cyano,
••carbocyclic aryl, ••heterocyclyl,
•mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by C C3 alkyl, •Cι-C3 alkylcalbonylamino,
•C1-C alkoxycalbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C C3 alkyl,
••mono- or di-Cι-C3 alkylamino,
•Cι-C3 alkylthio,
•Cι-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••C!-C alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•C -C6 cycloalkyl,
•C3-C6 cycloalkyl substituted by -C3 alkyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C2-C3 alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted Cι-C3 alkylsulfinyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C alkyl,
••CrC4 alkyl substituted by substituent(s) independently selected from
•••halogen,
•••hydroxy,
•••carbocyclic aryl,
•••mono- or di-carbocyclic arylamino,
•••mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected
••••halogen,
••••nitro,
••••C1-C3 alkyl,
••••Ci-C3 alkoxy,
••••halogenated C1-C3 alkoxy,
••CrC3 alkoxy,
••Cι-C3 alkoxy substituted by substituent(s) independently selected from
•••halogen,
•••carbocyclic aryl,
••carbocyclic aryloxy,
••Cχ-C3 alkoxycarbonyl,
••mono- or di-Cι-C3 alkylamino,
••C1-C3 alkylthio,
••halogenated C1-C3 alkylthio,
••Cι-C3 alkylsulfonyl,
••C3-C6 cycloalkyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••d-C, alkyl,
••C1-C3 alkoxy,
••C1-C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C8 alkenyl,
C2-C8 alkenyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkoxy,
•C1-C3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••Ci-C3 alkoxy,
••halogenated C1-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by nitro,
(iii) C2-C4 alkynyl,
C2-C4 alkynyl substituted by carbocyclic aryl,
(iv) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•C1-C3 alkyl substituted by substituent(s) independently selected from
••hydroxy,
••oxo,
••carbocyclic aryl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-Ci-C alkylamino substituted by carbocyclic aryl,
•carbocyclic aryl,
(v) C3-C6 cycloalkeyl,
C3-C6 cycloalkeyl substituted by C1-C3 alkyl,
(vi) carbocyclyl,
carbocyclyl substituted by substituent(s) independently selected from •hydroxy, •nitro,
(vii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, cyano, nitro,
C1-C9 alkyl, -Cg alkyl substituted by substituent(s) independently selected from halogen, hydroxy, •oxo,
•C1-C3 alkoxy, •carbocyclic aryloxy, •mono- or di-CXs alkylamino-N-oxy, •mono- or di-CXs alkylamino,
•mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl, •mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by CX3 alkoxy, •carbocyclic aryl, •halogenated carbocyclic aryl, •heterocyclyl,
•heterocyclyl substituted by C1-C3 alkyl, C2-C3 alkenyl,
C2-C3 alkenyl substituted by carbocyclic aryl, C C alkoxy,
Cι-C alkoxy substituted by substituent(s) independently selected from •hydroxy, •halogen, •carboxy,
••mono- or di-C!-C3 alkylamino,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••heterocyclyl,
•••heterocyclyl substituted by substituent(s) independently selected from
••••halogen,
••••C1-C3 alkyl,
••••halogenated CrC3 alkyl,
•C2-C3 alkenyloxy,
•C1-C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C4 alkyl,
••halogenated Cχ-C4 alkyl,
••C1-C3 alkoxy,
•heterocyclyloxy,
•heterocyclyloxy substituted by substituent(s) independently selected from
••halogen,
••C C3 alkyl,
••halogenated Ci-C3 alkyl,
•(carbocyclic aryl)S(O)2O,
•carboxy,
•C1-C3 alkoxycarbonyl,
•mono- or di-CXs alkylaminocarbonyl,
•mono- or di-CrC3 alkylaminocarbonyl substituted by carbocyclic aryl,
•amino,
•mono- or di-Cι-C alkylamino,
•mono- or di-Cι-C4 alkylamino substituted by cyano,
•mono- or di-carbocyclic arylamino,
•C1-C3 alkylcarbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by C1-C3 alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by C1-C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated Ci-C3 alkoxy,
•CrC3 alkylthio,
•halogenated CX3 alkylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by CX3 alkyl,
•heterocyclylthio,
•CX3 alkylsulfonyl,
•mono- or di-Ci-Gj alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••C1-C7 alkyl,
••halogenated Ci-C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(viii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C4 alkyl,
•Cι-C alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••C1-C3 alkylcarbonyloxy,
••CX3 alkoxycarbonyl,
••C1-C3 alkylthio,
••C1-C3 alkylthio substituted by carbocyclic aryl,
••CX3 alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
••heterocyclyl,
•C1-C3 alkoxy,
•CX3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by CX3 alkyl,
•mono- or di-Cι-C3 alkylamino,
•Cι-C4 alkylcarbonylamino,
•C1-C3 alkylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by C1-C3 alkoxycarbonyl,
•heterocyclylthio,
•heterocyclylthio substituted by CX3 alkyl,
•CX3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by CX4 alkyl,
•CX3 alkoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••halogenated Cj-C3 alkyl,
••C1-C3 alkoxy,
••halogenated Cι-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••halogenated C1-C3 alkyl,
••C1-C3 alkoxy,
••C1-C3 alkoxycarbonyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or C C3 alkyl;
R2 is Cι-C4 alkyl, C1-C4 alkyl substituted by substituent(s) independently selected from •hydroxy, •C1-C3 alkoxy, •amino, •-NHBoc, •C3-C6 cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••C1-C3 alkyl, ••C1-C3 alkoxy, ••-SO2NH2, •heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •C1-C3 alkyl, •Ci-C3 alkoxy, or a group of Formula IV;
wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C1-C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by Cι-C3 alkoxy;
L is selected from Formula N - XIX; wherein t is H or C1-C3 alkyl;
R5 is H, C1-C3 alkyl, or C1-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -(CH2)m, m is 0 or 1; wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl; carbocyclyl is 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, indanyl, or indenyl; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, IH-indolyl, lH-pyrrolo[2,3- c]pyridyl, IH-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-l-oxo- isoindolyl, 2,3-dihydro-benzo[l,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo- pyrazolyl, 2H-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 3,4- dihydro-2H-benzo[b][ 1,4] dioxepinyl, 4H-benzo[l,3]dioxinyl, 4H-benzopyranyl, 4-oxo- 1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,l-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperazyl, piperidyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, or thiolanyl; halogen is fluoro, chloro, bromo, or iodo.
Other preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) C1-C10 alkyl substituted by substituent(s) independently selected from •methoxy, •methoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•halogenated carbocyclic aryloxy,
•mono-C1-C2 alkylamino substituted by cyano,
•mono- or di-Cι-C2 alkylamino substituted by carbocyclic aryl,
•mono-carbocyclic arylamino,
•mono-carbocyclic arylamino substituted by methyl,
•carbocyclic arylsulfonylamino substituted by methyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C C4 alkyl,
••C1-C4 alkyl substituted by carbocyclic aryl,
••C1-C alkyl substituted by hydroxy,
••Cχ-C2 alkoxy,
••halogenated Cι-C2 alkoxy,
•heterocyclyl substituted by carbocyclic aryl,
(ii) C2-C8 alkenyl substituted by substituent(s) independently selected from
•methoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by methoxy,
(iii) C2-C4 aikynyl substituted by carbocyclic aryl,
(iv) cyclohexyl substituted by carbocyclic arylmethyl,
(v) carbocyclyl,
(vi) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•amino,
•C1-C9 alkyl,
•halogenated C C9 alkyl,
•C1-C9 alkoxy,
•CrC9 alkoxy substituted by substituent(s) independently selected from
••halogen,
••halogenated carbocyclic aryl,
•propenyloxy,
•methylamino,
•di-C1-C2 alkylamino,
•di-Ci-C2 alkylamino substituted by cyano,
•methylthio,
•halogenated methylthio,
(vii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C4 alkyl,
•Ci-C4 alkyl substituted by hydroxy,
•Cχ-C alkyl substituted by carbocyclic aryl,
•methoxy,
•Cι-C2 alkoxycarbonyl,
•carbocyclic arylthio substituted by methoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••halogenated methyl,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula Na, Villa, or IXa; wherein R4 and R5 are independently selected from H or CrC3 alkyl;
Y is -(CH2)m, m is 0 or 1; wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl; carbocyclyl is 9H-fluorenyl, acenaphthyl, or anthraquinonyl; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxolanyl, IH-indolyl, IH-pyrrolyl, 2,2',5,,2"-terthiophenyl, 2,2'-bitbiophenyl, 2,3-
dihydro-benzo[ 1,4] dioxinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 4-oxo-benzopyranyl, 9H- carbazolyl, 9H-xanthenyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, oxolanyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, 2H-benzopyranyl, 4H-benzo[ 1,3] dioxinyl, azetidinyl, imidazo[2,l-b]thiazolyl, morpholinyl, or 2,3-dihydro- benzofuryl; halogen is fluoro, chloro, bromo, or iodo.
Other more preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) C C7 alkyl substituted by substituent(s) independently selected from •methoxy,
•methoxy substituted by carbocyclic aryl, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •mono-ethylamino substituted by cyano, •di-methylamino substituted by carbocyclic aryl, •mono-carbocyclic arylamino, •mono-carbocyclic arylamino substituted by methyl, •carbocyclic arylsulfonylamino substituted by methyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro, ••Cι-C4 alkyl,
••Cι-C4 alkyl substituted by carbocyclic aryl, ••CrC4 alkyl substituted by hydroxy, ••metoxy,
••halogenated methoxy, •heterocyclyl substituted by carbocyclic aryl,
(ii) C2-C7 alkenyl substituted by substituent(s) independently selected from
•methoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by methoxy,
(iii) butynyl substituted by carbocyclic aryl,
(iv) cyclohexyl substituted by carbocyclic arylmethyl,
(v) carbocyclyl,
(vi) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•amino,
•C1-C2 alkyl,
•halogenated methyl,
•C1-C3 alkoxy,
•CX3 alkoxy substituted by substituent(s) independently selected from
••halogen,
••halogenated carbocyclic aryl,
•propenyloxy,
•di-C1-C2 alkylamino,
•di-CrC2 alkylamino substituted by cyano,
•methylthio,
•halogenated methylthio,
(vii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•Ci-C3 alkyl substituted by hydroxy,
•Ci-C3 alkyl substituted by carbocyclic aryl,
•methoxy,
•ethoxycarbonyl,
•carbocyclic arylthio substituted by methoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••halogenated methyl,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is -(CH2)m, m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is acenaphthyl; heterocyclyl is IH-indolyl, IH-pyrrolyl, 2,3-dihydro-benzo[l,4]dioxinyl, 9H- carbazolyl, benzo[l,3]dioxolyl, furyl, pyrazolyl, thienyl, 4-oxo-benzopyranyl, azetidinyl, imidazo[2,l-b]thiazolyl, pyridyl, imidazolyl, 2,3-dihydro-benzofuryl, or benzo[b]tbienyl;; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
cά π
ciχcrN»yy Cl
cχχcr»χya
dxx π-
oό
; or, in case of, a salt thereof.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
Ri represents (i) C Ciβ alkyl,
Cι-C1 alkyl substituted by substituent(s) independently selected from •halogen, •carbocyclyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro, ••C1-C3 alkyl, ••halogenated C C3 alkyl, (ii) C2-C3 alkenyl,
C2-C3 alkenyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •cyano, •nitro,
•d-Cs alkyl,
•Cι-C5 alkyl substituted by substituent(s) independently selected from ••halogen, ••oxo,
•C2-C3 alkenyl, •C1-C4 alkoxy,
•Cι-C4 alkoxy substituted by substituent(s) independently selected from ••halogen, ••heterocyclyl, ••halogenated heterocyclyl, •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••nitro,
•heterocyclyloxy,
•heterocyclyloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated CrC3 alkyl,
•Cι-C3 alkoxycarbonyl,
•mono- or di-Cι-C4 alkylamino,
•d-Cs alkylcarbonylamino,
•carbocyclic aryl diazo,
•carbocyclic aryl diazo substituted by mono- or di- C1-C3 alkylamino,
•Cι-C3 alkylsulfonyl,
•carbocyclic aryl,
(iv) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
• C1-C3 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
—C1-C3 alkyl,
•••halogenated C C3 alkyl,
•C1-C3 alkoxy,
•C!-C3 alkylcarbonylamino,
•carbocyclic arylsulfonyl,
•Ci-C3 alkoxycarbonyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••halogen,
••CrC3 alkyl,
••halogenated C1-C3 alkyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or C C3 alkyl;
R2b is C C4 alkyl, Cι-C4 alkyl substituted by substituent(s) independently selected from •hydroxy, •C1-Q3 alkoxy, •amino, •-NHBoc, •C3-C6 cycloalkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••C C3 alkyl, ••CrC3 alkoxy, ••-SO2NH2, •heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •C C3 alkyl, •CrC3 alkoxy, or a group of Formula IN; wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or Cχ-C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by Cι-C3 alkoxy;
L is selected from Formula N - XIX; wherein j is H or C C3 alkyl;
R5 is H, C1-C3 alkyl, or C1-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -S(O)2-; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl; heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, IH-pyrrolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, quinolyl, thiazolyl, or thienyl; halogen is fluoro, chloro, bromo, or iodo.
The following compounds are specially preffered;
or, in case of, a salt thereof.
Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Fomura II;
Ri is selected from H, -CO2 tBu, or -CO2Bn (Bn is a benzyl group);
R2 is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is a single bond; or a salt thereof.
One embodiment of the invention includes any compound of the invention which selectively binds an MCH receptor, such selective binding is preferably demonstrated by a Ki for one or more other GPCR(s), preferably NPY, being at least 10-fold greater than the Ki for any particular MCH receptor, preferable MCHRl .
As used herein, the term "alkyl" is intended to denote hydrocarbon compounds including straight chain and branched chain, including for example but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n- hexyl, and the like.
The term "alkoxy" is intended to denote substituents of the formula
-O-alkyl.
At various places in the present specification substituents of compounds of the invention are disclosed in groups. It is specifically intended that the invention include each and every individual subcombination of the members of such groups. G-protein coupled receptors (GPCRs) represent a major class of cell surface receptors with which many neurotransmitters interact to mediate their effects. GPCRs are predicted to have seven membrane-spanning domains and are coupled to their effectors via G-proteins linking receptor activation with intracellular biochemical sequelae such as stimulation of adenylyl cyclase. Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/modulator/regulator to alter a number of behavioral responses.
Mammalian MCH (19 amino acids) is highly conserved between rat, mouse, and human, exhibiting 100% amino acid identity, but its physiological roles are less clear. MCH
has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders. For reviews, see l. Baker, Int. Rev. Cytol. 126:1-47 (1991); 2. Baker, TEM 5:120-126 (1994); 3. Nahon, Critical Rev. inNeurobiol 221:221-262, (1994); 4. Knigge et al, Peptides 18(7): 1095-1097, (1996). The role of MCH in feeding or body weight regulation is supported by Qu et al., Nature 380:243-247, (1996), demonstrating that MCH is over expressed in the hypothalamus of ob/ob mice compared with ob/+mice, and that fasting further increased MCH mRNA in both obese and normal mice during fasting. MCH also stimulated feeding in normal rats when injected into the lateral ventricles as reported by Rossi et al., Endocrinology 138:351-355, (1997). MCH also has been reported to functionally antagonize the behavioral effects of α-MSH; see: Miller et al., Peptides 14:1-10, (1993); Gonzalez et al, Peptides 17:171-177, (1996); and Sanchez et al., Peptides 18:3933-396, (1997). In addition, stress has been shown to increase POMC mRNA levels while decreasing the MCH precursor preproMCH (ppMCH) mRNA levels; Presse et al., Endocrinology 131:1241-1250, (1992). Thus MCH may serve as an integrative neuropeptide involved in the reaction to stress, as well as in the regulation of feeding and sexual activity; Baker, Int. Rev. Cytol. 126:1-47, (1991); Knigge et al, Peptides 17:1063- 1073, (1996).
The localization and biological activities of MCH peptide suggest that the modulation of MCH receptor activity may be useful in a number of therapeutic applications. MCH is expressed in the lateral hypothalamus, a brain area implicated in the regulation of thirst and hunger: Grillon et al., Neuropeptides 31:131-136, (1997); recently orexins A and B, which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus; Sakurai et al, Cell 92:573-585 (1998). MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation; Herve and Fellmann, Neurpeptides 31 :237-242 (1997); after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA; Bahjaoui- Bouhaddi et al., Neuropeptides 24:251-258, (1994). Consistent with the ability of MCH to stimulate feeding in rats; Rossi et al., Endocrinology 138:351-355, (1997); is the observation that MCH mRNA levels are upregulated in the hypothalami of obese ob/ob mice; Qu et al., Nature 380:243-247, (1996); and decreased in the hypothalami of rats treated with leptin,
whose food intake and body weight gains are also decreased; Sahu, Endocrinology 139:795-798, (1998). MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis); Ludwig et al, Am. J. Physiol. Endocrinol. Metab. 274:E627-E633, (1998). Together these data suggest a role for endogenous MCH in the regulation of energy balance and response to stress, and provide a rationale for the development of specific compounds acting at MCH receptors for use in the treatment of obesity and stress-related disorders.
Accordingly, a MCH receptor antagonist is desirable for the prophylaxis or treatment of obesity or obesity related disorders. An obesity related disorder is a disorder that has been directly or indirectly associated to obesity, such as, type II diabetes, syndrome X, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis, insulin resistance associated with obesity and psoriasis, for treating diabetic complications and other diseases such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropafhy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders.
In species studied to date, a major portion of the neurons of the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subfhalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers; Bittencourt et al, J. Comp. Neural. 319:218-245, (1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it may be of some value to consider the involvement of this MCH system in movement disorders, such as Parkinson's disease and Huntingdon's Chorea in which extrapyramidal circuits are known to be involved.
Human genetic linkage studies have located authentic hMCH loci on chromosome 12 (12q23-24) and the variant hMCH loci on chromosome 5 (5ql2-13) (Pedeutour et al, 1994). Locus 12q23-24 coincides with a locus to which autosomal dominant cerebellar ataxiatype II (SCA2) has been mapped; Auburger et al, Cytogenet. Cell. Genet. 61 :252-256,
(1992); Twells et al., Cytogenet. Cell. Genet. 61:262-265, (1992). This disease comprises neurodegenerative disorders, including an olivopontocerebellar atrophy. Furthermore, the gene for Darier's disease, has been mapped to locus 12q23-24; Craddock et al., Hum. Mol. Genet. 2:1941-1943, (1993). Dariers' disease is characterized by abnormalities I keratinocyte adhesion and mental illnesses in some families. In view of the functional and neuroanatomical patterns of the MCH neural system in the rat and human brains, the MCH gene may represent a good candidate for SCA2 or Darier's disease. Interestingly, diseases with high social impact have been mapped to this locus. Indeed, the gene responsible for chronic or acute forms of spinal muscular atrophies has been assigned to chromosome 5ql2-13 using genetic linkage analysis; Melki et al., Nature (London) 344:767-768, (1990); Westbrook et al., Cytogenet. Cell. Genet. 61:225-231, (1992). Furthermore, independent lines of evidence support the assignment of a major schizophrenia locus to chromosome 5ql 1.2-13.3; Sherrington et al, Nature (London) 336:164-167, (1988); Bassett et al., Lancet 1:799-801, (1988); Gilliam et al., Genomics 5:940-944, (1989). The above studies suggest that MCH may play a role in neurodegenerative diseases and disorders of emotion.
Additional therapeutic applications for MCH-related compounds are suggested by the observed effects of MCH in other biological systems. For example, MCH may regulate reproductive functions in male and female rats. MCH transcripts and MCH peptide were found within germ cells in testes of adult rats, suggesting that MCH may participate in stem cell renewal and/or differentiation of early spermatocytes; Hervieu et al., Biology of Reduction 54:1161-1172, (1996). MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (NMN) stimulated sexual activity in female rats; Gonzalez et al., Peptides 17:171-177, (1996). In ovariectomized rats primed with estradiol, MCH stimulated luteinizing hormone (LH) release while anti-MCH antiserum inhibited LH release; Gonzalez et al., Neuroendocrinology 66:254-262, (1997). The zona incerta, which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the pre-ovulatory LH surge; MacKenzie et al., Neuroendocrinology 39:289-295, (1984). MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin. MCH analogues may also be useful in treating epilepsy. In the PTZ seizure model, injection of MCH prior to seizure induction prevented seizure activity in both rats and guinea pigs, suggesting that MCH-containing neurons may participate in the neural circuitry underlying PTZ-induced seizure; Knigge and Wagner,
Peptides 18: 1095-1097, (1997). MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats; McBride et al., Peptides 15:757-759, (1994); raising the possibility that MCH receptor antagonists may be beneficial for memory storage and/or retention. A possible role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. Finally, MCH may participate in the regulation of fluid intake. ICN infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume; Parkes, J. Νeuroendocrinol. 8:57-63, (1996). Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, the results indicate that MCH may be an important peptide involved in the central control of fluid homeostasis in mammals.
In a recent citation MCHRl antagonists surprisingly demonstrated their use as an anti-depressants and/or anti-anxiety agents. MCHRl antagonists have been reported to show antidepressant and anxiolytic activities in rodent models, such as, social interaction, forced swimming test and ultrasonic vocalization. Therefore, MCHRl antagonists could be useful to independently treat subjects with depression and/or anxiety. Also, MCHRl antagonists could be useful to treat subjects that suffer from depression and/or anxiety and obesity.
This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian MCH1 receptor which comprises administering to the subject an amount of a compound which is a mammalian MCH1 receptor antagonist effective to treat the abnormality. In separate embodiments, the abnormality is a regulation of a steroid or pituitary hormone disorder, an epinephrine release disorder, an anxiety disorder, genta gastrointestinal disorder, a cardiovascular disorder, an electrolyte balance disorder, hypertension, diabetes, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, a stress-related disorder, a fluid-balance disorder, a seizure disorder,
pain, psychotic behavior, morphine tolerance, opiate addiction or migraine.
Compositions of the invention may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980).
The compounds of the invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients which could facilitate the therapeutic effect of the compound.
Compounds of the present invention or a solvate or physiologically functional derivative thereof can be used as active ingredients in pharmaceutical compositions, specifically as a MCH receptor antagonists. By the term "active ingredient" is defined in the context of a "pharmaceutical composition" and shall mean a component of a pharmaceutical composition that provides the primary pharmaceutical benefit, as opposed to an "inactive ingredient" which would generally be recognized as providing no pharmaceutical benefit. The term "pharmaceutical composition" shall mean a composition comprising at one active ingredient and at least one ingredient that is not an active ingredient (for example and not limitation, a filler, dye, or a mechanism for slow release), whereby the composition is amenable to use for a specified, efficacious outcome in a mammal (for example, and not limitation, a human).
Pharmaceutical compositions, including, but not limited to, pharmaceutical compositions, comprising at least one compound of the present invention and/or an acceptable salt or solvate thereof (e.g., a pharmaceutically acceptable salt or solvate) as an active ingredient combined with at least one carrier or excipient (e.g., pharmaceutical carrier or excipient) may be used in the treatment of clinical conditions for which a MCH receptor antagonist is indicated. At least one compound of the present invention may be combined with the carrier in either solid or liquid form in a unit dose formulation. The pharmaceutical carrier must be compatible with the other ingredients in the composition and must be tolerated by the individual recipient. Other physiologically active ingredients may be incorporated into the pharmaceutical composition of the invention if desired, and if such ingredients are compatible with the other ingredients in the composition. Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if
necessary, forming the resulting mixture into a desired shape.
Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tabletting lubricants, and disintegrants may be used in tablets and capsules for oral administration. Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non- aqueous vehicles (including edible oils), preservatives, and flavorings and colorants may be added to the liquid preparations. Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.
It is noted that when the MCH receptor antagonists are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of MCH receptor antagonists for the treatment of obesity in domestic animals (e.g., cats and dogs), and MCH receptor antagonists in other domestic animals where no disease or disorder is evident (e.g., food-oriented animals such as cows, chickens, fish, etc.). Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.
Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water, in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, dioxane, or acetonitrile are preferred. For instance, when the compound (I) possesses an acidic functional group, it can form an inorganic salt such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, magnesium salt, barium salt, etc.), and an ammonium salt. When the compound (I) possesses a basic functional group, it can form an inorganic salt (e.g., hydrochloride, sulfate, phosphate, hydrobromate, etc.) or an organic salt (e.g., acetate, maleate, fumarate, succinate, methanesulfonate, p-toluenesulfonate, citrate, tartrate, etc.).
When a compound of the invention contains optical isomers, stereoisomers, regio isomers, rotational isomers, a single substance and a mixture of them are included as a
compound of the invention. For example, when a chemical formula is represented as showing no stereochemical designation(s), such as Formula IX, then all possible stereoisomer, optical isomers and mixtures thereof are considered within the scope of that formula. Accordingly, Formula XXII, specifically designates the cis relationship between the two amino groups on the cyclohexyl ring and therefore this formula is also fully embraced by Formula EX.
The novel substituted quinazolines of the present invention can be readily prepared according to a variety of synthetic manipulations, all of which would be familiar to one skilled in the art. Preferred methods for the preparation of compounds of the present invention include, but are not limited to, those described in Scheme 1-31.
The common intermediate (E) of the novel substituted quinazolines can be prepared as shown in Scheme 1. Commercially available lH,3H-quinazoline-2,4-dione (A) is converted to 2,4-dihalo-quinazoline (B) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCI3), phosphorous oxybromide (POBr3), or phosphorus pentachloride (PC15). The base includes a tertiary amine (preferably NN- diisopropylethylamine, etc.) or an aromatic amine (preferably NN-dimethylaniline, etc.). Reaction temperature ranges from about 100°C to 200°C, preferably about 140°C to 180°C. The halogen of 4-position of 2,4-dihalo-quinazoline (B) is selectively substituted by a primary or secondary amine (ΗΝR2aR2b, wherein R2a and R2b are as defined above) with or without a base in an inert solvent to provide the corresponding 4-substitued amino adduct (C). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2- propanol, or butanol, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane, etc.), or amide solvents (preferably NN-dimethylformamide or l-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 0°C to 200°C, preferably about 10°C to 150°C.
In turn, this is substituted by the mono-protected diamine (R^IΝ-A-ΝRsP, wherein R4HΝ-A-ΝR5P is as defined below, j and R5 are as defined above, and P is a protective group) with or without a base in an inert solvent to provide 2,4-disubstituted amino quinazoline (D). The base includes an alkali metal carbonate (preferably sodium carbonate
or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N- methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N- dimethylformamide or l-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50°C to 200°C, preferably about 80°C to 150°C. Also this reaction can be carried out under microwave conditions. Representative protecting groups suitable for a wide variety of synthetic transformations are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, second edition, John Wiley & Sons, New York, 1991, the disclosure of which is incorporated herein by reference in its entirety. The deprotection of the protective group leads to the common intermediate (E) of the novel substituted quinazolines.
Scheme 1
R4HN-A-NR5P IS,
,NR5P .NRSP ,NRSP
R4HN ^^ , R4H T ^-^ , R4HN
,NR5P /\ NR5P f/- Λ\NR5P
R4HN' ^^ , R4HN*^-^ , R4HN'
The conversion of the common intermediate (E) to the novel substituted quinazolines (F-H) of the present invention is outlined in Scheme 2.
The amine (E) is reacted with a sulfonyl chloride (RιSO2Cl) and a base in an inert solvent to provide the novel sulfonamide (F) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably NN-diisopropylefhylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), alcohol solvents (preferably 2-propanol, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about -20°C to 50°C, preferably about 0°C to 40°C.
The amine (E) is reacted with a carboxylic acid (RiCO2H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (G) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide hydrochloride (EDC'HCl), bromo-tris-pyrrolidino-phosnium hexafluorophosphate (PyBroP), O-(7-azabenzotriazol- 1 -yl)- 1,1,3,3 -tetramethyluronium hexafluorophosphate (HATU), or l-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably N,N-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBT), HOBT-6-carboxaamidomethyl polystyrene, or l-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about -20°C to 50°C, preferably about 0°C to 40°C.
Alternatively, the novel amide (G) of the present invention can be obtained by amidation reaction using an acid chloride (RiCOCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or
potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably N,N-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about -20°C to 50°C, preferably about 0°C to 40°C.
The novel amide (G) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amine (H) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-tert-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about -78°C to 200°C, preferably about 50°C to 120°C.
Alternatively, the novel amine (H) of the present invention can be obtained by reductive animation reaction using aldehyde (RiCHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about -20°C to 120°C, preferably about 0°C to 100°C. Also this reaction can be carried out under microwave conditions.
Scheme 2
F
(E) (G)
RiCHO
R-,S02CI reductive aminatioπ reduction sulfonamidation
(F) (H)
Compounds of Formula (I) can be prepared as shown in Scheme 3. The amine of commercially available trαrø-4-aminomemyl-cyclohexanecarboxylic acid is protected as tert-butyl carbamate. The carboxylic acid is reduced to the alcohol by sodium borohydride via the mixed acid anhydride. Tosylation of the alcohol with tosylchloride followed by azidation give the adide, which is converted to the amine by lithium aluminum hydride reduction. The coupling of the amine with the quinazoline core (C), which is synthesized in Scheme 1, gives 2,4-disubstituted amino quinazoline. The deprotection of Boc-group is achieved by an acid to give compounds of Formula (I).
Scheme 3
(I)
Compounds of Formula (K) can be prepared as shown in Scheme 4. Known cis-(4- aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester (J), synthesis of which is described in WO 01/72710, can be leaded to compounds of Formula (K) according to the method of scheme 3.
Scheme 4
1) phthalimide, DEAD, PP 3 2) NH2NH2-H20
3) (Boc)20
(J)
( )
Compounds of Formula (L) can be prepared as shown in Scheme 5. The amine of cw-[4-(2-amino-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester is protected as benzyl carbamate. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinazoline. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (L).
Scheme 5
(L)
Compounds of Formula (N) can be prepared as shown in Scheme 6. The amine of commercially available tr w-4-aminomethyl-cyclohexanecarboxylic acid is protected as tert-butyl carbamate. The carboxylic acid is transformed to benzyl carbamate (M) by curtius rearrangement. The deprotection of Z-group is acliieved by hydrogen reduction to give the amine. The amine is converted to compounds of Formula (N) according to the method of scheme 3.
Scheme 6
H°2C<^\ 1) (Boc)20 ZHN*y^ H2, Pd-C H2N«^
^
^' /NH2 2) DPPA; BnOH l\/) //NHBoc l/ NHBoc
(M)
(N)
Compounds of Formula (O) can be prepared from the compound of Formula (M), which is described in Scheme 6, as shown in Scheme 7. The compound of Formula (M) can be leaded to compounds of Formula (O) according to the method of scheme 5.
Scheme 7
(O)
Compounds of Formula (Q) can be prepared as shown in Scheme 8. [4- (Benzyloxycarbonylamino-methyl)-cyclohexyl] -carbamic acid tert-butyl ester (P), synthesis of which is described in WO 01/72710, can be leaded to compounds of Formula (Q) according to the method of scheme 5.
Scheme 8
1) SOCI2, eOH 1) phthalimide, DEAD, PPh3
2) (Boc)20 2) NH2NH2-H20
3) LiAIH4
3) ZCI
BocHN'
(P)
(Q)
Alternatively compounds of Formula (Q) can be prepared as shown in Scheme 9. The amine of commercially available cw-4-amino-cyclohexanecarboxylic acid is protected as tert-butyl carbamate. The carboxylic acid (R) is converted to the amide (S) by aqueous ammonia via the mixed acid anhydride. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinazoline. The amide is reduced to compounds of Formula (Q).
Scheme 9
C02H 2
(Boc)zO •C02H 1) ClC02Et ,CONH >-
2) NH4OH
H2N BocHN* BocHN'
(R) (S)
(Q)
Compounds of Formula (T) can be prepared from the compound of Formula (P), which is described in Scheme 8, as shown in Scheme 10. The compound of Formula (P) can be leaded to compounds of Formula (T) according to the method of scheme 6.
Scheme 10
(T)
Alternatively compounds of Formula (T) can be prepared as shown in Scheme 11. The amide (S), which is described in Scheme 9, is reduced to the amine. The amine can be leaded to compounds of Formula (T) according to the method of scheme 3.
Scheme 11
BocHN
(T)
Compounds of Formula (V) can be prepared as shown in Scheme 12. The mono- protection of commercially available
can be achieved by the method described in Synthetic communications, 20, 2559-2564 (1990). The conversion to compounds of Formula (V) can be accomplished according to the method of scheme 3.
Scheme 12
(V)
Compounds of Formula (X) can be prepared as shown in Scheme 13. The dicarboxylic acid of commercially available cts-cyclohexane-l^-dicarboxylic acid is transformed to dibenzyl carbamate by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the diamine. The mono-protection of the diamine can be achieved according to the method of scheme 12 to give the compound (W). The conversion to compounds of Formula (X) can be accomplished according to the method of scheme 3.
Scheme 13
(W)
(X)
Alternatively the compound of Formula (W) can be prepared as shown in Scheme 14. The carboxylic acid (R), which is described in Scheme 9, is transformed to benzyl carbamate by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the compound of Formula (W).
Scheme 14
BocHN
(R) (W)
Compounds of Formula (Y) can be prepared according to the method described in Scheme 12 by using commercially available 4-aminomethyl-benzylamine as a starting material (Scheme 15).
Scheme 15
NH, (Boc)2° NHBoc <C>
H2N H,N coupling
(Y)
Compounds of Formula (A') can be prepared as shown in Scheme 16. The mono- protection of commercially available 4-aminomethyl-phenylamine can be achieved by using an equimolecular amount of (Boc)2O to give mono-tert-butyl carbamate (Z). The amine can be leaded to compounds of Formula (A') according to the method of scheme 3.
Scheme 16
NH2 (Boc)20
H,N H2N
(Z)
(A')
Compounds of Formula (B') can be prepared from the compound of Formula (Z), which is described in Scheme 16, as shown in Scheme 17. The compound of Formula (Z) can be leaded to compounds of Formula (B5) according to the method of scheme 5.
Scheme 17
(B')
Compounds of Formula (C) can be prepared according to the method described in Scheme 3 by using commercially available (4-amino-phenyl)-carbamic acid tert-butyl ester as a starting material (Scheme 18).
Scheme 18
NHBoc (C)
H2N' coupling
(C)
Compounds of Formula (E') can be prepared as shown in Scheme 19. The selective protection of the secondary amine in the presence of the primary amine of commercially available 4-(aminomethyl)piperidin is achieved by the method described in Synthetic communications, 22, 2357-2360 (1992) to give the amine (D'). The amine is converted to compounds of Formula (E') according to the method of scheme 3.
Scheme 19
<E')
Compounds of Formula (F') can be prepared from the compound of Formula (D5), which is described in Scheme 19, as shown in Scheme 20. The compound of Formula (D') can be leaded to compounds of Formula (F') according to the method of Scheme 5.
Scheme 20
(F')
Compounds of Formula (G') can be prepared according to the method described in Scheme 5 by using commercially available l-benzyl-piperidin-4-ylamine as a starting material (Scheme 21).
Scheme 21
BnN
(G')
Compounds of Formula (H') can be prepared as shown in Scheme 22. The amine of commercially available l-benzyl-piperidin-4-ylamine is protected as tert-butyl carbamate. The deprotection of benzyl group is achieved by hydrogen reduction to give the amine. The amine can be leaded to compounds of Formula (H') according to the method of scheme 3.
Scheme 22
Compounds of Formula (F) can be prepared according to the method described in Scheme 3 by using commercially available pyrrolidin-3-yl-carbamic acid tert-butyl ester as a starting material (Scheme 23).
Scheme 23
Alternatively, the novel sulfonamide (F), the novel amide (G), and the novel amine (H) of the present invention are directly synthesized from the quinazoline core (C), which is synthesized in Scheme 1, as shown in Scheme 24. This coupling is performed with or without a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably NN-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or l-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50°C to 200°C, preferably about 80°C to 180°C. Also this reaction can be carried out under microwave conditions.
Scheme 24
(H)
Compounds of Formula (K') can be prepared as shown in Scheme 25. Commercially available tr rø-4-aminomethyl-cyclohexanecarboxylic acid is reacted with sulfonyl chloride (RιSO2Cl) to give the sulfonamide. The carboxylic acid is converted to the amide via the mixed acid anhydride. The amide is reduced to the amine (J') by borane reduction. The coupling of the amine with the quinazoline core (C), which is synthesized in Scheme 1, gives the novel sulfonamide (K') of the present invention.
Scheme 25
(K-)
Compounds of Formula (L') can be prepared from the compound of Formula (U), which is described in Scheme 12, as shown in Scheme 26. The amine (U) is reacted with sulfonyl chloride (R1SO2Cl) to give the sulfonamide. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives the novel sulfonamide (L') of the present invention.
Scheme 26
BocH
(U)
<L')
Compounds of Formula (M') can be prepared according to the method described in Scheme 26 by using the compound of Formula (D'), which is described in Scheme 19, as a starting material (Scheme 27).
Scheme 27
(iff)
Compounds of Formula (N') can be prepared according to the method described in Scheme 26 by using commercially available pyrrolidin-3-yl-carbamic acid tert-butyl ester as a starting material (Scheme 28).
Scheme 28
BocHN
(N')
Compounds of Formula (O) can be prepared from the compound of Formula (Z), which is described in Scheme 16, as shown in Scheme 29. The aniline (Z) is reacted with carboxylic acid (RiCO2H) to give the amide. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives the novel sulfonamide (O') of the present invention.
Scheme 29
BocHN acid
(0')
Compounds of Formula (P') can be prepared as shown in Scheme 30. The amine (W), which is synthesized in Scheme 13, is subjected to reductive amination by aldehyde (RiCHO). The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives the novel amine (P') of the present invention.
Scheme 30
( )
(P1)
Scheme 31 shows the preparation of compounds (Q') of the invention where Q of Formula I has Formula HI. The compound (J'), which is synthesized in Scheme 25, is reacted with ( 1 -tert-butoxycarbonylamino- 1 -trifluoromethanesulfonylimino-methyl)- carbamic acid tert-butyl ester. The deprotection of Boc-group is achieved by an acid to give the novel guanidine (Q') of the present invention.
Scheme 31
(J1)
(Q1)
Examples
The compounds of the invention and their synthesis are further illustrated by the following examples. The following examples are provided to further define the invention without, however, limiting the invention to the particulas of these examples. "Ambient temperature" as referred to in the following example is meant to indicate a temperature falling between 0 °C and 40 °C.
Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows :
*H NMR : proton nuclear magnetic resonance spectrum
AcOH : acetic acid
APCI : atmospheric pressure chemical ionization
(Boc)2O : di-tertiary-butyl dicarbonate
BuLi : butyl lithium
BuOH : butanol
CaCl2 : calcium chloride
CDC13 : deuterated chloroform
CF3CO2H : trifluoroacetic acid
CH2C12 : dichloromethane
CHCI3 : chloroform
CI : chemical ionization
CuCl : copper (I) chloride
D2O : deuterium oxide
DMAP : 4-dimethylaminopyridine
DMF : N,N-dimethylformamide
DMSO : dimethyl sulfoxide
EDC : l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
ESI : electrospray ionization
Et2O : diethyl ether
EtOAc : acetic acid ethyl ester
EtOH : ethanol
FAB : fast atom bombardment
H2SO4 : sulfuric acid
HATU : O-(7-azabenzotriazol-l-yl)-N,N5N'5N'-tetramethyluronium-
hexafluorophosphate HCHO : formaldehyde HCl : hydrogen chloride HO At : l-hydroxy-7-azabenzotriazole HOBt : 1-hydroxybenzotriazole HPLC : high performance liquid chromatography K2CO3 : potassium carbonate KHSO4 : potassium bisulfate Me2NH : dimethylamine MeNH2 : methylamine MeOH : methanol MgSO4 : magnesium sulfate Na2CO3 : sodium carbonate Na2SO4- 10H2O : sodium sulfate decahydrate NaBH(OAc)3 : sodium triacetoxyborohydride NaBH3CN : sodium cyanoborohydride NaBH4 : sodium borohydride NaHCO3 : sodium hydrogencarbonate NaN3 : sodium azide NaNO2 : sodium nitrate Pd(OH)2 : palladium hydroxide Pd/C : palladium carbon POCl3 : phosphoryl chloride PNP : poly(4-vinylpyridine)
PyBroP : bromo-tris-pyrrolidino phosphonium hexafluoro phosphate SOCl2 : thionyl chloride t-BuOH : tertiary butanol TFA : trifluoroacetic acid THF : tefrahydrofuran WSC : water solubule carbodiimide ZC1 : benzyloxycarbonyl chloride s : singlet
d : doublet t : triplet q : qualtet dd : doublet doublet dt : doublet triplet ddd : doublet doublet doublet brs : broad singlet m : multiplet
J : coupling constant
Hz : Hertz
The analytical condition of high performance liquid chromatography is as follows: Solvent A: 0.050% TFA in water Solvent B: 0.035% TFA in acetonitrile 5 - 100% B over 5 min, flow rate 3.5 ml/min
Example 1
^rαM5-4-Bromo-N-{4-[(4-dimethylamino-qumazolin-2-ylamino)-methyl]- cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of 2,4-dichloro-quinazoline.
To a suspension of lH-quinazoline-2,4-dione (150 g, 925 mmol) in POCl3 (549 mL, 5.89 mol) was added dimethyl-phenyl-amine (123 mL, 962 mmol). The mixture was stirred at reflux for 7 hr and concentrated. The solution was poured into ice water, and the aqueous layer was extracted with CΗC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel,
50% CHC13 in hexane to 10% EtOAc in CHC13) to give 2,4-dichloro-quinazoline (159g, 86%) as a pale yellow solid.
CI MS m/e 199, M+ ; Η NMR (300 MHz, CDC13) δ 8.27 (dt, J= 8.3, 1.1 Hz, 1 H), 7.95- 8.04 (m, 2 H), 7.71-7.81 (m, 1 H).
Ste B: Synthesis of (2-chIoro-quinazolin-4-yl)-dimethyϊ-amine.
A solution of 2,4-dichloro-quinazoline (102 g, 530 mmol) in THF (1.2 L) was cooled to 4 °C and 50% aqueous Me2NH (139 mL, 1.33 mol) was added. The mixture was stirred at ambient temperature for 80 min. The solution was alkalized with saturated aqueous NaHCO3 (pH = 9), and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated. The residue was suspended in 50% Et2O in hexane (250 mL) and stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with 50% Et2O in hexane, and dried at 80 °C to give (2-chloro-quinazolin-4-yl)-dimethyl-amine (104 g, 94%) as a pale yellow solid.
ESI MS m/e 207, M+ ; Η NMR (300 MHz, CDC13) δ 8.00 (d, J= 8.4 Hz, 1 H), 7.73-7.78 (m, 2 H), 7.68 (ddd, J= 8.4, 6.9, 1.4 Hz, 1 H), 3.41 (s, 6 H).
Step C: Synthesis of frø«s-4-(fert'-butoxycarbonylamino-methyl)- cyclohexanecarboxylic acid.
To a solution of tr w-4-aminomethyl-cyclohexanecarboxylic acid (150 g, 954 mmol) in 1.32 M aqueous sodium hydroxide (750 mL) were added t-BuOH (1680 mL) and (Boc)2O (215 g, 985 mmol). The reaction mixture was stirred at ambient temperature for 18 hr. To the reaction mixture was added H2O (2.8 L), and cooled at 5 °C. The aqueous layer was acidified with saturated aqueous KHSO4 (pH = 3), extracted with EtOAc (three times). The combined organic layer was washed with saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered, concentrated and dried under reduced pressure to give trα«5-4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid (165 g, 67%) as a white solid.
ESI MS m/e 280, M + Na+ ; Η NMR (300 MHz, CDC13) δ 4.60 (brs, 1 H), 2.98 (t, J= 6.3 Hz, 2 H), 2.19-2.33 (m, 1 H), 1.99-2.11 (m, 2 H), 1.77-1.90 (m, 2 H), 1.44 (s, 9 H), 1.34- 1.52 (m, 3 H), 0.86-1.05 (m, 2 H).
Step D: Synthesis of j'ra«5-(4-hydroxymethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester.
A suspension of trαrø-4-(tert-butoxycarbonylamino-methyl)-cyclohexane- carboxylic acid (155 g, 603 mmol) in CH2C12 (1.35 L) was cooled at -65 °C and triethylamine (126 mL, 904 mmol) and a solution of ethyl chloro formate (58 mL, 751 mmol) in CH2C12 (200 mL) were added below -60 °C. The reaction mixture was stirred at 0 °C for 50 min. The mixture was acidified with saturated aqueous KHSO4 (pH = 3), and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was washed with saturated aqueous Na2CO3 and brine, dried over MgSO4, filtered, and concentrated to give a colorless oil. A solution of the above oil in THF (1.5 L) was cooled at -65 °C and NaBH4 (26.6 g, 703 mmol) and MeOH (45 mL) were added. The mixture was stirred at -40 °C for 25 min, and stirred at 4 °C for 3 hr. The mixture was acidified with saturated aqueous KHSO4 (pH = 3), and the aqueous layer was extracted with EtOAc (three times). The combined organic layer was washed with saturated aqueous Na2CO3 and brine, dried over MgSO4, filtered, and concentrated, and purified by flash chromatography (silica gel, 17% MeOH in CHC13) to give trα«5,-(4-hydroxymethyl-cyclohexylmethyl)- carbamic acid tert-butyl ester (123 g, 84%) as a white solid.
ESI MS m/e 266, M + Na+ ; Η NMR (300 MHz, CDC13) δ 4.59 (brs, 1 H), 3.46 (d, J= 6.4 Hz, 2 H), 2.98 (t, J= 6.3 Hz, 2 H), 1.75-1.94 (m, 4 H), 1.45 (s, 9 H), 1.24-1.70 (m, 3 H), 0.81-1.12 (m, 4 H).
Step E: Synthesis of *røMs-(4-azidomethyI-cyclohexylmethyl)-carbamic acid tert-butyl ester.
A solution of trαrø-(4-hydroxymethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester (123 g, 505 mmol) in pyridine (1 L) was cooled at 4 °C and a solution of p- toluenesulfonyl chloride (125 g, 657 mmol) in pyridine (200 ml) was added below 10 °C. The mixture was stirred at ambient temperature for 15 hr and concentrated. After dissolution with EtOAc and H2O, the organic layer was separated. The aqueous layer was extracted with EtOAc (three times), the combined organic layer was washed with H2O, dried over MgSO4, filtered, and concentrated to give a pale yellow oil. To a solution of the above oil in DMF (1.6 L) was added NaN3 (98.8 g, 1.52 mol). The reaction mixture was stirred at ambient temperature for 14 hr and concentrated. After dissolution with CHC13 and saturated aqueous NaHCO3, the organic layer was separated. The aqueous layer was
extracted with CHC13 (three times), the combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 17% EtOAc in hexane) to give tr rø-(4-azidomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester (124 g, 91%>) as a colorless oil.
ESI MS m/e 291, M + Na+ ; Η NMR (300 MHz, CDCLJ δ 4.59 (brs, 1 H), 3.13 (d, J= 6.5 Hz, 2 H), 2.98 (t, J= 6.4 Hz, 2 H), 1.70-1.90 (m, 4 H), 1.44 (s, 9 H), 1.25-1.65 (m, 2 H), 0.87-1.07 (m, 4 H).
Step F: Synthesis of teα«s-(4-aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester.
A suspension of lithium aluminum hydride (2.76 g, 72.6 mmol) in THF (225 mL) was cooled at 0 °C and a solution of trαrø,-(4-azidomemyl-cyclohexylmethyl)-carbamic acid tert-butyl ester (15.0 g, 55.9 mmol) in THF (75 mL) was added over 1 hr. The reaction mixture was stirred at ambient temperature for 6 hr. The reaction was quenched with Na2SO4* 10H2O, filtered through a pad of celite, and concentrated. The residue was purified by flash chromatography (silica gel, 50% MeOH in CHC13) to give trans-(4- aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester (12.3 g, 91%) as a pale yellow oil.
ESI MS m/e 243, M + If ; Η NMR (300 MHz, CDC13) δ 4.60 (brs, 1 H), 2.97 (t, J= 6.3 Hz, 2 H), 2.53 (d, J= 6.4 Hz, 2 H), 1.70-1.92 (m, 4 H), 1.44 (s, 9 H), 1.08-1.54 (m, 4 H), 0.81-1.02 (m, 4 H).
Step G: Synthesis of te «5-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-carbamic acid tert-butyl ester.
A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine (15.2 g, 73.3 mmol) and trαrø-(4-aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester (14.8 g, 61.0 mmol) in 2-propanol (80 mL) was stirred at reflux for 4 days, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give t?- rø-{4-[(4- dimemylammo-qumazolm-2-ylamino)-memyl]-cyclohexylme yl}-carbamic acid tert- butyl ester (20.4 g, 81%) as a pale yellow solid.
ESI MS m/e 414, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 8.2 Hz, 1 H), 7.40- 7.52 (m, 2 H), 6.98-7.06 (m, 1 H), 4.93 (brs, 1 H), 4.59 (brs, 1 H), 3.35 (t, J= 62 Hz, 2 H), 3.26 (s, 6 H), 2.97 (t, J= 6.2 Hz, 2H), 1.72-1.95 (m, 4H), 1.44 (s, 9H), 1.30-1.62 (m, 2H), 0.84-1.12 (m, 4H).
Step H: Synthesis of fra«5-4-bromo-N-{4-[(4-dimethylamino-quinazoIin-2- ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride.
To a suspension of tr «5,-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]cyclohexylmethyl}-carbamic acid tert-butyl ester (3.84 g, 9.28 mmol) in EtOAc (50 mL) was added 4 M hydrogen chloride in EtOAc (38 mL). The mixture was stirred at ambient temperature for 40 min and concentrated to give a white solid. To a suspension of the solid in CH2C12 (50 mL) was added diisopropylethylamine (6.46 mL, 37.1 mmol). The mixture was cooled at 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (3.31 g, 9.75 mmol) in CH2C12 (10 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give trfl«j,-4-bromo-N-{4-[(4- dimethylamino-qumazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy- benzenesulfonamide (3.45 g, 60%) as a pale yellow solid.
ESI MS m/e 616, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 7.89 (d, J= 8.9 Hz, 1 H), 7.81 (d, J= 1.6 Hz, 1 H), 7.35-7.61 (m, 4 H), 7.02 (t, J= 6.8 Hz, 1 H), 4.96 (brs, 1 H), 3.35 (t, J = 6.1 Hz, 2 H), 3.26 (s, 6 H), 2.79 (d, J= 6.7 Hz, 2 H), 1.32-1.98 (m, 6 H), 0.72-1.12 (m, 4 H).
Example 2
-,ra«5-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-yIamino)-methyl]-
cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride
Step A: Synthesis of teα«s-4-bromo-N-{4-[(4-dimethylamino-quinazoIin-2- ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfona ide hydrochloride.
A solution of trα«5,-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide obtained step H of example 1 (3.45 g, 5.61 mmol) in EtOAc (100 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (1.66 mL) was added. The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. The solid was recrystallized from 16% EtOH in Et2O, and dried under reduced pressure to give traw-4-bromo-N-{4- [(4-dimemylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2- trifluoromethoxy-benzenesulfonamide hydrochloride (2.76g, 75%) as a white solid. ESI MS m/e 616, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 13.50 (brs, IH), 8.42 (t, J = 6.0 Hz, 1 H), 7.86-7.94 (m, 2 H), 7.51-7.68 (m, 4H), 7.21-7.28 (m, 1 H), 4.83 (d, J= 6.4 Hz, 1 H), 3.51 (s, 6 H), 3.35 (t, J = 6.0 Hz, 2H), 2.78 (t, J = 6.4 Hz, 2H), 1.73-1.95 (m, 4H), 1.35-1.65 (m, 2H), 0.81-1.12 (m, 4H).
Example 3
frαw5-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylanιino)-methyl]-cyclohexyl}- 2-trifluoromethoxy-benzenesuIfonamide
Step A: Synthesis of tfrα«s-[4-(tert-butoxycarbonylammo-methyl)-cyclohexyl]- carbamic acid benzyl ester.
To a suspension of trαrø-4-ammomethyl-cyclohexanecarboxylic acid (15.0 g, 95.4 mmol) in CHC13 (150 mL) were added 1 M aqueous sodium hydroxide (150 mL) and (Boc)2O (21.9 g, 100 mmol) successively. The reaction mixture was stirred at ambient
temperature for 15 hr, and partitioned between CHC13 and water. The aqueous layer was acidified with saturated aqueous KHSO4 (pH = 3), extracted with CHC13 (three times). The combined organic layer was washed with brine, dried over MgSO4, filtered, and concentrated to give a white solid. To a suspension of the above solid in benzene (75 mL) were added phosphorazidic acid diphenyl ester (16.2 g, 58.9 mmol) and triethylamine (5.94 g, 58.7 mmol). The reaction mixture was stirred at reflux for 3 hr (Caution! Vigorous exothermic reaction). Benzyl alcohol (6.65 g, 61.5 mmol) was added, the reaction mixture was stirred at reflux for 24 hr, concentrated. After dissolution with EtOAc and H2O, the organic layer was separated. The aqueous layer was extracted with EtOAc (twice), the combined organic layer was washed with 1 M aqueous KHSO4, saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. A suspension of the above solid in Et2O was stirred at ambient temperature for 30 min and filtered. The filtrate was washed with l^O and dried under reduced pressure to give trans- [4-(tert-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester (17.4 g, 50%) as a white solid.
ESI MS m/e 385, M + Na+ ; Η NMR (300 MHz, CDC13) δ 7.22-7.41 (m, 5 H), 5.09 (s, 2 H), 4.20-4.68 (m, 2 H), 3.23-3.60 (m, 1 H), 2.96 (t, 2 H, J= 6.4 Hz), 1.62-2.18 (m, 4 H), 1.44 (s, 9 H), 1.30-1.60 (m, 1 H), 0.90-1.23 (m, 4 H).
Step B: Synthesis of *røns-(4-aminomethyl-cyclohexyl)-carbamic acid benzyl ester hydrochloride.
To a suspension of tr w-[4-(tert-butoxycarbonylamino-methyl)-cyclohexyl]- carbamic acid benzyl ester (4.00 g, 11.0 mmol) in EtOAc (40 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). To the reaction mixture was added CHC13 (10 mL) and the mixture was stirred at ambient temperature for 3 hr. To the reaction mixture was 4 M hydrogen chloride in EtOAc (20 mL) and the mixture was stirred at ambient temperature for 1.5 hr, filtered, washed with EtOAc, and dried under reduced pressure to give trαrø-(4-aminomethyl-cyclohexyl)-carbamic acid benzyl ester hydrochloride (2.96 g, 90%) as a white solid.
ESI MS m/e 263, M (free) + H+ ; Η NMR (300 MHz, DMSO-d6) δ 8.12 (brs, 3 H), 7.25- 7.40 (m, 5 H), 7.21 (d, 1 H, J= 7.8 Hz), 5.00 (s, 2 H), 3.17-3.30 (m, 1 H), 2.62 (d, 2 H, J= 7.0 Hz), 1.64-1.88 (m, 4 H), 1.42-1.60 (m, 1 H), 0.90-1.21 (m, 4 H).
Step C: Synthesis of teff«s-{4-[(4-dimethylamino-quinazolin-2-yIamino)-methyl]- cyclohexyI}-carbamic acid benzyl ester .
A mixture of (2-chloro-quinazolin-4-yl)-dimefhyl-amine (1.50 g, 7.22 mmol) and tr rø-(4-ammomethyl-cyclohexyl)-carbamic acid benzyl ester hydrochloride (2.59 g, 8.67 mmol) in 2-propanol (15 mL) was stirred at reflux for 8 days and dissolved in CHC13 and MeOH. The mixture was poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography ( H-silica gel, 33% EtOAc in hexane) to give trΩrø-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexyl} -carbamic acid benzyl ester (1.20 g, 38%) as a pale yellow solid. ESI MS m/e 434, M + ET ; Η NMR (300 MHz, CDCL δ 7.76-7.82 (m, 1 H), 7.40-7.50 (m, 2 H), 7.25-7.40 (m, 5 H), 6.95-7.04 (m, 1 H), 5.08 (s, 2 H) , 4.82-5.05 (m, 1 H) , 4.40-4.70 (m, 1 H), 3.40-3.60 (m, 1 H), 3.35 (t, 2 H, J= 6.3 Hz), 3.26 (s, 6 H), 1.96-2.18 (m, 2 H), 1.80-1.96 (m, 2 H), 1.45-1.61 (m, 1 H), 1.00-1.20 (m, 4 H).
Step D: Synthesis of teα«s-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamide.
To a suspension of trβrø-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexyl} -carbamic acid benzyl ester (500 mg, 1.15 mmol) in MeOH (5 mL) was added 5% Pd/C (50 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 2 hr, at 50 °C for 8 hr, and at ambient temperature for 10.5 hr, filtered, and concentrated to give a colorless oil. To a solution of the above oil in CH2C12 (5 mL) was added diisopropylethylamine (420 μL, 2.41 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromefhoxy-benzenesulfonyl chloride (431 mg, 1.27 mmol) in CH2C12 (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% to 50% EtOAc in hexane) to give tτ"α/ϊ5-4-bromo-N-{4-[(4-dimemylamino-quinazolin-2-ylamino)- methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamide (560 mg, 81%) as a pale yellow solid.
ESI MS m/e 602, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 7.90 (d, 1 H, J= 8.9 Hz), 7.80
(dd, 1 H, J= 8.4, 0.9 Hz), 7.38-7.58 (m, 4 H), 7.01 (ddd, 1 H, J= 8.4, 6.7, 1.6 Hz), 4.85- 5.04 (m, 1 H), 3.31 (t, 2 H, J= 6.3 Hz), 3.24 (s, 6 H), 3.07-3.20 (m, 1 H), 1.70-1.90 (m, 4 H), 1.42-1.58 (m, 1 H) , 0.90-1.28 (m, 4 H).
Example 4
iV2-[l-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]--V,N!'- dimethyl-quinazoline-2,4-diamine
Step A: Synthesis of N2-(l-benzyl-piperidin-4-yl)-iV',i\^-diπιethyl-quinazoIine-2,4- diamine.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 362, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.80 (d, J= 7.6 Hz, 1 H), 7.20- 7.52 (m, 7 H), 6.97-7.05 (m, 1 H) , 4.74-4.90 (m, 1 H) , 3.90-4.05 (m, 1 H), 3.53 (s, 2 H), 3.26 (s, 6 H), 2.78-2.90 (m, 2 H), 2.02-2.24 (m, 4 H), 1.48-1.62 (m, 2 H).
Step B: Synthesis of N2-[l-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)- piperidin-4-yl]-N',iV'-dinιethyl-quinazoline-2,4-diamine.
To a solution of N2-(l-benzyl-piperidin-4-yl)-N/,N-dimethyl-quinazoline-2,4- diamine (500 mg, 1.38 mmol) in MeOH (5 mL) was added 20% Pd(OH)2 (100 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 hr, at 50 °C for 8 hr, at ambient temperature for 16.5 hr, filtered through a pad of celite, and concentrated. To a solution of the residue in CH2C12 (5 mL) was added diisopropylethylamine (510 μL, 2.93 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (493 mg, 1.45 mmol) in CH2C12 (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 2 hr. The reaction was quenched with saturated aqueous ΝaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4,
filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give N2-[l-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]- N/,N/-dimethyl-quinazoline-2,4-diamine (339 mg, 43%) as a pale yellow solid. ESI MS m/e 596, M + Νa+ ; Η NMR (300 MHz, CDCL δ 7.87 (d, J= 8.2 Hz, 1 H), 7.81 (dd, J= 8.3, 1.0 Hz, 1 H), 7.36-7.61 (m, 4 H), 7.04 (ddd, J= 8.3, 6.8, 1.4 Hz, 1 H), 4.77 (d, J= 7.8 Hz, 1 H), 3.97-4.14 (m, 1 H), 3.68-3.86 (m, 2 H), 3.25 (s, 6 H), 2.87-3.01 (m, 2 H), 2.10-2.23 (m, 2 H), 1.51-1.70 (m, 2 H).
Example 5
teα/i5-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of *røw.s-(4-amino-cycIohexyl)-carbamic acid tert-butyl ester.
To a solution of tr rø-cyclohexane-l,4-diamine (15.0 g, 131 mmol) in 1,4-dioxane (85 mL) was added (Boc)2O (3.61 g, 16.5 mmol) dropwise over 4 hr. The mixture was stirred at ambient temperature for 19 hr and concentrated. To the residue was added H2O and the insoluble material was removed by filtration. The filtrate was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated to give trαrø-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (3.15 g, 11% based on diamine, 89% based on (Boc)2O ) as a white solid. ESI MS m/e 215, M + H+ ; Η NMR (300 MHz, CDCLJ δ 4.43 (brs, 1 H), 3.36 (brs, 1 H), 2.57-2.70 (m, 1 H), 1.78-2.04 (m, 4 H), 1.44 (s, 9 H), 1.05-1.38 (m, 4 H).
Step B: Synthesis of /rα/ts-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyI]- carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 408, M + Na+ ; 1H NMR (300 MHz, CDCL δ 7.80 (d , J= 8.2 Hz, 1 H), 7.39-
7.52 (m, 2 H), 7.02 (ddd, 1 H, J= 8.3, 6.3, 1.9 Hz, 1 H), 4.68-4.78 (m, 1 H), 4.43 (brs, 1 H), 3.89 (brs, 1 H), 3.46 (brs, 1 H), 3.25 (s, 6 H), 2.15-2.24 (m, 2 H), 1.97-2.10 (m, 2 H), 1.45 (s, 9 H), 1.21-1.35 (m, 4 H).
Step C: Synthesis of /rα«5-4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide.
To a solution of tτα« ,-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]- carbamic acid tert-butyl ester (500 mg, 1.30 mmol) in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. To a suspension of the above solid in CH2C12 (7 mL) was added diisopropylethylamine (905 μL, 5.20 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (462 mg, 1.36 mmol) in CH2C12 (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. To the reaction mixture was added a solution of 4-bromo-2-trifluoromethoxy- benzenesulfonyl chloride (88 mg, 0.26 mmol) in CH2C12 (0.5 mL) and the mixture was stirred at 4 °C for 1 hr. To the reaction mixture was added diisopropylethylamine (230 μL, 1.32 mmol) and the mixture was stirred at 4 °C for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give trα« ,-4-bromo-N-[4- (4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy- benzenesulfonamid (339 mg, 44%) as a white solid.
ESI MS m/e 588, M + H+ ; Η MR (300 MHz, CDC13) δ 7.92 (d , J= 8.9 Hz, 1 H), 7.80 (dd , J= 8.3, 0.7 Hz, 1 H), 7.37-7.59 (m, 4 H), 6.99-7.06 (m, 1 H), 4.64-4.75 (m, 1 H), 3.78-3.94 (m, 1 H), 3.17-3.30 (m, 7 H), 2.09-2.20 (m, 2 H), 1.85-1.97 (m, 2 H), 1.12-1.47 (m, 4 H).
Example 6
teα«5,-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-yIamino)-cycIohexylmethyI]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of α«s-(4-amino-cycIohexylmethyl)-carbamic acid tert-butyl ester.
To a suspension of tr n>s-[4-(tert-butoxycarbonylamino-methyl)-cyclohexyl]- carbamic acid benzyl ester (4.00 g, 11.0 mmol) in MeOH (40 mL) was added 5% Pd/C (400 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1 hr, filtered through a pad of celite, and concentrated to give a white solid. A suspension of the above solid in hexane (15 mL) was stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with hexane, dried under reduced pressure to give trαra-(4-amino-cyclohexylmethyl)-carbamic acid tert-butyl ester (2.52 g, 100%) as a white solid.
ESI MS m/e 229, M + H1"; Η NMR (300 MHz, CDCLJ δ 4.56-4.88 (m, 1 H), 3.00 (t, J= 6.5 Hz, 2 H), 2.54-2.65 (m, 1 H), 1.70-1.94 (m, 4 H), 1.44 (s, 9 H), 1.18-1.50 (m, 1 H), 0.92-1.15 (m, 4 H).
Step B: Synthesis of teα«5-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl] -carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 422, M + Na+ ; Η NMR (300 MHz, CDCLJ 7.81 (d, J= 7.9 Hz, 1 H), 7.38- 7.52 (m, 2 H) , 6.96-7.07 (m, 1 H), 4.55-4.84 (m, 2 H), 3.75-3.97 (m, 1 H), 3.26 (s, 6 H), 3.01 (t, J= 6.4 Hz, 2 H), 2.15-2.30 (m, 2 H), 1.75-1.88 (m, 2 H), 1.45 (s, 9 H), 1.35-1.54 (m, I H), 1.00-1.30 (m, 4 H).
Step C: Synthesis of teβ«5-4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide.
To a suspension of tr w-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl] -carbamic acid tert-butyl ester (500 mg, 1.25 mmol) in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. To a suspension of the above solid in CH2C12 (7 mL) was added diisopropylethylamine (905 μL, 5.20 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (446 mg, 1.31 mmol) in CH2C12 (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. To the reaction mixture was added a solution of 4- bromo-2-trifluoromethoxy-benzenesulfonyl chloride (85mg, 0.25 mmol) in CH2C12 (0.5 mL) and the mixture was stirred at 4 °C for 1 hr. To the reaction mixture was added diisopropylethylamine (220 μL, 1.26 mmol) and the mixture was stirred at 4 °C for 1 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give trα«5-4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide (624 mg, 83%) as a pale yellow solid.
ESI MS m/e 602, M + H+ ; Η ΝMR (300 MHz, CDCLJ δ 7.89 (d, J= 8.9 Hz, 1 H), 7.80 (d, J= 8.5 Hz, 1 H), 7.39-7.60 (m, 4 H) , 7.04 (ddd, J= 8.2, 6.8, 1.6 Hz, 1 H), 3.71-3.92 (m, 1 H), 3.30 (s, 6 H), 2.85 (d, J= 6.5 Hz, 2 H), 2.10-2.22 (m, 2 H), 1.70-1.86 (m, 2 H), 1.37- 1.53 (m, 1 H), 0.98-1.32 (m, 4 H).
Example 7
N-[l-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-ylmethyl]-N ^\r4- dimethyl-quinazoline-2,4-diamine
Step A: Synthesis of 4-aminomethyl-piperidine-l-carboxylic acid tert-butyl ester.
To a solution of C-piperidin-4-yl-methylamine (15.0 g, 131 mmol) in toluene (165 mL) was added benzaldehyde (13.9 g, 131 mmol) and the mixture was stirred at reflux with a Dean-Stark trap under N2 atmosphere for 3 hr, and cooled on an ice-bath. To the reaction mixture was added (Boc)2O (31.5 g, 144 mmol) dropwise over 15 min. The mixture was stirred at ambient temperature for 2.5 days, and concentrated. To the residue was added 1 M aqueous KHSO4 and the mixture was stirred at ambient temperature for 7 hr, the aqueous layer was washed with EtjO (twice), alkalized with sodium hydroxide, and extracted with CHC13 (five times). The combined organic layer was dried over MgSO4, filtered, concentrated. The precipitate was suspended in hexane (10 mL) and the suspension was stirred at ambient temperature for 10 min. The solid was collected by filtration and dried under reduced pressure to give 4-aminomethyl-piperidine- 1-carboxylic acid tert-butyl ester (25.8 g, 92%) as a white solid.
ESI MS m/e 215, M + H+ ; Η NMR (300 MHz, CDC13) δ 3.85-4.22 (m, 2 H), 2.90 (d, J= 6.8 Hz, 2 H), 2.50-2.80 (m, 2 H), 1.70-2.02 (m, 3 H), 1.45 (s, 9 H), 1.10-1.28 (m, 2 H).
Step B: Synthesis of 4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- piperidine-1-carboxylic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 386, M + HT ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 8.4 Hz, 1 H), 7.41- 7.53 (m, 2 H), 6.99-7.06 (m, 1 H), 5.16 (brs, 1 H), 4.00-4.20 (m, 2 H), 3.41 (t, J= 6.1 Hz, 2 H), 3.26 (s, 6 H), 2.60-2.77 (m, 2 H), 1.67-1.84 (m, 3 H), 1.45 (s, 9 H), 1.11-1.28 (m, 2 H).
Step C: Synthesis of N2-[l-(4-bromo-2-trifluoromethoxy-benzenesulfonyI)- piperidin-4-ylmethyl]-7Y',Λ^-dimethyI-quinazoline-2,4-diamine.
To a suspension of 4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- piperidine- 1-carboxylic acid tert-butyl ester (500 mg, 1.30 mmol) in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. To a suspension of the above solid in CH2C12 (5 mL) was added diisopropylethylamine (480 μL, 2.76 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (462 mg, 1.36 mmol) in CH2C12 (2 mL) was added below 5 °C. The reaction
mixture was stirred at 4 °C for 3 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 14% to 20% EtOAc in hexane) to give N2-[l-(4-bromo-2- trifluoromethoxy-benzenesulfonyl)-piperidin-4-ylmethyl]-N",N/-dimethyl-quinazoline-2,4- diamine (420 mg, 55%) as a yellow solid.
ESI MS m/e 588, M + Ε ; Η ΝMR (300 MHz, CDCLJ δ 7.85 (d, J= 8.9 Hz, 1 H), 7.81 (dd, J= 8.7, 0.9 Hz, 1 H), 7.40-7.56 (m, 4 H), 7.04 (ddd, J- 8.2, 6.7, 1.6 Hz, 1 H), 5.10- 5.46 (brs, 1 H), 3.85 (d, J= 12.4 Hz, 2 H), 3.40 (t, J= 6.4 Hz, 2 H), 3.27 (s, 6 H), 2.56- 2.67 (m, 2 H), 1.64-1.91 (m, 3 H), 1.23-1.43 (m, 2 H).
Example 8
4-Bromo-N-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of 4-(benzyloxycarbonylamino-methyl)-piperidine-l-carboxylic acid tert-butyl ester.
To a solution of 4-aminomethyl-piperidine- 1-carboxylic acid tert-butyl ester (7.00 g, 32.7 mmol) in CHCL, (70 mL) was added triethylamine (3.64 g, 36.0 mmol). The resulting solution was cooled to 4 °C and ZC1 (6.13 g, 35.9 mmol) was added below 8 °C over 15 min. The reaction mixture was stirred at ambient temperature for 18 hr, and poured into saturated aqueous NaHCO3. The aqueous layer was extracted with CHC13 (three times), dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 33% to 50% EtOAc in hexane) to give 4-(benzyloxycarbonylamino-methyl)- piperidine- 1-carboxylic acid tert-butyl ester (10.7 g, 94%) as a colorless oil. ESI MS m/e 371, M + Na+ ; Η NMR (300 MHz, CDC13) δ 7.26-7.37 (m, 5 H), 5.09 (s, 2 H), 4.84-5.01 (m, 1 H), 3.95-4.22 (m, 2 H), 2.98-3.16 (m, 2 H), 2.66 (t, J= 12.4 Hz, 2 H),
1.58-1.72 (m, 3 H), 1.45 (s, 9 H), 0.98-1.18 (m, 2 H).
Step B: Synthesis of piperidin-4-ylmethyl-carbamic acid benzyl ester hydrochloride.
A solution of 4-(benzyloxycarbonylamino-methyl)-piperidine- 1-carboxylic acid tert-butyl ester (10.2 g, 29.3 mmol) in EtOAc (100 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (100 mL) was added. The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in hexane (30 mL) and the mixture was stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with hexane, and dried under reduced pressure to give piperidin-4- ylmethyl-carbamic acid benzyl ester hydrochloride (7.24 g, 87%) as a white solid. ESI MS m/e 271, M (free) + Na+; Η NMR (300 MHz, DMSO-d6) δ 9.10 (brs, 2 H), 7.20- 7.50 (m, 6 H), 5.02 (s, 2 H), 3.15-3.28 (m, 2 H), 2.68-3.02 (m, 4 H), 1.56-1.82 (m, 3 H), 1.20-1.52 (m, 2 H).
Step C: Synthesis of [l-(4-dimethylamino-quinazolm-2-yl)-piperidin-4-ylmethyl]- carbamic acid benzyl ester.
Using the procedure for the step C of example 3, the title compound was obtained. ESI MS m/e 420, M + H+ ; Η NMR (300 MHz, CDCLJ δ 7.78 (d, J= 8.2 Hz, 1 H), 7.21- 7.49 (m, 7 H), 6.95-7.04 (m, 1 H), 5.06-5.17 (m, 2 H), 4.83-4.98 (m, 3 H), 3.24 (s, 6 H), 3.00-3.16 (m, 2 H), 2.77-2.91 (m, 2 H), 1.58-1.97 (m, 3 H), 1.12-1.33 (m, 2 H).
Step D: Synthesis of 4-bromo-N-[l-(4-dimethylamino-quinazolin-2-yI)-piperidin-4- yhnethyl]-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step D of example 3, the title compound was obtained. ESI MS m/e 588, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.87 (d, J= 8.7 Hz, 1 H), 7.78 (d, J= 8.2 Hz, 1 H), 7.44-7.59 (m, 4 H), 6.97-7.06 (m, 1 H), 4.94-5.04 (m, 1 H), 4.89 (d, J = 13.2 Hz, 2 H), 3.25 (s, 6 H), 2.75-2.88 (m, 4 H), 1.64-1.82 (m, 3 H), 1.05-1.28 (m, 2 H).
Example 9
cw-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of cw-(4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.
To a suspension of cw-cyclohexane-l,4-dicarboxylic acid (25.0 g, 145 mmol) in benzene (125 mL) were added phosphorazidic acid diphenyl ester (81.9 g, 298 mmol) and triethylamine (30.1 g, 297 mmol). The reaction mixture was stirred at reflux for 2.5 hr (Caution! Vigorous exothermic reaction). Benzyl alcohol (32.2 g, 298 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H2O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was washed with 1 M aqueous KHSO4, saturated aqueous NaHCO3, and brine, dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give CM-(4-benzyloxycarbonylamino-cyclohexyl)- carbamic acid benzyl ester (52.0 g, 94%) as a colorless oil.
ESI MS m/e 405, M + Na+ ; Η NMR (300 MHz, CDC13) δ 7.15-7.40 (m, 10 H), 5.07 (s, 4 H), 4.70-5.00 (m, 2 H), 3.52-3.80 (m, 2 H), 1.60-1.80 (m, 4 H), 1.45-1.60 (m, 4 H).
Step B: Synthesis of c s-(4-amino-cycIohexyl)-carbamic acid tert-butyl ester.
To a solution of cw-(4-benzyloxycarbonylammo-cyclohexyl)-carbamic acid benzyl ester (91.7 g, 240 mmol) in MeOH (460 mL) was added 5% Pd/C (9.17 g). The reaction mixture was stirred at ambient temperature under hydrogen atmosphere for 2.5 days, filtered through a pad of celite, and concentrated to give a diamine as a colorless oil. To a solution of the diamine in MeOH (550 mL) was added a solution of (Boc)2O (6.59 g, 30.2 mmol) in MeOH (80 mL) dropwise over 4 hr. The reaction mixture was stirred at
ambient temperature for 1.5 days and concentrated. After dissolution with H2O, the aqueous layer was exfracted with CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated to give cw-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (7.78 g, 15%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO4, filtered, and concentrated to give a recovered diamine (32.9 g) as a colorless oil. To a solution of the recovered diamine (32.9 g, 288 mmol) in MeOH (660 mL) was added a solution of (Boc)2O (6.29 g, 28.8 mmol) in MeOH (80 mL) dropwise over 5 hr. The reaction mixture was stirred at ambient temperature for 10 hr and concentrated. After dissolution with H2O, the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated to give cis-(4-am_no- cyclohexyl)-carbamic acid tert-butyl ester (8.16 g, 16%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO4, filtered, and concentrated to give a recovered diamine (23.1 g) as a colorless oil. To a solution of the recovered diamine (23.1 g, 202 mmol) in MeOH (462 mL) was added a solution of (Boc)2O (4.42 g, 20.3 mmol) in MeOH (56 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 3.5 days and concentrated. After dissolution with H2O, the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated to give cis-(4- amino-cyclohexyl)-carbamic acid tert-butyl ester (5.01 g, 10% based on starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO4, filtered, and concentrated to give a recovered diamine (16.0 g) as a colorless oil. To a solution of the recovered diamine (16.0 g, 140 mmol) in MeOH (320 mL) was added a solution of (Boc)2O (3.06 g, 14.0 mmol) in MeOH (40 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 13 hr and concentrated. After dissolution with H2O, the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated to give s-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (3.53 g, 7% based on the starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO4, filtered, and concentrated to give a recovered diamine (11.1 g) as a colorless oil.
ESI MS m/e 215, M + lA ; Η NMR (300 MHz, CDC13) δ 4.30-4.82 (m, 1 H), 3.50-3.80 (m, 1 H), 2.78-2.95 (m, 1 H), 1.44 (s, 9H), 1.20-1.80 (m, 8 H).
Step C: Synthesis of cw-N2-(4-amino-cyclohexyl)-Nl/,iV'-dimethyl-quinazoline-2,4- diamine.
A mixture of (2-chloro-quinazolin-4-yl)-dimefhyl-amine obtained in step B of example 1 (3.00 g, 14.4 mmol) and cω-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (3.72 g, 17.4 mmol) in 2-propanol (10 mL) was stirred at reflux for 5.5 days, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give cis-[4-(4- dimethylamino-quinazolin-2-ylamino)-cyclohexyl] -carbamic acid tert-butyl ester including solvent (5.44 g) as a colorless oil. To a solution of the above material (5.44 g) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (50 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalized with saturated aqueous NaHCO3, and the precipitate was collected by filtration to give cw-N2-(4-amino-cyclohexyl)-N4,N4-dimethyl-quinazoline-2,4-diamine (2.26 g, 55%) as a white solid. The aqueous layer was extracted CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated to give cw-N2-(4-amino- cyclohexyl)-N')N'/-dimethyl-quinazoline-2,4-diamine (687 mg, 17%) as a white solid. ESI MS m/e 285, M+ ; ΗΝMR (300 MHz, DMSO-d6) δ 7.86 (d, J= 7.5 Hz, 1 H), 7.47 (t, J= 8.3 Hz, 1 H), 7.29 (d, J= 8.3 Hz, 1 H), 7.01 (t, J= 7.6 Hz, 1 H), 6.56 (d, J= 7.5 Hz, 1 H), 3.83-4.06 (m, 1 H), 3.38-3.52 (m, 1 H), 3.20 (s, 6 H), 1.22-1.82 (m, 8 H).
Step D: Synthesis of CM,-4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cycIohexyl]-2-trifluoromethoxy-benzenesulfonamide.
To a suspension of cw-N -(4-amino-cyclohexyl)-N',N'-dimethyl-quinazoline-2,4- diamine (680 mg, 2.38 mmol) in CH2C12 (7 mL) was added diisopropylethylamine (620 μL,
3.56 mmol). The mixture was cooled on an ice-bath and a solution of 4-bromo-2- trifluoromethoxy-benzenesulfonyl chloride (849 mg, 2.50 mmol) in CH2C12 (3 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 6.5 hr. The reaction was quenched with saturated aqueous ΝaHCO3 The aqueous layer was extracted with
CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give cw-4-bromo-N-[4-(4-dimemylamino-quinazolin-2-ylamino)-cyclohexyl]-2-
trifluoromethoxy-benzenesulfonamide (782 mg, 56%) as a pale yellow solid. ESI MS m/e 588, MVH NMR (300 MHz, CDC13) δ 7.92 (d, J= 8.9 Hz, 1 H), 7.81 (dd, J = 8.3, 1.2 Hz, 1 H), 7.41-7.58 (m, 4 H), 7.04 (ddd, J= 8.3, 6.6, 1.6 Hz, 1 H), 4.00-4.12 (m, 1 H), 3.36-3.45 (m, 1 H), 3.31 (s, 6 H), 1.54-1.84 (m, 8 H).
Example 10
teα«5-iV-{4-[(4-Dimethylamino-quinazolin-2-ylaπιino)-methyl]-cyclohexylmethyl}- methanesulfonamide
Step A: Synthesis of te«M5-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}- methane sulfonamide.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 392, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 7.8 Hz, 1 H), 7.38- 7.53 (m, 2 H), 7.02 (ddd, J= 8.3, 6.6, 1.6 Hz, 1 H), 5.07 (brs, 1 H), 4.61 (brs, 1 H), 3.36 (t, J= 6.2 Hz, 2 H), 3.27 (s, 6 H), 2.94 (s, 3 H), 2.91-3.01 (m, 2 H), 1.76-1.98 (m, 4 H), 1.37- 1.64 (m, 2 H), 0.85-1.12 (m, 4 H).
Example 11
^ /i5-iV-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2- trifluoromethoxy-benzamide
Step A: Synthesis of teα«s-N-{4-[(4-dimethylamino-quinazoIin-2-ylamino)-methyl]-
cyclohexylmethyl}-2-trifluoromethoxy-benzamide.
To a suspension of trαπ>y-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]cyclohexylmethyl}-carbamic acid tert-butyl ester obtained in step G of example 1 (800 mg, 1.93 mmol) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 60 min and concentrated to give a white solid. To a suspension of the solid in CH2C12 (10 mL) was added diisopropylethylamine (706 μL, 4.05 mmol). The mixture was cooled at 4 °C and a solution of 2-(trifluoromethoxy)benzoyl chloride (455 mg, 2.03 mmol) in CH2C12 (4 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 90 min. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHCLj (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give trα«5,-N-{4-[(4-dimemylammo-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}- 2-trifluoromethoxy-benzamide (772 mg, 80%) as a pale yellow solid. ESI MS m/e 502, M + H÷ ; Η ΝMR (300 MHz, CDCLJ δ 7.90 (dd, J = 7.4, 1.6, Hz, 1 H), 7.81 (d, J= 8.1 Hz, 1 H), 7.33-7.55 (m, 4 H), 7.29 (d, J= 8.8, Hz, 1 H), 6.96-7.08 (m, 1 H), 6.55 (brs, 1 H), 4.97 (brs, 1 H), 3.28-3.43 (m, 4 H), 3.26 (s, 6 H), 1.76-2.10 (m, 4 H), 1.44-1.72 (m, 2 H), 0.90-1.21 (m, 4 H).
Example 12
αHs-Butane-l-sulf onic acid {4- [(4-dimethyIamino-quinazolin-2-ylamino)- methyl] -cy clohexyImethyl}-amide
Step A: Synthesis of teα«s-butane-l-suIfonic acid {4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-cyclohexylmethyl}-amide.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 434, M + HT ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 8.2 Hz, 1 H), 7.35-
7.54 (m, 2 H), 6.97-7.07 (m, 1 H), 4.41 (t, J- 6.1 Hz, 1 H), 3.36 (t, J= 6.1 Hz, 2 H), 3.27 (s, 6 H), 2.89-3.05 (m, 4 H), 1.71-1.97 (m„ 6 H), 1.37-1.65 (m, 4 H), 0.82-1.12 (m, 7 H).
Example 13
frα«5,-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-2-trifluoromethoxy-benzamide
Step A: Synthesis of 4-bromo-2-trifluoromethoxy-benzaldehyde.
A solution of 4-bromo-l-iodo-2-trifluoromethoxy-benzene (1.00 g, 2.72 mmol) in THF (15 mL) was cooled to -78 °C, and 2.66 M BuLi in hexane (2.05 mL, 5.44 mmol) was added dropwise. The reaction mixture was stirred at —78 °C for 1.5 h, and N- formylmorpholine (0.57 mL, 5.63 mmol) was added. The reaction mixture was stirred at — 78 °C for 15 min and at ambient temperature for 80 min. The reaction was quenched with 0.25 M aqueous citric acid (10 mL), and the resulting mixture was extracted with EtOAc (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 2% to 5% EtOAc in hexane) to give 4- bromo-2-trifluoromethoxy-benzaldehyde (560 mg, 77%) as a pale brown solid. CI MS m/e 269, M + ET; ΗΝMR (300 MHz, CDCL,) δ 10.33 (s, 1 H), 7.85 (d, J= 8.1 Hz, 1 H), 7.50-7.67 (m, 2 H).
Srep B: Synthesis of 4-bromo-2-trifluoromethoxy-benzoic acid.
A solution of 4-bromo-2-trifluoromethoxy-benzaldehyde (550 mg, 2.04 mmol) in 1,4-dioxane (27 mL) and H2O (9 mL) was cooled at 4 °C. To the solution were added amidosulfuric acid (296 mg, 3.05 mmol) and sodium dihydrogen phosphate dihydrate (1.4 g, 8.98 mmol). The mixture was stirred at 4 °C for 15 min. To the reaction mixture was added a solution of sodium chlorite (238 mg, 2.63 mmol) in H2O (1.5 mL) and stirred at 4 °C for 15 min. To the reaction mixture was added Νa2CO3 (304 mg, 2.41 mmol) and stirred
at 4 °C for 15 min. The mixture was acidified with conc-HCl (pH = 1), and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over
MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 1%
MeOH in CHC13) to give 4-bromo-2-trifluoromethoxy-benzoic acid (471 mg, 81%) as a white solid.
ESI MS m/e 284, IVf ; Η NMR (300 MHz, CDCLJ δ 7.98 (d, J= 8.4 Hz, 1 H), 7.53-7.62
(m, 2 H).
Step C: Synthesis of teαw5-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide.
To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid (454 mg, 1.59 mmol) in CH2C12 (6 mL) were added DMF (1.5 μL, 0.02 mmol) and SOCl2 (158 μL, 2.17 mmol). The mixture was stirred at reflux for 1 hr and concentrated to give acid chloride as a pale yellow oil. To a suspension of trαπ5-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]cyclohexylmethyl} -carbamic acid tert-butyl ester obtained in step G of example 1 (624 mg, 1.51 mmol) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (8 mL). The mixture was stirred at ambient temperature for 40 min and concentrated to give a white solid. To a suspension of the solid in CH2C12 (6 mL) was added diisopropylethylamine (552 μL, 3.17 mmol). The mixture was cooled at 4 °C and a solution of acid chloride in CH2C12 (6 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 2.5 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH- silica gel, 33% EtOAc in hexane) to give t7'αrø-4-bromo-N-{4-[(4-dimethylamino- quinazolin-2-ylammo)-memyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide (309 mg, 35%) as a pale yellow solid.
ESI MS m/e 580, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 7.89 (d, J= 8.4 Hz, 1 H), 7.81 (d, J= 8.2 Hz, 1 H), 7.39-7.67 (m, 4 H), 7.02 (ddd, J= 8.2, 6.4, 1.9 Hz, 1 H), 6.53 (brs, 1 H), 4.99 (brs, 1 H), 3.37 (t, J= 6.5 Hz, 2 H), 3.32 (t, J= 6.3 Hz, 2 H), 3.27 (s, 6 H), 1.76-2.02 (m„ 4 H), 1.48-1.67 (m, 2 H), 0.94-1.16 (m, 4 H).
Example 14
i'rα« -N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cycIohexylmethyl}-2- trifluoromethoxy-benzenesulfonamide.
Step A: Synthesis of ^rα«5-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide.
To a suspension of trα -{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]cyclohexylmethyl}-carbamic acid tert-butyl ester obtained in step G of example 1 (500 mg, 1.21 mmol) in EtOAc (8 mL) was added 4 M hydrogen chloride in EtOAc (7 mL). The mixture was stirred at ambient temperature for 40 min and concentrated to give a white solid. To a suspension of the solid in CH2C12 (7 mL) was added pyridine (215 μL, 2.66 mmol). The mixture was cooled at 4 °C and a solution of 2-trifluoromethoxy- benzenesulfonyl chloride (331 mg, 1.27 mmol) in CH2C12 (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 2 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was exfracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give trαrø-N-{4-[(4- dimemylannno-quinazolm-2-ylamino)-methyl] -cyclohexylmethyl } -2-frifluoromethoxy- benzenesulfonamide (231 mg, 36%) as a pale yellow solid.
ESI MS m/e 538, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 8.03 (dd, J= 8.0, 1.6 Hz, 1 H), 7.81 (d, J= 8.2 Hz, 1 H), 7.57-7.66 (m, 1 H), 7.36-7.52 (m, 4 H), 7.02 (ddd, J= 8.3, 6.5, 1.7 Hz, 1 H), 4.94 (brs, 1 H), 4.66 (brs, 1 H), 3.34 (t, J= 6.4 Hz, 2 H), 3.26 (s, 6 H), 2.78 (t, J= 6.2 Hz, 2 H), 1.68-2.01 (m, 4 H), 1.29-1.60 (m, 2 H), 0.79-1.07 (m, 4 H).
Example 15
te««5-N2-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}- JV*jN -dimethyl-quinazoline-2,4-diamine
Step A: Synthesis of rα«5-N-(4-aminomethyl-cyclohexylmethyl)-iV',iV'-dimethyl- quinazoline-2,4-diamine.
To a suspension of trα«^-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl} -carbamic acid tert-butyl ester (20.1 g, 48.6 mmol) in EtOAc (200 mL) was added 4 M hydrogen chloride in EtOAc (200 mL). The mixture was stirred at ambient temperature for 90 min and concentrated to give a solid. The solid was alkalized with saturated aqueous NaHCO3 (pH = 9), concentrated, and purified by flash chromatography (NH silica gel, 33% MeOH in CHCL,) to give trαrø-N2-(4-aminomethyl- cyclohexylmemyl)-N^N^-dimethyl-quinazoline-2,4-diamine (14.7 g, 97%) as a white solid. ESI MS m/e 314, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 7.81 (d, J= 8.2 Hz, 1 H), 7.42- 7.52 (m, 2 H), 7.01 (ddd, J= 8.2, 6.2, 0.9 Hz, 1 H), 4.95 (brs, 1 H), 3.36 (t, J= 6.3 Hz, 2 H), 3.26 (s, 6 H), 2.52 (d, J= 6.4 Hz, 2 H), 1.75-1.96 ( , 5 H), 1.48-1.66 (m, 1 H), 0.82- 1.40 (m, 6 H).
Step B: Synthesis of i'r «^-N2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)- methyl]-cyclohexylmethyl}-Λ^,-V-dimethyl-quinazoline-2,4-diamine.
To a solution of trαrø-N2-(4-aminomethyl-cyclohexylmethyl)-N"',NJ-dimethyl- quinazoline-2,4-diamine (500 mg, 1.59 mmol) in CH2C12 (5 mL) were added 4-bromo-2- trifluoromethoxy-benzaldehyde obtained in step A of example 13 (428 mg, 1.59 mmol), acetic acid (95 mg, 1.59 mmol), and ΝaBH(OAc)3 (505 mg, 2.38 mmol). The reaction mixture was stirred at ambient temperature for 4 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by
flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give trans-N2-{4-[(4- bromo-2-trifluoromethoxy-benzylamino)-methyl] -cy clohexylmethyl } -N4, N4-dimethyl- quinazoline-2,4-diamine (783 mg, 89%) as a pale yellow solid.
ESI MS m/e 566, M + H+ ; Η ΝMR (300 MHz, CDC13) δ 7.80 (d, J= 8.2 Hz, 1 H), 7.34- 7.52 (m, 5 H), 7.01 (ddd, J= 8.3, 6.2, 2.0 Hz, 1 H), 5.00 (brs, 1 H), 3.77 (s, 2 H), 3.36 (t, J = 6.3 Hz, 2 H), 3.26 (s, 6 H), 2.43 (d, J= 6.1 Hz, 2 H), 1.76-1.95 (m„ 4 H), 1.34-1.65 (m, 2 H), 0.83-1.12 (m, 4 H).
Example 16
ώ- κs-4-Bromo-N- {4- [(4-dimethylamino-quinazolin-2-ylamino)-methyl] - cyclohexylmethyl}-N-methyl-2-trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of teα«5-4-bromo-iV-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-cyclohexylmethyl}-N-methyl-2-trifluoromethoxy-benzenesulfonamide.
To a solution of trα«6,-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide obtained in step H of example 1 (380 mg, 0.61 mmol) in DMF (2 mL) was added 60% sodium hydride in oil (24.6 mg, 0.61 mmol). The reaction mixture was stirred at ambient temperature for 80 min. The reaction mixture was cooled at 0 °C and iodomethane (38.3 μL, 0.61 mmol) was added and stirred at ambient temperature for 3 hr. The reaction was quenched with saturated aqueous ΝaHCO3. The aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane, and silica gel, 5% MeOH in CHC13) to give tr w-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-N-methyl-2-trifluoromethoxy-benzenesulfonamide (268 mg, 69%) as a pale yellow solid. ESI MS m/e 630, M + ET ; Η ΝMR (300 MHz, CDC13) δ 7.88 (d, J= 9.2 Hz, 1 H), 7.81 (d,
J= 8.4 Hz, 1 H), 7.41-7.57 (m, 4 H), 7.03 (ddd, J= 8.4, 6.3, 1.8 Hz, 1 H), 3.37 (t, J= 6.2 Hz, 2 H), 3.27 (s, 6 H), 2.97 (d, J= 7.5 Hz, 2H), 2.81 (s, 3H), 1.73-1.97 (m, 4H), 1.46-1.66 (m, 2H), 0.83-1.12 (m, 4H).
Example 17
tefl«5-N2-(4-{[(4-Bromo-2-trifluoromethoxy-benzyl)-methyl-amino] -methylJ-cyclohexylmethy^-^Λ^-dimethyl-quinazoline^^-diamine
Step A: Synthesis of ι"rαM5-N2-(4-{[(4-bromo-2-trifluoronιethoxy-benzyl)-methyl- amino]-methyl}-cyclohexylmethyl)-iV',N!'-dimethyl-quinazoline-2,4-diamine.
To a solution of trans- N2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl] -cyclohexylnιemyl}-N,N^-dime1hyl-qumazoline-2,4-diamine obtained in step B of example 15 (290 mg, 0.52 mmol) in CH2C12 (3 mL) were added 37% aqueous formaldehyde (42 mg, 0.52 mmol), acetic acid (31 mg, 0.52 mmol), and ΝaBH(OAc)3 (165 mg, 0.78 mmol). The reaction mixture was stirred at ambient temperature for 19 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane) to give tr««i,-N2-(4-{[(4-bromo-2-trifluoromethoxy-benzyl)-methyl-amino]- methyl}-cyclohexylmethyl)-N4,N4-dimethyl-quinazoline-2,4-diamine (153 mg, 51%) as a pale yellow solid.
ESI MS m/e 580, M + ET ; Η ΝMR (300 MHz, CDC13) δ 7.81 (d, J= 7.6 Hz, 1 H), 7.34- 7.53 (m, 5 H), 7.02 (ddd, J= 8.3, 6.2, 2.0 Hz, 1 H), 3.44 (s, 2 H), 3.36 (t, J= 6.3 Hz, 2 H), 3.27 (s, 6 H), 2.14 (s, 3H), 2.11-2.18 (m, 2 H), 1.81-1.96 (m„ 4H), 1.36-1.66 (m, 2 H), 0.73-1.13 (m, 4 H).
Example 18
trans- 3-Trifluoromethoxy-biphenyl-4-sulfonic acid {4-[(4-dimethylamino-quinazoIin- 2-yIamino)-methyl]-cyclohexylmethyl}-amide
Step A: Synthesis of trans- 3-trifluoromethoxy-biphenyI-4-sulfonic acid {4-[(4- dimethyIamino-quinazoIin-2-ylamino)-methyl]-cyclohexylmethyl}-amide.
To a solution of trαrø-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-cyclohexylmethyl}-2-frifluoromethoxy-benzenesulfonamide obtained in step H of example 1 (122 mg, 0.198 mmol) in toluene (2.7 mL) were added MeOH (0.9 mL), 2 M aqueous K2CO3 (0.9 mL), phenylboronic acid (29.0 mg, 0.237 mmol), and tetrakis(triphenylphosphine)palladium (23.0 mg, 0.02 mmol). The reaction mixture was stirred at 130 °C for 10 hr. The mixture was poured into water, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (ΝH-silica gel, 25% EtOAc in hexane and silica gel, 9% MeOH in CHC13) to give trα«.y-3-frifluoromethoxy-biphenyl-4- sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}- amide (77 mg, 0.125 mmol) as a white solid.
ESI MS m/e 614, M + H+; ΗΝMR (200 MHz, CDC13) δ 8.07 (d, J= 8.4 Hz, 1 H), 7.82 (d, J= 8.8 Hz, 1 H), 7.38-7.67 (m, 9 H), 7.03 (ddd, J= 8.4, 6.2, 2.2 Hz, 1 H), 5.11 (brs, 1 H), 4.71 (brs, 1 H), 3.35 (t, J= 6.2 Hz, 2 H), 3.27 (s, 6 H), 2.73-2.90 (m, 2 H), 1.67-2.03 (m„ 4 H), 1.30-1.64 (m, 2 H), 0.75-1.16 (m, 4 H).
Example 19
tefl« -Octane-l-sulfonic acid{4-[(4-dimethyIamino-quinazolin-2-ylamino)-methyI]- cy clohexylmethyl} -amide
Step A: Synthesis of tfrαws-octane-l-sulfonic acid{4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-cyclohexylmethyl}-amide.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 490, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 7.8 Hz, 1 H), 7.38- 7.54 (m, 2 H), 7.02 (ddd, J= 8.3, 6.6, 1.7 Hz, 1 H), 5.01 (brs, 1 H), 4.45 (t, J= 6.2 Hz, 1 H), 3.36 (t, J= 6.2 Hz, 2 H), 3.26 (s, 6 H), 2.86-3.04 (m, 4 H), 1.70-1.96 (m, 6 H), 1.12- 1.65 (m, 11 H), 0.76-1.11 (m, 8 H).
Example 20
#*αn$-Propane-2-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cy clohexylmethyl} -amide
Step A: Synthesis of trans- propane-2-sulfonic acid {4-[(4-dimethylamino-quinazolin- 2-ylamino)-methyl]-cyclohexylmethyl}-amide.
To a suspension of tr rø-N2-(4-aminomethyl-cyclohexylmethyl)-N',N''-dimethyl- quinazoline-2,4-diamine obtained in step A of example 15 (227 mg, 0.72 mmol) in CH2C12 (4 mL) was added diisopropylethylamine (263 μL, 1.51 mmol). The mixture was cooled at 4 °C and a solution of 2-propanesulfonyl chloride (108 mg, 0.76 mmol) in CH2C12 (1 mL)
was added below 5 °C. The reaction mixture was stirred at ambient temperature for 12 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 66V. EtOAc in hexane) to give tr rø-propane-2-sulfonic acid {4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-cyclohexylmethyl} -amide (135 mg, 45%) as a pale yellow solid. ESI MS m/e 420, M + L ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 7.8 Hz, 1 H), 7.39- 7.52 (m, 2 H), 7.02 (ddd, J= 8.3, 6.5, 1.7 Hz, 1 H), 5.02 (brs, 1 H), 4.22 (t, J= 6.2 Hz, 1 H), 3.36 (t, J= 6.2 Hz, 2 H), 3.27 (s, 6 H), 3.09-3.21 (m, 1 H), 2.97 (t, J = 6.5 Hz, 2 H), 1.75-1.97 (m, 4 H), 1.39-1.64 (m, 2 H), 1.37 (d, J= 6.8 Hz, 6 H), 0.85-1.12 (m, 4 H).
Example 21
N2-[l-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin-3-yl]r/V,iV*- dimethyl-quinazoline-2,4-diamine
Step A: Synthesis of l-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin-3- ylamine hydrochloride.
To a solution of pyrrolidin-3-yl-carbamic acid tert-butyl ester (1.00 g, 5.37 mmol) in CH2C12 (10 mL) was added diisopropylethylamine (1.96 mL, 5.92 mmol). The mixture was cooled at 0 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (2.01 g, 5.92 mmol) in CH2C12 (10 mL) was added below 10 °C. The reaction mixture was stirred at 4 °C for 15 min, dissolved in CHCL, and saturated aqueous NaHCO3 The two phases were separated, the aqueous layer was extracted with CHCL, (twice). The combined organic layer was dried over MgSO4, filtered, concentrated, and dried under reduced pressure to give a pale brown solid. To a solution of the above solid in CHC13 (50 mL) was added 4 M hydrogen chloride in EtOAc (50 mL). The mixture was stirred at ambient temperature for 1 hr, filtered, washed with EtOAc, and dried under reduced pressure to
give 1 -(4-bromo-2-trifluoromemoxy-benzenesulfonyl)-ρyrrolidin-3-ylamine hydrochloride (1.83 g, 80%) as a white solid.
ESI MS m/e 388, M*" ; Η NMR (300 MHz, DMSO-d6) δ 8.44 (brs, 3 H), 7.82-7.94 (m, 3 H), 3.76-3.84 (m, 1 H), 3.42-3.58 (m, 2 H) , 3.23-3.40 (m, 2 H) , 2.10-2.23 (m, 1 H) , 1.88- 2.02 (m, 1 H).
Step B: Synthesis of N2-[l-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin- 3-yl]-N*,/ -dimethyl-quinazoline-2,4-diamine
Using the procedure for the step C of example 3, the title compound was obtained. ESI MS m/e 560, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.82-7.89 (m, 2 H), 7.40-7.75 (m, 4 H), 7.08 (ddd, J= 8.3, 6.8, 1.5 Hz, 1 H), 4.83 (brs, 1 H), 4.53-4.64 (m, 1 H), 3.75 (dd, J = 10.3, 5.8 Hz, 1 H), 3.48-3.64 (m, 2 H), 3.44 (dd, J= 10.3, 4.4 Hz, 1 H), 3.27 (s, 6 H), 2.21-2.36 (m, 1 H), 1.86-2.00 (m, 1 H).
Example 22
c 5-4-Bromo-iV-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of -[4-(tert-butoxycarbonylamino-methyl)-cyclohexyImethyl]- carbamic acid tert-butyl ester.
To MeOH (220 mL) cooled at 0 °C was added thionyl chloride (52 mL) below 10
°C over 2.5 hr and the solution was stirred at 0 °C for 1 hr. To the reaction mixture was added czs-cyclohexane-l^-dicarboxylic acid (30.0 g, 174 mmol) and the mixture was stirred at ambient temperature for 14 hr and concentrated. The residue was dissolved in
CHCLj, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with
CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concentrated. A suspension of lithium aluminum hydride (13.2 g, 348 mmol) in THF (400 mL) was cooled at -20 °C. A solution of the above residue in THF (200 mL) was added
dropwise, and the mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with Na2SO4- 10H2O, filtered through a pad of celite, and concentrated. To a solution of the above residue in toluene (500 mL) was added triphenylphosphine (37.2 g, 142 mmol). To the mixture cooled at 4 °C were added phthalimide (20.9 g, 142 mmol) and 40% diethyl azodicarboxylate (DEAD) in toluene (61.7 mL, 136 mmol) over 25 min. The reaction mixture was stirred at ambient temperature for 12 hr, poured into H2O. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated. The precipitate was suspended in Et2O, filtered, washed with MeOH and Et2O, and dried under reduced pressure to give a white solid (16.5 g). To a suspension of the above solid (16.5 g, 41.0 mmol) in EtOH (735 mL) was added hydrazine hydrate (20.5 g, 410 mmol). The mixture was stirred at reflux for 2.5 hr, cooled, and concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (120 mL) and 1, 4-dioxane (160 mL). To the mixture cooled on an ice-bath was added (Boc)2O (30.4 g, 139 mmol) and the mixture was stirred at ambient temperature for 2.5 hr, and poured into H2O. The aqueous layer was extracted with CHC13 (ten times). The combined organic layer was dried over MgSO4, filtered and concentrated. The precipitate was suspended in hexane, filtered, washed with hexane, and dried under reduced pressure to give cis- [4-(tert-butoxycarbonylamino-methyl)-cy clohexylmethyl] -carbamic acid tert- butyl ester (5.10 g, 9%) as a white solid.
ESI MS m/e 365, M + Na+ ; Η NMR (300 MHz, CDC13) δ 4.49-4.59 (m, 2 H), 3.05 (t, J= 6.6 Hz, 4 H), 1.29-1.69 (m, 28 H).
Step C: Synthesis of -(4-aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester.
To a solution of cw-[4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]- carbamic acid tert-butyl ester (2.55 g, 7.45 mmol) in CH2C12 (40 mL) was added 4 M hydrogen chloride in EtOAc (4 mL). The reaction mixture was stirred at ambient temperature for 5 hr and concentrated. The residue was dissolved in 1, 4-dioxane (20 mL) and 10% aqueous sodium hydroxide (40 mL) and the resulting solution was cooled on an ice-bath. (Boc)2O (829 mg, 3.80 mmol) was added dropwise and the mixture was stirred at ambient temperature for 3 h. The aqueous layer was exfracted with CHC13 (three times).
The combined organic layer was dried over MgSO4, filtered and concentrated, and purified by flash chromatography (silica gel, 9% MeOH in CHC13) to give cw-(4-aminomethyl-
cyclohexylmethyl)-carbamic acid tert-butyl ester (255 mg, 14%) as a pale yellow oil.
ESI MS m e 243, M + HT ; Η NMR (300 MHz, CDC13) δ 4.58 (brs, 1 H), 3.06 (t, J= 6.1
Hz, 2 H) , 2.60 (d, J= 5.9 Hz, 2 H), 1.28-1.70 ( , 19 H).
Step D: Synthesis of cώ-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 414, M + Ff ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 7.8 Hz, 1 H) ,7.42- 7.52 (m, 2 H), 7.02 (ddd, J= 8.3, 6.3, 1.9 Hz, 1 H), 4.52 (brs, 1 H), 3.45 (t, J= 6.6 Hz, 2 H), 3.27 (s, 6 H), 3.08 (t, J= 6.5 Hz, 2 H), 1.34-1.86 (m, 19 H).
Step E: Synthesis of c s-4-bromo-N-{4-[(4-dimethylamino-quinazoIin-2-yIamino)- methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 616, M + FT ; Η NMR (300 MHz, CDC13) δ 7.90 (d, J= 8.9 Hz, 1 H) , 7.81 (d, J= 7.8 Hz, 1 H) ,7.41-7.58 (m, 4 H), 7.03 (ddd, J= 8.2, 6.6, 1.5 Hz, 1 H) , 3.41 (t, J= 6.5 Hz, 2 H) ,3.50 (s, 6 H), 2.90 (d, J= 7.3 Hz, 2 H), 1.32-1.86 (m, 10 H).
Example 23
cιs-4-Bromo-iV-{4-[(4-dimethylamino-quinazolin-2-yIamino)-methyl]-cycIohexyl}-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of c s-(4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester..
A suspension of cw-4-amino-cyclohexanecarboxylic acid (244 g, 1.70 mol) in MeOH (2.45 L) was cooled to -8 °C . Thionyl chloride (45.0 L, 617 mmol) was added dropwise. The resulting solution was stirred at ambient temperature for 4.5 hr and concentrated to give a white solid. To a suspension of the above solid in CHC13 (3.00 L)
were added triethylamine (261 mL, 1.87 mol) and (Boc)2O (409 g, 1.87 mol) successively. The reaction mixture was stirred at ambient temperature for 5 hr and poured into water. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, CHCL, only to 10% MeOH in CHC13) to give a colorless oil (531 g). To a suspension cooled at -4 °C of lithium aluminum hydride (78.3 g, 2.06 mol) in Et2O (7.9 L) was added a solution of above oil (530.9 g) in Et2O (5.3 L) below 0 °C. The resulting suspension was stirred at ambient temperature for 2 hr. The reaction mixture was cooled on an ice- bath, quenched with cold water, filtered through a pad of celite. The filtrate was dried over MgSO4, filtered, and concentrated. The precipitate was suspended in hexane (300 mL), filtered, washed with hexane, and dried under reduced pressure to give cis-(4- hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (301 g, 77%) as a white solid. ESI MS m/e 252, M + Na+ ; Η NMR (300 MHz, CDC13) δ 4.30-4.82 (m, 1 H), 3.75 (brs, 1 H), 3.51 (d, J= 6.2 Hz, 1 H), 1.52-1.77 (m, 7 H), 1.45 (s, 9 H), 1.16-1.36 (m, 2 H).
Step B: Synthesis of s-[4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester.
To a solution of cw-(4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (17.7 g, 77.2 mmol) in THF (245 mL) were added friphenylphosphine (20.2 g, 77.0 mmol) and phthalimide (11.4 g, 77.5 mmol) successively. The resulting suspension was cooled on an ice-bath and 40% diethyl azodicarboxylate (DEAD) in toluene was added over 1 hr. The reaction mixture was stirred at ambient temperature for 2.5 days, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. To a suspension of above solid (27.5 g) in EtOH (275 L) was added hydrazine hydrate (5.76 g, 115 mmol). The mixture was stirred at reflux for 2.25 hr, cooled, concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (350 mL). The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered and concentrated. To a solution of the above residue in CHC13 (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0 °C and ZC1 (14.4 g, 84.4 mmol) was added below 5 °C. The reaction mixture was stirred at ambient temperature for 16 hr, and poured into saturated aqueous NaHCO3. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 2%
MeOH in CHC13) to give czs-[4-(benzyloxycarbonylamino-methyl)-cyclohexyl] -carbamic acid tert-butyl ester (25.3 g, 91%) as a colorless oil.
ESI MS m/e 385, M + Na+ ; Η NMR (300 MHz, CDC13) δ 7.27-7.38 (m, 5 H), 5.09 (s, 2 H), 4.76-4.92 (m, 1 H), 4.42-4.76 (m, 1 H), 3.72 (brs, 1 H), 3.10 (t, J= 6.4 Hz, 2 H), 1.48- 1.75 (m, 7 H), 1.44 (s, 9 H), 1.13-1.31 (m, 2 H).
Step C: Synthesis of -{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexyl} -carbamic acid tert-butyl ester.
A mixture of cw-^- enzyloxycarbonylamino-methy^-cyclohexyl] -carbamic acid tert-butyl ester (4.00 g, 11.0 mmol) and 5% Pd/C (400 mg) in MeOH (40 mL) was stirred under hydrogen atmosphere at ambient temperature for 8.5 hr and at 50 °C for 12 hr, filtered through a pad of celite, and concentrated. The precipitate was suspended in hexane and the suspension was stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with hexane, and dried (3.03 g). A mixture of (2-chloro-quinazolin-4- yl)-dimemyl-anιine obtained in step B of example 1 (1.00 g, 4.82 mmol) and the above solid (1.65 g, 7.23 mmol) in 2-propanol (10 mL) was stirred at reflux for 5 days, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give cw-{4- [(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (629 mg, 43%) as a pale yellow solid.
ESI MS m/e 400, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 8.2 Hz, 1 H), 7.42- 7.56 ( , 2 H), 6.98-7.06 (m, 1 H), 4.64-4.75 (m, 1 H), 3.67-3.82 (m, 1 H), 3.29-3.44 (m, 2 H), 3.28 (s, 6 H), 1.50-1.78 (m, 7 H), 1.45 (s, 9 H), 1.21-1.42 (m, 2 H).
Step D: Synthesis of cw-4-bromo-iV-{4-[(4-dimethylammo-quinazoIin-2-ylamino)- methyI]-cycIohexyl}-2-trifluoromethoxy-benzenesuIfonamid.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 602, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.91 (d, J= 8.9 Hz, 1 H), 7.82 (dd, J= 8.0, 1.0 Hz, 1 H), 7.42-7.56 (m, 4 H), 7.04 (ddd, J= 8.3, 6.6, 1.6 Hz, 1 H), 3.44- 3.50 ( , 1 H), 3.40 (t, J= 6.0 Hz, 2 H), 3.28 (s, 6 H), 1.22-1.78 (m, 9 H).
Example 24
c s-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cycIohexylmethyl]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of -(4-amino-cycIohexylmethyI)-carbamic acid benzyl ester.
To a solution of cw-^-^enzyloxycarbonylamino-methy^-cyclohexyy-carbamic acid tert-butyl ester obtained in step C of example 23 (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtered, washed with EtOAc, and dried under reduced pressure. The solid was dissolved in saturated aqueous NaHCO3. The aqueous layer was exfracted with CHC13 (five times), dried over MgSO , filtered and concentrated, and dried under reduced pressure to give cw-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.
ESI MS m/e 263, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.36 (s, 5 H), 5.12 (brs, 3 H), 2.96-3.32 (m, 3 H), 1.36-1.98 (m, 9 H).
Step B: Synthesis of c s-[4-(4-dimethylamino-quinazoIin-2-ylamino)- cyclohexylmethylj-carbamic acid benzyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 434, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 9.0 Hz, 1 H), 7.26- 7.52 (m, 7 H), 7.01 (ddd, J= 8.2, 6.5, 1.7 Hz, 1 H), 5.10 (s, 2 H), 4.93-5.06 (m, 1 H), 4.82- 4.93 (m, 1 H), 4.18-4.28 (m, 1 H), 3.26 (s, 6 H), 3.11 (t, J= 6.3 Hz, 2 H), 1.80-1.93 (m, 2 H), 1.52-1.73 (m, 5 H), 1.23-1.40 (m, 2 H).
Step C: Synthesis of cis-4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step D of example 3, the title compound was obtained.
ESI MS m/e 602, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.90 (d, J= 8.9 Hz, 1 H), 7.81 (dd, J= 8.3, 1.3 Hz, 1 H), 7.38-7.59 (m, 4 H), 7.02 (ddd, J= 8.2, 6.8, 1.2 Hz, 1 H), 4.75- 5.24 (m, 1 H), 4.16-4.27 (m, 1 H), 3.27 (s, 6 H), 2.86 (d, J= 6.4 Hz, 2 H), 1.78-1.91 (m, 2 H), 1.51-1.70 (m, 5 H), 1.21-1.38 (m, 2 H).
Example 25
4-Bromo-N-[l-(4-dimethylamino-quinazolin-2-yl)-pyrrolidin-3-yl]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of [l-(4-dimethylamino-quinazolin-2-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 358, M + If ; Η NMR (300 MHz, CDC13) δ 7.81 (d, J= 8.2 Hz, 1 H), 7.45- 7.54 (m, 2 H), 6.98-7.05 (m, 1 H), 4.67-4.80 (m, 1 H), 4.25-4.40 (m, 1 H), 3.85-3.94 (m, 1 H), 3.68-3.79 (m, 2 H), 3.52-3.62 (m, 1 H), 3.27 (s, 6 H), 2.16-2.28 (m, 1 H), 1.86-2.01 (m, I H), 1.45 (s, 9 H).
Step B: Synthesis of 4-bromo-iV-[l-(4-dimethylamino-quinazolin-2-yl)-pyrrolidin-3- yl]-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 560, M + H1" ; Η NMR (300 MHz, CDC13) δ 7.94 (d, J= 8.4 Hz, 1 H), 7.81 (d, J= 8.1 Hz, 1 H), 7.44-7.58 (m, 4 H), 7.03 (ddd, J= 8.4, 5.7, 2.6 Hz, 1 H), 4.76-5.04 (m, 1 H), 3.96-4.11 (m, 1 H), 3.70-3.82 (m, 2 H), 3.58-3.68 (m, 1 H), 3.45-3.54 (m, 1 H), 3.25 (s, 6 H), 2.11-2.24 (m, 1 H), 1.86-1.99 (m, 1 H).
Example 26
4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-benzyl]-2-trifluoromethoxy- benzene sulfonamide
Step A: Synthesis of (4-amino-benzyl)-carbamic acid tert-butyl ester.
To a solution of 4-aminomethyl-phenylamine (1.00 g, 8.19 mmol) in CHC13 (10 mL) was added frie ylamine (870 mg, 8.60 mmol). After cooling on an ice-bath, (Boc)2O (1.88 g, 8.61 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 55 min and poured into saturated aqueous NaHCO3. The aqueous layer was extracted with CHC13 (tliree times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 9% MeOH in CHCLJ to give (4-amino-benzyl)-carbamic acid tert-butyl ester (1.79 g, 99%) as a yellow solid.
ESI MS m/e 245, M + Na+ ; Η NMR (200 MHz, CDC13) δ 7.07 (d, J= 8.4 Hz, 2 H), 6.63 (d, J= 8.4 Hz, 2 H), 4.76 (brs, 1 H), 4.18 (d, J= 5.3 Hz, 2 H), 3.65 (brs, 2 H), 1.45 (s, 9 H).
Step B: Synthesis of 4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-benzyl]- 2-trifluoromethoxy-benzenesulfonamide.
A mixture of (2-cMoro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (1.00 g, 4.82 mmol) and (4-amino-benzyl)-carbamic acid tert-butyl ester (1.28 g, 5.76 mmol) in 2-propanol (10 mL) was stirred at reflux for 3 hr, cooled, poured into saturated aqueous NaHCO3, and the aqueous layer was exfracted with CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give a pale yellow solid (2.32 g). To a solution of the above solid (750 mg, 1.91 mmol) in EtOAc (7 mL) was added 4 M hydrogen chloride in EtOAc (7 L). The mixture was stirred at ambient
temperature for 2 hr, concenfrated to give a white solid. To a suspension of the above solid in CH2C12 (5 mL) was added diisopropylethylamine (730 μL, 4.19 mmol). The mixture was cooled on an ice-bath and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (777 mg, 2.29 mmol) in CH2C12 (2 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 9 hr, poured into saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give 4-bromo-N-[4-(4- dimemylamino-qumazolm-2-ylanfrno)-benzyl]-2-trifluoromethoxy-benzenesulfonamide (519 mg, 56%) as a pale yellow solid.
ESI MS m/e 618, M + Νa+ ; Η NMR (300 MHz, CDCLJ δ 7.88 (t, J= 9.0 Hz, 2 H), 7.64 (d, J= 8.6 Hz, 2 H), 7.48-7.61 (m, 4 H), 6.98-7.20 (m, 4 H), 4.96 (brs, 1 H),4.13 (s, 2 H), 3.34 (s, 6 H).
Example 27
4-Bromo-N-{4-[(4-dimethylamino-quinazoIin-2-ylamino)-methyl]-benzyl}-2- trifiuoromethoxy-benzenesulfonamide
Step A: Synthesis of (4-aminomethyl-benzyl)-carbamic acid tert-butyl ester.
To a solution of 4-aminomethyl-benzylamine (15.0 g, 110 mmol) in CHCL, (85 mL) was added a solution of (Boc)2O (3.03 g, 13.9 mmol) in CHC13 (45 mL) dropwise over 3.5 hr. The reaction mixture was stirred at ambient temperature for 13 hr, and concenfrated. After dissolution with H2O, the aqueous layer was extracted with EtOAc (three times). The combined organic layer was washed with H2O (three times), dried over MgSO4, filtered, and concentrated to give (4-aminomethyl-benzyl)-carbamic acid tert- butyl ester (3.20 g, 12%) as a white solid.
ESI MS m/e 237, M + ET ; Η NMR (300 MHz, CDC13) δ 7.21-7.30 (m, 4 H), 4.86-5.02 (m, 1 H), 4.29 (d, J= 5.8 Hz, 2 H), 3.84 (s, 2 H), 1.46 (s, 9 H).
Step B: Synthesis of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}- carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 408, M + H+ ; Η NMR (300 MHz, CDCLJ δ 7.85 (d, J= 8.2 Hz, 1 H), 7.47- 7.55 (m, 2 H), 7.37 (d, J = 8.0 Hz, 2 H), 7.24 (d, J = 8.0 Hz, 2 H), 7.05-7.10 (m, 1 H), 5.35-5.45 (m, 1 H), 4.90-5.04 (m, 1 H), 4.72 (d, J= 5.8 Hz, 2 H), 4.31 (d, J= 5.8 Hz, 2 H), 3.27 (s, 6 H), 1.49 (s, 9 H).
Step C: Synthesis of 4-bromo-N-{4-[(4-dimethylamino-qumazohn-2~ylamino)- methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 610, M + JA ; Η NMR (300 MHz, CDC13) δ 7.83 (d, J= 8.4 Hz, 2 H), 7.44- 7.54 (m, 4 H), 7.29 (d, J= 7.9 Hz, 2 H), 7.11 (d, J= 8.1 Hz, 2 H), 7.06 (ddd, J= 8.3, 6.3, 2.0 Hz, 1 H), 4.67 (d, J= 5.9 Hz, 2 H), 4.15 (s, 2 H), 3.26 (s, 6 H).
Example 28
c/5-N2-[4-(4-Bromo-2-trifluoromethoxy-benzyIamino)-cycIohexyl]r/V,N4-dimethyI- quinazo!ine-2,4-diamine
Step A: Synthesis of c 5-N2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)- cyclohexyl] -iV',Λ^-dimethyl-quinazoline-2 ,4-diamine.
Using the procedure for the step B of example 15, the title compound was obtained. ESI MS m/e 560, M + Na+ ; Η NMR (300 MHz, CDC13) δ 7.80 (dd, J= 7.9, 0.9 Hz, 1 H),
7.36-7.51 (m, 5 H), 7.01 (ddd, J= 8.3, 6.4, 1.9 Hz, 1 H), 4.95-5.18 (m, 1 H), 4.08-4.22 (m, 1 H), 3.81 (s, 2 H), 3.25 (s, 6 H), 2.55-2.70 (m, 1 H), 1.65-1.90 (m, 6 H), 1.29-1.65 (m, 2 H).
Example 29
c -N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy- benzenesulfonamide
Step A: Synthesis of c/5-N-[4-(4-dimethyIamino-quinazolin-2-ylamino)-cycIohexyl]-2- trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step A of example 20, the title compound was obtained. ESI MS m/e 532, M + Na+ ; Η NMR (300 MHz, CDC13) δ 8.06 (dd, J= 8.1, 1.9 Hz, 1 H), 7.81 (dd, J= 8.4, 1.4 Hz, 1 H), 7.36-7.66 (m, 5 H), 7.03 (ddd, J= 8.3, 6.7, 1.5 Hz, 1 H), 4.72-5.07 (m, 2 H) , 3.95-4.10 (m, 1 H), 3.32-3.48 (m, 1 H), 3.25 (s, 6 H), 1.37-2.17 (m, 8 H).
Example 30
N2-[l-(4-Bromo-2-trifluoromethoxy-benzyl)-piperidin-4-yl]-Λ^,iV#-dimethyl- quinazoline-2,4-diamine
Step A: Synthesis of N2-(l-benzyl-piperidin-4-yl)-N',iV/-dimethyl-quinazoline-2,4- diamine.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 362, M + ET ; Η NMR (300 MHz, CDCL δ 7.80 (d, J= 7.6 Hz, 1 H), 7.20- 7.52 (m, 7 H), 6.97-7.05 ( , 1 H) , 4.74-4.90 (m, 1 H) , 3.90-4.05 (m, 1 H), 3.53 (s, 2 H), 3.26 (s, 6 H), 2.78-2.90 (m, 2 H), 2.02-2.24 (m, 4 H), 1.48-1.62 (m, 2 H).
Step B: Synthesis of iV→,iV/-dimethyl-N2-piperidin-4-yl-quinazoIine-2,4-diamine.
To a solution , of N2-(l-benzyl-piperidin-4-yl)-Nf,N/-dimethyl-quinazoline-2,4- diamine (1.80 g, 4.98 mmol) in MeOH (18 mL) was added 20% Pd(OH)2 (360 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 3 days, filtered through a pad of celite, and concentrated to give N4N -dimethyl-N2-piperidin-4-yl-quinazoline-2,4- diamine (1.33 g, 99%) as a pale yellow solid.
ESI MS m/e 272, M + ET ; Η ΝMR (300 MHz, CDC13) δ 7.86 (d, J= 8.6 Hz, 1 H), 7.43- 7.62 (m, 2 H), 7.15 (t, J= 8.2 Hz, 1 H), 4.12-4.29 (m, 1 H), 3.29-3.47 (m, 2 H), 3.37 (s, 6 H), 2.96-3.12 (m, 2 H), 2.20-2.34 (m, 2 H), 1.79-1.97 (m, 2 H).
Step C: Synthesis of N2-[l-(4-bromo-2-trifluoromethoxy-benzyl)-piperidin-4-yl]- NVV -dimethyl-quinazoline-2,4-diamine.
Using the procedure for the step B of example 15, the title compound was obtained.
ESI MS m/e 546, M + Νa+ ; Η NMR (300 MHz, CDCLJ δ 7.80 (dd, J= 8.7, 0.9 Hz, 1 H), 7.34-7.54 (m, 5 H), 7.01 (ddd, J= 8.3, 6.6, 1.6 Hz, 1 H), 4.76-4.95 (m, 1 H), 3.87-4.06 (m, 1 H), 3.52 (s, 2 H), 3.25 (s, 6 H), 2.71-2.86 (m, 2 H), 2.17-2.33 (m, 2 H), 1.97-2.12 (m, 2 H), 1.44-1.61 (m, 2 H).
Example 31
N',/ -Dimethyl-N2-[l-(2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]- quinazoline-2,4-diamine
Step A: Synthesis of Nl/,NI?-dimethyI-N2-[l-(2-trifluoromethoxy-benzenesulfonyl)- piperidin-4-yl]-quinazoline-2,4-diamine.
Using the procedure for the step A of example 20, the title compound was obtained. ESI MS m/e 518, M + Na+; Η NMR (300 MHz, CDCLJ δ 8.02 (dd, J= 1.9, 1.9 Hz, 1 H), 7.81 (dd, J = 8.4, 0.7 Hz, 1 H), 7.34-7.67 (m, 5 H), 7.04 (ddd, J= 8.3, 6.7, 1.5 Hz, 1 H), 4.81 (brs, 1 H), 3.95-4.12 (m, 1 H), 3.78 (d, J= 12.8 Hz, 2 H), 3.25 (s, 6 H), 2.85-3.05 (m, 2 H), 2.05-2.28 (m, 2 H), 1.50-1.71 ( , 2 H).
Example 32
4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy- benzenesulfonamide
Step A: Synthesis of [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 402, M + Na+ ; Η NMR (300 MHz, CDC13) δ 10.05 (brs, 1 H), 7.94 (d, J = 8.4 Hz, 1 H), 7.50-7.66 (m, 4 H), 7.23-7.38 (m, 3 H), 6.57-6.64 (m, 1 H), 3.48 (s, 6 H), 1.53 (s, 9 H).
Step B: Synthesis of 4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]- 2-trifluoromethoxy-benzenesuIfonamide
To a suspension of [4-(4-dimemylamino-quinazolin-2-ylamino)-phenyl]-carbamic acid tert-butyl ester (380 mg, 1.00 mmol) in EtOAc (4 mL) and CH2C12 (4 mL) was added 4 M hydrogen chloride in EtOAc (4 mL). The mixture was stirred at ambient temperature for 4 hr and concentrated to give a white solid. The solid was alkalized with saturated aqueous NaHCO3 filtered, washed with H2O and hexane, and dried at 50 °C under reduced
pressure. To a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (680 mg, 2.00 mmol) in CH2C12 (30 mL) was added PNP (8 mL). To the resulting suspension was added a solution of the above solid in CH2C12 (5 mL). The mixture was stirred at ambient temperature for 10.5 hr and filtered. The filtrate was washed with saturated aqueous ΝaHCO3, dried over MgSO4, filtered, concenfrated, and purified by medium-pressure liquid chromatography (NH-silica gel, EtOAc) to give a solid . The solid was washed with Et2O and dried at 50 °C under reduced pressure to give 4-bromo-N-[4-(4-dimethylamino- quinazolin-2-ylamino)-ρhenyl]-2-trifluoromethoxy-benzenesulfonamide (202 mg, 35%) as a pale yellow solid.
ESI MS m/e 582, M + ET ; Η ΝMR (300 MHz, CDC13) δ 7.88 (d, J= 8.4 Hz, 1 H), 7.73 (d, J= 8.4 Hz, 1 H), 7.64 (d, J= 8.9 Hz, 2 H), 7.51-7.58 (m, 3 H), 7.44 (dd, J= 8.4, 1.7 Hz, 1 H), 7.07-7.24 (m, 1 H), 7.02 (d, J= 8.9 Hz, 2 H), 3.32 (s, 6 H).
Example 33
4-Bromo-iV-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of [4-(tert-butoxycarbonylamino-methyl)-phenyl]-carbamic acid benzyl ester.
To a solution of 4-aminomethyl-phenylamine (3.00 g, 24.6 mmol) in CHCL, (30 mL) was added triethylamine (2.61 g, 25.8 mmol). After cooling on an ice-bath, (Boc)2O
(5.63 g, 25.8 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 55 min and poured into saturated aqueous NaHCO3. The aqueous layer was extracted with CHCL, (three times) and the combined organic layer was dried over
MgSO4, filtered, and concentrated to give a pale yellow oil. To a solution of the above oil in CHCL, (30 mL) was added diisopropylethylamine (3.33 g, 25.8 mmol). The resulting solution was cooled to 4 °C and ZC1 (4.40 g, 25.8 mmol) was added below 10 °C over 5 min. The reaction mixture was stirred at ambient temperature for 12 hr, and poured into
saturated aqueous NaHCO3. The aqueous layer was extracted with CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 2% MeOH in CHCL,) to give [4-(tert- butoxycarbonylamino-methyl)-phenyl]-carbamic acid benzyl ester (2.64 g, 30%) as a white solid.
ESI MS m/e 379, M + Na+ ; Η NMR (300 MHz, CDCLJ 6 7.11 -7.44 (m, 9 H), 6.76 (brs, 1 H), 5.19 (s, 2 H), 4.81 (brs, 1 H), 4.25 (d, J= 5.1 Hz, 2 H), 1.45 (s, 9 H).
Step B: Synthesis of (4-aminomethyl-phenyl)-carbamic acid benzyl ester hydrochloride.
A solution of [4-(tert-butoxycarbonylamino-methyl)-phenyl] -carbamic acid benzyl ester (1.25 g, 3.51 mmol) in EtOAc (20 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (20 mL) was added. The mixture was stirred at ambient temperature for 20 min. The precipitate was collected by filtration, washed with EtOAc, and dried under reduced pressure to give (4-aminomethyl-phenyl)-carbamic acid benzyl ester hydrochloride (957 mg, 93%) as a white solid.
ESI MS m/e 279, M + Na+ ; Η NMR (300 MHz, DMSO-d6) δ 9.90 (s,.1 H), 8.37 (brs, 3 H), 7.29-7.55 (m, 9 H), 5.15 (s, 2 H), 3.85-4.01 (m, 2 H).
Step C: Synthesis of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}- carbamic acid benzyl ester.
Using the procedure for the step C of example 3, the title compound was obtained. ESI MS m/e 428, M + ET ; Η NMR (300 MHz, CDC13) δ 7.82 (d, J= 7.5 Hz, 1 H), 7.25- 7.52 (m, 11 H), 6.98-7.07 (m, 1 H), 6.74 (brs, 1 H), 5.28 (brs, 1 H), 5.19 (s, 2 H), 4.65 (d, J = 5.9 Hz, 2 H), 3.25 (s, 6 H).
Step D: Synthesis of 4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-phenyl}-2-trifluoromethoxy-benzenesulfonamide.
To a solution of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}- carbamic acid benzyl ester (318 mg, 0.744 mmol) in MeOH (3 mL) was added 5% Pd/C
(30 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 41.5 hr, filtered through a pad of celite, and concentrated. To a solution of 4-bromo-2-trifluoromethoxy- benzenesulfonyl chloride (505 mg, 1.49 mmol) in CH2C12 (12 mL) was added PNP (6 mL).
To the resulting suspension was added a solution of the above residue in CH2C12 (10 mL). The mixture was stirred at ambient temperature for 1.5 days, filtered, poured into saturated aqueous NaHCO3. The aqueous layer was extracted with CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane) to give 4- bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-2- trifluoromethoxy-benzenesulfonamide (330 mg, 74%) as a pale brown solid. ESI MS m/e 596, M + H÷ ; Η ΝMR (300 MHz, CDCLJ δ 7.83 (d, J= 8.4 Hz, 1 H), 7.77 (d, J= 8.4 Hz, 1 H), 7.41-7.60 (m, 4 H), 7.22 (d, J= 8.6 Hz, 2 H), 7.08-7.18 (m, 1 H), 6.99 (d, J= 8.6 Hz, 2 H), 4.56 (d, J= 5.6 Hz, 2 H), 3.34 (s, 6 H).
Example 34
i,r «5-iV',iV'-Dimethyl-N2-{4-[(2-trifiuoromethoxy-benzylamino)-methyl]- cyclohexyImethyI}-quinazoline-2,4-diamine
Step A: Synthesis of i!r««5-Nl/,iV'-dimethyl-N2-{4-[(2-trifluoromethoxy-benzylamino)- methyl]-cyclohexylmethyl}-quinazoline-2,4-diamine.
Using the procedure for the step B of example 15, the title compound was obtained.
ESI MS m/e 510, M + Νa+ ; Η NMR (300 MHz, CDC13) δ 7.80 (d, J= 8.2 Hz, 1 H), 7.39- 7.57 (m, 3 H), 7.15-7.35 (m, 3 H), 7.02 (ddd, J= 8.3, 6.0, 2.2 Hz, 1 H), 3.83 (s, 2 H), 3.35 (t, J= 6.3 Hz, 2 H), 3.27 (s, 6 H), 2.45 (d, J= 6.5 Hz, 2 H), 1.69-2.04 (m, 4 H), 1.37-1.69 (m, 2 H), 0.84-1.12 (m, 4 H).
Example 35
Λ^,tV-Dimethyl-N2-[l-(2-trifluoromethoxy-benzyl)-piperidin-4-yI]-quinazoline-2,4- diamine
Step A: Synthesis of N*,N'-dimethyl-N2-[l-(2-trifluoromethoxy-benzyI)-piperidin-4- yl] -quinazoline-2,4-diamine.
Using the procedure for the step B of example 15, the title compound was obtained.
ESI MS m/e 468, M + Na+ ; Η NMR (300 MHz, CDC13) δ 7.80 (d, J= 7.8 Hz, 1 H), 7.37- 7.63 (m, 3 H), 7.17-7.35 (m, 3 H), 7.02 (ddd, J= 8.3, 6.4, 1.9 Hz, 1 H), 5.12 (brs, 1 H), 3.86-4.07 (m, 1 H), 3.60 (s, 2 H), 3.26 (s, 6 H), 2.74-2.94 (m, 2 H), 2.18-2.37 (m, 2 H), 1.98-2.15 (m, 2 H), 1.45-1.69 (m, 2 H).
Example 36
2HCI te n5-N*,N*-Dimethyl-iV2-(4-{[(3-trifluoromethoxy-biphenyl-4-ylmethyl)-amino]- methyl}-cyclohexylmethyl)-quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of ra«5-N',A'='-dimethyl-N2-(4-{[(3-trifluoromethoxy-biphenyI-4- ylmethyl)-amino]-methyl}-cyclohexylmethyl)-quinazoline-2,4-diamine- dihydrochloride.
To a solution of tr rø-N2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]- cyclohexylmethyl}-N/,N'-dimethyl-quinazoline-2,4-diamine obtained in step B of example
15 (300 mg, 0.529 mol) in toluene (6.6 mL) were added MeOH (2.2 mL), 2 M aqueous K2CO3 (2.2 mL), phenylboronic acid (77 mg, 0.635 mmol), and tefrakis (friphenylphosphine) palladium (61 mg, 0.053 mmol). The reaction mixture was stirred at 130 °C for 12 hr. The mixture was poured into water, and the aqueous layer was exfracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated and, purified by flash chromatography (NH-silica gel, 33% CHC13 in hexane and silica gel, 9% MeOH in CHCL,) to give pale yellow oil. To a solution of above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (0.1 mL). The mixture was stirred at ambient temperature for 20 min and concentrated. A solution of the residue in Et2O (2 mL) was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with Et2O, and dried under reduced pressure to give trαrø-N4,N4- dimethyl-N2-(4-{[(3-trifluoromethoxy-biphenyl-4-ylmethyl)-amino]-methyl}- cyclohexylmethyl)-quinazoline-2,4-diamine dihydrochloride (70 mg, 21% ) as a white solid.
ESI MS m/e 564, M (free) + H+ ; Η ΝMR (300 MHz, CDCL.) δ 13.27 (s, 1 H), 9.96 (brs, 2 H), 8.17-8.32 (m, 2 H), 7.89 (d, J= 7.9 Hz, 1 H), 7.34-7.64 (m, 9 H), 7.20 (t, J= 7.7 Hz, 1 H), 4.29 (brs, 2 H), 3.50 (s, 6 H), 3.28 (t, J= 6.1 Hz, 2 H), 2.69 (brs, 2 H), 1.79-2.11 (m, 4 H), 1.44-1.68 (m, 2 H), 0.91-1.16 (m, 4 H).
Example 37
2HCI c s-N2-{4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-iV',7y,- dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde.
To a suspension of (methoxymethyl) friphenylphosphonium chloride (5.29 g, 14.9 mol) in Et2O (50 mL) was added 1.8 M phenyl lithium in 30% Et2O in cyclohexane (8.58 mL, 15.5 mmol). The mixture was stirred at ambient temperature for 10 min. To the
reaction mixture was added 4-bromo-2-trifluoromethoxy-benzaldehyde (4 g, 14.9 mmol) in Et2O (18 mL). The mixture was stirred at ambient temperature for 4 hr, filtrated, and concenfrated. To the above residue was added 10% H2SO4 in AcOH (40 mL). The mixture was stirred at ambient temperature for 90 min. The solution was poured into H2O, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was washed with saturated aqueous NaHCO3, washed with brine, dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 9% EtOAc in hexane) to give (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde .(1.25 g, 30 %) as a pale brown oil.
ESI MS m/e 284, M + H+ ; Η NMR (200 MHz, CDCLJ δ 9.74 (t, J= 1.5 Hz, 1 H), 7.41- 7.51 (m, 2 H), 7.16 (d, J= 8.4 Hz, 1 H), 3.75 (d, J= 1.5 Hz, 2 H).
Step B: Synthesis of c y-N2-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino] -cyclohexyl}-N',iV'-dimethyl-quinazoline-2,4-diamine dihydrochloride.
To a suspension of cM-N2-(4-amino-cyclohexyl)-N'/,N'/-dimethyl-quinazoline-2,4- diamine obtained in step C of example 9 (300 mg, 1.05 mmol) in CH2C12 (3 mL) were added (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde (357 mg, 1.26 mmol), AcOH (76 mg, 1.26 mmol), and ΝaBH(OAc)3 (334 mg, 1.57 mmol). The reaction mixture was stirred at ambient temperature for 4.5 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a pale yellow solid. To a solution of above solid in EtOAc (0.8 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 30 min and concentrated. A solution of the residue in Et2O (2 mL) was stirred at ambient tempareture for 30 min. The precipitate was collected by filtration, washed with Et2O, and dried under reduced pressure to give cw-N2-{4-[2-(4-bromo-2-frifluoromethoxy-phenyl)-ethylamino]- cyclohexy -N^N^dimemyl-quinazoline^^-diamine dihydrochloride (161 mg, 25% ) as a white solid.
ESI MS m/e 552, M (free)+ ; Η ΝMR (200 MHz, CDCLJ δ 12.66 (brs, 1 H), 9.91 (brs, 2 H), 8.71 (brs, 1 H), 7.93 (d, J= 6.6 Hz, 1 H), 7.19-7.77 (m, 6 H), 4.31 (brs, 1 H), 3.54 (s, 6 H), 3.09-3.78 (m, 5 H), 2.00-2.48 (m, 6 H), 1.62-1.96 (m, 2 H).
Example 38
2HCI cw /V,iV^-Dimethyl-iV2-[4-(2-trifluoromethoxy-benzylamino)-cyclohexyI]-quinazoline-
2,4-diamine dihydrochloride
Step A: Synthesis of cis-N7',Λ^-dimethyl-N2-[4-(2-trifluoromethoxy-benzylamino)- cyclohexyl]-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 460, M (free) + H+ ; Η NMR (300 MHz, CDCL.) δ 8.68 (d, J= 7.6 Hz, 1 H), 8.19-8.33 (m, 1 H), 7.95 (d, J= 8.2 Hz, 1 H), 7.66 (t, J= 7.7 Hz, 1 H), 7.47 (d, J= 8.1 Hz, 1 H), 7.18-7.44 (m, 4 H), 4.35 (s, 2 H), 4.15-4.47 (m, 1 H), 3.53 (s, 6 H), 3.02-3.31 (m, 1 H), 1.95-2.37 (m, 6 H), 1.51-1.85 (m, 2 H).
Example 39
2HCI c 5-N2-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-7Y',iV'-dimethyI- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of cw-N2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)- cyclohexyl]-iV',iV-dimethyl-quinazolme-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 2, the title compound was obtained. ESI MS m/e 538, M (free) + H+; Η NMR (300 MHz, CDC13) δ 8.77 (d, J= 7.5 Hz, 1 H), 8.11 (d, J= 8.4 Hz, 1 H), 7.92 (d, J= 8.6 Hz, 1 H), 7.67 (t, J= 7.7 Hz, 1 H), 7.41-7.53 (m,
2 H), 7.37 (s, 1 H), 7.28 (t, J= 7.8 Hz, 1 H), 4.19-4.40 (m, 1 H), 4.26 (s, 2 H), 3.52 (s, 7 H), 3.07-3.25 (m, 1 H), 2.00-2.39 (m, 6 H), 1.61-1.88 (m, 2 H).
Example 40
HCl cis-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2- trifluoromethoxy-benzenesulfonamide hydrochloride
Step A: Synthesis of c s-N-[4-(4-dimethylamino-qumazolin-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide hydrochloride.
To a solution of c/i'-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-carbamic acid benzyl ester obtained in step B of example 24 (4.57 g, 10.5 mmol) in MeOH (46 L) was added 5% Pd/C (460 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 3 days, filtered, and concentrated to give a white solid (3.79 g). To a solution of the above solid (500 mg, 1.67 mmol) in CH2C12 (5 mL) was added diisopropylethylamine (440 μL, 2.53 mmol). The mixture was cooled on an ice-bath and a solution of 2-trifluoromethoxy-benzenesulfonyl chloride (457 mg, 1.75 mmol) in CH2C12 (2 L) was added dropwise. The reaction mixture was stirred on an ice-bath for 10 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHCL. (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concenfrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cw-N-[4-(4-dimemylanfrno-quinazolin-2-ylamino)-cyclohexylmethyl]-2- trifluoromethoxy-benzenesulfonamide hydrochloride (262 mg, 34%) as a white solid. ESI MS m/e 524, M (free) + ¥t ; Η ΝMR (300 MHz, CDC13) δ 13.18 (s, 1 H), 8.75 (d, J=
7.6 Hz, 1 H), 8.03 (dd, J= 8.0, 1.7 Hz, 1 H), 7.89 (d, J= 8.2 Hz, 1 H), 7.56-7.71 ( , 2 H), 7.34-7.55 ( , 3 H) , 7.24 (t, J= 7.5 Hz, 1 H), 4.99 (t, J= 6.5 Hz, 1 H), 4.20-4.33 (m, 1 H), 3.50 (s, 6 H), 2.88 (t, J= 6.3 Hz, 2 H), 1.78-1.99 (m, 2 H), 1.38-1.77 (m, 7 H).
Example 41
2HCI c s-N2-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-iV',iV'- dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c/5-N2-{4-[(4-bromo-2-trifluoromethoxy-benzyIamino)-methyl]- cyclohexyI}-N ^V4-dimethyl-quinazoline-2,4-diamine dihydrochloride.
To a solution of cti,-[4-(4-dimethylamino-quinazolin-2-ylamino)- cy clohexylmethyl] -carbamic acid benzyl ester obtained in step B of example 24 (4.57 g,
10.5 mmol) in MeOH (46 mL) was added 5% Pd/C (460 mg). The mixture was stirred at
50 °C under hydrogen atmosphere for 3 days, filtered, and concenfrated to give a colorless solid (3.79 g). To a solution of the above solid (500 mg, 1.67 mmol) in CH2C12 (5 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step A of example 13
(449 mg, 1.67 mmol), AcOH (100 mg, 1.67 mmol), and NaBH(OAc)3 (531 g, 2.51 mmol).
The reaction mixture was stirred at ambient temperature with CaCl2 tube for 9 hr, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 25% EtOAc in hexane), and concenfrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concenfrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cz'i'-N2-{4-[(4- bromo-2-frifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-N4,N4-dimethyl- quinazoline-2,4-diamine dihydrochloride (147 mg, 34%) as a white solid.
ESI MS m/e 552, M (free) + ET; Η ΝMR (300 MHz, CDC13) δ 12.62 (s, 1 H), 10.07 (brs,
2 H), 8.66 (d, J= 1.6 Hz, 1 H), 8.22 (d, J= 8.4 Hz, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.65 (t, J= 1.6 Hz, 1 H), 7.52 (dd, J= 8.3, 1.8 Hz, 1 H), 7.33-7.48 (m, 2 H), 7.26 (t, J= 7.5 Hz, 1 H), 4.11-4.36 (m, 3 H), 3.51 (s, 6 H), 2.76-2.97 (m, 2 H), 1.51-2.27 (m, 9 H).
Example 42
cJ -Nrf,/ -DimethyI-N2-{4-[(2-trifluoromethoxy-benzylamino)-methyI]-cyclohexyl}- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c 5,-iV',Λ^-dimethyl-N2-{4-[(2-trifluoromethoxy-benzylamino)- methyl]-cycIohexyI}-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 41, the title compound was obtained. ESI MS m/e 474, M (free) + H* ; Η NMR (300 MHz, CDC13) δ 12.81 (s, 1 H), 9.97 (brs, 1 H), 8.69 (d, J= 7.5 Hz, 1 H), 8.16-8.28 (m, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.63 (t, J= 7.6 Hz, 1 H), 7.18-7.51 (m, 4 H), 4.31 (brs, 2 H), 4.15-4.30 (m, 1 H), 3.50 (s, 6 H), 2.70-2.94 (m, 2 H), 1.41-2.28 (m, 1 O H).
Example 43
HCl cis-3-Trifluoromethoxy-biphenyI-4-sulfonic acid [4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexyl]-amide hydrochloride
Step A: Synthesis of s-3-trifluoromethoxy-biphenyl-4-sulfonic acid [4-(4-
dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride.
Using the procedure for the step A of example 36, the title compound was obtained. ESI MS m/e 586, M (free) + ET ;Η NMR (300 MHz, CDCLJ δ 13.20 (brs, 1 H), 8.82 (d, J = 8.1 Hz, 1 H), 8.09 (d, J= 8.6 Hz, 1 H), 7.88 (d, J= 7.8 Hz, 1 H), 7.40-7.73 (m, 8 H), 7.25 (t, J= 8.4 Hz, 1 H), 5.41 (d, J= 8.6 Hz, 1 H), 4.07-4.22 (m, 1 H), 3.49 (s, 6 H), 3.37- 3.62 (m, 1 H), 1.57-2.01 (m, 8 H).
Example 44
c s-N2-{4-[Bis-(4-bromo-2-trifiuoromethoxy-benzyl)-amino]-cyclohexyl}-Λr'JV'- dimethyl-quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of -N2-{4-[bis-(4-bromo-2-trifluoromethoxy-benzyl)-amino]- cyclohexyl}-/ ,/ -dimethyI-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 790, M (free) + H+ ; Η NMR (300 MHz, CDC13) δ 12.50-12.82 (m, 2 H), 9.50-9.69 (m, 1 H), 8.39 (d, J= 8.1 Hz, 2 H), 7.91 (d, J= 8.1 Hz, 1 H), 7.66 (t, J= 7.8 Hz, 1 H), 7.48 (t, J= 8.7 Hz, 2 H), 7.07-7.43 (m, 4 H), 4.06-4.67 (m, 5 H), 3.51 (s, 6 H), 2.97- 3.27 (m, 1 H), 2.21-2.59 (m, 4 H), 1.89-2.17 (m, 2 H), 1.36-1.82 (m, 2 H)
Example 45
2HCI c y-iV',iV'-Dimethyl-N2-{4-[(3-trifluoromethoxy-biphenyl-4-yImethyl)-amino]- cyclohexyl}-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c s-N,/,iV*-dimethyl-N2-{4-[(3-trifIuoromethoxy-biphenyI-4- ylmethyl)-amino]-cyclohexyl}-quinazoIine-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 43, the title compound was obtained. ESI MS m/e 536, M (free) + H+ ; Η NMR (300 MHz, CDCL.) δ 12.63 (brs, 1 H), 10.07 (brs, 2 H), 8.68 (d, J= 7.3 Hz, 1 H), 8.33 (d, J= 8.1 Hz, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.17-7.68 (m, 10 H), 4.40 (s, 2 H), 4.19-4.33 (m, 1 H) , 3.50 (s, 6 H), 3.16-3.37 (m, 1 H), 2.03-2.48 (m, 6 H), 1.64-1.88 (m, 2 H).
Example 46
2HCI teflM5-N^-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cycIohexyl]-N*,N*-dimethyI- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of rα«5-N2-[4-(4-bromo-2-trifluoromethoxy-benzyIamino)- cyclohexylJ-A^j/V-dimethyl-quinazoline^^-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 537, M (free)+ ; Η NMR (300 MHz, CDCLJ δ 13.00 (brs, 1 H), 10.08 (brs, 2 H), 8.40 (d , J= 7.2 Hz, 1 H), 8.05 (d, J= 8.2 Hz, 1 H), 7.91 (d , J= 8.4 Hz, 1 H), 7.65 (t,
J= 1.1 Hz, 1 H), 7.38-7.57 (m, 3 H), 7.26 (t, J= 1.6 Hz, 1 H), 4.17 (s, 2 H), 3.83-4.06 (m, 1 H), 3.53 (s, 6 H), 2.76-2.99 (m, 1 H), 2.09-2.46 (m, 4 H), 1.74-2.00 (m, 2 H), 1.28-1.58 (m, 2 H).
Example 47
l-(4-Bromo-2-trifluoromethoxy-phenyl)-l-[4-(4-dimethyIamino-quinazoIin-2- ylamino)-piperidin-l-yl]-methanone hydrochloride
Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-[4-(4-dimethylamino- quinazoIin-2-yIamino)-piperidin-l-yl]-methanone hydrochloride.
To a solution of 4-bromo-2-frifluoromethoxy-benzoic acid obtained in step B of example 13 (440 mg, 1.47 mmol) in CH2C12 (5 mL) were added DMF (1.1 μL, 15 μmol) and SOCl2 (175 μL, 2.09 mmol). The mixture was stirred at reflux for 30 min and concentrated to give acid chloride as a pale yellow oil. To a solution of N/,N'-dimethyl-N2- piperidin-4-yl-quinazoline-2,4-diamine obtained in step B of example 30 (400 mg, 1.47 mmol) in CH2C12 (4 mL) was added diisopropylethylamine (538 μL, 3.08 mmol). The mixture was cooled at 4 °C and a solution of above acid chloride in CH2C12 (3 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 3 hr. The reaction was quenched with saturated aqueous ΝaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane) to give a pale yellow oil. To a solution of above oil in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (0.26 mL). The mixture was stirred at ambient temperature for 50 min and concenfrated. A solution of the residue in Et2O (5 mL) was stirred at ambient tempareture for 30 min. The precipitate was collected by filtration, washed with Et2O, and dried under reduced pressure to give (4-bromo-2-trifluoromethoxy-phenyl)-[4- (4-dimethylamino-quinazolin-2-ylamino)-piperidin- 1 -yl] -mefhanone hydrochloride (126
mg, 16% ) as a white solid.
ESI MS m/e 538, M (free) + H+ ; Η NMR (200 MHz, CDCL δ 13.35 (brs, 1 H), 9.06 (d, J
= 7.5 Hz, 1 H), 7.93 (d, J= 8.4 Hz, 1 H), 7.67 (dt, J= 1.1, 0.9 Hz, 1 H), 7.43-7.61 (m, 3 H),
7.18-7.41 (m, 2 H), 4.00-4.44 (m, 2 H), 3.54 (s, 6 H), 3.03-3.78 (m, 3 H), 1.52-2.24 (m, 4
H).
Example 48
HCl c s-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzamide dihydrochloride
Step A: Synthesis of 4-bromo-N-[4-(4-dimethylamino-quinazoIin-2-ylamino)- cyclohexyl]-2-trifluoromethoxy-benzamide dihydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 551, M (free)+ ; Η NMR (200 MHz, CDC13) δ 13.24 (brs, 1 H), 8.95 (d, J = 7.9 Hz, 1 H), 7.92 (d, J= 8.4 Hz, 1 H), 7.71 (d, J= 8.4 Hz, 1 H), 7.60-7.67 (m, 1 H), 7.44- 7.58 (m, 3 H), 7.20-7.34 (m, 1 H), 6.57 (d, J= 8.4 Hz, 1 H), 4.00-4.41 (m, 2 H), 3.53 (s, 6 H), 1.66-2.04 (m, 8 H).
Example 49
HCl 5-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2- trifluoromethoxy-benzamide hydrochloride
Step A: Synthesis of 4-bromo-N-[4-(4-dimethylamino-quinazoIin-2-yIamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 565, M (free)+ ; Η NMR (200 MHz, CDCLJ δ 13.20 (brs, 1 H), 8.93 (d, J = 7.9 Hz, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.84 (d, J= 8.4 Hz, 1 H), 7.42-7.70 (m, 4 H), 7.18- 7.34 (m, 1 H), 6.87 (t, J= 5.5 Hz, 1 H), 4.34 (brs, 1 H), 3.51 (s, 6 H), 3.43 (t, J= 5.7 Hz, 2 H), 1.52-2.17 (m, 9 H).
Example 50
2HCI c/5-N2-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-7Λ^-methyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of (2-chloro-quinazolin-4-yl)-methyl-amine.
A solution of 2,4-dichloro-quinazoline obtained in step A of example 1 (125 g, 628 mmol) in THF (1 L) was cooled to 4 °C and 40% aqueous MeNH2 (136 mL, 1.57 mol) was added. The mixture was stirred at ambient temperature for 80 min. The solution was alkalized with saturated aqueous NaHCO3 (pH = 9) and concentrated. The precipitate was collected by filtration, washed with H2O and hexane, and dried at 80 °C to give (2-chloro- quinazolin-4-yl)-methyl-amine (114 g, 94%) as a white solid.
ESI MS m/e 193, M+ ; Η NMR (300 MHz, CDC13) δ 7.68-7.78 (m, 3 H), 7.39-7.48 (m, 1 H), 6.34 (brs, 1 H), 3.22 (d, J= 4.8 Hz, 3 H).
Step B: Synthesis of c/s-[4-(4-methylamino-quinazolin-2-ylamino)-cycIohexyl]- carbamic acid tert-butyl ester.
Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 372, M + ET ; Η NMR (300 MHz, CDC13) δ 7.36-7.56 (m, 3 H), 7.06 (ddd, J = 8.2, 6.8, 1.3 Hz, 1 H), 5.71 (brs, 1 H), 5.10 (brs, 1 H), 4.45-4.72 (m, 1 H), 4.00-4.26 (m,
1 H), 3.49-3.76 (m, 1 H), 3.12 (d, J= 4.8 Hz, 3 H), 1.50-1.93 (m, 8 H), 1.46 (s, 9 H).
Step C: Synthesis of c s-N2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)- cyclohexyl]-N'-methyI-quinazoIine-2,4-diamine dihydrochloride.
To a suspension of c/j,-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]- carbamic acid tert-butyl ester (1.75 g, 4.71mmol) in EtOAc (5mL) and CHC13 (10 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalized with saturated aqueous NaHCO3 and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated (2.15 g). To a suspension of the above residue (300 mg, 1.11 mmol) in CH2C12 (3 mL) were added 4- bromo-2-trifluoromethoxy-benzaldehyde obtained in Step A of Example 13 (297 mg, 1.10 mmol), AcOH (66 mg, 1.10 mmol), and NaBH(OAc)3 (351 mg, 1.66 mmol). The reaction mixture was stirred at ambient temperature with CaCl2 tube for 4 hr, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane), and concentrated to give a pale yellow oil (91 mg). To a solution of the residue (71 mg) in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cw-N2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)- cyclohexyl]-N4-methyl-quinazoline-2,4-diamine dihydrochloride (62 mg, 20%) as a white solid.
ESI MS m/e 524, M (free) + H* ; Η ΝMR (300 MHz, CDCL.) δ 7.34-7.57 (m, 6 H), 7.05 (ddd, J= 8.2, 6.8, 1.4 Hz, 1 H), 5.52 (brs, 1 H), 4.09-4.27 (m, 1 H), 3.82 (s, 2 H), 3.12 (d, J= 4.8 Hz, 3 H), 2.57-2.72 (m, 1 H), 1.41-1.94 (m, 8 H).
Example 51
2HCI c/5-N2-{4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4- methyI-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c/s,-iV2-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyIamino]- cyelohexyl}-iV -methyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step C of example 50, the title compound was obtained.
ESI MS m/e 538, M (free) + H+; Η NMR (300 MHz, CDCLJ δ 12.18 (brs, 1 H), 9.93 (brs, 3 H), 8.74 (d, J= 6.2 Hz, 1 H), 7.71-7.94 (m, 1 H), 7.60 (t, 1 H, J= 7.7 Hz, 1 H), 7.21- 7.45 (m, 5 H), 3.94-4.26 (m, 1 H), 3.35-3.58 (m, 2 H), 3.08-3.33 (m, 3 H), 2.94 (brs, 3 H), 1.64-2.42 (m, 8 H).
Example 52
2HCI 5-NI'-MethyI-iV2-[4-(2-trifluoromethoxy-benzylamino)-cyclohexyl]-quinazoIine- 2,4-diamine dihydrochloride
Step A: Synthesis of cis-iV#-methyl-N5-[4-(2-trifluoromethoxy-benzylamino)- cyclohexyl]-quinazoIine-2,4-diamine dihydrochloride.
Using the procedure for the step C of example 50, the title compound was obtained.
ESI MS m/e 446, M (free) + H+ ; Η NMR (300 MHz, CDCLJ δ 7.36-7.56 (m, 4 H), 7.17- 7.33 (m, 3 H), 7.04 (ddd, 1 H, J= 8.2, 6.8, 1.4 Hz, 1 H), 5.66 (brs, 1 H), 5.18 (brs, 1 H), 4.11-4.27 (m, 1 H), 3.87 (s, 2 H), 3.10 (d, J= 4.8 Hz, 3 H), 2.60-2.74 (m, 1 H) , 1.45-1.95 (m, 8 H).
Example 53
HCl c 5-4-Bromo-N-[4-(4-methylamino-quinazolin-2-yIamino)-cyclohexyl]-2- trifluoromethoxy-benzamide hydrochloride
Step A: Synthesis of CM,-4-bromo-N-[4-(4-methylamino-quinazolin-2-yIamino)- cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride.
To a suspension of ew-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]- carbamic acid tert-butyl ester obtained in step B of example 50 (1.75 g, 4.71mmol) in EtOAc (5 mL) and CHC13 (10 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalized with saturated aqueous NaHCO3 and the aqueous layer was exfracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated. To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid obtained in step B of example 13 (331 mg, 1.16 mmol) in CH2C12 (5 mL) were added DMF (1 μL, 0.01 mmol) and SOCl2 (120 μL, 1.65 mmol). The mixture was stirred at reflux for 30 min and concentrated to give acid chloride as a pale yellow oil. To a suspension of cw-N2-(4-amino- cyclohexyl)-N4-methyl-quinazoline-2,4-diamine (300 mg, 1.11 mmol) in CH2C12 (3 mL) was added diisopropylethylamine (410 μ L, 2.35 mmol). The mixture was cooled on an ice-bath and a solution of the above residue in CH2C12 (3 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 3.5 hr. The reaction was quenched with saturated aqueous ΝaHCO3 The aqueous layer was extracted with CHCL. (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by
flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a pale yellow solid. To a solution of the residue (116 mg) in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 L). The reaction mixture was stirred at ambient temperature for 30 min, and concenfrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give 4-bromo-N-[4-(4- methylamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzamide (102 mg, 16%) as a white solid.
ESI MS m/e 538, M (free) + If ; Η ΝMR (300 MHz, CDCL.) δ 12.72 (s, 1 H), 8.66 (d, J= 7.1 Hz, 1 H), 8.35 (brs, 1 H), 8.16 (d, J= 7.7 Hz, 1 H), 7.74 (d, J= 8.4 Hz, 1 H), 7.48-7.60 (m, 2 H), 7.40-7.43 (m, 1 H), 7.30 (d, J= 8.4 Hz, 1 H), 7.19 (t, J= 7.8 Hz, 1 H), 6.57 (d, J = 8.1 Hz, 1 H), 4.34 (brs, 1 H), 4.15 (brs, 1 H), 3.22 (d, J= 3.9 Hz, 3 H), 1.90 (m, 8 H).
Example 54
HCl cw-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2- trifluoromethoxy-benzamide hydrochloride
Step A: Synthesis of c/s-N-[4-(4-dimethylamino-quinazohn-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.
To a solution of cw-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-carbamic acid benzyl ester obtained in step B of example 24 (4.57 g,
10.5 mmol) in MeOH (46 mL) was added 5% Pd/C (460 mg). The mixture was stirred at
50 °C under hydrogen atmosphere for 3 days, filtered, and concentrated to give a white solid (3.79 g). To a solution of the above solid (300 mg, 1.00 mmol) in CH2C12 (3 mL) was added triethylamine (280 μL, 2.01 mmol). The mixture was cooled on an ice-bath and a solution of 2-frifluoromethoxy-benzoyl chloride (236 mg, 1.05 mmol) in CH2C12 (2 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 5 hr. The reaction was quenched with saturated aqueous ΝaHCO3 The aqueous layer was exfracted with
CHCL, (three times). The combined organic layer was dried over MgSO4, filtered,
concentrated, purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane and silica gel, 10% MeOH in CHCL,), and concenfrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cw-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]- 2-frifluoromethoxy-benzamide hydrochloride (134 mg, 31%) as a white solid. ESI MS m/e 510, M (free) + Νa+ ; Η NMR (300 MHz, CDCL.) δ 13.29 (s, 1 H), 8.89 (d, J = 7.9 Hz, 1 H), 7.93 (dd, J= 1.1, 1.8 Hz, 1 H), 7.89 (d, J= 8.4 Hz, 1 H), 7.63 (t, J= 7.3 Hz, 1 H), 7.52 (d, J= 7.9 Hz, 1 H), 7.47 (dd, J= 8.1, 1.9 Hz, 1 H), 7.39 (t, J= 7.6 Hz, 1 H), 7.29 (d, J= 9.0 Hz, 1 H), 7.23 (d, J= 7.3 Hz, 1 H), 6.77 (t, J= 5.6 Hz, 1 H), 4.18-4.36 (m, 1 H), 3.51 (s, 6 H), 3.42 (t, J= 6.3 Hz, 2 H), 1.35-2.02 (m, 9 H).
Example 55
HCl cw,-N-[4-(4-Methylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy- benzamide hydrochloride
Step A: Synthesis of c 5-N-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzamide hydrochloride.
Using the procedure for the step A of example 54, the title compound was obtained. ESI MS m/e 460, M (free) + H+ ; Η NMR (300 MHz, CDC13) δ 12.61 (s, 1 H), 8.70 (d, J= 4.4 Hz, 1 H), 8.57 (d, J= 7.6 Hz, 1 H), 8.26 (d, J= 8.1 Hz, 1 H), 7.82 (dd, J= 7.7, 1.8 Hz, 1 H), 7.08-7.57 (m, 6 H), 6.60 (d, J= 8.1 Hz, 1 H), 4.25-4.45 (m, 1 H), 4.01-4.25 (m, 1 H), 3.20 (d, J= 4.5 Hz, 3 H), 1.53-2.18 (m, 8 H).
Example 56
HCl eϊ5-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy- benzamide hydrochloride
Step A: Synthesis of c s-iV-[4-(4-dimethyIamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzamide hydrochloride.
To a suspension of polymer supported DMAP (2.45 g, 7.35 mmol) in CH2C12 (6 mL) were added 2-trifluoromethoxy-benzoyl chloride (472 mg, 2.10 mmol) and cw-N2-(4- amino-cyclohexyl)-N N^-dmιethyl-quinazoline-2,4-diamine obtained in step C of example 9 (300 mg, 1.05 mmol). The mixture was stirred at ambient temperature for 24 h, filtered, poured into saturated aqueous ΝaHCO3. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 25% EtOAc in hexane), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The reaction mixture was stirred at ambient temperature for 1 hr, and concentrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cis-N- [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl] -2-trifluoromethoxy- benzamide hydrochloride (145 mg, 27%) as a white solid.
ESI MS m/e 474, M + H+ ; Η NMR (300 MHz, CDCL.) δ 13.22 (s, 1 H), 8.88 (d, J= 7.5 Hz, 1 H), 7.90 (d, J= 8.2 Hz, 1 H), 7.79 (dd, J= 7.6, 1.9 Hz, 1 H), 7.64 (t, J= 7.5 Hz, 1 H), 7.52 (d, J= 8.7 Hz, 1 H), 7.47 (dd, J= 8.1, 1.9 Hz, 1 H), 7.37 (dt, J= 7.5, 1.2 Hz, 1 H), 7.20-7.33 (m, 2 H), 6.66 (d, J= 8.4 Hz, 1 H), 4.06-4.36 (m, 2 H), 3.52 (s, 6 H), 1.55-2.21 (m, 8 H).
Example 57
c/5-N2-[4-(4-Bromo-2-trifluoromethoxy-phenylamino)-cyclohexyl]-iV',N'-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of cw-iV2-[4-(4-bromo-2-trifluoromethoxy-phenylamino)- cyclohexyl]-Λ^,iV*-dimethyI-quinazoline-2,4-dianπne dihydrochloride.
To a glass flask were added 18-crown-6 (647 mg, 2.45 mmol), 4-Bromo-l-iodo-2- trifluoromethoxy-benzene (770 mg, 2.10 mmol), ew-N2-(4-amino-cyclohexyl)-/Nr,N'- dimethyl-quinazoline-2,4-diamine obtained in step C of example 9 (500 mg, 1.75 mmol), sodium tert-butoxide (235 mg, 2.45 mmol), fris(dibenzylideneacetone)dipalladium (160 mg, 0.175 mmol), (R)-(+)-2,2'-Bis(diphenylphosphino)-l,l'-binaphthyl (160 mg, 0.175 mmol) and THF (3.5 mL). The reaction mixture was stirred at reflux 18 hr. The mixture was filtered through a pad of celite, concentrated, and purified by flash chromatography (ΝH-silica gel, 33% EtOAc in hexane) to give a pale yellow oil. To a solution of above oil in Et2O (2 mL) was added 4 M hydrogen chloride in EtOAc (0.3 mL). The mixture was stirred at ambient temperature for 30 min and concentrated. A solution of the residue in Et2O (2 mL) was stirred at ambient tempareture for 15 min. The precipitate was collected by filtration, washed with Et2O, and dried under reduced pressure to give cw-N2-[4-(4- bromo-2-frifluoromethoxy-phenylamino)-cyclohexyl]-N^;N''-dimethyl-quinazoline-2,4- diamine dihydrochloride (189 mg, 18% ) as a white solid.
ESI MS m/e 524, M (free) + J- ; Η ΝMR (300 MHz, CDCLJ δ 13.04 (s, 1 H), 8.85 (d, J= 7.9 Hz, 1 H), 7.90 (d, J= 8.1 Hz, 1 H), 7.61-7.70 (m, 1 H), 7.53 (d, J = 7.6 Hz, 1 H), 7.22- 7.31 (m, 1 H), 6.94 (s, 1 H), 6.79 (s, 1 H), 6.65 (s, 1 H), 4.28 (brs, IH), 3.52 (s, 6 H), 3.30- 3.45 (m, 2 H), 1.64-2.08 (m, 8 H).
Example 58
c 5-N-[4-(4-Methylamino-quinazolin-2-ylamino)-cyclohexylmethyI]-2- trifluoromethoxy-benzamid hydrochloride
Step A: Synthesis of c/5-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]- carbamic acid benzyl ester.
Using the procedure for the step G of Example 1, the title compound was obtained. ESI MS m/e 420, M (free) + Ef ; Η NMR (300 MHz, CDCLJ δ 7.20-7.59 (m, 8 H), 7.04 (ddd, J= 8.2, 6.8, 1.3 Hz, 1 H), 5.54-5.76 (m, 1 H), 5.10 (s, 2 H), 4.78-5.24 (m, 2 H), 4.18- 4.36 (m, 1 H), 3.11 (d, J= 4.8 Hz, 3 H), 2.92-3.16 (m, 2 H), 1.06-1.94 (m, 9 H).
Step B: Synthesis of cis-N- [4-(4-methylamino-quinazolin-2-ylamino)- cyclohexyImethyl]-2-trifluoromethoxy-benzamid hydrochloride.
To a solution of cis- [4-(4-methylamino-quinazolin-2-ylamino)-cy clohexylmethyl] - carbamic acid benzyl ester (2.73 g, 6.50 mmol) in MeOH (27 mL) was added 10% Pd/C
(273 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 14 hr, filtered, and concentrated to give a colorless solid (1.95 g). To a suspension of polymer supported
DMAP (2.45 g, 7.35 mmol) in CH2C12 (10 mL) were added 2-frifluoromethoxy-benzoyl chloride (472 mg, 2.10 mmol) and the above solid (300 mg, 1.05 mmol). The mixture was stirred at ambient temperature for 2.5 days, filtered, poured into saturated aqueous
NaHCO3. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) and flash chromatography
(silica gel, 20% MeOH in CHC13), and concentrated. To a solution of the residue in EtOAc
(1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in
Et2O (5 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cώ-N-[4-(4-memylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2- trifluoromethoxy-benzamide hydrochloride (20 mg, 4%) as a white solid.
ESI MS m/e 474, M + H+ ; Η ΝMR (500 MHz, CDC13) δ 12.82 (s, 1 H), 8.63 (d, J= 7.3
Hz, 1 H), 7.97-8.12 (m, 2 H), 7.91 (dd, J= 1.6, 1.5 Hz, 1 H), 7.54 (t, J= 7.6 Hz, 1 H), 7.48 (dt, J= 1.9, 1.8 Hz, 1 H), 7.38 (t, J= 7.0 Hz, 1 H), 7.26-7.35 (m, 2 H), 7.19 (t, J= 7.6 Hz, 1 H), 6.77 (t, J= 5.8 Hz, 1 H), 4.30-4.41 (m, 1 H), 3.41 (t, J= 6.4 Hz, 2 H), 3.20 (d, J = 3.7 Hz, 3 H), 1.48-2.01 (m, 9 H).
Example 59
cis-iV/-MethyI-N2-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of s-7Y'-methyl-iV2-{4-[(2-trifluoromethoxy-benzylamino)-methyl]- cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.
To a solution of cis- [4-(4-methylamino-quinazolin-2-ylamino)-cy clohexylmethyl] - carbamic acid benzyl ester obtained in step A of example 58 (2.73 g, 6.50 mmol) in MeOH (27 mL) was added 10% Pd/C (273 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 14 hr, filtered, and concenfrated to give a colorless solid (1.95 g). To a solution of the above solid (300 mg, 1.05 mmol) in MeOH (3 mL) were added 2- trifluoromethoxy-benzaldehyde (200 mg, 1.05 mmol), AcOH (63 mg, 1.05 mmol), and NaBH3CN (99 mg, 1.58 mmol). The reaction mixture was stirred at ambient temperature with CaCl2 tube for 4 hr, poured into 1 M aqueous sodium hydroxide, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH- silica gel, 50% EtOAc in hexane) and flash chromatography (silica gel, 10% MeOH in CHCL,), and concenfrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et20 (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cw-N4-methyl-N2-{4-[(2-frifluoromethoxy-benzylamino)-methyl]-cyclohexyl}- quinazoline-2,4-diamine dihydrochloride (175 mg, 33%) as a white solid.
ESI MS m/e 460, M (free) + ET ; Η NMR (300 MHz, CDC13) δ 11.49 (brs, 1 H), 9.74 (brs, 1 H), 9.57 (d, J= 4.4 Hz, 1 H), 8.43 (d, J= 8.4 Hz, 1 H), 8.27 (d, J= 8.4 Hz, 1 H), 8.13 (dd, J= 7.5, 1.8 Hz, 1 H), 7.24-7.51 (m, 4 H), 6.95-7.16 (m, 2 H), 4.28 (s, 2 H), 4.13-4.38 (m, 1 H), 2.99 (d, J= 4.5 Hz, 3 H), 2.92 (d, J= 4.8 Hz, 2 H), 1.41-2.19 (m, 9 H).
Example 60
2HCI cιs-N2-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]- cyclohexyl}-iV^-methyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c/5-N2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]- cyclohexyl}-./V-methyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of Example 59, the title compound was obtained.
ESI MS m/e 538, M (free) + H+; ΗNMR (500 MHz, CDC13) δ 11.23 (brs, 1 H), 9.75 (brs, 2 H), 9.46 (brs, 1 H), 8.43 (d, J= 7.9 Hz, 1 H), 8.29 (d, J= 8.5 Hz, 1 H), 8.08 (d, J= 8.5 Hz, 1 H), 7.55 (dd, J= 8.6, 1.8 Hz, 1 H), 7.44-7.52 (m, 2 H), 7.14 (t, J= 7.3 Hz, 1 H), 7.07 (d, J= 7.9 Hz, 1 H), 4.24 (s, 2 H), 4.19-4.30 (m, 1 H), 2.88-3.05 (m, 5 H), 1.38-1.84 (m, 9 H).
Example 61
HCl
cM-4-Bromo-N-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2- trifiuoromethoxy-benzamide hydrochloride
Step A: Synthesis of c s-4-bromo-N-[4-(4-methylamino-quinazohn-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.
To a solution of cw-[4-(4-Methylamino-quinazolin-2-ylamino)-cy clohexylmethyl] - carbamic acid benzyl ester obtained in step A of example 58 (2.73 g, 6.50 mmol) in MeOH (27 mL) was sdded 10% Pd/C (273 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 14 hr, filtered, and concentrated to give cts-N2-(4-Aminomefhyl- cyclohexyl)-N4-methyl-quinazoline-2,4-diamine (1.95 g) as a white solid. To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid obtained in step B of example 13 (599 mg, 2.10 mmol) in CH2C12 (6 mL) was added DMF (1 μL, 14.7 μmol) and SOC12 (190 μL, 2.60 mmol). The mixture was stirred at reflux for 30 min and concentrated to give acid chloride as a pale yellow oil. To a suspension of polymer supported DMAP (2.45 g, 7.35 mmol) in CH2C12 (6 mL) were added above acid chloride and cw-N2-(4-aminomethyl-cyclohexyl)- N4-methyl-quinazoline-2,4-diamine (300 mg). The mixture was stirred at ambient temperature for 24 hr, filtered, poured into saturated aqueous ΝaHCO3. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH- silica gel, 50% EtOAc in hexane), and concenfrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The reaction mixture was stirred at ambient temperature for 1 hr, and concentrated. A solution of the residue in Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give ct,y-4-bromo-N-[4-(4-methylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride (47 mg, 8%) as a white solid.
ESI MS m/e 551, M (free)+ ; Η ΝMR (500 MHz, CDCLJ δ 12.61 (s, 1 H), 8.56 (d, J= 7.3 Hz, 1 H), 8.40 (brs, 1 H), 8.15 (d, J= 8.5 Hz, 1 H), 7.78 (d, J= 8.5 Hz, 1 H), 7.47-7.55 (m, 2 H), 7.42 (t, J= 1.5 Hz, 1 H), 7.26 (d, J= 8.5 Hz, 1 H), 7.17 (t, J= 7.6 Hz, 1 H), 6.88 (t, J
= 5.8 Hz, 1 H), 4.32-4.44 (m, 1 H), 3.40 (t, J = 6.1 Hz, 2 H), 3.20 (d, J= 4.3 Hz, 3 H), 1.49-2. 00 (m, 8 H).
Example 62
2HCI c s-iV2-{4-[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino] -cyclohexyl}-iV,i\^-dimethyl-quinazoUne-2,4-diamine dihydrochloride
Step A: Synthesis of (E)-3-(4-bromo-2-trifluoromethoxy-phenyl)-acrylic acid ethyl ester.
To a solution of (e oxy-me oxymemyl-phosphinoyl)-acetic acid ethyl ester (3.45 g, 15.4 mmol) in THF (230 mL) was added 60% sodium hydride in oil (370 mg, 15.4 mmol). The mixture was stirred at ambient temperature for 50 min and cooled at 4 °C. To the reaction mixture was added 4-bromo-2-trifluoromethoxy-benzaldehyde (3 g, 11.2 mmol) in THF (100 mL). The mixture was stirred at ambient temperature for 15 hr. The solution was poured into H2O, and the aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 5% EtOAc in hexane) to give (E)-3-(4- Bromo-2-trifluoromethoxy-phenyl)-acrylic acid ethyl ester (2.98 g, 79 %) as a colorless oil.
CI MS m/e 339, M + H+ ; Η NMR (300 MHz, CDC13) δ 7.85 (d, J= 15.8 Hz, 1 H), 7.42- 7.58 (m, 3 H), 6.48 (d, J= 15.8 Hz, 1 H), 4.29 (q, J= 7.0 Hz, 2 H), 1.35 (t, J= 7.0 Hz, 3 H).
Step B: Synthesis of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-l-ol.
A suspension of lithium aluminum hydride (834 mg, 22.0 mmol) in Et2O (20 mL) was cooled at 4 °C. A solution of (E)-3-(4-bromo-2-trifluoromethoxy-phenyl)-acrylic acid ethyl ester (2.98 g, 8.79 mmol) in Et2O (9 mL) was added dropwise, and the mixture was
stirred at ambient temperature for 90 min. The reaction was quenched with EtOAc (6 mL) and saturated aqueous NH4C1 was added dropwise. The aqueous layer was extracted with EtOAc (three times). The combined organic layer was washed with 1 M aqueous HCl, dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 25% EtOAc in hexane) to give 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-l-ol (1.14 g, 43 %) as a colorless oil.
El MS m/e 298, M+ ; Η NMR (300 MHz, CDCLJ δ 7.10-7.43 (m, 3 H)s 3.68 (t, J= 6.4 Hz, 2 H), 2.67-2.80 (m, 2 H), 1.75-1.94 (m, 2 H).
Step C: Synthesis of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propionaldehyde.
A solution of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-l-ol (1.03 g, 3.44 mmol) in CH2C12 (47 mL) was cooled at 4 °C and added celite (1.4 g) and pyridinium chlorochromate (1.11 g, 5.16 mmol). The reaction mixture was stirred at ambient temperature for 6 hr and filtered through a pad of celite, concentrated, and purified by flash chromatography (silica gel, 16% EtOAc in hexane) to give 3-(4-bromo-2- trifluoromethoxy-phenyl)-propionaldehyde (659 mg, 64%) as a colorless oil. CI MS m/e 297, M + H÷; Η NMR (300 MHz, CDCL,) δ 9.80 (t, J= 1.1 Hz, 1 H), 7.32- 7.42 (m, 2 H), 7.17 (d, J= 8.4, Hz, 1 H), 2.96 (t, J= 7.4 Hz, 2 H), 2.72-2.81 (m, 2 H).
Step D: Synthesis of -N-{4-[3-(4-bromo-2-trifluoromethoxy-phenyl)- propylamino]-cyclohexyl}-N*,/V*-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 566, M (free) + H* ; Η NMR (300 MHz, CDCL.) δ 8.81 (d, J= 7.2 Hz, 1 H), 7.91 (d, J= 7.9 Hz, 1 H), 7.60-7.70 (m, 1 H), 7.49 (d, J= 8.4 Hz, 1 H), 7.12-7.42 (m, 5 H), 4.31 (brs, 1 H), 3.52 (s, 6 H), 3.23 (brs, 1 H), 3.02-3.14 (m, 2 H), 2.78 (t, J= 7.8 Hz, 2 H), 1.97-2.36 (m, 8 H), 1.59-1.85 (m, 2 H).
Example 63
c 5-N2-{4-[4-(4-Bromo-2-trifIuorometho y-phenyl)-butylamino]-cyclohe yl}- V,',N^'- dimethyl-quinazo!ine-2,4-diamine dihydrochloride
Step A: Synthesis of (E)-4-(4-bromo-2-trifluoromethoxy-phenyl)-but-2-enoic acid ethyl ester.
Using the procedure for the step A of example 62, the title compound was obtained. ESI MS m/e 352, M÷; Η NMR (300 MHz, CDC13) δ 7.33-7.53 (m, 3 H), 6.64 (d, J= 16.2 Hz, 1 H), 6.37 (dt, J= 16.0, 7.1 Hz, 1 H), 4.18 (q, J= 7.2 Hz, 2 H), 3.28 (dd, J- 7.1, 1.5 Hz, 2 H), 1.29 (t, J- 7.2 Hz, 3 H).
Step B: Synthesis of 4-(4-bromo-2-trifluoromethoxy-phenyl)-butan-l-oI.
Using the procedure for the step B of example 62, the title compound was obtained.
El MS m/e 312, M+; Η NMR (200 MHz, CDCLJ δ 7.10-7.42 (m, 3 H), 3.68 (t, J= 5.1 Hz, 2 H), 2.60-2.82 (m, 2 H), 1.50-1.79 (m, 4 H), 1.10-1.50 (brs, 1 H).
Step C: Synthesis of 4-(4-bromo-2-trifluoromethoxy-phenyl)-butyraldehyde.
Using the procedure for the step C of example 62, the title compound was obtained.
ESI MS m/e 311, M + BT ; Η NMR (200 MHz, CDCL.) δ 9.79 (s, 1 H), 7.02-7.22 (m, 3 H), 2.60-2.84 (m, 2 H), 2.49 (t, J= 5.9 Hz, 2 H), 1.80-2.03 (m, 2 H).
Step D: Synthesis of c -N2-{4-[4-(4-bromo-2-trifluoromethoxy-phenyI)-butylamino]- cyclohexyl}-iV^,N*-dimethyl-quinazoline-2,4-diamine dihydrochloride.
To a suspension of cw-N2-(4-amino-cyclohexyl)-N',N'/-dimethyl-quinazoline-2,4- diamine obtained in step C of example 9 (240 mg, 0.84 mmol) in MeOH (3 mL) were added 4-(4-bromo-2-trifluoromethoxy-phenyl)-butyraldehyde (262 mg, 0.84 mmol), acetic acid (79 mg, 1.26 mmol), and ΝaBH3CΝ (79 mg, 1.26 mmol). The reaction mixture was
stirred at ambient temperature for 8 hr. The reaction was quenched with saturated aqueous NaHCO3 The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by medium- pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a pale yellow solid. To a solution of above solid in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et2O (20 mL) was stirred at ambient tempareture for 1 hr. The solid was collected by filtration, washed with Et2O, and dried under reduced pressure to give cw-N2-{4-[4-(4-bromo-2-trifluoromethoxy-phenyl)-butylamino]- cyclohexyl}-N/,N/-dimethyl-quinazoline-2,4-diamine dihydrochloride (220 mg, 40% ) as a white solid.
ESI MS m/e 580, M (free) + H÷ ; Η ΝMR (200 MHz, CDCL.) δ 12.73 (brs, 1 H), 9.55 (brs, 2 H), 8.66-8.88 (m, 1 H), 7.92 (d, J= 7.9 Hz, 1 H), 7.66 (t, J= 7.3 Hz, 1 H), 7.48 (d, J= 7.7 Hz, 1 H), 7.12-7.40 (m, 3 H), 4.20-4.42 (m, 1 H), 3.52 (s, 6 H), 2.92-3.42 (m, 3 H), 2.60-2.78 (m, 2 H), 1.58-2.59 (m, 12 H).
Example 64
2HCI cϊ5-N2-(4-{[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}- cyclohexyl)-7Y',7Y'-dimethyl-quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of N2-(4-aminomethyl-cyclohexyl)-N*^V/-dimethyl-quinazoline-2,4- diamine.
To a solution of ct5,-[4-(4-dimethylamino-quinazolin-2-ylamino)- cy clohexylmethyl] -carbamic acid benzyl ester obtained in step B of example 24 (12.1 g, 27.9 mmol) in MeOH (120 mL) was added 10% Pd/C (1.21 g). The mixture was stirred at 50 °C under hydrogen atmosphere for 19 hr, filtered, concentrated, and purified by flash
chromatography (NH-silica gel, 66% EtOAc in hexane to 15% MeOH in chloroform) to give N2-(4-aminomethyl-cyclohexyl)-N',N';-dimethyl-quinazoline-2,4-diamine (6.9 g, 83%) as a yellow solid.
CI MS m/e 300, M + H ; Η ΝMR (300 MHz, CDC13) δ 7.81 (d, J= 8.4 Hz, 1 H), 7.40- 7.51 (m, 2 H), 6.98-7.04 (m, 1 H), 5.04 (d, J= 7.3 Hz, 1 H), 4.24-4.30 (m, 1 H), 3.27 (s, 6 H), 2.60 (d, J= 6.4 Hz, 2 H), 1.81-1.96 (m, 2 H), 1.57-1.76 (m, 4 H), 0.90-1.51 (m, 5 H).
Step B: Synthesis of c/5-N2-(4-{[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]- methyl}-cycIohexyl)-7Y',NI'-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 566, M (free) + H+ ; Η ΝMR (300 MHz, CDC13) δ 12.45 (s, 1 H), 9.74 (brs, 2 H), 8.70 (d, J= 1.6 Hz, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.66 (t, J= 7.6 Hz, 1 H), 7.17-7.52 (m, 4 H), 4.30 (brs, 1 H), 3.52 (s, 6 H), 3.32-3.50 (m, 2 H), 3.17 (brs, 2 H), 3.01 (brs, 2 H), 1.56-2.10 (m, 9 H).
Example 65
2HCI c 5-N2-(4-{[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}- cyclohexyl)-Λ^-methyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of cw-N2-(4-{[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]- methyl}-cyclohexyl)-iV*-methyl-quinazohne-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 59, the title compound was obtained. ESI MS m/e 552 M (free) + H+ ; Η NMR (300 MHz, CDCLJ δ 11.66 (s, 1 H), 9.62 (brs, 1 H), 9.40 (brs, 1 H), 8.05-8.50 (m, 2 H), 7.21-7.58 (m, 4 H), 6.96-7.21 (m, 2 H), 4.26 (brs, 1 H), 3.41 (brs, 2 H), 2.75-3.31 (m, 7H), 1.30-2.24 (m, 9 H).
Example 66
2HCI cis-iV',iV'-Dimethyl-N2-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of cis-N',7y-dimethyl-N2-{4-[2-(2-trifluoromethoxy-phenyl)- ethylammo]-cyclohexyl}-quinazoline-2,4-diamme dihydrochloride.
To a solution of ew-N -{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]- cyclohexyl}-N/,N'-dimethyl-quinazoline-2,4-diamine dihydrochloride obtained in step B of example 37 (250 mg, 0.4 mmol) in EtOH (5 mL) was added 10% Pd/C (75 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 17 hr, filtered, poured into saturated aqueous ΝaHCO3. The aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of above oil in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended with Et2O (15 mL) and stirred at ambient tempareture for 1 hr. The solid was collected by filtration, washed with Et^O, and dried under reduced pressure to give cw-N',N'-dimethyl-N2-{4-[2-(2-trifluoromethoxy-phenyl)- e ylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride (104 mg, 48% ) as a white solid.
ESI MS m/e 474, M (free) + ET ; Η ΝMR (300 MHz, CDC13) δ 12.62 (s, 1 H), 9.78 (brs, 2 H), 8.71 (brs, 1 H), 7.93 (d, J= 8.4 Hz, 1 H), 7.39-7.77 (m, 3 H), 7.14-7.37 (m, 4 H), 4.33 (brs, 1 H), 3.15-3.71 (m, 11 H), 1.93-2.53 (m, 6 H), 1.62-1.89 (m, 2 H).
Example 67
HCl
c 5-2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexyl]-acetamide hydrochloride
Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-acetic acid.
Using the procedure for the step B of example 13, the title compound was obtained.
ESI MS m/e 298, M+ ; Η NMR (300 MHz, CDCLJ δ 7.39-7.47 (m, 2 H), 7.22 (d, J= 8.1 Hz, l H), 3.70 (s, 2 H).
Step B: Synthesis of s-2-(4-bromo-2-trifluoromethoxy-phenyl)-N-[4-(4- dimethyIamino-quinazoIin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 566, M (free) + ET ; Η NMR (300 MHz, CDCLJ δ 13.15 (s, 1 H), 8.91 (d, J = 7.7 Hz, 1 H), 7.89 (d, J= 8.4 Hz, 1 H), 7.61-7.70 (m, 1 H), 7.48-7.56 (m, 1 H), 7.39-7.45 (m, 1 H), 7.21-7.33 (m, 2 H), 6.02 (d, J= 8.8 Hz, 1 H), 4.19-4.33 (m, 1 H), 3.82-4.03 (m, 1 H), 3.53 (s, 2 H), 3.51 (s, 6 H), 1.64-1.97 (m, 8 H).
Example 68
cw-2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexylmethyl]-acetamide hydrochloride
Step A: Synthesis of ds-2-(4-bromo-2-trifluoromethoxy-phenyI)-N-[4-(4- dimethylamino-quinazolin-2-ylamino)-cycIohexylmethyl]-acetamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained.
ESI MS m/e 580, M (free) + H+ ; ΗNMR (300 MHz, CDCLJ δ 12.85 (brs, 1 H), 9.08 (d, J = 8.4 Hz, 1 H), 7.90 (d, J= 8.8 Hz, 1 H), 7.58-7.72 (m, 1 H), 7.19-7.54 (m, 5 H), 6.81-6.98 (m, 1 H), 4.28-4.51 (m, 1 H), 3.83 (s, 2 H), 3.51 (s, 6 H), 3.29-3.34 (m, 2 H), 1.42-2.03 (m, 9 H).
Example 69
c y-3-(4-Bromo-2-trifluoromethoxy-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)cyclohexyl]-propionamide hydrochloride
Step A: Synthesis of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propionic acid.
To a solution of 3-(4-bromo-2-frifluoromethoxy-phenyl)-propan-l-ol obtained in step B of example 62 (1 g, 3.34 mmol) in acetone (15 mL) was added Jones reagent (4 mL) at 4 °C. The mixture was stirred at ambient temperature for 2 hr. The solution was poured into water (50 mL), and the aqueous layer was exfracted with Et2O (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated, and purified by flash chromatography (silica gel, 25% EtOAc in hexane) to give 3-(4-Bromo-2- trifluoromethoxy-phenyl)-propionic acid (930 mg, 89%) as a colorless oil. ESI MS m/e 313, M+ ; Η NMR (200 MHz, CDCL.) δ 7.31-7.50 (m, 2 H), 7.10-7.29 (m, 1 H), 2.97 (t, J= 1.1 Hz, 2 H), 2.65 (t, J= 7.7 Hz, 2 H).
Step B: Synthesis of d5-3-(4-bromo-2-trifluoromethoxy-phenyl)-N-[4-(4- dimethyIamino-quinazolin-2-ylamino)cycIohexyl]-propionamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 580, M(free) + H+ ; Η NMR (300 MHz, CDC13) δ 13.12 (brs, 1 H), 8.92 (d, J = 7.9 Hz, 1 H), 7.90 (d, J= 8.3 Hz, 1 H), 7.47-7.73 (m, 2 H), 7.15-7.44 (m, 3 H), 5.92 (d, J = 8.4 Hz, 1 H), 4.18-4.38 (m, 1 H), 3.76-4.03 (m, 1 H), 3.51 (s, 6 H), 2.98 (t, J= 7.7 Hz, 2 H), 2.44 (t, J= 7.7 Hz, 2 H), 1.55-1.96 (m, 9 H).
Example 70
c 5-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-(2-trifluoromethoxy- phenyl)-acetamide hydrochloride
Step A: Synthesis of c s-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2- (2-trifluoromethoxy-phenyl)-acetamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 488, M (free) + H1" ; Η NMR (300 MHz, CDCLJ δ 13.20 (s, IH), 8.84 (d, J= 1.6 Hz, 1 H), 7.89 (d, J= 8.7 Hz, 1 H), 7.60-7.70 (m, 1 H), 7.49-7.56 (m, 1 H), 7.20-7.43 (m, 5 H), 5.98 (d, J= 7.6 Hz, 1 H), 4.23 (brs, 1 H), 3.84-4.03 (m, 1 H), 3.59 (s, 2 H), 3.50 (s, 6 H), 1.62-1.98 (m, 8 H).
Example 71
c 5-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-(2- trifluoromethoxy-phenyl)-acetamide hydrochloride
Step A: Synthesis of cw-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-2-(2-trifluoromethoxy-phenyl)-acetamide hydrochloride
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 502, M (free) + H+ ; Η NMR (300 MHz, CDC13) δ 12.99 (s, 1 H), 8.99 (d, J= 8.5 Hz, 1 H), 7.90 (d, J= 8.2 Hz, 1 H), 7.63 (t, J= 7.62 Hz, 1 H), 7.38-7.54 (m, 2 H), 7.16-
7.34 (m, 4 H), 6.55 (brs, 1 H), 4.28-4.43 (m, 1 H), 3.81 (s, 2 H), 3.51 (s, 6 H), 3.27 (s, 2 H), 1.46-1.99 (m, 9 H).
Example 72
cz5-N?,Λ^-Dimethyl-N2-(4-{[2-(2-trifluoromethoxy-phenyl)-ethylamino]-methyl}- cyclohexyl)-quinazoline-2,4-diamine dihydrochloride
Step A: cis-/V,7Y'-dimethyl-N2-(4-{[2-(2-trifluoromethoxy-phenyl)-ethyIamino]- methyl}-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride
To a solution of ct5-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-2-(2-trifluoromethoxy-phenyl)-acetamide (free) obtained in step A of example 71 (246 mg, 0.5 mmol) in THF (3.5 mL) was added 1 M borane-THF complex (2.45 mL, 2.45 mmol). The mixture was stirred at reflux for 2.5 h, and concentrated. To a solution of above residue in THF (3.5 mL) was added 1 M hydrochloric acid (4.41 mL, 4.41 mmol) . The mixture was stirred at reflux for 1 hr, and cooled to ambient temperature. To the reaction mixture was added 2 M aqueous sodium hydroxide, and the aqueous layer was extracted with CHC13 (tliree times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by medium-pressure liquid chromatography (ΝH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of above oil in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et2O (15 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et2O, and dried under reduced pressure to give cw-N N'-dimethyl- N2-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride (81 mg, 30% ) as a white solid.
FAB MS m/e 488, M + ET ; Η ΝMR (300 MHz, CDC13) δ 12.56 (s, 1 H), 9.72 (brs, 1 H), 8.72 (d, J= 1.1 Hz, 1 H), 7.90 (d, J= 8.2 Hz, 1 H), 7.66 (t, J= 1.1 Hz, 1 H), 7.42-7.54 (m, 2 H), 7.15-7.32 (m, 4 H), 4.22-4.35 (m, 1 H), 3.51 (s, 6 H), 3.38-3.59 (m, 2 H), 3.11-3.30
(m, 2 H), 2.92-3.07 (m, 2 H), 2.21 (brs, 1 H), 1.50-2.01 (m, 8 H).
Example 73
c/5-7y-Methyl-N2-(4-{[2-(2-trifluoromethoxy-phenyl)-ethylamino]-methyl}- cyclohexyl)-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c/5-7Y'-methyl-N2-(4-{[2-(2-trifluoromethoxy-phenyl)- ethyIamino]-methyl}-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 66, the title compound was obtained. ESI MS m/e 474, M (free) + H+ ; Η NMR (200 MHz, CDCLJ δ 11.72 (s, 1 H), 9.23-9.94 (m, 3 H), 8.00-8.66 (m, 2 H), 6.64-7.66 (m, 7 H), 4.26 (brs, 1 H), 2.73-3.65 (m, 9 H), 1.27- 2.44 (m, 9 H).
Example 74
2HCI -iV^-Methyl-N2-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cycIohexyl}- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of cw-t -methyl-N2-{4-[2-(2-trifluoromethoxy-phenyl)-ethyIamino]- cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 66, the title compound was obtained. ESI MS m/e 460, M (free) + ET ; Η NMR (200 MHz, CDCLJ δ 12.20 (brs, 1 H), 9.84 (brs, 3 H), 8.59-8.79 (m, 1 H), 7.79-8.02 (m, 1 H), 7.10-7.70 (m, 7 H), 3.95-4.26 (m, 1 H), 3.09- 3.54 (m, 5 H), 2.82-3.03 (m, 3 H), 1.57-2.43 (m, 8 H).
Example 75
c/5-3-(4-Bromo-2-trifluoromethoxy-phenyl)-iV-[4-(4-dimethylamino-quinazoIin-2- ylamino)-cyclohexylmethyl]-propionamide hydrochloride
Step A: Synthesis of c s-3-(4-bromo-2-trifluoromefhoxy-phenyl)-N-[4-(4- dimethylamino-quinazolin-2-ylamino)-cycIohexylmethyl]-propionamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 594, M (free)+ ; Η NMR (300 MHz, CDCL.) δ 12.72 (s, 1 H), 9.01 (d, J= 8.7 Hz, 1 H), 7.90 (d, = 8.2 Hz, 1 H), 7.65 (t, J = 7.6 Hz, 1 H), 7.47 (d, J= 7.6 Hz, 1 H), 7.21-7.41 (m, 3 H), 6.96 (brs, 1 H), 4.31-4.44 (m, 1 H), 3.51 (s, 6 H), 3.23-3.35 (m, 2 H), 3.03 (t, J= 7.6 Hz, 2 H), 2.76 (t, J= 7.6 Hz, 2 H), 1.38-1.98 (m, 9 H).
Example 76
2HCI c 5-N2-(4-{[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-methyl}- cyclohexyl)-N',7 -dimethyl-quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of rø-N2-(4-{[3-(4-bromo-2-trifluoromethoxy-phenyl)- propylamino]-methyl}-cyclohexyl)-iV',iV'-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained.
ESI MS m/e 580, M (free) + H+ ; Η NMR (200 MHz, CDCL.) δ 12.56 (s, 1 H), 9.40-9.71 (m, 2 H), 8.56-8.76 (m, 1 H), 7.91 (d, J= 8.4 Hz, 1 H), 7.66 (t, J= 1.6 Hz, 1 H), 7.13-7.47 (m, 5 H), 4.17-4.39 (m, 1 H), 3.51 (s, 6 H), 2.83-3.16 (m, 4 H), 2.67-2.82 (m, 2 H), 1.38- 2.53 (m, 11 H).
Example 77
3HCI c 5-N2-[4-(4-Amino-2-trifluoromethoxy-benzylamino)-cyclohexyI]-/ ,N!?-dimethyl- quinazoline-2,4-diamine trihydrochloride
Step A: Synthesis of ci$'-N2-[4-(4-amino-2-trifluoromethoxy-benzylamino)- cyclohexyl]-7Y',iV -dimethyl-quinazoline-2,4-diamine trihydrochloride.
To a solution of c/5,-N2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]- N^N4-dimethyl-quinazoline-2,4-diamine obtained in step A of example 28 (1.5 g, 2.79 mmol) in EtOH (25 mL) were added copper powder (443 mg, 6.93 mmol), CuCl (690 mg, 2.79 mmol), and 28% aqueous ΝH3 (25 mL). The reaction mixture was stirred at reflux for 3.5 hr. The mixture was poured into water, and the aqueous layer was extracted with CHCL. (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of above oil in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et2O (15 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et2O, and dried under reduced pressure to give cw-N2-[4-(4-amino-2- trifluoromethoxy-benzylamino)-cyclohexyl]-N^N-dimethyl-quinazoline-2,4-diamine trihydrochloride (104 mg, 6% ) as a white solid.
ESI MS m/e 475, M (free) + T ; Η ΝMR (300 MHz, DMSO-d6) δ 13.08 (brs, 1 H), 9.15 (brs, 2 H), 8.32-8.48 (m, 1 H), 8.19 (d, J= 8.1 Hz, 1 H), 7.73-7.85 (m, 1 H), 7.46 (d, J =
8.4 Hz, 1 H), 7.37 (t, J= 7.4 Hz, 2 H), 6.56-6.71 (m, 2 H), 3.94-4.26 (m, 3 H), 3.49 (s, 6 H), 3.02-3.24 (m, 1 H), 1.59-2.09 (m, 8 H).
Example 78
c 5-N2-(4-{[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-methyI}- cyclohexyI)-N*-methyl-quinazoϊine-2,4-diamine dihydrochloride
Step A: Synthesis of N2-(4-aminomethyl-cyclohexyl)-N4-methyl-quinazoline-2,4- diamine
Using the procedure for the step A of example 64, the title compound was obtained. ESI MS m/e 286, M + H+ ; Η NMR (300 MHz, CDCLJ δ 7.35-7.59 (m, 3 H), 6.97-7.11 (m, 1 H), 5.59 (brs, 1 H), 5.00-5.18 (m, 1 H), 4.21-4.39 (m, 1 H), 3.13 (d, J= 4.8 Hz, 3 H), 2.61 (d, J= 6.2 Hz, 2 H), 1.57-1.99 (m, 5 H), 1.04-1.52 (m, 4 H).
Step B: Synthesis of ci5-N2-(4-{[3-(4-bromo-2-trifluoromethoxy-phenyl)- propylamino]-methyl}-cyclohexyl)-iV^-methyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step D of example 63, the title compound was obtained.
ESI MS m/e 566, M (free) + H+ ; ΗNMR (300 MHz, CDCLJ δ 11.63 (s, 1 H), 9.45 (brs, 3 H), 8.41 (d, J = 8.5 Hz, 1 H), 8.32 (d, J= 7.9 Hz, 1 H), 7.46 (t, J= 7.54 Hz, 1 H), 7.24- 7.39 (m, 3 H), 6.99-7.17 (m, 2 H), 4.13-4.35 (m, 1 H), 2.85-3.12 (m, 7 H), 2.75 (t, J- 7.6 Hz, 2 H), 2.27-2.47 (m, 2 H), 1.97-2.18 (m, 1 H), 1.37-1.91 (m, 8 H).
Example 79
2HCI c 5-N2-{4-[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-cyclohexyI}-A^- methyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of cis-N2-{4-[3-(4-bromo-2-trifluoromethoxy-phenyl)- propylamino]-cyclohexyl}-iV'-methyl-quinazoIine-2,4-diamine dihydrochloride
To a suspension of cw-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]- carbamic acid tert-butyl ester obtained in step B of example 50 (8.68 g, 23.4 mmol) in
CHC13 (87mL) was added 4 M hydrogen chloride in EtOAc (100 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concenfrated. The residue was alkalized with saturated aqueous NaHCO3 and the aqueous layer was extracted with CHC13
(three times). The combined organic layer was dried over MgSO4, filtered, concentrated
(10.57 g). To a suspension of the above residue (594 mg) in MeOH (6 mL) were added 3-
(4-bromo-2-trifluoromethoxy-phenyl)-propionaldehyde obtained in step C of example 62
(650 mg, 2.19 mmol), AcOH (132 mg, 2.19 mmol), and NaBH3CN (207 mg, 3.29 mmol).
The reaction mixture was stirred at ambient temperature for 16 hr, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane and silica gel, 16% MeOH in CHCLJ to give a yellow oil. To a solution of the residue in EtOAc (6 mL) was added 4 M hydrogen chloride in EtOAc (0.14 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in
Et2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give cw-N2-{4-[3-(4-bromo-2-trifluoromethoxy-phenyl)-propylamino]- cyclohexyl}-N^-methyl-quinazoline-2,4-diamine dihydrochloride (59 mg, 7%) as a white solid.
ESI MS m/e 552, M (free) + H" ; Η ΝMR (300 MHz, CDC1J δ 12.37 (s, 1 H), 9.78 (brs, 1
H), 9.59 (brs, 2 H), 8.68 (d, J= 8.2 Hz, 1 H), 7.55-7.67 (m, 2 H), 7.27-7.43 (m, 5 H), 3.78-
3.96 (m, 1 H), 2.94-3.24 (m, 3 H), 2.50-2.89 (m, 5 H), 2.09-2.50 (m, 6 H), 1.60-1.98 (m, 4
H).
Example 80
2HCI c 5-N2-[4-(4-Chloro-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N*,7Λ^-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c s-N2-[4-(4-chloro-2-trifluoromethoxy-benzylamino)- cyclohexyl]-i\^,7Λ^-dimethyl-quinazoline-2,4-diamine dihydrochloride.
A mixture of cone. HCl (420 μL) and NaNO2 (44 mg, 0.64 mmol) were stirred at 70 °C for 10 min. To the reaction mixture was added a solution of cw-N2-[4-(4-amino-2- trifluoromethoxy-benzylamino)-cyclohexyl]-N^N/-dimethyl-quinazoline-2,4-diamine (free) obtained in step A of example 77 in AcOH (15 mL), and stirred at ambient temperature for 10 min. To the reaction mixture was added a solution of CuCl (146 mg, 1.47 mmol) in cone. HCl (1 mL), and stirred at 80 °C for 6 hr. The reaction mixture was alkalized with saturated aqueous ΝaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a yellow oil. To a solution of above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et2O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with EtjO, and dried under reduced pressure to give cw-N2-[4-(4-chloro-2- trifluoromethoxy-benzylamino)-cyclohexyl]-N',N/-dimethyl-quinazoline-2,4-diamine dihydrochloride (70 mg, 29% ) as a white solid.
ESI MS m/e 494, M (free) + H* ; Η ΝMR (300 MHz, CDC1J δ 12.66 (s, 1 H), 9.82-10.28 (m, 2 H), 8.78 (d, J = 1.6 Hz, 1 H), 8.24 (d, J = 8.3 Hz, 1 H), 7.92 (d, J= 8.2 Hz, 1 H), 7.67 (t, J= 1.6 Hz, 1 H), 7.47 (d, J= 8.1 Hz, 1 H), 7.18-7.41 (m, 3 H), 4.20-4.44 (m, 3 H), 3.52 (s, 6 H), 3.23 (brs, 1 H), 2.02-2.65 (m, 6 H), 1.75 (t, J- 12.8 Hz, 2 H).
Example 81
F F
X HxT 2HCItxx
^rαM5-N2-{4-[(4-Bromo-2-trifluoromethoxy-benzyIamino)-methyl]-cyclohexyl}-Λ^,Λ^- dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of N2-(4-aminomethyl-cyclohexyl)-7 ,iV^-dimethyl-quinazoline-2,4- diamine
To a suspension of trαrø-[4-(4-dimethylamino-quinazolin-2-ylamino)- cy clohexylmethyl] -carbamic acid tert-butyl ester obtained in step B of example 6 (400 mg, 1.00 mmol) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 80 min. The reaction mixture was alkalized with 2 M aqueous sodium hydroxide, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated, purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane to 3% MeOH in CHC1J to give N2-(4-aminomethyl-cyclohexyl)-N/,N^-dimethyl- quinazoline-2,4-diamine (250 mg, 83%>) as a pale yellow oil.
ESI MS m/e 300, M + If ; Η ΝMR (300 MHz, CDC1J δ 7.80 (d, J= 9.3 Hz, 1 H), 7.38- 7.53 (m, 2 H), 6.97-7.05 (m, 1 H), 4.77 (d, J= 9.3 Hz, 1 H), 3.73-4.02 (m, 1 H), 3.26 (s, 6 H), 2.57 (d, J= 6.2 Hz, 2 H), 2.13-2.31 (m, 2 H), 1.75-1.96 (m, 2 H), 0.92-1.45 (m, 7 H).
Step B: Synthesis of teαHS-N2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)- methyl]-cycIohexyl}-iV^,Λ^-dimethyl-quinazoline-2,4-diamine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained ESI MS m/e 552, M (free) + H+ ; Η ΝMR (300 MHz, CDCLJ δ 12.72 (s, 1 H), 10.19 (brs, 2 H), 8.18 (d, J= 8.9 Hz, 1 H), 8.06 (d, J= 7.9 Hz, 1 H), 7.91 (d, J= 8.3 Hz, 1 H), 7.42- 7.65 (m, 3 H), 7.35 (d, J= 8.3 Hz, 1 H), 7.23 (t, J= 7.5 Hz, 1 H), 4.18-4.29 (m, 2 H), 3.69- 3.89 (m, 1 H), 3.52 (s, 6 H), 2.64-2.81 (m, 2 H), 1.90-2.24 (m, 5 H), 1.02-1.56 (m, 4 H).
Example 82
teαn5-N2-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexylmethyl]-iV^,Λ^- dhnethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of t:m« -N2-(4-amino-cyclohexylmethyl)-N*,iV!'-dimethyl- quinazoline-2,4-diamine.
To a solution of trα«^-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexyl} -carbamic acid benzyl ester obtained in step C of example 3 (330 mg, 0.76 mmol) in MeOH (3.3 mL) was added 10%» Pd/C (33 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 25 hr, filtered, concenfrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give trαw^-N2- (4-amιino-cyclohexylmethyl)-N'/,N'-dimethyl-quinazoline-2,4-diamine (250 mg, 98%) as a pale yellow oil.
ESI MS m/e 300, M + H+ ; Η ΝMR (300 MHz, CDC1J δ 7.80 (d, J= 8.1 Hz, 1 H), 7.40- 7.55 (m, 2 H), 6.95-7.07 (m, 1 H), 4.86-5.02 (m, 1 H), 3.36 (t, J- 6.3 Hz, 2 H), 3.26 (s, 6 H), 2.53-2.70 (m, 1 H), 1.77-1.98 (m, 4 H), 0.93-1.64 (m, 7 H).
Step B: Synthesis of t1 «j-N2-[4-(4-bromo-2-trifluoromethoxy-benzyIamino)- cy clohexylmethyl] -iV^,Λ^-dimethy l-quinazoline-2 ,4-diamine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 552, M (free)+ ; Η ΝMR (300 MHz, CDCLJ δ 13.21 (s, 1 H), 10.03 (brs, 2 H), 8.34-8.47 (m, 1 H), 8.07 (d, J= 8.4 Hz, 1 H), 7.91 (d, J= 8.4 Hz, 1 H), 7.38-7.71 (m, 4 H), 7.20-7.34 (m, 1 H), 4.03-4.20 (m, 2 H), 3.51 (s, 6 H), 3.28-3.42 (m, 2 H), 2.65-2.92 (m, 1 H), 2.16-2.35 (m, 2 H), 1.86-2.05 (m, 2 H), 1.56-1.83 (m, 3 H), 0.89-1.16 (m, 2 H).
Example 83
2HCI c 5-iV2-[4-(2,2-Diphenyl-ethylamino)-cyclohexyl]-Λ^,7 -dimethyl-quinazoline-2,4- diamine dihydrochloride
Step A: Synthesis of cis-N2-[4-(2,2-diphenyl-ethylamino)-cyclohexyl]-N/,N4-dimethyI- quinazoline-2,4-diamine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 466, M (free) + H+ ; Η NMR (300 MHz, CDC1J δ 12.60 (brs, 1 H), 8.76- 9.28 ( , 3 H), 7.91 (d, J= 8.3 Hz, 1 H), 7.59-7.71 (m, 2 H), 7.14-7.51 (m, 10 H), 5.00 (t, J = 7.7 Hz, 1 H), 4.30-4.40 (m, 1 H), 3.72 (d, J= 7.4 Hz, 2 H), 3.51 (s, 6 H), 3.19-3.43 (m, 1 H), 1.85-2.31 (m, 6 H), 1.52-1.76 (s, 2 H).
Example 84
2HCI {2-[3-(4-Bromo-2-trifluoromethoxy-benzylamino)-pyrrolidin-l-yl]-quinazolin-4-yl}- dimethyl-amine dihydrochloride
Step A: Synthesis of [2-(3-amino-pyrrolidin-l-yl)-quinazolin-4-yl]-dimethyl-amine.
Using the procedure for the step A of example 81, the title compound was obtained. ESI MS m/e 258, M + If ; Η NMR (300 MHz, CDCLJ δ 7.80 (d, J= 8.2 Hz, 1 H), 7.41- 7.57 (m, 2 H), 6.93-7.06 (m, 1 H), 3.61-4.02 ( , 4 H), 3.40 (dd, J= 11.0, 4.97 Hz, 1 H), 3.26 (s, 6 H), 2.09-2.30 (m, 1 H), 1.68-1.87 (m, 1 H), 1.22-1.63 (m, 2 H).
Step B: Synthesis of {2-[3-(4-bromo-2-trifluoromethoxy-benzylammo)-pyrroIidin-l- yl]-quinazolin-4-yl}-dimethyl-amine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 510, M (free) + If ; Η NMR (300 MHz, CDC1J δ 8.05-8.61 (m, 2 H), 7.61- 7.96 (m, 2 H), 7.33-7.57 (m, 2 H), 7.17-7.31 (m, 1 H), 4.42-4.64 (m, 2 H), 4.34 (s, 2 H), 3.58-4.24 (m, 3 H), 3.46 (s, 6 H), 2.81 (brs, 1 H), 2.31-2.60 (m, 1 H).
Example 85
2HCI (2-{3-[2-(4-Bromo-2-trifluoromethoxy-phenyI)-ethylamino]-pyrrolidin-l-yl}- quinazoIin-4-yl)-dimethyl-amine dihydrochloride
Step A: Synthesis of (2-{3-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyIamino]- pyrrolidin-l-yl}-quinazolin-4-yl)-dimethyl-amine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 524, M (free) It ; Η NMR (300 MHz, CDC1J δ 8.15-8.53 (m, 1 H), 7.70- 7.93 (m, 1 H), 7.62 (t, J= 1.6 Hz, 1 H), 7.11-7.46 (m, 4 H), 3.60-4.70 (m, 5 H), 3.45 (s, 6 H), 3.04-3.59 (m, 4 H), 2.29-2.98 (m, 2 H).
Example 86
N2-[l-(2,2-Diphenyl-ethyl)-piperidin-4-yl]-N',NI'-dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of N2-[l-(2,2-diphenyl-ethyl)-piperidin-4-yl]-N',/ -dimethyl- quinazoline-2,4-diamine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained ESI MS m/e 452, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.54 (brs, 1 H), 12.42 (s, 1 H), 9.82 (d, J= 8.4 Hz, 1 H), 7.92 (d, J= 8.1 Hz, 1 H), 7.66-7.74 (m, 1 H), 7.40-7.54 (m, 5 H), 7.27-7.39 (m, 5 H), 7.14-7.26 (m, 2 H), 5.17 (t, J= 6.3 Hz, 1 H), 4.39-4.56 (m, 1 H), 3.70-3.87 (m, 2 H), 3.34-3.60 (m, 7 H), 3.07-3.25 (m, 2 H), 2.55-2.87 (m, 2 H), 1.61-1.94 (m, 4 H).
Example 87
HCl l-[4-(4-Dimethylamino-quinazoIin-2-ylamino)-piperidin-l-yl]-3,3-diphenyl-propan-l- one hydrochloride
Step A: Synthesis of l-[4-(4-dimethylamino-quinazolin-2-ylamino)-piperidin-l-yl]- 3,3-diphenyl-propan-l-one hydrochloride
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 502, M + Na+ ; Η NMR (300 MHz, CDCIJ δ 13.45 (brs, 1 H), 8.73 (d, J = 6.9 Hz, 1 H), 7.89 (d, J= 8.2 Hz, 1 H), 7.61-7.70 (m, 1 H), 7.56 (d, J= 1.6 Hz, 1 H), 7.25- 7.39 (m, 11 H), 4.67 (t, J= 7.5 Hz, 1 H), 3.97-4.14 (m, 2 H), 3.70-3.89 (m, 1 H), 3.50 (s, 6 H), 3.13-3.30 (m, 2 H), 2.99-3.12 (m, 2 H), 1.31-1.99 (m, 4 H).
Example 88
HCl cϊ5-iV-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,3-diphenyI- propionamide hydrochloride
Step A: Synthesis of c 5-iV-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]- 3,3-diphenyl-propionamide hydrochloride
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 494, M (free) + H+ ; Η NMR (300 MHz, CDCIJ δ 13.20 (s, 1 H), 8.77 (d, J= 8.2 Hz, 1 H), 7.88 (d, J= 1.1 Hz, 1 H), 7.60-7.69 (m, 1 H), 7.53 (d, J= 17.1 Hz, 1 H), 7.12-7.33 (m, 11 H), 5.72 (d, J= 9.2 Hz, 1 H), 4.57 (t, J= 8.0 Hz, 1 H), 4.11-4.23 (m, 1 H), 3.72-3.87 (m, 1 H), 3.49 (s, 6 H), 2.88 (d, J= 7.9 Hz, 2 H), 1.47-1.85 (m, 8 H).
Example 89
(2-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]-piperidin-l-yl}- quinazolin-4-yl)-dimethyl-amine dihydrochloride
Step A: Synthesis of [2-(4-aminomethyl-piperidin-l-yl)-quinazoIin-4-yl]-dimethyl- amine.
Using the procedure for the step A of example 64, the title compound was obtained. ESI MS m/e 286, M + If ; Η NMR (300 MHz, CDCIJ δ 7.79 (d, J= 8.3 Hz, 1 H), 7.42- 7.52 (m, 1 H), 7.23-7.36 (m, 1 H), 6.94-7.07 (m, 1 H), 4.94 (d, J= 12.7 Hz, 2 H), 3.26 (s, 6 H), 2.74-3.01 (m, 2 H), 2.61 (d, J= 6.6 Hz, 2 H), 1.46-1.99 (m, 4 H), 1.01-1.39 (m, 3 H).
Step B: Synthesis of (2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]- piperidin-l-yl}-quinazolin-4-yl)-dimethyl-amine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained. ESI MS m/e 538, M (free) +H+ ; Η NMR (300 MHz, CDCIJ δ 12.66 (s, 1 H), 8.50 (d, J=
8.1 Hz, 1 H), 8.23 (d, J= 8.6 Hz, 1 H), 7.88 (d, J= 8.4 Hz, 1 H), 7.66 (t, J= 7.9 Hz, 1 H), 7.50 (dd, J= 8.4, 1.9 Hz, 1 H), 7.36-7.41 (m, 1 H), 7.24-7.34 (m, 1 H), 5.01 (brs, 2 H), 4.27 (s, 2 H), 3.49 (s, 6 H), 3.05-3.37 (m, 2 H), 2.44-2.92 (m, 3 H), 1.82-2.37 (m, 2 H), 1.14-1.62 (m, 2 H).
Example 90
2HCI [2-(4-{[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-piperidin-l-yl)- quinazolin-4-yl] -dimethyl-amine dihydrochloride
Step A: Synthesis of [2-(4-{[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]- methyl}-piperidin-l-yl)-quinazolin-4-yl]-dimethyl-amine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained. ESI MS m/e 552, M (free) + If ; XH NMR (300 MHz, CDCIJ δ 12.63 (s, 1 H), 8.48 (d, J=
8.2 Hz, 1 H), 7.79-7.97 (d, J= 7.5 Hz, 1 H), 7.58-7.73 (m, 1 H), 7.19-7.48 (m, 4 H), 5.02 (brs, 2 H), 3.49 (s, 6 H), 2.82-3.69 (m, 6 H), 1.98-2.79 (m, 5 H), 1.52 (brs, 2 H).
Example 91
2HCI
N2-{l-[2-(4-Bromo-2-trifIuoromethoxy-phenyl)-ethyl]-piperidin-4-yl}-N!',N'-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of N2-{l-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin- 4-yl}-iV',Λ^-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 538, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.61 (brs, 1 H), 12.43 (s, 1 H), 9.97 (d, J= 8.1 Hz, 1 H), 7.94 (d, J= 7.9 Hz, 1 H), 7.65-7.76 (m, 1 H), 7.28-7.52 (m, 5 H), 4.48-4.62 (m, 1 H), 3.12-3.73 (m, 14 H), 2.68-2.92 (m, 2 H), 1.96-2.13 (m, 2 H).
Example 92
N2-[l-(3,3-Diphenyl-propyl)-piperidin-4-yl]-N*,/V'-dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of N2-[l-(3,3-diphenyl-propyl)-piperidin-4-yl]-iV^,N'-dimethyl- quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained. ESI MS m e 466, M (free) + If ; Η NMR (300 MHz, CDCLJ δ 12.42 (s, 1 H), 12.26 (brs, 1 H), 9.87 (d, J= 8.2 Hz, 1 H), 7.93 (d, J= 8.2 Hz, 1 H), 7.65-7.74 (m, 1 H), 7.47 (ά, J = 8.2 Hz, 1 H), 7.13-7.37 (m, 11 H), 4.44-4.60 (m, 1 H), 3.98 (t, J= 7.9 Hz, 1 H), 3.28-3.65 (m, 10 H), 2.93-3.09 (m, 2 H), 2.63-2.88 (m, 4 H), 1.84-2.02 (m, 2 H).
Example 93
2HCI
c 5-N2-[4-(3,3-Diphenyl-propylamino)-cyclohexyl]-N4,Λ^-dimethyl-quinazoline-2,4- diamine dihydrochloride
Step A: Synthesis of cts-iV2-[4-(3,3-diphenyl-propylamino)-cyclohexyl]-iV',N='- dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained. ESI MS m/e 480, M (free) + H+ ; Η NMR (300 MHz, CDCLJ δ 12.58 (s, 1 H), 9.53 (s, 2 H), 8.58 (d, J= 7.9 Hz, 1 H), 7.91 (d, J= 8.1 Hz, 1 H), 7.64 (t, J= 7.7 Hz, 1 H), 7.48 (d, J = 7.9 Hz, 1 H), 7.08-7.33 (m, 11 H), 4.18-4.33 (m, 1 H), 4.11 (t, J= 1.1 Hz, 1 H), 3.50 (s, 6 H), 3.16 (brs, 1 H), 2.96 (brs, 2 H), 2.64-2.84 (m, 2 H), 1.87-2.25 (m, 6 H), 1.53-1.75 (m, 2 H).
Example 94
2HCI c/5-N2-{4-[(2,2-Diphenyl-ethylamino)-methyl]-cyclohexyl}-N*,7Y'-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of 5-N2-{4-[(2,2-diphenyl-ethylamino)-methyl]-cyclohexyl}- V, V,- dimethyl-quinazoline-2,4-diamine dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 480, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.78 (s, 1 H), 8.94 (brs, 2 H), 8.80 (d, J= 8.4 Hz, 1 H), 7.89 (d, J= 8.1 Hz, 1 H), 7.60-7.69 (m, 1 H), 7.44-7.58 (m, 2 H), 7.18-7.42 (m, 9 H), 4.91 (t, J= 8.0 Hz, 1 H), 4.19-4.34 (m, 1 H), 3.61-3.76 (m, 2 H),
3.50 (s, 6 H), 2.81-2.97 (m, 2 H), 2.04-2.19 (m, 1 H), 1.74-1.91 (m, 2 H), 1.45-1.69 (m, 6 H).
Example 95
N2-[l-(4-Bromo-2-trifluoromethoxy-ben2yl)-piperidin-4-ylmethyl]-Λ^,N*-dimethyl- quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of N!',iV<-dimethyl--V2-piperidin-4-ylmethyl-qumazoline-2,4- diamine.
Using the procedure for the step A of example 81, the title compound was obtained. ESI MS m/e 408, M + Na+ ; Η NMR (300 MHz, CDCIJ δ 7.82 (d, J= 8.3 Hz, 1 H), 7.39- 7.59 (m, 2 H), 6.96-7.12 (m, 1 H), 4.79-5.11 (m, 1 H), 3.94-4.31 (m, 2 H), 3.42 (t, J= 5.9 Hz, 2 H), 3.27 (s, 6 H), 2.70 (t, J= 12.1 Hz, 2 H), 1.63-1.92 (m, 3 H), 1.46 (s, 9 H), 0.99- 1.37 (m, 2 H).
Step B: Synthesis of N2-[l-(4-bromo-2-trifluoromethoxy-benzyl)-piperidin-4- ylmethylJ-iV^-dimethyl-quinazoline^^-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 538, M (free) + If ; ΗNMR (300 MHz, CDCIJ δ 13.13 (s, 1 H), 12.69 (brs, 1 H), 8.73 (t, J= 6.3 Hz, 1 H), 8.19 (d, J= 8.2 Hz, 1 H), 7.90 (d, J= 7.6 Hz, 1 H), 7.45- 7.73 (m, 4 H), 7.22-7.33 (m, 1 H), 4.10-4.24 (m, 2 H), 3.36-3.67 (m, 10 H), 2.61-2.86 (m, 2 H), 1.80-2.33 (m, 5 H).
Example 96
N2-{l-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin-4-ylmethyl}-iV→,N!'- dimethyI-quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of iV2-{l-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin- 4-ylmethyl}-iV/,N?-dimethyl-quinazoline-2,4-diamme dihydrochloride
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 552, M (free) + H+ ; Η NMR (300 MHz, CDCIJ δ 13.16 (brs, 1 H), 8.74 (m, 1 H), 7.92 (d, J= 8.2 Hz, 1 H), 7.67 (t, J= 7.5 Hz, 1 H), 7.53 (d, J = 7.6 Hz, 1 H), 7.22- 7.46 (m, 5 H), 3.44-3.71 (m, 10 H), 3.26-3.39 (m, 2 H), 3.01-3.15 (m, 2 H), 2.63-2.86 (m, 2 H), 1.87-2.33 (m, 5 H).
Example 97
2HCI N2-[l-(4-Bromo-2-trifluoromethoxy-benzyl)-pyrrolidin-3-yl]-iV*,Λ^-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of 7N2-(l-benzyl-pyrrolidin-3-yl)-iV,iV'-dimethyl-quinazoline-2,4- diamine.
A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (5.1 g, 28.9 mmol) and l-Benzyl-ρyrrolidin-3-ylamine (5.1 g, 28.9 mmol) in
BuOH (8 mL) was stirred at reflux for 26 hr, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHCL, (three times). The combined organic layer was dried over MgSO4, filtered, concenfrated, and purified by flash chromatography (NH-silica gel, 10% to 16% EtOAc in hexane) to give ^-(l-benzyl-pyrrolidin-S-y - N^-dimethyl-
quinazoline-2,4-diamine (3.37 g, 50%) as a pale yellow solid.
ESI MS m/e 348, M + If ; Η NMR (300 MHz, CDCLJ δ 7.80 (d, J= 9.0 Hz, 1 H), 7.46 (m, 2 H), 7.18-7.38 (m, 5 H), 7.02 (ddd, J = 8.3, 6.3, 1.9 Hz, 1 H), 5.30 (brs, 1 H), 4.59- 4.75 (m, 1 H), 3.63 (d, J= 2.5 Hz, 2 H), 3.25 (s, 6 H), 2.88 (dd, J= 9.6, 6.6 Hz, 1 H), 2.70- 2.81 (m, 1 H), 2.28-2.60 (m, 3 H), 1.64-1.78 (m, 1 H).
Step B: Synthesis of iVjiV^-dimethyl-^-pyrrolidin-S-yl-quinazoline^^-diamine.
To a solution of N2-(l-benzyl-pyrrolidin-3-yl)-NJ,N'-dimethyl-quinazoline-2,4- dia ine (3.3 g, 9.5 mmol) in MeOH (33 mL) was added Pd(OH)2 (660 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 13 hr, and stirred at 50 °C for 6 hr. The mixture was filtered, concentrated, and purified by medium-pressure liquid chromatography (ΝH-silica gel, 1% to 3% MeOH in CHC1J to give N^N'-dimethyl- N2-pyrrolidin-3-yl-quinazoline-2,4-diamine (2.3 g, 93%) as a yellow oil. ESI MS m/e 258, M + H+ ; Η ΝMR (300 MHz, CDCIJ δ 7.82 (d, J= 7.8 Hz, 1 H), 7.42- 7.54 (m, 2 H), 7.03 (ddd, J= 8.3, 6.4, 1.8 Hz, 1 H), 5.03 (brs, 1 H), 4.52 (brs, 1 H), 3.26 (s, 6 H), 2.83-3.24 (m, 4 H), 1.97-2.30 (m, 2 H), 1.57-1.77 (m, 1 H).
Step C: Synthesis of N2-[l-(4-bromo-2-trifluoromethoxy-benzyl)-pyrrolidin-3-yl]- N V*-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 510, M (free) + H+ ; ΗΝMR (300 MHz, CDCIJ δ 13.22 (brs, 1 H), 12.87 (s, 1 H), 9.68 (d, J= 7.4 Hz, 1 H), 8.11 (d, J= 8.4 Hz, 1 H), 7.95 (d, J= 8.4 Hz, 1 H), 7.71 (t, J- 8.3 Hz, 1 H), 7.43-7.63 (m, 3 H), 7.28-7.38 (m, 1 H), 4.94-5.15 (m, 1 H), 4.41 (s, 2 H), 4.00-4.17 (m, 1 H), 3.26-3.82 (m, 8 H), 3.00-3.16 (m, 1 H), 2.59-2.82 (m, 1 H), 2.18-2.37 (m, 1 H).
Example 98
2HCI
N2-{l-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethyl]-pyrrolidin-3-yl}-N',iV^- dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of N -{l-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyl]-pyrrolidin- 3-yl}-NVV^-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 524, M (free) + T ; Η NMR (300 MHz, CDCIJ δ 9.61-9.78 (m, 1 H), 7.96 (d, J= 8.4 Hz, 1 H), 7.71 (t, J= 7.7 Hz, 1 H), 7.55 (d, J= 8.2 Hz, 1 H), 7.29-7.47 (m, 4 H), 4.89-5.12 (m, 1 H), 4.07-4.28 (m, 1 H), 2.99-3.97 (m, 13 H), 2.55-2.79 (m, 1 H), 2.22-2.42 (m, 1 H).
Example 99
l-(4-Bromo-2-trifluoromethoxy-phenyl)-l-{4-[(4-dimethylamino-quinazobin-2- ylamino)-methyl]-piperidin-l-yl}-methanone hydrochloride
Step A: Synthesis of l-(4-bromo-2-trifluoromethoxy-phenyl)-l-{4-[(4-dimethylamino- quinazolin-2-ylamino)-methyl]-piperidin-l-yl}-methanone hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 552, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 13.44 (brs, 1 H), 8.53- 8.77 (m, 1 H), 7.90 (d, J= 8.5 Hz, 1 H), 7.66 (t, J= 1.1 Hz, 1 H), 7.43-7.61 (m, 3 H), 7.19- 7.37 (m, 1 H), 4.69-4.85 (m, 1 H), 3.20-3.63 (m, 10 H), 2.61-3.13 ( , 2 H), 1.76-2.14 (m, 3 H), 1.08-1.48 ( , 2 H).
Example 100
HCl c 5-3-(3,4-Difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexyl]-propionamide hydrochloride
Step A: Synthesis of c/s-3-(3,4-difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexyl]-propionamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 454, M (free) + H+ ; Η NMR (300 MHz, CDCIJ δ 13.05 (s, 1 H), 8.87 (d, J = 8.1 Hz, 1 H), 7.89 (d, J= 8.2 Hz, 1 H), 7.65 (t, J= 1.1 Hz, 1 H), 7.51 (d, J= 7.3 Hz, 1 H), 7.20-7.27 (m, 1 H), 6.88-7.09 (m, 3 H), 5.97 (d, J= 8.5 Hz, 1 H), 4.26 (brs, 1 H), 3.91 (brs, 1 H), 3.51 (s, 6 H), 2.92 (t, J= 1.6 Hz, 2 H), 2.44 (t, J= 1.6 Hz, 2 H), 1.61-1.93 (brs, 8 H).
Example 101
2HCI
c 5-N2-{4-[3-(3,4-Difluoro-phenyl)-propylamino]-cyclohexyl}-iV',iV^-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c/5-N2-{4-[3-(3,4-difluoro-phenyl)-propylamino]-cyclohexyl}- JV*,N -dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained. ESI MS m/e 440, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.62 (s, 1 H), 9.54 (s, 2 H), 8.72 (d, J= 7.6 Hz, 1 H), 7.91 (d, J= 8.4 Hz, 1 H), 7.62-7.70 ( , 1 H), 7.48 (d, = 7.6 Hz, 1 H), 7.24-7.33 (m, 1 H), 6.90-7.06 (m, 3 H), 4.29 (brs, 1 H), 3.52 (s, 6 H), 3.00-3.42
(m, 3 H), 2.67-2.81 (m, 2 H), 1.93-2.43 (m, 8 H), 1.60-1.80 (m, 2 H).
Example 102
HCl teα«5-4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cycIohexylmethyl]-2- trifluoromethoxy-benzamide hydrochloride
Step A: Synthesis of N2-(4-aminomethyl-cyclohexyl)-Λ^^V^-dimethyl-quinazoline-2,4- diamine.
Using the procedure for the step A of example 81 , the title compound was obtained. ESI MS m/e 300, M + H+ ; Η NMR (300 MHz, CDCIJ δ 7.79 (d, J= 8.4 Hz, 1 H), 7.45 (m, 2 H), 7.00 (ddd, J= 8.4, 6.3, 1.9 Hz, 1 H), 4.80 (d, J= 8.2 Hz, 1 H), 3.82-3.94 (m, 1 H), 3.24 (s, 6 H), 2.56 (d, J= 6.2 Hz, 2 H), 2.14-2.28 (m, 2 H), 1.78-1.92 (m, 2 H), 0.95- 1.42 (m, 7 H).
Step B: Synthesis of te«« -4-bromo-N-[4-(4-dimethylamino-quinazolin-2-yIamino)- cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 566, M + H+ ; Η NMR (300 MHz, CDCIJ δ 13.48 (s, 1 H), 8.34 (d, J= 7.5 Hz, 1 H), 7.83-7.94 (m, 2 H), 7.43-7.69 (m, 4 H), 7.20-7.29 (m, 1 H), 6.49-6.62 (m, 1 H), 3.72-3.93 (m, 1 H), 3.50 (s, 6 H), 3.39 (t, J= 6.3 Hz, 2 H), 2.09-2.22 (m, 2 H), 1.85-1.98 (m, 2 H), 1.37-1.69 (m, 3 H), 1.08-1.28 (m, 2 H).
Example 103
4-Bromo-N-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2- trifluoromethoxy-benzamide hydrochloride
Step A: Synthesis of 4-bromo-N-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4- ylmethyl] -2-trifluoromethoxy-benzamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 552, M (free)* ; Η NMR (300 MHz, CDCLJ δ 13.50 (s, 1 H), 8.73 (d, J= 8.5 Hz, 1 H), 7.86 (d, J= 8.4 Hz, 1 H), 7.81 (d, J= 8.4 Hz, 1 H), 7.62-7.71 (m, 1 H), 7.53 (dd, J= 8.4, 1.87 Hz, 1 H), 7.45 (s, 1 H), 7.23-7.32 (m, 1 H), 6.77-6.87 (m, 1 H), 3.30-3.55 (m, 10 H), 2.96-3.27 (m, 2 H), 1.89-2.15 (m, 3 H), 1.28-1.57 (m, 2 H).
Example 104
HCl c 5-2-(3,4-Difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cy clohexylmethyl] -acetamide hydrochloride
Step A: Synthesis of c 5-2-(3,4-difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cy clohexylmethyl] -acetamide hydrochloride
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 454, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.66 (s, 1 H), 9.08 (d, J= 8.9 Hz, 1 H), 7.90 (d, J= 8.1 Hz, 1 H), 7.66 (ddd, J= 8.4, 7.2, 1.2 Hz, 1 H), 7.48 (dd, J = 8.4, 0.9 Hz, 1 H), 7.32-7.41 (m, 1 H), 7.12-7.31 (m, 3 H), 6.97-7.08 (m, 1 H), 4.35-4.48 (m, 1 H), 3.78 (s, 2 H), 3.52 (s, 6 H), 3.28-3.36 (m, 2 H), 1.42-2.05 (m, 9 H).
Example 105
5-N-[4-(4-Dimethylamino-quinazoIin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro- benzamide hydrochloride
Step A: Synthesis of αs-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 440, M (free) + H+ ; Η NMR (300 MHz, CDCIJ δ 12.89 (s, 1 H), 9.11 (d, J = 8.2 Hz, 1 H), 7.88 (m, 3 H), 7.64 (ddd, J= 8.4, 7.2, 1.2 Hz, 1 H), 7.49 (dd, J= 8.4, 0.9 Hz, 1 H), 7.18-7.29 (m, 2 H), 6.96-7.07 (m, 1 H), 4.29-4.44 (m, 1 H), 3.51 (s, 8 H), 1.55- 2.02 (m, 9 H).
Example 106
2HCI cw-iV2-(4-{[2-(3,4-Difluoro-phenyl)-ethylamino]-methyl}-cyclohexyl)-iV',iV'-dimethyl- quinazoIine-2,4-diamine dihydrochloride
Step A: Synthesis of c s-N2-(4-{[2-(3,4-difluoro-phenyl)-ethylamino]-methyl}- cyclohexyl)-N',iV/-dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained. ESI MS m/e 440, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.43 (s, 1 H), 9.64 (brs, 2 H), 8.66 (d, J= 8.3 Hz, 1 H), 7.91 (d, J= 8.3 Hz, 1 H), 7.67 (t, J= 7.8 Hz, 1 H), 7.46 (d, J= 8.3 Hz, 1 H), 7.28 (t, J= 7.8 Hz, 1 H), 6.97-7.17 (m, 3 H), 4.24-4.37 (m, 1 H), 3.52 (s, 6 H), 3.30-3.44 (m, 2 H), 2.94-3.25 (m, 4 H), 1.57-2.28 (m, 9 H).
Example 107
2HCI c 5-N2-{4-[(3,4-Difluoro-benzylamino)-methyl]-cyclohexyl}-iV'^V'-dimethyl- quinazo!ine-2,4-diamine dihydrochloride
Step A: Synthesis of c/5-N2-{4-[(3,4-difluoro-benzylamino)-methyl]-cyclohexyl}-iV^V'- dimethyl-quinazoline-2,4-diamine dihydrochloride
Using the procedure for the step A of example 72, the title compound was obtained. ESI MS m/e 426, M (free) + If ; Η NMR (300 MHz, DMSO-dJ δ 9.39 (s, 2 H), 8.44 (m, 1 H), 8.17 (d, J= 8.4 Hz, 1 H), 7.72-7.88 (m, 2 H), 7.27-7.61 (m, 4 H), 4.11-4.31 (m, 3 H), 3.48 (s, 6 H), 2.81 (d, J= 6.1 Hz, 2 H), 1.32-2.03 (m, 9 H).
Example 108
2-(4-Bromo-2-trifluoromethoxy-phenyl)-l-{4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-piperidin-l-yl}-ethanone hydrochloride
Step A: Synthesis of 2-(4-bromo-2-trifluoromethoxy-phenyl)-l-{4-[(4-dimethylamino- quinazolin-2-yIamino)-methyl]-piperidin-l-yl}-ethanone hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 566, M (free) + I ; Η NMR (300 MHz, CDCIJ δ 13.48 (s, 1 H), 8.65 (t, J= 5.8 Hz, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.53-7.70 (m, 2 H), 7.37-7.44 (m, 2 H), 7.20-7.32 (m, 2 H), 4.59-4.72 (m, 1 H), 3.80-3.94 (m, 1 H), 3.68 (d, J= 6.1 Hz, 2 H), 3.25-3.58 (m, 8 H), 2.94-3.12 (m, 1 H), 2.50-2.68 (m, 1 H), 1.75-2.03 (m, 3 H), 1.06-1.32 (m, 2 H).
Example 109
HCl i'rfl«5-2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexylmethyl]-acetamide
Step A: Synthesis of tra«s-2-(4-bromo-2-trifluoromethoxy-phenyl)-N-[4-(4- dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 580, M (freef ; Η NMR (300 MHz, CDCIJ δ 8.28 (d, J= 6.7 Hz, 1 H), 7.87- 7.90 (d, J= 8.5 Hz, 1 H), 7.52-7.66 (m, 2 H), 7.39-7.44 (m, 2 H), 7.20-7.33 (m, 2 H), 5.85- 5.98 (m, 1 H), 3.70-3.91 (m, 1 H), 3.58 (s, 2 H), 3.50 (s, 6 H), 3.16 (t, J= 6.5 Hz, 2 H), 2.03-2.20 (m, 2 H), 1.28-1.88 (m, 5 H), 0.96-1.18 (m, 2 H).
Example 110
HCl cϊ5-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluoro- benzamide hydrochloride
Step A: Synthesis of cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]- 3,4-difluoro-benzamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 448, M (free) + Na+ ; Η NMR (300 MHz, CDCIJ δ 13.01 (s, 1 H), 8.96 (d, J = 8.1 Hz, 1 H), 7.91 (d, J= 8.2 Hz, 1 H), 7.55-7.79 (m, 4 H), 7.49-7.54 (m, 1 H), 7.15-7.32 (m, 2 H), 6.76 (d, J= 8.4 Hz, 1 H), 4.30-4.41 (m, 1 H), 4.03-4.22 (m, 1 H), 3.52 (s, 6 H),
1.67-2.07 (m, 8 H).
Example 111
HCl cw-3-(3,4-Difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cy clohexylmethyl] -propionamide hydrochloride
Step A: Synthesis of c/5-3-(3,4-difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexylmethyl]-propionamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 468, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 12.70 (s, 1 H), 9.00 (d, J = 8.3 Hz, 1 H), 7.90 (d, J= 8.3 Hz, 1 H), 7.66 (ddd, J= 8.3, 7.2, 1.0 Hz, 1 H), 7.48 (dd, J = 8.3, 1.0 Hz, 1 H), 7.11-7.31 (m, 2 H), 6.84-7.06 ( , 3 H), 4.32-4.44 (m, 1 H), 3.51 (s, 6 H), 3.26-3.33 (m, 2 H), 2.96 (t, J= 7.5 Hz, 2 H), 2.76 (t, J= 7.4 Hz, 2 H), 1.34-1.94 (m, 9 H).
Example 112
c 5-N2-[4-(3,4-Difluoro-benzylamino)-cyclohexyl]-/ ,7Y'-dimethyl-quinazoline-2,4- diamine dihydrochloride
Step A: Synthesis of ci5-N2-[4-(3,4-difluoro-benzylamino)-cyclohexyl]-iV,,iV -dimethyl- quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained.
ESI MS m/e 434, M (free) + Na+ ; Η NMR (300 MHz, DMSO-dJ δ 13.03 (s, 1 H), 9.50
(brs, 2 H), 8.31-8.40 (m, 1 H), 8.19 (d, J= 8.2 Hz, 1 H), 7.73-7.90 (m, 2 H), 7.29-7.60 (m, 4 H), 4.04-4.28 (m, 3 H), 3.46 (s, 6 H), 3.06-3.22 (m, 1 H), 1.61-2.10 (m, 8 H).
Example 113
2HCI c s-N2-(4-{[3-(3,4-Difluoro-phenyl)-propylamino]-methyl}-cyclohexyl)-N',iV*- dimethyl-quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of c/5-N2-(4-{[3-(3,4-difluoro-phenyl)-propylamino]-methyl}- cyclohexy^-N'jTy-dimethyl-quinazoline^^-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained.
ESI MS m/e 454, M (free) + H+ ; Η NMR (300 MHz, CDCIJ δ 12.50 (s, 1 H), 9.43 (brs, 2 H), 8.60 (d, J= 7.93 Hz, 1 H), 7.90 (d, J= 8.2 Hz, 1 H), 7.65 (ddd, J= 8.2, 7.2, 1.1 Hz, 1 H), 7.46 (d, J = 8.6 Hz, 1 H), 7.23-7.30 (m, 1 H), 6.91-7.08 (m, 3 H), 4.22-4.34 (m, 1 H), 3.51 (s, 6 H), 2.87-3.07 (m, 4 H), 2.68 (t, J= 7.7 Hz, 2 H), 1.53-2.43 (m, 11 H).
Example 114
2-(4-Bromo-2-trifluoromethoxy-phenyI)-N-[l-(4-dimethylamino-quinazolin-2-yI)- piperidin-4-ylmethyl] -acetamide hydrochloride
Step A: Synthesis of 2-(4-bromo-2-trifluoromethoxy-phenyl)-N-[l-(4-dimethylamino- quinazolin-2-yl)-piperidin-4-ylm ethyl] -acetamide hydrochloride
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 588, M (free) + Na+ ; Η NMR (300 MHz, CDCLJ δ 13.32 (s, 1 H), 8.68 (d, J = 8.4 Hz, 1 H), 7.86 (d, J= 7.4 Hz, 1 H), 7.65 (ddd, J= 8.4, 7.1, 1.2 Hz, 1 H), 7.23-7.42 (m, 4 H), 6.59-6.69 (m, 1 H), 3.60 (s, 2 H), 3.48 (s, 7 H), 2.90-3.37 (m, 5 H), 1.78-2.08 (m, 3 H), 1.19-1.46 (m, 2 H).
Example 115
HCl j'rαns-2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-{4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-cyclohexylmethyl}-acetamide hydrochloride
StepA: Synthesis of tørøs-2-(4-bromo-2-trifluoromethoxy-phenyl)-N-{4-[(4- dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-acetamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 616, M (free) + Na" ; Η NMR (300 MHz, CDCLJ δ 8.37-8.49 (m, 1 H), 7.89 (d, J= 8.5 Hz, 1 H), 7.53-7.68 (m, 2 H), 7.40-7.45 (m, 2 H), 7.20-7.32 (m, 2 H), 5.60-5.71 (m, 1 H), 3.55 (s, 2 H), 3.50 (s, 6 H), 3.35 (t, J= 6.1 Hz, 2 H), 3.08 (t, J= 6.4 Hz, 2 H), 0.77-2.00 (m, 1 O H).
Example 116
HCl
cis-2-(3,4-Difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexylj-acetamide hydrochloride
Step A: Synthesis of cw-2-(3,4-difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexyl] -acetamide hydrochloride
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 440, M (free) + If ; Η NMR (300 MHz, CDCIJ δ 13.01 (s, 1 H), 8.85 (d, J = 8.2 Hz, 1 H), 7.89 (d, J= 8.2 Hz, 1 H), 7.65 (ddd, J= 8.2, 7.1, 1.2 Hz, 1 H), 7.52 (d, J= 8.2 Hz, 1 H), 6.95-7.33 (m, 4 H), 6.32 (d, J= 7.6 Hz, 1 H), 4.19-4.34 (m, 1 H), 3.82-4.01 (m, 1 H), 3.51 (s, 6 H), 3.47 (s, 2 H), 1.61-2.01 (m, 8 H).
Example 117
2HCI c 5-N2-{4-[2-(3,4-Difluoro-phenyl)-ethylamino]-cyclohexyl}-iV^,Λ^-dimethyl- quinazoline-2,4-diamine dihydrochloride
Step A: Synthesis of 5-N2-{4-[2-(3,4-difluoro-phenyl)-ethyIamino]-cyclohexyl}-N',7V#- dimethyl-quinazoline-2,4-diamine dihydrochloride.
Using the procedure for the step A of example 72, the title compound was obtained. ESI MS m/e 426, M (free) + H+ ; ΗNMR (300 MHz, CDCIJ δ 12.51 (s, 1 H), 9.70 (brs, 2 H), 8.67 (d, J= 7.5 Hz, 1 H), 7.92 (d, J= 8.0 Hz, 1 H), 7.68 (t, J= 8.0 Hz, 1 H), 7.52 (d, J = 8.4 Hz, 1 H), 7.30 (t, J= 7.8 Hz, 1 H), 6.97-7.22 (m, 3 H), 4.34 (brs, 1 H), 3.53 (s, 6 H), 3.12-3.41 (m, 5 H), 1.62-2.40 (m, 8 H).
Example 118
4-Bromo-N-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-2-trifluoromethoxy- benzenesulfonamide
Step A: Synthesis of [2-(4-amino-piperidin-l-yl)-quinazolin-4-yl]-dimethyl-amine.
To a solution of l-benzyl-piperidin-4-ylamine (2.00 g, 10.5 mmol) in THF (20 mL) was added (Boc)2O (2.52 g, 11.5 mmol) . The mixture was stirred at ambient temperature for 40 min, and concenfrated. To a solution of the residue in MeOH (20 mL) was added 20%o Pd(OH)2 (400 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 20 hr. Additionally, 20% Pd(OH)2 (400 mg) was added and the mixture was stirred at ambient temperature under hydrogen atmosphere for 7 hr, at 50 °C for 4.5 hr, and at ambient temperature for 12 hr, filtered through a pad of celite, and concentrated to give a white solid. A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (1.10 g, 5.30 mmol) and the above solid (1.27 g, 6.34 mmol) in 2- propanol (11 mL) was stirred at reflux for 20 hr. The precipitate was collected by filtration, washed with 2-propanol, dissolved in 50% MeOH in CHC13 (60 mL). The solution was poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with CHC13 (three times). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (NH-silica gel, EtOAc to CHC1J to give [2-(4- amino-piperidm-l-yl)-quinazolin-4-yl]-dimethyl-amine (864 mg, 68%) as a colorless oil. ESI MS m/e 272, M + H" ; Η NMR (300 MHz, CDCIJ δ 7.79 (d, J= 8.2 Hz, 1 H), 7.45- 7.55 (m, 2 H), 6.96-7.05 (m, 1 H), 4.83 (d, J= 13.4 Hz, 2 H), 3.26 (s, 6H), 2.84-3.03 (m, 3 H), 1.85-1.95 (m, 2 H), 1.20-1.50 (m, 4 H).
Step B: Synthesis of 4-bromo-N-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4- yl]-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step A of example 20, the title compound was obtained.
ESI MS m/e 574, M +tt ; Η NMR (300 MHz, CDCIJ δ 7.94 (d, J= 8.7 Hz, 1 H), 7.80 (d, J= 8.2 Hz, 1 H), 7.39-7.61 (m, 4 H), 6.98-7.07 (m, 1 H), 4.60-4.81 (m, 3 H), 3.39-3.61 (m, 1 H), 3.25 (s, 6 H), 2.98-3.08 (m, 2 H), 1.73-1.92 (m, 2 H), 1.33-1.54 (m, 2 H).
Example 119
{2-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-piperidin-l-yl]-quinazolin-4-yl}- dimefhyl-amine dihydrochloride
Step A: Synthesis of {2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-piperidin-l- yl]-quinazolin-4-yl}-dimethyl-amine dihydrochloride.
Using the procedure for the step B of example 37, the title compound was obtained.
ESI MS m/e 524, M (free) + H+ ; Η NMR (300 MHz, CDCLJ δ 8.43 (d, J= 8.1 Hz, 1 H), 8.20 (d, J= 8.4 Hz, 1 H), 7.90 (d, J= 8.4 Hz, 1 H), 7.67 (t, J= 7.5 Hz, 1 H), 7.26-7.49 (m, 3 H), 5.13 (brs, 2 H), 4.27 (s, 2 H), 3.08-3.60 (s, 9 H), 2.08-2.78 (m, 4 H).
Example 120
4-Bromo-N-[l-(4-dimethyIamino-quinazolin-2-yl)-piperidin-4-yl]-2-trifluoromethoxy- benzamide hydrochloride
Step A: Synthesis of 4-bromo-iV-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4- yl]-2-trifluoromethoxy-benzamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 560, M (free) Na" ; Η NMR (300 MHz, CDCIJ δ 13.68 (s, 1 H), 8.73 (d, J=
7.8 Hz, 1 H), 7.80-7.91 (m, 2 H), 7.68 (ddd, J= 8.4, 7.1, 1.3 Hz, 1 H), 7.55 (dd, J= 8.4,
1.9 Hz, 1 H), 7.42-7.46 (m, 1 H), 7.29 (ddd, J= 8.4, 7.1, 1.3 Hz, 1 H), 6.67 (d, J= 7.3 Hz, 1 H), 5.04 (brs, 2 H), 4.23-4.42 (m, 1 H), 3.27-3.61 (m, 8 H), 2.19-2.36 (m, 2 H), 1.57- 1.81 (m, 2 H).
Example 121
2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-[l-(4-dimethylamino-quinazolin-2-yl)- piperidin-4-yl]-acetamide hydrochloride
Step A: Synthesis of 2-(4-bromo-2-trifluoromethoxy-phenyl)-N-[l-(4-dimethylamino- quinazolin-2-yl)-piperidin-4-yl]-acetamide hydrochloride.
Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 574, M (free) + Na" ; Η NMR (300 MHz, CDCIJ δ 13.08 (s, 1 H), 8.61 (d, J = 8.4 Hz, 1 H), 7.86 (d, J= 7.5 Hz, 1 H), 7.56-7.68 (m, 2 H), 7.21-7.39 (m, 4 H), 4.70-5.10 (m, 2 H), 4.04-4.22 (m, 1 H), 3.68 (s, 2 H), 3.34-3.61 (m, 8 H), 1.59-2.19 (m, 4 H).
Example 122 - 301.
To a solution of amine obtained in step A of example 15 (30 μmol) and pyridine
(120 μmol) in CH2C12 (400 μL) was added an appropriate sulfonyl chloride (60 μmol) in
CH2C12 (200 μL) at 25 °C. After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N2. To the residue was partitionated between CHC13 and saturated aqueous NH4C1. The aqueous layer was extracted with CHC13. The combined organic layers were dried over MgSO4. After concentration by a sfream of dry N2, dry CH2C12 (600 μL) and PSA (300 μL) were added to the residue. After the stirring at 25 °C for 20 hr, the reaction mixture was filtrated and purified by flash chromatography (NH-silica gel, 33% MeOH in CHC1J to give the desired product.
Example 302 - 588.
To a solution of amine obtained in step C of example 9 or step A of example 64 (30 μmol) in CH2C12 (200 μL) were added poly(4-vinylpyridine) (75 μL) in CH2C12 (200 μL) and acid chloride (60 μmol) in CH2C12 (200 μL) at 25 °C. After stirring at the same temperature for 20 hr, the reaction mixture was filtered and concenfrated by a sfream of dry N2. To the residue were added dry CH2CL_ (600 μL) and PSA (300 μL). After the stirring at 25 °C for 20 hr, the reaction mixture was filtrated and purified by flash chromatography (NH-silica gel, 33% MeOH in CHC1J to give the desired product.
Example 589 - 1136.
To a solution of carboxylic acid (200 μL, 60 μmol) in CH2C12 (200 μL) were added l-cyclohexyl-3-methylpolystyrene-carbodiimide (150 μL, 126 μmol) in CH2C12 (200 μL) and amine obtained in step C of example 9 or step A of example 64 (30 μmol) in CH2C12 (200 μL) at 25 °C. After stirring at the same temperature for 20 hr, the reaction mixture was filtered through NH-silica gel, and concenfrated by a sfream of dry N2. To the residue were added dry CH2C12 (700 μL) and polystyrene linked benzaldehyde (75 μL, 60 μmol). After the stirring at 50 °C for 20 hr, the reaction mixture was filtrated, and concenfrated by a stream of dry N2 to give the desired product.
Example 1137 - 1745.
To a solution of the amide product in THF (200 μl) was added 1 M borane-THF
complex in THF (300 μl, 300 μmol). The mixture was stirred at 80 °C for 1 hr, and concentrated by a sfream of dry N2. To the residue were added 1 M aqueous HCl (300 μl) and THF (300 μl). The mixture was stirred at 80 °C for 1 hr, and concentrated by a sfream of dry N2. To the residue was partitionated between CHC13 and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHC13. The combined organic layers were dried over MgSO4. The mixture was concentrated by a stream of dry N2, and the purified by flash chromatography (silica gel, 2% to 7% 2 M NH3/MeOH in CHC1J to give the desired product.
Example 1746 - 2184.
To a solution of amine obtained in step C of example 9 or step A of example 64 (36 μmol) in MeOH (200 μL) were added aldehyde (30 μmol) in MeOH (200 μL) and AcOH (90 μmol) at 25 °C. The reaction mixture was stirred at the same temperature for 1 hr. To the mixture was added NaBH3CN (120 μmol) in MeOH (200 μL). After stirring at the same temperature for 20 hr, the reaction mixture was concenfrated by a stream of dry N2. To the residue was partitionated between CHC13 and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHC13. The combined organic layers were dried over MgSO4. The mixture was concenfrated by a stream of dry N2, and purified by flash chromatography (silica gel, 2% to 7% 2 M NH3/MeOH in CHCLJ to give the desired product.
Example 2185 - 2328.
To a solution of alcohol (35 μmol) in CH2C12 (200 μL) was added Dess-Martin periodinane (63 μmol) in CH2C12 (200 μL) at 25 °C, and the reaction mixture was stirred at the same temperature for 20 hr. To the reaction mixture were added amine obtained in step C of example 9 or step A of example 64 (36 μmol) in MeOH (200 μL) and AcOH (90 μL), and the mixture was stirred at the same temperature for 1 hr. To the mixture was added NaBHjCN (120 μmol) in MeOH (200 μL). After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N2. To the residue was partitionated between CHC13 and 2 M aqueous sodium hydroxide. The aqueous layer was
extracted with CHC13. The combined organic layers were dried over MgSO4. The mixture was concenfrated by a stream of dry N2, and purified by flash chromatography (silica gel, 2% to 7% 2 M NH3/MeOH in CHCLJ to give the desired product.
611
Example 2329
frø« -4-Bromo-N- {4- [(4-methylamino-quinazolin-2-ylamino)-methyl] - cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride
Step A: Synthesis of frøκs-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- methylj-cyclohexanecarboxylic acid.
To a solution of tr rø-4-aminomethyl-cyclohexanecarboxylic acid (3.14 g, 20 mmol) in THF (20 L) and 1 M aqueous sodium hydroxide (42 mL) was added a solution of 4-bromo-2 -trifluoromethoxy benzenesulfonyl chloride (6.9 g, 20.4 mmol) in THF (20 mL) and the mixture was stirred for 2 hr at ambient temperature. The resulting mixture was concentrated and 1 M aqueous HCl (45 mL) was added. The resulting precipitate was filtered, washed with water and hexanes to give trαrø-4-[(4-bromo-2- trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid (7.18 g, 78%) as a white powder.
ESI MS m/e 460/462 M + I ; Η NMR (500 MHz, DMSO-d6) δ 12.00 (brs, 1 H), 7.99 (brs, 1 H), 7.84-7.80 (m, 3 H), 2.72 (d, J= 6.3 Hz, 2 H), 2.10 ( , 1 H), 1.86 (m, 2 H), 1.71 (m, 2 H), 1.31 (m, 1 H), 1.23 (m, 2 H), 0.87 (m, 2 H).
Step B: Synthesis of *rαns-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- methyl]-cyclohexanecarboxylic acid amide.
A solution of trα -4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- methylj-cyclohexanecarboxylic acid (7.14 g, 15.5 mmol) and triethylamine (2.35 L,
16.9 mmol) in THF (25 mL) was cooled to 0 °C. To the mixture was added ethyl chloroformate (1.62 mL, 17 mmol) in THF (5 mL) over 10 min. After stirring at 0 °C for
15 min, aqueous ammonia (27 mL) was added dropwise and the mixture was stirred at ambient temperature for 2 hr. The mixture was concentrated under reduced pressure and the concentrate was treated with water to give a solid. The solid was filtered and washed with water and hexanes to give tra/w-4-[(4-bromo-2-trifluoromethoxy-
benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid amide as a white solid (4.2 g,
ESI MS m/e 459/461 M + ϊ ; Η NMR (500 MHz, DMSO-d6) δ 7.98 (brs, 1 H), 7.84-7.80 (m, 3 H), 7.13 (s, 1 H), 6.62 (s, 1 H), 2.72 (d, J= 6.5 Hz, 2 H), 1.98 (m, 1 H), 1.70 (m, 4 H), 1.29 (m, 1 H), 1.23 ( , 2 H), 0.83 (m, 2 H).
Step C: Synthesis of frα« -N-(4-aminomethyI-cyclohexylmethyl)-4-bromo-2- trifluoromethoxy-benzenesulfonamide.
To a solution of trαrø-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- methyi]-cyclohexanecarboxylic acid amide (4.2 g, 9.2 mmol) in THF (40 mL) was added a solution of 1 M BH3 in THF (32 mL, 32 mmol) over 40 min. The mixture was refluxed for 2 hr. After cooling to 0 °C, the mixture was quenched with water (7 mL). To the resulting mixture were added 4 M HCl in EtOAc (28 mL) and MeOH (28 mL) and the mixture was concentrated. To the residue was added MeOH (28 mL) and the mixture was once again concentrated. The resulting HCl-salt was recrystallized from Et2O and subsequently neutralized with 1 M aqueous sodium hydroxide. The aqueous layer was extracted with CH2C12 (twice), the organic layers combined, dried over sodium sulfate, and concentrated under reduced pressure to give trαn^-N-(4-aminomethyl-cyclohexylmethyl)- 4-bromo-2-trifluoromethoxy-benzenesulfonamide as a white solid (3.0 g, 74%). ESI MS m e 445/447 M + ϊt ; Η ΝMR (500 MHz, DMSO-d6) δ 7.84-7.79 (m, 3 H), 3.42 (brs, 2 H), 2.72 (d, J= 6.8 Hz, 2 H), 2.33 (d, J= 6.5 Hz, 2 H), 1.73 (m, 4 H), 1.27 (m, 1 H), 1.09 (m, 1 H), 0.80 (m, 4 H).
Step D: Synthesis of <r ns-4-Bromo-iV-{4-[(4-methylamino-quinazolin-2-ylamino)- methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride.
A mixture of (2-chloro-quinazolin-4-yl)-methylamine obtained in step A of example 50 (58 mg, 0.3 mmol) and trαrø-N-(4-aminomethyl-cyclohexylmethyl)-4- bromo-2-trifluoromethoxy-benzenesulfonamide amide (133 mg, 0.3 mmol) in 2-propanol
(0.5 mL) was stirred at reflux for 24 hr. The mixture was cooled and the resulting white solid was collected by filtration and washed with 2-propanol to give trαw-4-Bromo-N-{4-
[(4-methylamino-quinazolin-2-ylamino)-methyl] -cy clohexylmethyl } -2-trifluoromethoxy- benzenesulfonamide hydrochloride as a white solid (121 mg, 67%).
ESI MS m/e 602/604 M + it ; Η ΝMR (500 MHz, DMSO-d6) δ 12.61 (brs, 1 H), 9.70
(brs, 1 H), 8.26 (d, J= 8.1 Hz, 1 H), 8.15 (brs, 1 H), 8.02 (t, J= 5.7 Hz, 1 H), 7.84-7.74 (m, 4 H), 7.41 (m, 1 H), 3.32 (m, 2 H), 3.07 (d, J= 3.5 Hz, 3 H), 2.73 (t, J= 6.2 Hz, 2 H), 1.77 (m, 4 H), 1.53 (m, 1 H), 1.32 (m, 1 H), 0.96 (m, 2 H), 0.82 (m, 2 H).
Example 2330
tra«5-N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2,5- bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide hydrochloride
Step A: Synthesis of frflK -4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]- methyl}-cyclohexanecarboxylic acid.
To a solution of trαrø-4-aminomethyl-cyclohexanecarboxylic acid (1.5 g, 10 mmol ) in THF (10 mL) and 1 M aqueous sodium hydroxide (27 mL) was added a solution of 2,5-bis(2,2,2-trifluoroethoxy) benzenesulfonyl chloride (3.8 g, 10.25 mmol) in THF (10 mL) dropwise and the mixture was stirred at ambient temperature for 2 hr. The resulting mixture was concentrated and 1 M aqueous HCl (22.5 mL) was added. The resulting precipitate was filtered, washed with water and hexanes to give trα«^-4-{[2,5-bis-(2,2,2- trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid as a white powder (2.8 g, 57%).
ESI MS m/e 494 M + H+ ; Η NMR (500 MHz , DMSO-d6) δ 7.36 (m, 3 H), 7.23 (brs, 1 H), 4.88 (m, 4 H), 2.73 (m, 2 H), 2.1.0 (m, 1 H), 1.87 (m, 2 H), 1.72 (m, 2 H), 1.30 (m, 1 H), 1.23 (m, 2 H), 0.87 (m, 2 H).
Step B: Synthesis of *røβs-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)- benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid amide.
A solution of trαrø-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]- methyl}-cyclohexanecarboxylic acid (2.78 g, 5.63 mmol) and triethylamine (1.9 mL,
13.6 mmol) in THF (25 mL) was cooled to 0 °C. To the mixture was added ethyl chloroformate (0.586 mL, 6.2 mmol) in THF (5 mL) over 10 min. After stirring at 0 °C for 15 min, 25% aqueous ammonia (10 mL) was added dropwise. The mixture was stirred at ambient temperature for 2 hr. The resulting mixture was concentrated under reduced pressure and the concentrate was diluted with water to give a solid. The solid was filtered and washed with water and hexanes to give trαw-4-{[2,5-bis-(2,2,2-trifluoro- ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid amide as a white solid (2.7 g, 98%).
ESI MS m/e 493 M + FT ; Η NMR (500 MHz, DMSO-d6) δ 7.36 (m, 3 H), 7.23 (t, J= 6.1 Hz, 1 H), 7.13 (s, 1 H), 6.62 (s, 1 H), 4.88 (m, 4 H), 2.74 (t, J= 6.4 Hz, 2 H), 1.99 (m, 1 H), 1.75 (m, 4 H), 1.28 (m, 1 H), 1.23 (m, 2 H), 0.83 (m, 2 H).
Step C: Synthesis of ^««5'-N-(4-aminomethyI-cyclohexylmethyl)-2,5-bis-(2,2,2- trifluoro-ethoxy)-benzenesulfonamide.
To a solution of trαrø-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]- methyl}-cyclohexanecarboxylic acid amide (2.7 g, 5.5 mmol) in THF (20 mL) was added a solution of 1 M BH3 in THF (20 mL, 20 mmol) over 40 min. The mixture was stirred at reflux for 2 hr. After cooling to 0 °C, the mixture was quenched with water (7 mL). To the mixture were added 4 M HCl in EtOAc (28 mL) and MeOH (50 mL) and the mixture was concentrated. To the residue was added MeOH (50 mL) and the mixture was once again concentrated. The resulting HCl-salt was recrystallized from E^O and subsequently neutralized with 1 M aqueous sodium hydroxide. The aqueous layer was extracted with CH2C12 (twice), the combined organic layers were dried over sodium sulfate, and concentrated under reduced pressure to give trαrø-N-(4-aminomethyl- cyclohexylmethyl)-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide as a white solid (1.5 g, 57%).
ESI MS m/e 479 M + Jt ; Η ΝMR (500 MHz, DMSO-d6) δ 7.36-7.32 (m, 3 H), 6.62 (brs, 1 H), 4.88-4.78 (m, 4 H), 3.42 (b, 2 H), 2.73 (d, J= 6.6 Hz, 2 H), 2.34 (d, J= 6.3 Hz, 2 H), 1.73 (m, 4 H), 1.27 (m, 1 H), 1.10 (m, 1 H), 0.77 (m, 4 H).
Step D: Synthesis of ^ «5-N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexylmethyl}-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide hydrochloride.
A mixture of (2-chloro-quinazoline-4-yl)-dimethyl-amine obtained in step B of example 1 (41.4 mg, 0.2 mmol) and trαπ5-N-(4-aminomethyl-cyclohexylmethyl)-2,5-bis- (2,2,2-trifluoro-ethoxy)-benzenesulfonamide (95.6 mg, 0.2 mmol) in 2-propanol was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was purified by column chromatography (silica gel) to give the product as a white foam. The product was dissolved in CH2C12 and treated with 1 M HCl in Et2O. The mixture was concentrated to give tr w-N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]- cy clohexylmethyl} -2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide hydrochloride as a white foam (101 mg, 78%).
ESI MS m/e 650 M + Jt ; Η ΝMR (500 MHz, DMSO-d6) δ 8.16 (d, J= 8.2 Hz, 1 H), 8.00 (brs, 1 H), 7.78 (t, J= 7.9, 1 H), 7.44 (brs, 1 H), 7.34 (m, 4 H), 7.24 (t, J= 5.9 Hz, 1 H), 4.88 (m, 4 H), 3.32 (s, 6 H), 3.29 (m, 2 H), 2.75 (t, J= 6.2 Hz, 2 H), 1.74 (m, 4 H), 1.52 (m, 1 H), 1.32 (m, 1 H), 0.94 (m, 2 H), 0.83 (m, 2 H).
Example 2331
frα«5-4-Bromo-N-(4-guanidinomethyl-cyclohexylmethyl)-2-trifluoromethoxy- benzenesulfonamide dihydrochloride
Step A: Synthesis of ^rα« -[({4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- methyl]-cyclohexylmethyl}-amino)-ter^-butoxycarbonylamino-methyl]-carbamic acid tert-butyl ester.
To a solution of trα«j'-N-(4-aminomethyl-cyclohexylmethyl)-4-bromo-2- trifluoromethoxy-benzenesulfonamide obtain in step C of example 2329 (45 mg, 0.1 mmol) and triethylamine (14 μL, 0.1 mmol) in CH2C12 (5 mL) was added (tert- butoxycarbonylamino-trifluoromethanesulfonylimino-methyl)-carbamic acid tert-butyl ester (39.1 mg, 0.1 mmol). The reaction mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was purified by column chromatography (silica gel,
CH2C12 to 10% MeOH in CH2C12) to give trarø-[({4-[(4-bromo-2-triπuoromethoxy- benzenesulfonylamino)-methyl]- cyclohexylmethyl } -amino)-tert-butoxycarbonylamino-methyl] -carbamic acid tert-butyl ester as a white solid (63 mg, 92%).
ESI MS m/e 687/689 M + H0 ; Η NMR (400 MHz , DMSO-d6) δ 11.45 (s, 1 H), 8.22 (t, J
= 5.6 Hz , 1 H), 7.97 (t, J= 5.6 Hz, 1 H), 7.99-7.79 (m, 3 H), 3.13 (t, J= 6.4 Hz, 2 H), 2.72
(t, J= 6 Hz, 2 H), 1.70 (m, 4 H), 1.46 (s, 9 H), 1.38 (s, 9 H), 1.31 (m, 2 H), 0.83 (m, 4 H).
Step B: Synthesis of rflM5-4-bromo-N-(4-guanidinomethyl-cyclohexylmethyl)-2- trifluoromethoxy-benzenesulfonamide dihydrochloride.
A solution of trα«^-[({4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- methyl] -cy clohexylmethyl } -amino)-tert-butoxycarbonylamino-methyl] -carbamic acid tert- butyl ester (53 mg, 0.077 mmol) in 50% TFA in CH2C12 (2 mL) was stirred at ambient temperature for 3 hr and the reaction mixture was concentrated. To the residue was added a solution of 1 M HCl in Et2O (0.5 mL) and the mixture was concentrated to give t7'αw-4-Bromo-N-(4-guanidinomethyl-cyclohexylmethyl)-2-trifluoromethoxy- benzenesulfonamide dihydrochloride as a white solid (29 mg, 68%). ESI MS m/e 487/489 M + FT" ; Η ΝMR (500 MHz, DMSO-d6) δ 8.01 (t, J= 5.5 Hz, 1 H), 7.84 (m, 3 H), 7.68 (m, 1 H), 7.30 (m, 2 H), 6.85 (m, 2 H), 2.94 (t, J= 6.1 Hz, 2 H), 2.74 (t, J= 6.1 Hz, 2 H), 1.71 (m, 2 H), 1.31 (m, 4 H), 0.86 ( , 4 H).
Example 2332
2 CF3C02H cw-N*^V'-Dimethyl-N2-{4-[(2-trifluoromethyl-benzylamino)-methyl]-cyclohexyl}- quinazoline-2,4-diamine ditrifluoro-acetic acid
Step A: Synthesis of m-4-tert-butoxycarbonylamino-cycIohexanecarboxylic acid.
To a solution of cw-4-amino-cyclohexanecarboxylic acid (50 g, 350 mmol) in THF
(200 mL) and 1 M aqueous sodium hydroxide (380 mL, 380 mmol) was added (Boc)2O (83.5 g, 360 mmol). The reaction mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was cooled to 0 °C followed by acidification with 1 M HCl (pH = 3). The resulting white solid was filtered, washed with water and hexanes to give czA4-tert-butoxycarbonylamino-cyclohexanecarboxylic acid (71g, 83%) as a white solid. ESI MS m/e 244 M + H0 ; ]H NMR (400 MHz, DMSO-d6) δ 12.00 (brs, 1 H), 6.74 (d, J= 4.25, 1 H), 3.30 (brs, 1 H), 2.35 (m, 1 H), 1.87 (m, 2 H), 1.55-1.37 (m, 15 H).
Step B: Synthesis of -(4-carbamoyI-cyclohexyl)-carbamic acid tert-butyl ester.
To a solution cooled at 0°C of α's-4-tert-butoxycarbonylamino- cyclohexanecarboxylic acid (68.0 g, 280 mmol) and triethylamine (31.1 g, 307 mmol) in THF (300 mL) was added ethyl chloroformate (29.3 mL, 308 mmol) dropwise. After stirring at 0 °C for 30 min, 25% aqueous ammonia (168 mL) was added dropwise. The reaction mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was extracted with EtOAc (three times). The combined organic layer was washed with saturated aqueous NaHCO3, 1 M HCl, brine, and water, dried over Na^O^ filtered, and concentrated to give cz5,-(4-carbamoyl-cyclohexyl)-carbamic acid tert-butyl ester (62.0 g, 88%) as a white solid.
ESI MS m/e 243 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 7.10 (brs, 1 H), 6.69 (b, 2 H), 3.41 (brs, 1 H), 2.14 (m, 1 H), 1.79 (m, 2 H), 1.59 (m, 2 H), 1.45-1.37 (m, 13 H).
Step C: Synthesis of cZs-4-amino-cyclohexanecarboxylic acid amide hydrochloride.
To a solution of cw-(4-carbamoyl-cyclohexyl)-carbamic acid tert-butyl ester (62 g, 256 mmol) in CH2C12 (250 mL) was added TFA (250 mL) and the mixture was stirred at ambient temperature for 1 hr. The mixture was concentrated and 2 M HCl in Et2O (150 mL) was added to give a white precipitate. The mixture was concentrated to give cis-4- amino-cyclohexanecarboxylic acid amide hydrochloride (45 g, 98%) as a white solid. ESI MS m/e 143 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 8.08 (m, 3 H), 7.28 (s, 1 H), 6.78 (s, 1 H), 3.10 (m, 1 H), 2.24 (m, 1 H), 1.90 (m, 2 H), 1.66 (m, 4 H), 1.50 (m, 2 H).
Step D: Synthesis of ciy-4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexanecarboxylic acid amide.
A solution of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of
example 1 (31.05 g, 150 mmol) and czA4-amino-cyclohexanecarboxylic acid amide hydrochloride (26.7 g, 150 mmol) in pyridine (150 mL) was stirred at reflux for overnight. The reaction mixture was concentrated and residue was dissolve in CH2C12. The organic layer was washed with saturated aqueous NaHCO3 and the aqueous layer was extracted with CH2C12. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica gel, 2% to 10% 2 M NH3/MeOH in CH2C12) to give a slightly brown solid and the solid was recrystallized from CH2C12 to give et5'-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid amide (20.6 g, 44%) as yellow crystals.
ESI MS m/e 314 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 8.19 (brs, 1 H), 8.15 (d, J = 8.4 Hz, 1 H), 7.77 (t, J= 8.0 Hz, 1 H), 7.42 (d, J= 7.2 Hz, 1 H), 7.35 (t, J= 8.4 Hz, 1 H), 7.21 (s, 1 H), 6.74 (s, 1 H), 4.12 (m, 1 H), 3.46 (m, 6 H), 2.24 (m, 1 H), 1.79-1.61 (m, 8 H).
Step E: Synthesis of c 5-N -(4-aminomethyl-cyclohexyl)-N4^V4-dimethyl-quinazoline- 2,4-diamine.
To a solution of ew-4-(4-dimethylamino-quinazolin-2-ylamino)- cyclohexanecarboxylic acid amide (18.78 g, 60 mmol) in THF (200 mL) was added a solution of 1 M BH3 in THF (300 mL, 300 mmol). The mixture was stirred at reflux for 2 hr. After cooling the reaction mixture to 0 °C, 4 M HCl in EtOAc (100 mL) and MeOH (200 mL) were added. The mixture was concentrated. The mixture was treated with 1 M aqueous sodium hydroxide and the aqueous layer was extracted with CH2C12. The organic layer was dried over sodium sulfate, concentrated, and purified by column chromatography (silica gel, 10% 2 M NH3/MeOH in CH2C12) to give cz,y-N2-(4- aminomethyl-cyclohexyl)-Y,N4-dimethyl-quinazoline-2,4-diamine as a white solid (10.6 g, 59%).
ESI MS m/e 300 M + Jet ; Η ΝMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 8.4 Hz, 1 H), 7.46 (t, J= 6.8 Hz, 1 H), 7.26 (d, J= 8.4 Hz, 1 H), 6.99 (t, J= 6.8 Hz, 1 H), 6.28 (brs, 1 H), 4.02 (m, 1 H), 3.19 (m, 6 H), 2.47 (d, J= 6.8 Hz, 2 H), 2.73 (m 2 H), 1.68-1.33 (m, 9 H).
Step F: Synthesis of cw-iV^^-dimethyl-N2-{4-[(2-trifluoromethyl-benzylamino)- methyl]-cyclohexyl}-quinazoline-2,4-diamine ditrifluoro-acetic acid.
A solution of cw-N2-(4-aminomethyl-cyclohexyl)-N4,N4-dimethyl-quinazoline-2,4- diamine (33 mg, 0.11 mmol) and 2-trifluoromethyl benzaldehyde (17.41 mg, 0.1 mmol) in MeOH (1 mL) was stirred at ambient temperature for 3 hr. To the mixture was added ΝaBH(OAc)3 (85 mg, 0.4 mmol) and the mixture was stirred at ambient temperature for overnight. This resulting mixture was quenched with 50% DMSO in water (2 mL) and the solution was purified by preparative HPLC. The pure fractions were combined and lyophilized to give cw-N",N-dimethyl-N2-{4-[(2-trifluoromethyl-benzylamino)-methyl]- cyclohexyl}-quinazoline-2,4-diamine ditrifluoro-acetic acid (41.4 mg, 60%) as a white solid.
ESI MS m/e 458 M + H+ ; Η ΝMR (400 MHz, DMSO-d6) δ 13.12 (brs, 1 H), 8.94 (b, 2 H), 8.65 (d, J = 6.8 Hz, 1 H), 8.16 (d, J = 8.8 Hz, 1 H), 7.77-7.66 ( , 5 H), 7.41 (d, J = 8.4 Hz, 1 H), 7.35 (t, J= 8 Hz, 1 H), 4.22 (s, 2 H), 4.17 (m, 1 H), 3.46 (b, 6 H), 2.94 (m, 2 H), 1.87-1.44 (m, 9 H).
Example 2333
CF3C02H
c/5-5-(4-Chloro-phenyl)-2-trifluoromethyl-furan-3-carboxylic acid [4-(4- dimethyIamino-quinazolin-2-ylamino)-cyclohexylmethyl]-amide trifluoro-acetic acid
Step A: Synthesis of c 5-5-(4-chloro-phenyl)-2-trifluoromethyl-furan-3-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-amide trifluoro- acetic acid.
A solution of cw-N2-(4-aminomethyl-cyclohexyl)-N4,Y-dimethyl-quinazoline-2,4- diamine obtained in step E of example 2332 (30 mg, 0.1 mmol), 5-(4-chloro-phenyl)-2- trifluoromethyl-furan-3-acid chloride (37 mg, 0.12 mmol), and pyridine (12 μL, 0.15 mmol) in DMF (0.5 mL) was stirred at ambient temperature for overnight. The resulting mixture was diluted with DMSO (0.8 mL) and the mixture was purified by preparative
HPLC. The pure fractions were combined and lyophilized to give czJA5-(4-chloro- phenyl)-2-1xifluoromethyl-furan-3 -carboxylic acid [4-(4-dimethylamino-quinazolin-2- ylamino)-cyclohexylmethyl]-amide trifluoro-acetic acid (17.5 mg, 26%) as a white solid. ESI MS m/e 572 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 12.30 (brs, 1 H), 8.65 (t, J = 6.8 Hz, 1 H), 8.19 (brs, 1 H), 8.14 (d, J = 8.0 Hz, 1 H), 7.83-7.30 (m, 8 H), 4.1 (m, 1 H), 3.46 (b, 6 H), 3.09 (m, 2 H), 1.77-1.38 (m, 9 H).
Example 2334
CF3C02H
c s-iV-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4,5- trimethoxy-benzamide trifluoro-acetic acid
Step A: Synthesis of c s-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- cy clohexylmethyl] -3 ,4,5-trimethoxy-benzamide trifluoro-acetic acid.
To HOBt-6-carboxaamidomethyl polystyrene 200-400 mesh (77 mg, 0.1 mmol) were added a solution of 0.3 M PyBroP in DMF (1 mL, 0.3 mmol), 3,4,5- trimethoxybenzoic acid (63 mg, 0.3 mmol), and diisopropylethylamine (85 μL, 0.5 mmol). The mixture was stirred at ambient temperature for 5 hr. The resin was washed with DMF (3 times), CH2C12 (3 times), MeOH (3 times), CH2C12 (2 times), and DMF (2 times). To the resin was added cw-N2-(4-aminomethyl-cyclohexyl)-N4,N4-dimethyl-quinazoline- 2,4-diamine obtained in step E of example 2332 (28 mg, 0.09 mmol) in DMF (0.5 mL) and the mixture was stirred at ambient temperature for overnight. The resin was filtered and washed with 0.5 mL DMSO (2 times). The combined filtrates were purified by preparative HPLC. The pure fractions were combined and lyophilized to give cis N-[4- (4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4,5-trimethoxy-benzamide trifluoro-acetic acid (7.4 mg, 12%) as a white solid.
ESI MS m/e 494 M + H+ ; Η ΝMR (400 MHz, DMSO-d6) δ 12.25 (brs, 1 H), 8.45 (t, J = 5.6 Hz, 1 H), 8.17 (brs, 1 H), 8.14 (d, J = 8.0 Hz, 1 H), 7.76 (t, J = 8.4 Hz, 1 H), 7.42 (d, J
= 7.2 Hz, 1 H), 7.34 (t, J= 7.6 Hz, 1 H), 7.15 (s, 2 H), 4.13 (m, 1 H), 3.44 (s, 3 H), 3.39 (s, 3 H), 3.20 (m, 2 H), 1.77-1.37 (m, 9 H).
Example 2335
Biphenyl-4-carboxylic acid {4-[(4-dimethylamino-quinazolin-2-yIamino)-methyl]- phenyl}-amide
Step A: Synthesis of (4-amino-benzyl)-carbamic acid tert-butyl ester.
A solution of 4-aminomethyl-phenylamine (12.2 g, 100 mmol) and (Boc)2O (21.8 g, 100 mmol) in CH2C12 (100 mL) was stirred at ambient temperature for overnight. The mixture was concentrated and the residue was purified by column chromatography (silica gel, CH2Cl2 to 10% MeOH in CH2C12) to give (4-amino-benzyl)-carbamic acid tert-butyl ester (11.6 g, 52%) as a slightly yellow solid.
ESI MS m/e 223 M + FT ; Η NMR (400 MHz, DMSO-d6) δ 7.27 (t, J = 6.0 Hz, 1 H), 6.86 (d, J = 8.0 Hz, 2 H), 6.47 (d, J = 6.4 Hz, 2 H), 4.89 (s, 2 H), 3.91 (d, J = 6.0 Hz, 2 H), 1.39 (s, 9 H).
Step B: Synthesis of biphenyl-4-carboxylic acid (4-aminomethyl-phenyl)-amide hydrochloride.
To a solution of (4-amino-benzyl)-carbamic acid tert-butyl ester (1.11 g, 5 mmol), biphenyl carboxylic acid (0.99 g, 5 mmol), EDC (1.2 g, 6.25 mmol), and HO At (0.82 g, 6 mmol) in CH2C12 (10 mL) was added triethylamine (pH = 10) and the mixture was stirred at ambient temperature for overnight. The organic layer was washed with saturated aqueous NaHCO3, 1 M aqueous HCl, water, dried over Na2SO4, filtered, and concentrated. The residue was dissolved in 50% TFA in CH2C12 (10 mL) and the mixture was stirred at ambient temperature. After 30 minutes, the mixture was concentrated and diluted with 1 M HCl in Et2O (5 mL). The mixture was concentrated to give biphenyl-4-carboxylic acid (4-aminomethyl-phenyl)-amide hydrochloride (828 mg, 49%).
ESI MS m/e 303 M + H+; Η NMR (400 MHz, DMSO-d6) δ 10.40 (s, 1 H), 8.34 (b, 3 H), 8.07 (d, J = 8.0 Hz, 2 H), 7.83-7.73 (m, 6 H), 7.51-7.38 (m, 5 H), 4.0 (q , J= 5.6 Hz, 2 H).
Step C: Synthesis of biphenyl-4-carboxylic acid {4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl]-phenyl}-amide.
A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (42 mg, 0.2 mmol) and biphenyl-4-carboxylic acid (4-ammomethyl-phenyl)- amide hydrochloride (49 mg, 0.14 mmol) in 2-propanol (1 mL) and triethylamine (200 μL) was stirred at reflux for 2 days. The resulting mixture was concentrated and purified by column chromatography (silica gel, CH2Cl2 to 10% 2 M NH3/MeOH in CH2C12) to give biphenyl-4-carboxylic acid {4- [(4-dimethylamino-quinazolin-2-ylamino)-methyl] - phenyl}-amide (10 mg, 15%) as a white solid.
ESI MS m/e 474 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 10.19 (s, 1 H), 8.02 (d, J = 7.2 Hz, 2 H), 7.86 (d, J = 8.4 Hz, 1 H), 7.80 (d, J = 8.4 Hz, 2 H), 7.73 (d, J = 7.2 Hz, 2 H), 7.68 (d, J = 7.6 Hz, 2 H), 7.50-7.15 (m, 8 H), 7.01 (t, J = 8.4 Hz, 1 H), 4.51 (d, J - 6.4 Hz, 2 H), 3.30 (s, 3 H), 3.2 (s, 3 H).
Example 2336
2 CF3C02H rø-N -{4-[2-(4-Bromo-2-trifluoromethoxy-benzylamino)-ethyl]-cycIohexyl}-iV ^V4- dimethyI-quinazoline-2,4-diamine ditrifluoro-acetic acid
Step A: Synthesis of -[4-(2-benzyloxycarbonylamino-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester.
To a solution of cw-[4-(2-amino-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester
(4.84 g, 20 mmol) in CH2C12 (50 mL) and triethylamine ( 3.06 mL, 22 mmol) was added benzyl chloroformate (3.13 mL, 22 mmol) and the mixture was stirred for 4 hr. The resulting mixture was washed with water, 1 M aqueous HCl, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica gel,
CH2C12 to 10% MeOH in CH2C12) to give cz's-[4-(2-benzyloxycarbonylamino-ethyl)- cyclohexyl]-carbamic acid tert-butyl ester (5.46 g, 73%) as a colorless oil.
ESI MS m/e 377 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 7.36-7.24 (m, 5 H), 7.19 (t, J
= 5.6 Hz, 1 H), 6.76 (d, J = 6.8.Hz, 1 H), 4.91 (s, 2 H), 3.40 (m, 1 H), 2.99 (m, 2 H), 1.44-
1.33 (m, 20H).
Step B: Synthesis of cis- [2-(4-amino-cyclohexyl)-ethyl] -carbamic acid benzyl ester.
A solution of cw-[4-(2-benzyloxycarbonylamino-ethyl)-cyclohexyl] -carbamic acid tert-butyl ester (5.26 g, 14 mmol) in 50% TFA in CH2C12 (60 mL) was stirred at ambient temperature for 1 hr. The mixture was concentrated and the residue was diluted with saturated aqueous NaHCO3. The aqueous layer was extracted with CH2C12 (therr times). The organic layer was dried over Na2SO4 and concentrated to give cw-[2-(4-amino- cyclohexyl)-ethyl]-carbamic acid benzyl ester (3.5 g, 91%) as a colorless oil. ESI MS m/e 277 M + ϊt; Η NMR (400 MHz, DMSO-d6) δ 7.72 (b, 2 H), 7.34-7.27 (m, 5 H), 7.21 (t, J = 5.2 Hz, 1 H), 4.97 (s, 2 H), 3.14 (m, 1 H), 2.99 (q, J = 6.4 Hz, 2 H), 1.58- 1.34 (m, 11 H).
Step C: Synthesis of cis{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]- ethylj-carbamic acid benzyl ester.
A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (2.45 g, 10.2 mmol) and czN[2-(4-amino-cyclohexyl)-ethyl]-carbamic acid benzyl ester (3.3 g, 10.2 mmol) and triethylamine (1.65 mL, 10.2 mmol) in 2-propanol (15 mL) was heated at 170 °C for 45 min using a Smith Microwave Synthesizer. The mixture was concentrated and the residue was purified by column chromatography (silica gel, CH2Cl2to 10% 2 M NH3/MeOH in CH2C12) to give cw{2-[4-(4-dimethylamino-quinazolin- 2-ylamino)-cyclohexyl]-ethyl} -carbamic acid benzyl ester (4.48g, 85%) as a yellow oil. ESI MS m/e 448 M + ϊt ; Η NMR (400 MHz, DMSO-d6) δ 8.07-7.20 (m, 11 H), 4.98 (s, 2 H), 4.08 (m, 1 H), 3.39 (b, 6 H), 3.04 (m, 2 H), 1.7-1.3 (m, 11 H).
Step D: Synthesis of c 5-N2-[4-(2-amino-ethyl)-cyclohexyl]-N'^-dimethyl- quinazoline-2,4-diamine.
To a solution of c^-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-
ethyl} -carbamic acid benzyl ester (4.47 g, 10 mmol) in EtOH (20 mL) was added 1,4- cyclohexadiene (20 mL) and 200 mg of 10%> Pd/C. The reaction mixture was stirred at ambient temperature for 18 hr, filtered through pad of celite, and concentrated. The residue was purified by column chromatography (silica gel, 5% to 15% 2 M NH3/MeOH in CH2C12) to give cw-N -[4-(2-amino-ethyl)-cyclohexyl]-N',N0dimethyl-quinazoline-2,4- diamine (2.4 lg, 77%) as a yellow oil.
ESI MS m/e 314 M + FT; Η ΝMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 8.0 Hz, 1 H), 7.44 (t, J = 6.8 Hz, 1 H), 7.27 (d, J = 8.0 Hz, 1 H), 6.97 (t, J = 6.8 Hz, 1 H), 6.31 (brs, 1 H), 3.97 (m, 1 H), 3.37 (b, 2 H), 3.17 (s, 3), 3.14 (s, 3 H), 2.62 (t, J = 7.6 Hz, 2 H), 1.68-1.31 (m, 11 H).
Step E: Synthesis of ci$'-N-{4-[2-(4-bromo-2-trifluoromethoxy-benzylamino)-ethyl]- cyclohexyl}-N /V -dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.
A solution of cw-N2-[4-(2-amino-ethyl)-cyclohexyl]-Y,N0dimethyl-quinazoline- 2,4-diamine (31.4 mg, 0.1 mmol) and 4-bromo-2 -trifluoromethoxy benzaldehyde (26.9 mg, 0.1 mmol) in MeOH (1 mL) was stirred at ambient temperature. After 3 hr, ΝaBH(OAc)3 (85 mg, 0.4 mmol) was added and the resulting mixture was stirred at ambient temperature for overnight. The reaction mixture was quenched with 50% DMSO in water (2 mL). The mixture was concentrated and purified by preparative HPLC. The pure fractions were combined and lyophilized to give cw-N2-{4-[2-(4-bromo-2-trifluoromethoxy- benzylaimno)-ethyl]-cyclohexyl}-\^,N4-dimethyl-quinazoline-2,4-diamine ditrifluoro- acetic acid (32.2 mg, 41%) as a white solid.
ESI MS m/e 566/568 M + H+; Η ΝMR (400 MHz, DMSO-d6) δ 12.76 (brs, 1 H), 8.81 (b, 2 H), 8.43 (m, 1 H), 8.09 (d, J - 8.4 Hz, 1 H), 7.71-7.56 (m, 4 H), 7.35 (d, J = 8.0 Hz, 1 H), 7.29 (t, J = 8.0 Hz, 1 H), 4.15 (m, 3 H), 3.39 (m, 6 H), 2.97 (m, 2 H), 1.67-1.30 (m, 11 H).
Example 2337
CF3C02H ciy-2,6-Dichloro-N-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-ethyl}- benzamide trifluoro-acetic acid
Step A: Synthesis of rø-2,6-dichloro-N-{2-[4-(4-dimethylamino-quinazoIin-2- ylamino)-cyclohexyl]-ethyl}-benzamide trifluoro-acetic acid.
To a solution of cw-N2-[4-(2-amino-ethyl)-cyclohexyl]-Y,N0dimethyl- quinazoline-2,4-diamine (31.4 mg, 0.1 mmol) and 2,6-dichlorobenzoyl chloride (20.7 mg, 0.1 mmol) in DMF (0.5 mL) was added triethylamine (20 uL, 0.14 mmol). After stirring the mixture at ambient temperature for 6 hr , DMSO (0.5 mL) was added and the mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give cw-2,6-dichloro-N-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]- ethyl}-benzamide trifluoro-acetic acid (17.6 mg, 29%) as a white solid. ESI MS m/e 486 M + FT; Η ΝMR (400 MHz, DMSO-d6) δ 11.93 (brs, 1 H), 8.26 (t, J = 5.2 Hz, 1 H), 8.14 (d, J = 8.0 Hz, 1 H), 7.95 (brs, 1 H), 7.76 (t, J = 8.4 Hz, 1 H), 7.52-7.31 (m, 5 H), 4.15 (m, 1 H), 3.45 (b, 6 H), 3.29 (m, 2 H), 1.76-1.31 (m, 11 H).
Example 2338
cw-N2-[4-(2-Ethoxy-benzylamino)-cyclohexylmethyl]-N'^V/-dimethyl-quinazoline-2,4- diamine ditrifluoro-acetic acid
Step A: Synthesis of c^-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester.
To a solution of cw-(4-carbamoyl-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 2332 (9.68 g, 40 mmol) in THF (100 mL) was added a solution of 1 M BH3 in THF (80 mL, 80 mmol) over 30 min. The mixture was stirred at reflux for 2 hr. After cooling the reaction mixture to ambient temperature, 1 M aqueous sodium hydroxide was carefully added. The solvents were removed under reduced pressure and the aqueous layer was extracted with CH2C12 (twice). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give cis-(4- aminomethyl-cyclohexyi)-carbamic acid tert-butyl ester as colorless oil (5.16 g, 57%). ESI MS m/e 229 M + H+; Η NMR (400 MHz, DMSO-d6) δ 6.67 (d, J = 6.8 Hz, 1 H), 3.43 (m, 1 H), 2.41 (d, J= 6.4 Hz, 2 H) 1.49-1.22 (m, 18 H).
Step B: Synthesis of cis-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexyl}-carbamic acid tert-butyl ester.
A mixture of cz'j,-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (1.14 g, 5 mmol), (2-chloro-quinazoline-4-yl)-dimethyl-amine obtained in step B of example 1 (1.035 g, 5 mmol), and triethylamine (1.5 mL, 11 mmol) in 2-propanol (2.5 mL) was heated at 170 °C for 35 min using a Smith Microwave Synthesizer. The mixture was concentrated and the residue was purified by column chromatography (silica gel, CH2C12 to 10% 2 M NH3/MeOH in CH2C12) to give cis-{ - [(4-dimethylamino-quinazolin-2- ylamino)-methyl]-cyclohexyl} -carbamic acid tert-butyl ester (1.28 g, 80%) as a white solid.
ESI MS m/e 400 M + H+; Η NMR (400 MHz, DMSO-d6) δ 8.04-7.06 (m, 4 H), 6.77 (d, J = 6.0 Hz, 1 H), 3.40-3.16 (m, 9 H), 1.70-1.37 (m, 18 H).
Step C: Synthesis of cis-iV2-(4-amino-cy clohexylmethyl)- V, Λ^-dimethyl- quinazoline-2,4-diamine.
A solution of ct5,-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- cyclohexyl} -carbamic acid tert-butyl ester (1.2 g, 3 mmol) in 50%> TFA in CH2C12 (20 mL) was stirred at ambient temperature. After 30 minutes, the mixture was concentrated and the residue was diluted with 1 M aqueous sodium hydroxide. The aqueous layer was extracted with CH2C12 (twice). The combined organic layer was dried over Na2SO4, filtered and concentrated to give CM-N2-(4-amino-cyclohexylmethyl)-Y,N0dimethyl- quinazoline-2,4-diamine (0.88 g, 98%) as a white solid.
ESI MS m/e 300 M + ϊt; Η NMR (400 MHz, DMSO-d6) δ 7.85 (d, J = 7.6 Hz, 1 H), 7.47 (t , J = 6.8 Hz, 1 H), 7.27 (brs, 1 H), 7.0 (t, J = 7.2 Hz, 1 H), 6.66 (brs, 1 H), 3.33-3.14 (m, 9 H), 1.69-1.48 (m, 9 H).
Step D: Synthesis of c -N2-[4-(2-ethoxy-benzylamino)-cyclohexylmethyl]-N/ >/y- dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.
A solution of c/i,-N2-(4-amino-cyclohexylmethyl)-N'y/V0dimethyl-quinazoline-2,4- diamine (30 mg, 0.1 mmol) and 2-ethoxy benzaldehyde (15 mg, 0.1 mmol) in MeOH (1 mL) was stirred at ambient temperature. After 3 hr, ΝaBH(OAc)3 (85 mg, 0.4 mmol) was added and the mixture was stirred at ambient temperature for overnight. The resulting mixture was quenched with 50% DMSO in water (2 mL) and the solution was purified by preparative HPLC. The pure fractions were combined and lyophilized to give cw-N2-[4- (2-ethoxy-benzylamino)-cyclohexylmethyl]-Y,N0dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (33 mg, 50%) as a white solid.
ESI MS m/e 434 M + PL ; Η ΝMR (400 MHz, DMSO-d6) δ 13.03 (brs, 1 H), 8.79 (brs, 1 H), 8.49 (m, 2 H), 8.15 (d, J = 8.4 Hz, 1 H), 7.77 (t, J = 7.6 Hz, 1 H), 7.40-7.33 (m, 4 H), 7.07 (d, J= 7.6 Hz, 1 H), 6.99 (t, J= 7.2 Hz, 1 H), 4.11-4.06 (m, 4 H), 3.47-3.41 (m, 8 H), 3.15 (m, 1 H), 1.90-1.60 (m, 9 H), 1.37 (t, J= 7.2 Hz, 3 H).
Example 2339
c 5-3,5-Dichloro-N-{4-[(4-dimethylamino-quinazolin-2-yIamino)-methyl]-cyclohexyl}- benzamide trifluoro-acetic acid
Step A: Synthesis of cis-3,5-dichlόro-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-cyclohexyl}-benzamide trifluoro-acetic acid.
A solution of cM-N2-(4-amino-cyclohexylmethyl)-Y,N'/-dimethyl-quinazoline-2,4-
diamine (30 mg, 0.1 mmol) and 3,5-dichlorobenzoylchloride (20.9 mg, 0.1 mmol) and pyridine (12 μL, 0.25 mmol) in DMSO (1 mL) was stirred at ambient temperature for overnight. The mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give cz -3,5-dichloro-N-{4-[(4-dimethylamino-quinazolin-2- ylamino)-methyl] -cyclohexyl} -benzamide trifluoro-acetic acid.( 18 mg , 31%o) as a white solid.
ESI MS m/e 472 M + H+; Η ΝMR (400 MHz, DMSO-d6) δ 12.13 (brs, 1 H), 8.34 (d, J = 7.2 Hz, 1 H), 8.15 (d, J = 8.8 Hz, 1 H), 8.06 (brs, 1 H), 7.82-7.73 (m, 4 H), 7.45 (d, J = 7.6 Hz, 1 H), 7.36 (t, J = 7.6 Hz, 1 H), 3.9 (m, 1 H), 3.47-3.25 (m, 8 H), 1.83-1.56 (m, 9 H).
Example 2340
2 CF3C02H
^rα«5-N2-{4-[(2,3-Dinιethoxy-benzylamino)-methyl]-cyclohexyl}-iV'^V*-dimethyl- quinazoline-2,4-diamine ditrifluoro-acetic acid
Step A: Synthesis of ^rα«5-4-(tert-butoxycarbonylamino-methyl)- cyclohexanecarboxylic acid.
To a solution of trarø-4-amino-cyclohexanecarboxylic acid (37.7 g, 0.24 mol) in a mixture of dioxane (250 ml) and water (200 ml) cooled in an ice bath were added 1 M aqueous sodium hydroxide (10.07 g, 0.25 mol) and (Boc)2O (57.6 g, 0.26 mol). The reaction mixture was stirred at ambient temperature. After 3 hr, the mixture was concentrated and the residue was dissolved in water. The aqueous layer was washed with
Et2O (3 times). The aqueous layer was cooled in an ice bath and acidified with 1 M aqueous HCl (pH = 2) and the resulting white precipitate was dried to give trans-4-(tert- butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid (47.4 g, 76.8%) as a white solid.
ESI MS m/e 258 M + H+ ; Η ΝMR (400 MHz, CDC13) δ 11.95 (brs, 1 H), 6.79 (t, J =
6.0 Hz, 1 H), 2.76 (t, J = 6.0 Hz, 2 H), 2.11 (m, 1 H), 1.87 (m, 2 H), 1.69 (m, 2 H), 1.36 (s,
9 H), 1.27 (m, 3 H), 0.9 (m, 2 H).
Step B: Synthesis of *r«/«-[4-(tert-butoxycarbonylamino-nιethyI)~cyclohexyl]- carbamic acid benzyl ester.
To a solution of trαw-4-(tert-butoxycarbonylamino-methyl)- cyclohexanecarboxylic acid (46.9 g, 0.18 mol) in benzene (300 mL) were added triethylamine (24.2 g, 0.24 mol) and diphenylphosphoryl azide (55.9 g, 0.20 mol). The reaction mixture was stirred at 80 °C for 1 hr. To the mixture was added benzyl alcohol (25.9 g, 0.24 mol) and stirred at 100 °C for 4 hr. The mixture was subsequently cooled to ambient temperature for overnight, concentrated, and the resulting pale orange solid dissolved in EtOAc. The organic layer was washed with water (three times), concentrated, and the residue was purified by column chromatography (silica gel, 50% EtOAc in hexane) to give t7" zzi'-[4-(tert-butoxycarbonylamino-methyl)-cyclohexyl]- carbamic acid benzyl ester (66.1%, 100%) as a white solid.
ESI MS m/e 363 M + ϊt ; Η NMR (400 MHz, CDC13) δ 7.24-7.23 (m, 5 H), 5.06 (s, 2 H), 4.57 (m, 2 H), 3.44 (brs, 1 H), 2.97 (t, J = 6.4 Hz, 2 H), 2.04 (m, 2 H), 1.79 (m, 2 H), 1.43 (s, 9 H), 1.08-0.76 (m, 5 H).
Step C: Synthesis of tfrøns-(4-amino-cyclohexylmethyI)-carbamic acid tert-butyl ester.
To a solution of trαwj'-^-^ert-butoxycarbonylamino-metliy^-cyclohexyy-carbamic acid benzyl ester (5.32 g, 0.015 mol) in EtOH (200 mL) was added 10% Pd/C (50 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 4 hr. The resulting mixture was filtered through a pad of celite and concentrated. The residue was purified by column chromatography (silica gel, 3% 2 M NH3/MeOH in CH2C12) to give trαnγ4-amino-cyclohexylmethyl)-carbamic acid tert-butyl ester as a colorless solid (3.197 g, 95.4%).
ESI MS m/e 229 M + ϊt ; Η NMR (400 MHz, CDC13) δ 8.44 (brs, 1 H), 4.59 (b, 1 H), 2.96 (m, 2 H), 2.08 (m, 2 H), 1.83 (m, 2 H), 1.43 (s, 9 H), 1.08 (m, 5 H).
Step D: Synthesis of ^α«5-N2-(4-aminomethyl-cyclohexyl)-N'^V'-dimethyl- quinazoline-2,4-diamine ditrifluoro-acetic acid
A mixture of tr «i,-(4-amino-cyclohexylmethyl)-carbamic acid tert-butyl ester
(0.24 g, 1 mmol) and (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (0.32 g, 1.4 mmol) in 2-propanol (5 mL) was heated to 170 °C for 30 min using a Smith Microwave Synthesizer. This procedure was repeated 19 times. The reaction mixtures were combined and purified by column chromatography (silica gel) to give 1.13 g of a yellow solid. The yellow solid was dissolved in 50% TFA in CH2C12 (20 mL) and the mixture was stirred at ambient temperature. After 10 hours, the mixture was concentrated and the residue was purified by preparative HPLC. The pure fractions were combined and lyophilized to give trαrø-N2-(4-aminomethyl-cyclohexyl)-N,N/-dimethyl- quinazoline-2,4-diamine ditrifluoro-acetic acid (0.49 g, 5%) as a white solid. ESI MS m/e 300 M + FT" ; Η ΝMR (400 MHz, CDC13) δ 9.16 (d, J = 5.6 Hz, 1 H), 8.11 (m, 2 H), 7.86 (d, J = 8.0 Hz, 1 H), 7.51 (t, J = 7.6 Hz, 1 H), 7.41 (d, J = 8.0 Hz, 1 H),
7.18 (t, J = 6.8 Hz, 1 H), 3.8 (brs, 1 H), 3.47 (s, 6 H), 2.10 (m, 2 H), 1.92 (m, 2 H), 1.42- 1.12 (m, 5 H).
Step E: Synthesis of ^rα«5-N2-{4-[(2,3-dimethoxy-benzylamino)-methyl]-cyclohexyl}- iV*^-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.
A mixture of 2,3-dimethoxy benzaldehyde (15 mg, 0.09 mmol), trα«>y-N2-(4- aminomethyl-cyclohexyl)-N'/ :Y-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (28 mg, 0.053 mmol), ΝaBH(OAc)3 (76 mg, 0.36 mmol), and MeOH (2 mL) was heated at 100 °C for 40 seconds using a Smith Microwave Synthesizer. The resulting mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give trans-N2-{4- [(2,3 -dimethoxy-benzylamino)-methyl] -cyclohexyl} -N'Nødimethyl- quinazoline-2,4-diamine ditrifluoro-acetic acid (10.2 mg, 28 %»).
ESI MS m/e 450 M + ϊt ; Η NMR (400 MHz, CDC13) δ 9.68 (d, J = 6.0 Hz, 1 H), 9.41 (brs, 1 H), 7.85 (d, J - 7.6 Hz, 1 H), 7.52 (t, J = 7.2 Hz, 1 H), 7.46 (d, J = 8.0 Hz, 1 H),
7.19 (t, J = 7.2 Hz, 1 H), 7.09 (t, J = 8.0 Hz, 1 H), 6.98 (d, J = 7.2 Hz, 1 H), 6.90 (d, J = 7.6 Hz, 1 H), 4.16 (s, 2 H), 3.96 (s, 3 H), 3.87 (s, 3 H), 3.75 (m, 1 H), 3.47 (m, 6 H), 2.80 (m, 2 H), 2.11 (m, 2 H), 1.86 (m, 2 H), 1.48-1.50 (m, 5 H).
Example 2341
2 CF3C02H
-N2-[4-(3,5-Dichloro-benzylamino)-cyclohexyl]-N4^V4-dimethyl-quinazoline-2,4- diamine ditrifluoro-acetic acid
Step A: Synthesis of c/5-(4-tert-butoxycarbonylamino-cyclohexyϊ)-carbamic acid benzyl ester.
To a suspension of cw-4-tert-butoxycarbonylamino-cyclohexanecarboxylic acid (50.0 g, 206 mmol) in benzene were added triethylamine (26.9 g, 266 mmol) and phosphorazidic acid diphenyl ester (62.2 g, 226 mmol). The reaction mixture was stirred at 80°C for 1 hr. Benzyl alcohol (31.4 g, 290 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H2O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was dried over MgSO4, filtered, concentrated, and purified by flash chromatography (silica gel, 30% EtOAc in hexane) to give czA(4-te?"t-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (54.1 g, 16%) as a colorless oil.
ESI MS m/e 349 M + ϊt; Η NMR (400 MHz, DMSO-d6) δ 7.34-7.28 (m, 5 H), 7.12 (d, J = 5.6 Hz, 1 H), 6.62 (brs, 1 H), 4.98 (s, 2 H), 3.39-3.37 (m, 2 H), 1.60-1.45 (m, 8 H), 1.37 (s, 9 H).
Step B: Synthesis of rø-(4-amino-cycIohexyl)-carbamic acid tert-butyl ester.
Using the procedure for the step C of example 2340, the title compoimd was obtained.
ESI MS m/e 215 M + ϊt ; Η NMR (400 MHz, DMSO-d6) δ 6.60 (d, J = 6.0 Hz, 1 H), 3.30-3.28 ( , 1 H), 2.74 (s, 1 H), 1.59-1.51 (m, 2 H), 1.45-1.37 (m, 15 H).
Step C: Synthesis of s-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cycIohexyl]-
carbamic acid tert-butyl ester.
A solution of cz (4-amino-cyclohexyl)-carbamic acid tert-butyl ester (0.5 g, 2.3 mmol), (2-chloro-quinazolin-4-yl)-dimethly-amine obtained in step B in example 1 (0.53, 2.6 mmol), diisopropylethylamine (1.22 mL, 7.0 mmol) and 2-propanol (1.0 mL) was heated using a Smith Microwave Synthesizer at 170 °C for 1 hour. This reaction procedure was repeated 39 more times and the resulting reaction mixtures were combined. The mixture was concentrated and the residue was purified by column chromatography (silica gel, 2% to 4% 2 M NH3/MeOH in CH2C12) to give c/.s-[4-(4-dimethlyamino- quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (22.1 g, 0.057 mol, 61%) as a colorless oil.
ESI MS m/e 386 M + H0 ; Η NMR (400 MHz, DMSO-d6) δ 7.85 (d, J= 8.0 Hz, 1 H), 7.47 (t, J= 8.4 Hz, 1 H), 7.27 (d, J= 8.0 Hz, 1 H), 7.00 (t, J= 7.6 Hz, 1 H), 6.60 (brs, 1 H), 6.18 (brs, 1 H), 3.89-3.88 (m, 1 H), 3.39 (brs, 1 H), 3.19 (s, 6 H), 1.77-1.71 (m, 2 H), 1.68- 1.52 (m, 6 H), 1.38 (s, 9 H).
Step D: Synthesis of c s-N2-(4-amino-cyclohexyl)-iV4^V -dimethyl-quinazolin-2,4- diamine.
Using the procedure for the step C of example 2338, the title compound was obtained.
ESI MS m/e 286 M + PL ; Η NMR (400 MHz, DMSO-d6) δ 7.84 (d, J= 8.4 Hz, 1 H), 7.45 (t, J= 6.8 Hz, 1 H), 7.26 (d, J= 8.4 Hz, 1 H), 6.99 (t, J= 7.6 Hz, 1 H), 6.20 (brs, 1 H), 3.90-3.89 (m, 1 H), 3.18 (s, 6 H), 2.79 (s, 1 H), 1.74-1.71 (m, 2 H), 1.57-1.41 (m, 8 H).
Step E: Synthesis of cw-N -[4-(3,5-dichloro-benzylamino)-cyclohexyl]-N4 > V -dimethyl- quinazoline-2,4-diamine ditrifluoro-acetic acid.
To a solution of cw-N2-(4-amino-cyclohexyl)-N4,N4-dimethyl-quinazolin-2,4- diamine (31.4 mg, 0.11 mmol) in MeOH (0.5 mL) was added 3,5-dichlorobenzaldehyde
(17.5 mg, 0.10 mmol). The mixture was stirred at ambient temperature for 0.5 hr and sodium triacetoxyborohydride (85 mg, 0.40mmol) was added. The mixture was stirred for overnight and the reaction was quenched with 50% DMSO in water (1.0 mL). The mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give cw-N2-[4-(3,5-dichloro-benzylamino)-cyclohexyl]-Y,Y-dimethyl- quinazoline-2,4-diamine ditrifluoro-acetic acid (23 mg, 0.041 mmol, 37%) as a white
solid.
ESI MS m/e 444 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 13.55 (s, 1 H), 8.90 (brs, 3 H), 8.17 (d, J- 8.0 Hz, 1 H), 7.79 (t, 7.6 Hz, 1 H), 7.68 (s, 1 H), 7.61 (s, 2 H), 7.41 (d, J= 7.6 Hz, 1 H), 7.36 (t, J= 1.6 Hz, 1 H), 4.23 (s, 2 H), 4.07 (s, 1 H), 3.48 (s, 6 H), 2.00-1.92 (m, 4 H), 1.82-1.74 (m, 4 H).
Example 2342
CF3C02H
cis-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluoro- benza ide trifluoro-acetic acid.
Step A: Synthesis of c/s-N-[4-(4-dimethylamino-quinazolin-2-yIamino)-cyclohexyl]- 3,4-difluoro-benzamide trifluoro-acetic acid.
Using the procedure for the step A of example 2333, the title compound was obtained.
ESI MS m/e 426 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 12.46 (brs, 1 H), 8.36 (s, 1 H), 8.15 (d, J= 8.0 Hz, 1 H), 7.97 (brs, 1 H), 7.94-7.89 (m, 1 H), 7.77-7.73 (m, 2 H), 7.56- 7.49 (m, 1 H), 7.41 (brs, 1 H), 7.36 (t, J- 7.6 Hz, 1 H), 4.07 (m, 1 H), 3.87 (m, 1 H), 3.47 (brs, 6 H), 1.89 (m, 2 H), 1.74 (m, 6 H).
Example 2343
2 CF3C02H c $'-4-Dimethlyamino-N-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]- benzamide ditrifluoro-acetic acid
Step A: Synthesis of cis-4-dimethlyamino-N-[4-(4-dimethlyamino-quinazolin-2- ylamino)-cyclohexyl]-benzamide ditrifluoro-acetic acid.
To a solution of 4-dimethylaminobenzoic acid (16.5 mg, 0.10 mmol) in DMF (0.5 mL) were added HATU (45.6 mg, 0.12 mmol), diisopropylethylamine (34.8 uL, 0.20 mmol), and ct ,-N2-(4-amino-cyclohexyl)-N4,N4-dimethyl-quinazolin-2,4-diamine obtained in step D of example 2341 (28.5 mg, 0.10 mmol) and stirred at ambient temperature for overnight. The resulting mixture was diluted with DMSO (0.5 mL) and purified by preparative HPLC. The pure fractions combined and lyophilized to give cfj,-4- dimeMyamino-N-[4-(4-dimetWyamino-quinazolin-2-ylamino)-cyclohexyl]-benzamide ditrifluoro-acetic acid (34.1 mg, 0.052mmol, 52%) as a white solid. ESI MS m e 433 M + ϊt ; Η ΝMR (400 MHz, DMSO-d6) δ 12.73 (s, 1 H), 8.34 (s, 1 H), 8.16 (d, J= 8.0 Hz, 1 H), 7.78-7.70 (m, 4 H), 7.43 (d, J= 7.6 Hz, 1 H), 7.35 (t, J= 8.0 Hz, 1 H), 6.67 (d, J= 8.8 Hz, 2 H), 4.05 (m, 1 H), 3.86 (m, 1 H), 3.47 (s, 6 H), 2.95 (s, 3 H), 2.53 (s, 3 H), 1.91 (m, 2 H), 1.75-1.72 (m, 6 H).
Example 2344
trα«5-4-Bromo-N-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of £rø#.s-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester.
To a solution of tr rø-l,4-diamino-cyclohexane (10 g, 0.088 mol) in 1,4-dioxane (400 mL) was added a solution of (Boc)2O (4.78 g, 0.022 mol) in 1,4-dioxane (100 ml) over 30 min. The mixture was stirred at ambient temperature for overnight and then the dioxane was removed in vacuo. The resulting precipitate was dissolved in H2O (500 mL) and left to sit for 1 hour. During tins time, the di-Boc-protected diamino-cyclohexane fell out as a white crystalline precipitate. This was subsequently filtered from the aqueous solvent. The aqueous layer was extracted with EtOAc (three times). The organic layers were combined and washed with H2O. The organic layer was dried over MgSO4 and concentrated to give trαrø-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (4 g, 0.019 mol, 85%).
ESI MS m/e 215 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 6.63 (d, J- 8.0 Hz, 1 H), 3.11-3.09 (m, 1 H), 2.44-2.37 (m, 1 H), 1.70-1.67 (m, 4 H), 1.41-1.31 (m, 11 H), 1.20-0.95 (m, 4 H).
Step B: Synthesis of rα/ιs-[4-(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)- cyclohexyl] -carbamic acid tert-butyl ester.
To a solution of trαra,-(4-ammo-cyclohexyl)-carbamic acid tert-butyl ester (1 g, 0.0047 mol) in CH2C12 were added diisopropylethylamine (1.63 mL, 0.0093 mol) and 4- bromo-2-trifluoromethoxy-benzenesulfonyl chloride (1.03 L, 0.0051 mol). The reaction mixture was stirred at ambient temperature for 1 hr and then washed with water. The aqueous layer was extracted with CH2C12 (twice), the organic layers were combined, dried over MgSO4, and concentrated. The resulting precipitate was recrystallized with CH2C12 and hexanes to give trαrø-[4-(4-bromo-2-trifluoromethoxy- benzenesulfonylamino)-cyclohexyl]-carbamic acid tert-butyl ester (2.39 g, 0.0046 mol,
ESI MS m/e 517 M + ET; Η NMR (400 MHz, DMSO-d6) δ 7.99 (d, J= 1.6 Hz, 1 H), 7.85 (d, J= 8.0 Hz, 1 H), 7.79-7.77 (m, 1 H), 6.67 (d, J= 8.0 Hz, 1 H), 3.14-2.94 (m, 2 H), 1.70-1.60 (m, 4 H), 1.34 (s, 9 H), 1.30-1.18 (m, 2 H), 1.14-1.03 (m, 2 H).
Step C: Synthesis of ^ra«5-N-(4-amino-cyclohexyl)-4-bromo-2-trifluoromethoxy- benzenesulfonamide.
Using the procedure for the step C of example 2338, the title compound was obtained.
ESI MS m/e 417/419 M + H+; Η NMR (400 MHz, DMSO-d6) δ 7.85 (d, J= 8.4 Hz, 1 H), 7.79-7.76 (m, 3 H), 3.32 (brs, 2 H), 3.03-2.95 (m, 1 H), 2.41-2.36 (m, 1 H), 1.67-1.57 (m, 4 H), 1.28-1.18 (m, 2 H), 0.99-0.89 (m, 2 H).
Step D: Synthesis of tfrα«s-4-bromo-N-[4-(4-dimethlyamino-quinazolin-2-ylamino)- cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide.
To a solution of trαzzj,-N-(4-amino-cyclohexyl)-4-bromo-2-trifluoromethoxy- benzenesulfonamide (100 mg, 0.24 mmol) in 2-propanol (0.5 mL) was added (2-chloro- quinazolin-4-yl)-dimethly-amine obtained in step B of example 1 (54.7 mg, 0.26mmol). The mixture was heated using a Smith Microwave Synthesizer at 170 °C for 15 min. The mixture was concentrated and the residue was purified by chromatography (2% to 4% 2 M ΝH3/MeOH in CH2C12) to give tz' «5,-4-bromo-N-[4-(4-dimethlyamino-quinazolin-2- ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide (42 mg, 0.71 mmol, 30%) as a white solid.
ESI MS m/e 588/590 M + H+ ; Η ΝMR (400 MHz, DMSO-d6) δ 8.02 (d, J= 7.6 Hz, 1 H), 7.88 (d, J= 8.4 Hz, 1 H), 7.82-7.77 (m, 3 H), 7.45-7.41 (m, 1 H), 7.25-7.41 (m, 1 H), 6.99 (t, J= 7.2 Hz, 1 H), 6.37 (brs, 1 H), 3.68-3.67 (m, 1 H), 3.16 (s, 6 H), 3.09-3.02 (m, 1 H), 1.89-1.86 (m, 2 H), 1.69-1.67 (m, 2 H), 1.40-1.17 (m, 4 H).
Example 2345
trans-4 -Fluoro-biphenyl-4-carboxylic acid [4-(4-dimethlyamino-quinazolin-2- ylamino)-cyclohexyl]-amide.
Step A: Synthesis of 4 -fluoro-biphenyl-4-carboxylic acid.
To a solution of 4-bromobenzoic acid (5 g, 0.025 mol) in THF (150 mL) under an
atmosphere of argon were added tetrakis(triphenylphosphine) palladium(O) (862 mg, 0.75 mmol), 2 M aqueous Na2CO3 (30 mL), and a solution 4-fluorophenyboronic acid (3.48 g, 0.025 mol) in a minimal amount of ethanol (~10 mL). The resulting reaction mixture was stirred at reflux under an argon atmosphere for overnight. The reaction mixture was cooled to ambient temperature and acidified with addition of 1 M HCl aqueous. The aqueous layer was extracted with Et2O (tliree times). The organic layers were combined, dried over MgSO4, filtered and concentrated. The resulting precipitate was crystallized in Et2O and hexane to give 4 -fluoro-biphenyl-4-carboxylic acid (4.4 g, 0.020 mol, 82%) as a white solid.
Η NMR (400 MHz, DMSO-d6) δ 12.96 (s, 1 H), 8.00-7.98 (m, 2 H), 7.78-7.75 (m, 4 H), 7.34-7.31 (m, 2 H).
Step B: Synthesis of /raws- [4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyI]- carbamic acid tert-butyl ester.
Using the procedure for the step D of example 2344, the title compound was obtained.
ESI MS m/e 386 M + H+; Η NMR (400 MHz, DMSO-d6) δ 7.83 (d, J= 8.0 Hz, 1 H), 7.46 (t, J= 6.8 Hz, 1 H), 1.21-1.25 (m, 1 H), 6.99 (t, J= 7.2 Hz, 1 H), 6.71 (d, J= 8.4 Hz, 1 H), 6.38 (brs, 1 H), 3.72 (m, 1 H), 3.17 (s, 6 H), 1.92-1.90 (m, 2 H), 1.79-1.76 (m, 2 H), 1.37 (s, 9 H), 1.34-1.23 (m, 4 H).
Step C: Synthesis of trans-4 -fluoro-biphenyl-4-carboxylic acid [4-(4-dimethIyamino- quinazoIin-2-ylamino)-cyclohexyl]-amide.
To a solution of trαrø-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]- carbamic acid tert-butyl ester (0.76 g, 0.20 mmol) in CH2C12 (20 mL) was added TFA (304 μL, 0.39 mmol). The solution was stirred at ambient temperature for 4 hr. The resulting mixture was concentrated and the residue was dissolved in CH2C12. The organic layer was washed with a dilute aqueous NaOH and aqueous NaHCO3 solution. The aqueous layer was extracted with CH2C12 (twice) and the organic layers combined, dried over
MgSO4, and concentrated. To a solution of the residue (0.1 g) and 4 -fluoro-biphenyl-4- carboxylic acid (76 mg, 0.35 mmol) in CH2C12 were added HOAt (62 mg, 0.46 mmol),
WSC-HC1 (87 mg, 0.46 mmol), and diisopropylethylamine (31 uL, 0.18 mmol). The mixture was stirred for 1 hr at ambient temperature and the reaction was quenched with
water. The aqueous layer was extracted with CH2C12 (twice). The organic layers were combined, dried over MgSO4, concentrated and the residue purified by column chromatography (silica gel, 2% to 4% 2 M NH3/MeOH in CH2C12) to give trαzwY-fluoro- biphenyl-4-carboxylic acid [4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl] - amide (35 mg, 0.072, 21 >) as a white solid.
ESI MS m/e 484 M + ϊt ; lΪJ NMR (400 MHz, DMSO-d6) δ 8.30 (brs, 1 H), 8.12 (brs, 2 H), 7.92 (d, J= 8.4 Hz, 2 H), 7.77-7.72 (m, 5 H), 7.44 (brs, 1 H), 7.34-7.28 (m, 3 H), 3.82 (brs, 2 H), 3.47 (brs, 6 H), 2.04 (m, 2 H), 1.94 (m, 2 H), 1.54-1.48 (m, 4 H).
Example 2346
2 CF3C02H c s-iV2-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-iV'-tert-butyl- quinazo!ine-2,4-diamine ditrifluoro-acetic acid
Step A: Synthesis of tert-butyl-(2-chloro-quinazolin-4-yl)-amine.
To a solution of 2,4-dichloro-quinazoline obtained in step B of example 1 (4 g, 20 mmol) in THF (50 mL) were added tert-butyl amine (2.15 mL, 20.5 mmol) and diisopropylethylamine (3.5 mL, 21 mmol). The mixture was stirred at ambient temperature for 2 hr. The mixture was concentrated and the residue was dissolved in EtOAc. The organic layer was washed with water, dried over Na^O,,, and filtered. The mixture was concentrated to give tert-butyl-(2-chloro-quinazolin-4-yl)-amine as a white solid (3 g, 64%).
ESI MS m/e 236 M + t ; Η NMR (400 MHz , DMSO-d6) δ 8.40 (d, J = 8.4 Hz, 1 H), 7.75-7.36 (m, 2 H), 7.58 (d, J = 8.4 Hz, 1 H), 7.48 (t, J = 7.2 Hz, 1 H), 1.52 (s, 9 H).
Step B: Synthesis of cw-N2-(4-amino-cyclohexyl)-iV'-tert-butyl-quinazoline-2,4- diamine.
To a suspension of czN(4-ammo-cyclohexyl)-carbamic acid tert-butyl ester (122
mg, 0.57 mmol) in 2-propanol (2 mL) were added tert-butyl-(2-chloro-quinazolin-4-yl)- a ine (100 mg, 0.42 mmol) and diisopropylethylamine (180 μL, 1 mmol) and the mixture was heated at 170 °C for 1 hr using a Smith Microwave Synthesizer. The resulting solution was concentrated and purified by column chromatography (silica gel, 3% MeOH in CH2C12) to give [4-(4-tert-butylamino-quinazolin-2-ylamino)-cyclohexyl] -carbamic acid tert-butyl ester (112 mg, 65%) as a yellow solid. To a suspension of cz',s-[4-(4-tert- butylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (95 mg, 0.23 mmol) in CH2C12 (3 L) was added trifluoroacetic acid (2 mL) dropwise. The reaction mixture was stirred at ambient temperature for 2 hr. The solution was concentrated, alkalized with saturated aqueous NaHCO3 and 1 M aqueous sodium hydroxide (pH = 9), and the aqueous layer was extracted with CH2C12 (three times). The combined organic layer was dried over MgSO4, filtered, and concentrated. The solid was collected by filtration to give cw-N2-(4-amino-cyclohexyl)-N0tert-butyl-quinazoline-2,4-diamine (44.6 mg, 53%o) as a yellow solid.
ESI MS m/e 314 M + H+ ; Η ΝMR (400 MHz, CDC13) δ 7.48 (t, J = 6.8 Hz, 1 H), 7.38 (m, 2 H), 7.04 (t, J = 8.0 Hz, 1 H), 5.42 (brs, 1 H), 4.15 (m, 1 H), 2.85 (m, 1 H), 1.2-1.9 (m, 17 H).
Step C: Synthesis of c s-N2-[4-(4-bromo-2-trifluoromethoxy-benzyIamino)- cyclohexyl]-N -tert-butyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.
Using the procedure for the step C of example 2341, the title compound was obtained.
ESI MS m/e 566 M + H+ ; Η ΝMR (400 MHz, CDC13) δ 9.36 (d, J = 8.0 Hz, 1 H), 7.67- 7.64 (m, 2 H), 7.53-7.48 (m, 3 H), 7.43 (s, 1 H), 7.33 (m, 1 H), 6.17 (s, 1 H), 4.45 (m, 1 H), 4.28 (s, 2 H), 3.35 (m, 1 H), 2.14 -1.6 (m, 17 H).
Example 2347
4-Bromo-iV-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-2- trifluoromethoxy-benzenesulfonamide
Step A: Synthesis of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyI}- carbamic acid tert-butyl ester.
Using the procedure for the step D of example 2330, the title compoimd was obtained.
ESI MS m/e 377 M + Jt ;Η NMR (400 MHz, DMSO-d6) δ 8.38 (brs, 1 H), 8.08 (brs, 1 H), 7.70 (brs, 1 H), 7.47 (brs, 1 H), 7.36 (t, J = 6.2 Hz, 1 H), 7.30 (d, J= 8.0 Hz, 3 H), 7.16 (d, J= 7.6 Hz, 2 H), 4.60 (d, J= 6.4 Hz, 2 H), 4.07 (d, J= 6.0 Hz, 2 H), 3.39 (s, 6 H), 1.37 (s, 9 H).
Step B: Synthesis of N2-(4-aminomethyl-benzyI)-Λ^,Λ^-dimethyl-quinazoIine-2,4- diamine hydrochloride.
To a cooled solution of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]- benzyl} -carbamic acid tert-butyl ester (3.90 g, 9.57 mmol) in MeOH was added 1 M HCl in Et2O (67.0 ml, 67.0 mmol) and the solution was stirred for overnight. The resulting mixture was concentrated to give N2-(4-aminomethyl-benzyl)-N/, Nødimethyl- quinazoline-2,4-diamine hydrochloride as a white crystalline solid (3.48 g, 95.6%). ESI MS m/e 308.2 M + H+ ; Η ΝMR (400 MHz, CD3OD) δ 8.16 (d, J = 7.2 Hz, 1 H), 7.75 (brs, 1 H), 7.48 (m, 5 H), 7.39 (brs, 1 H), 4.76 (s, 2 H), 4.12 (s, 2 H), 3.51 (m, 6 H).
Step C: Synthesis of 4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide.
A solution of N2-(4-aminomethyl-benzyl)-N"/, Y-dimethyl-quinazoline-2,4-diamine hydrochloride (50.0 mg, 0.131 mmol), 4-bromo-2-trifluorornethoxy-benzenesulfonyl chloride (53.3 mg, 0.157 mmol) and diisopropylethylamine (91 μl, 0.524 mmol) in 2-
propanol (1.5 mL) was stirred at ambient temperature for 2 hr. The resulting mixture was concentrated, and the residue was purified by column chromatography (silica gel, 10%> MeOH in CH2C12) to give 4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)- methyl] -benzyl} -2-trifluoromethoxy-benzenesulfonamide as a white crystalline compound (40 mg, 50%).
ESI MS m/e 612 M + ϊt ; Η ΝMR (400 MHz, DMSO-d6) δ 8.51 (t, J = 6.4 Hz, 1 H), 8.06 (brs, 1 H), 7.76-7.67 (m, 4 H), 7.54-7.41 (m, 2 H), 7.24 (d, J = 7.6 Hz, 3 H), 7.14 (d, J = 8.0 Hz, 2 H), 4.56 (d, J= 6.0 Hz, 2 H), 4.08 (d, J= 6.0 Hz, 2 H), 3.36 (s, 6 H).
Example 2348
4-bromo-iV-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy- benzenesulfonamide
Step A: Synthesis of (4-amino-phenyl)-carbamic acid tert-butyl ester.
Using the procedure for the step A of example 2344, the title compound was obtained.
ESI MS m/e 209 M + H+ ; Η ΝMR (400 MHz, DMSO-d6) δ 8.75 (s, 1 H), 7.03 (d, J = 7.6 Hz, 2 H), 6.43 (dt, J = 9.5, 2.7 Hz, 2 H), 4.71 (s, 2 H), 1.43 (s, 9 H).
Step B: Synthesis of N2-(4-amino-phenyl)-iV V4-dimethyl-quinazoline-2,4-diamine hydrochloride.
A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (0.5 g, 2.6 mmol) and (4-amino-phenyl)-carbamic acid tert-butyl ester (0.5 g, 2.6 mmol) in CH2C12 (2 mL) was heated by Smith Synthesizer at 130 °C for 20 min. The mixture was concentrated to give [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]- carbamic acid tert-butyl ester as a pale yellow solid (0.86 g, 87%). The reaction was repeated six times, and the total product combined was 8.5 g. To a solution of above product (8.5 g, 22.4 mmol) in MeOH (250 mL) was added 4 M HCl in dioxane (8.4 ml,
33.6 mmol) dropwise, and the mixture was stirred at ambient temperature for overnight. The mixture was concentrated to give N2-(4-amino-phenyl)-N'/,Y-dimethyl-quinazoline- 2,4-diamine hydrochloride as a pale pink solid (6.2 g, 87.5%).
ESI MS m/e 280 M + H+ ; Η ΝMR (400 MHz, D2O) δ 7.84 (d, J = 8.8 Hz, 1 H), 7.54 (td, J = 7.8, 1.2 Hz, 1 H), 7.46 (dt, J = 9.5, 2.7 Hz, 2 H), 7.27-7.16 (m, 4 H), 3.35 (b, 3 H), 3.12 (b, 3 H).
Step C: Synthesis of 4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)- phenyl]-2-trifluoromethoxy-benzenesulfonamide.
Using the procedure for the step C of example 2347, the title compound was obtained.
ESI MS m/e 584 M + PL; Η ΝMR (400 MHz, DMSO-d6) δ 10.27 (brs, 1 H), 9.14 (brs, 1 H), 7.98 (d, J = 8.4 Hz, 1 H), 7.80-7.71 (m, 5 H), 7.60-7.56 (m, 1 H), 7.44 (d, J = 8.4 Hz, 1 H), 7.15 (t, J = 7.4 Hz, 1 H), 6.95 (d, J = 16.8 Hz, 2 H), 9.29 (s, 6 H).
Example 2349
CF3C02H 4'-Chloro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)- phenyl] -amide trifluoro-acetic acid
Synthesis of 4'-chloro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2- ylamino)-phenyl] -amide trifluoro-acetic acid.
A solution of N2-(4-amino-phenyl)-Y,N'/-dimethyl-quinazoline-2,4-diamine hydrochloride obtained in step B of example 2348 (81.6 mg, 0.258 mmol), 4'-chloro- biphenyl-4-caxboxylic acid (50.0 mg, 0.215 mmol), HATU (106 mg, 0.280 mmol), and diisopropylethylamine (150 μL, 0.860 mmol), in CH2C12 (2 mL) was stirred at ambient temperature for overnight, and the mixture was concentrated. The residue was purifided by HPLC to give 4'-chloro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2- ylamino)-phenyι]-amide trifluoro-acetic acid as a white solid (10 mg, 9 %).
ESI MS m/e 494 M + H+ ; Η NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1 H), 8.17 (d, J = 8.0 Hz, 1 H), 8.80 (d, J = 8.8 Hz, 2 H), 7.85-7.75 (m, 7 H), 7.63-7.53 (m, 6 H), 7.36 (t, J = 7.6 Hz, I H), 3.46 (s, 6 H).
Example 2350
N-[l-(4-Dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-fluoro- b enzenesulf onamide
Step A: Synthesis of N-[l-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2- fluoro-benzenesulfonamide.
To a solution of 4-aminomethyl-piperidine- 1-carboxylic acid tert-butyl ester (60 mg, 0.28 mmol) and diisopropylethylamine (49 mL, 0.28 mmol) in CH2C12 (2 mL) was added 2-fluorobenzenesulfonyl chloride (54 mg, 0.28 mmol) and the mixture was stirred at ambient temperature for 18 hr. To the resulting mixture was added trifluoroacetic acid
(0.70 mL) and stirred at ambient temperature for 18 hr. The reaction mixture was concentrated and neutralized with saturated aqueous NaHCO3. The aqueous layer was extracted with EtOAc, and the organic layer was concentrated to give 2-fluoro-N- piperidin-4-ylmethyl-benzenesulfonamide as a pale yellow solid. To a solution of above solid (0.076 g, 0.28 mmol) and diisopropylethylamine (0.072 mL, 0.42 mmol) in 2- propanol (3 mL) was added (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (0.044 g, 0.21 mmol) and the resulting mixture was stirred at 100 °C for 18 hr. The mixture was concentrated, and the residue was purified by column chromatography (silica gel, 5% MeOH in CH2C12) to give N-[l-(4-dimethylamino- quinazolin-2-yl)-piperidin-4-ylmethyl]-2-fluoro-benzenesulfonamide as a pale yellow solid (0.024 g, 26%).
ESI MS m/e 444 M + ϊt; Η ΝMR (400 MHz, DMSO-d6) δ 7.98 (m, 1 H), 7.86 (m, 1 H),
7.77 (m 1 H), 7.67 (m, 1 H), 7.47-7.29 (m, 4 H), 7.02 (m, 1 H), 4.69 (m, 2 H), 3.21 (s, 6 H),
2.76 (m, 4 H), 1.66 (m, 3 H), 1.00 (m, 2 H).
Using the procedure for example 2329 and purification by preparative HPLC, the compounds of example 2351 - 2819 were obtained.
Using the procedure for example 2331 and purification by preparative HPLC, the compounds of example 2820 - 2842 were obtained.
Using the procedure for example 2332, the compounds of example 2843 - 3003 were obtained.
Using the procedure for example 2333, the compounds of example 3004 - 3090 were obtained.
Using the procedure for example 2334, the compounds of example 3091 - 3161 were obtained.
Using the procedure for example 2335 and purification by preparative HPLC, the compounds of example 3162 - 3178 were obtained.
Using the procedure for example 2336, the compounds of example 3179 - 3208 were obtained.
Using the procedure for example 2337, the compounds of example 3209 was obtained.
Using the procedure for example 2338, the compounds of example 3210 - 3225 were obtained.
Using the procedure for example 2339, the compoxinds of example 3226 - 3228 were obtained.
Using the procedure for example 2340, the compounds of example 3229 - 3231 were obtained.
Using the procedure for example 2341, the compounds of example 3232 - 3393 were obtained.
Using the procedure for example 2342, the compounds of example 3394 - 3472 were obtained.
Using the procedure for example 2343, the compounds of example 3473 - 3527 were obtained.
Using the procedure for example 2346, the compounds of example 3528 - 3535 were obtained.
Using the procedure for example 2347 and purification by preparative HPLC, the compounds of example 3536 - 3545 were obtained.
Using the procedure for example 2348 and purification by preparative HPLC, the compounds of example 3546 - 3548 were obtained.
Using the procedure for example 2349, the compounds of example 3549 - 3567 were obtained.
Using the procedure for example 2350 and purification by preparative HPLC, the compounds of example 3568 - 3579 were obtained.
Assay Procedures
Compounds identified and disclosed throughout this patent document were assayed according to the protocols found in co-pending patent application having U.S. Serial Number 09/826,509, which is incorporated herein by reference.
Example 3580
Preparation of Endogenous MCH Receptor.
The endogenous human MCH receptor was obtained by PCR using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94°C for 1 min, 56°C for lmin and 72 °C for 1 min and 20 sec. The 5' PCR primer contained a Hindlll site with the sequence: 5'-GTGAAGCTTGCCTCTGGTGCCTGCAGGAGG-3' (SEQ.ID.NO.:l) and the 3' primer contained an EcoRI site with the sequence: 5'-GCAGAATTCCCGGTGGCGTGTTGTGGTGCCC-3 ' (SEQ.ID.NO.:2).
The 1.3 kb PCR fragment was digested with Hindlll and EcoRI and cloned into Hindlll-EcoRI site of CMVp expression vector. Later the cloning work by Lakaye et al showed that there is an intron the coding rgion of the gene. Thus the 5' end of the cDNA was obtained by 5' RACE PCR using Clontech's marathon-ready hypothalamus cDNA as template and the manufacturer's recommended protocol for cycling condition. The 5' RACE PCR for the first and second round PCR were as follows: 5'-CATGAGCTGGTGGATCATGAAGGG-3' (SEQ.ID.NO.:3) and 5'-ATGAAGGGCATGCCCAGGAGAAAG-3' (SEQ.ID.NO.:4).
Nucleic acid and amino acid sequences were thereafter determined and verified with the published sequences found on GenBank having Accession Number U71092.
Example 3581
Preparation of Non-Endogenous, Constitutively Active MCH Receptor.
Preparation of a non-endogenous version of the human MCH receptor was accomplished by creating a MCH-IC3-SST2 mutation (see; SEQ.ID.NO.:7 for nucleic acid sequence, and SEQ.ID.NO.:8 for amino acid sequence). Blast result showed that MCH receptor had the highest sequence homology to known SST2 receptor. Thus the third intracellular loop ("IC3") of MCH receptor was replaced with that of the IC3 of SST2
receptor to see if the chimera would show constitutive activity.
The BamHI-BstEII fragment containing IC3 of MCH receptor was replaced with synthetic oligonucleotides that contained the IC3 of SST2. The PCR sense mutagenesis primer used had the following sequence:
5'-GATCCTGCAGAAGGTGAAGTCCTCTGGAATCCGAGTGGGCTCCTCTAAGAG GAAGAAGTCTGAGAAGAAG-3 ' (SEQ. ID. O.: 9) and the antisense primer had the following sequence:
5'-GTGACCTTCTTCTCAGACTTCTTCCTCTTAGAGGAGCCCACTCGGATTCCAG AGGACTTCACCTTCTGCAG-3 ' (SEQ.ID.NO. : 10). The endogenous MCH receptor cDNA was used as a template.
Example 3582
GPCR Fusion Protein Preparation.
MCH Receptor-Giα Fusion Protein construct was made as follows: primers were designed for endogenous MCH receptor was as follows: 5'-GTGAAGCTTGCCCGGGCAGGATGGACCTGG-3 ' (SEQ.ID.NO.:ll; sense) 5'-ATCTAGAGGTGCCTTTGCTTTCTG-3' (SEQ.ID.NO.: 12; anitsense). The sense and anti-sense primers included the restriction sites for KB4 and Xbal, respectively.
PCR was utilized to secure the respective receptor sequences for fusion within the Giα universal vector disclosed above, using the following protocol for each: lOOng cDNA for MCH receptor was added to separate tubes containing 2ul of each primer (sense and anti-sense), 3uL of lOmM dNTPs, lOuL of lOXTaqPlus™ Precision buffer, luL of TaqPlus™ Precision polymerase (Stratagene: #600211), and 80uL of water. Reaction temperatures and cycle times for MCH receptor were as follows: the initial denaturing step was done it 94°C for five minutes, and a cycle of 94°C for 30 seconds; 55°C for 30 seconds; 72°C for two minutes. A final extension time was done at 72°C for ten minutes. PCR product for was run on a 1% agarose gel and then purified (data not shown). The purified product was digested with KB4 and Xbal (New England Biolabs) and the desired inserts will be isolated, purified and ligated into the Gi universal vector at the respective restriction site. The positive clones was isolated following transformation and determined by restriction enzyme digest; expression using 293 cells was accomplished
following the protocol set forth infra. Each positive clone for MCH receptor: Gi-Fusion Protein was sequenced and made available for the direct identification of candidate compounds. (See, SEQ.ID.NO.:13 for nucleic acid sequence and SEQ.ID.NO. :14 for amino acid sequence).
Endogenous version of MCH receptor was fused upstream from the G protein Gi and is located at nucleotide 1 through 1,059 (see, SEE.ID.NO.:13) and amino acid residue 1 through 353 (see, SEQ .ID .NO.: 14). With respect to the MCH receptor, 2 amino acid residues (an equivalent of 6 nucleotides) were placed in between the endogenous (or non- endogenous) GPCR and the start codon for the G protein Giα. Therefore, the Gi protein is located at nucleotide 1,066 through 2,133 (see, SEQ.ID.NO.: 13) and at amino acid residue 356 through 711 (see, SEQ.ID.NO.:14). Those skilled in the art are credited with the ability to select techniques for constructing a GPCR Fusion Protein where the G protein is fused to the 3' end of the GPCR of interest.
Example 3583
ASSAY FOR DETERMINATION OF CONSTITUTIVE ACTIVITY OF NON- ENDOGENOUS GPCRS
A. Intracellular IP3 Accumulation Assay
On day 1, cells comprising the receptors (endogenous and/or non-endogenous) can be plated onto 24 well plates, usually lxl 05 cells/well (although his umber can be optimized. On day 2 cells can be transfected by firstly mixing 0.25ug DNA in 50 ul serum free DMEM/well and 2 ul lipofectamine in 50 μl serum-free DMEM/well. The solutions are gently mixed and incubated for 15-30 min at room temperature. Cells are washed with 0.5 ml PBS and 400 μl of serum free media is mixed with the transfection media and added to the cells. The cells are then incubated for 3-4 hrs at 37°C/5%CO2 and then the transfection media is removed and replaced with 1 ml/well of regular growth media. On day 3 the cells are labeled with 3H-myo-inositol. Briefly, the media is removed and the cells are washed with 0.5 ml PBS. Then 0.5 ml inositol-free/serum free media (GIBCO BRL) is added/well with 0.25 μCi of 3H-myo-inositol/ well and the cells are incubated for 16-18 hrs o/n at 37°C/5%CO2 . On Day 4 the cells are washed with 0.5 ml PBS and 0.45 ml of assay medium is added containing inositol-free/serum free media lOμM pargyline 10 mM lithium chloride or 0.4 ml of assay medium and 50 ul of lOx
ketanserin (ket) to final concentration of lOμM. The cells are then incubated for 30 min at 37°C. The cells are then washed with 0.5 ml PBS and 200 ul of fresh/ice cold stop solution (1M KOH; 18 mM Na-borate; 3.8 mM EDTA) is added/well. The solution is kept on ice for 5-10 min or until cells were lysed and then neutralized by 200 μl of fresh ice cold neutralization sol. (7.5 % HCL). The lysate is then transf erred into 1.5 ml eppendorf tubes and 1 ml of chloroform/methanol (1 :2) is added/tube. The solution is vortexed for 15 sec and the upper phase is applied to a Biorad AG1-X8™ anion exchange resin (100-200 mesh). Firstly, the resin is washed with water at 1 : 1.25 W/V and 0.9 ml of upper phase is loaded onto the column. The column is washed with 10 mis of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60mM Na-formate. The inositol tris phosphates are eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/ 1 M ammonium formate. The columns are regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and rinsed twice with H2O and stored at 4°C in water.
Reference is made to Figure 1. Figure 1 provides an illustration of IP3 production from several non-endogenous, constitutively activated version of MCH receptor as compared with the endogenous version of this receptor. When compared to the endogenous version of MCH receptor ("MCH-R wt"), MCH-IC3-SST2 evidenced about a 27% increase in IP3 accumulation.
Example 3584
Determination of Compound Using [35S]GTPγS ASSAY
Direct identification of candidate compounds was initially screened using [35S]GTPγS Assay (see, Example 6 of co-pending patent application 09/826,509). Preferably, an MCH receptor: Gi Fusion Protein was utilized, according to Example 6(2) of co-pending patent application 09/826,509. Several lead hits were identified utilizing [35S]GTPγS Assay.
Example 3585
High Throughput Functional Screening: FLIPR™
Subsequently, a functional based assay was used to confirm the lead hits, referred to as FLIPR™ (the Fluorometric Imaging Plate Reader) and FDSS6000™ (Functional
Drug Screening System). This assay utilized a non-endogenous version of the MCH receptor, which was created by swapping the third intracellular loop of the MCH receptor with that of the SST2 receptor (see Example 2(B)(2) of patent application serial number 09/826,509).
The FLIPR and FDSS assays are able to detect intracellular Ca2+ concentration in cells, which can be utilized to assess receptor activation and determine whether a candidate compound is an, for example, antagonist, inverse agonist or agonist to a Gq- coupled receptor. The concentration of free Ca2+ in the cytosol of any cell is extremely low, whereas its concentration in the extracellular fluid and endoplasmic reticulum (ER) is very high. Thus, there is a large gradient tending to drive Ca2+ into the cytosol across both the plasma membrane and ER. The FLIPR™ and FDSS6000™ systems (Molecular Devices Corporation, HAMAMATSU Photonics K.K.) are designed to perform functional cell-based assays, such as the measurement of intracellular calcium for high-throughput screening. The measurement of fluorescent is associated with calcium release upon activation of the Gq-coupled receptors. Gi or Go coupled receptors are not as easily monitored through the FLIPR™ and FDSS6000™ systems because these G proteins do not couple with calcium signal pathways.
To confirm the lead hits identified using the [35S]GTPγS assay, Fluorometric Imaging Plate Reader system was used to allow for rapid, kinetic measurements of intracellular fluorescence in 96 well microplates (or 384 well microplates). Simultaneous measurements of fluorescence in all wells can be made by FLIPR or FDSS6000™ every second with high sensitivity and precision. These systems are ideal for measuring cell- based functional assays such as monitoring the intracellular calcium fluxes that occur within seconds after activation of the Gq coupled receptor.
Briefly, the cells are seeded into 96 well at 5.5x104 cells/well with complete culture media (Dulbecco's Modified Eagle Medium with 10 % fetal bovine serum, 2 mM L- glutamine, 1 mM sodium pyruvate and 0.5 mg/ml G418, pH 7.4) for the assay next day. On the day of assay, the media is removed and the cells are incubated with 100 μl of loading buffer (4 μM Fluo4-AM in complete culture media containing 2.5 mM Probenicid, 0.5 mg/ml and 0.2% bovine serum albumin) in 5% CO2 incubator at 37°C for 1 hr. The loading buffer is removed, and the cells are washed with wash buffer (Hank's Balanced Salt Solution containing 2.5 mM Probenicid, 20 mM HEPES, 0.5 mg/ml and 0.2% bovine
serum albumin, pH 7.4)). One hundred fifty μl of wash buffer containing various concentrations of test compound are added to the cells, and the cells are incubated in 5% CO2 incubator at 37°C for 30 min. Fifty μl of wash buffer containing various concentration of MCH are added to each well, and transient changes in [Ca2+]i evoked by MCH are monitored using the FLIPR or FDSS in 96 well plates at Ex. 488 nm and Em. 530 nm for 290 second. When antagonist activity of compound is tested, 50 nM of MCH is used.
Use of FLIPR™ and FDSS6000™ can be accomplished by following manufacturer's instruction (Molecular Device Corporation and HAMAMATSU Photonics K.K.).
The results were shpwn below.
It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.
Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.
Claims (20)
1. A compound of Formula I:
wherein Q is
II III
Ri represents (i) Ci-Ciβ alkyl,
C Ciβ alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•C C3 alkoxy,
•Cι-C3 alkoxy substituted by substituent(s) independently selected from ••carbocyclic aryl, ••heterocyclyl,
••heterocyclyl substituted by Cχ-C3 alkyl, •Cι-C3 alkylcarbonyloxy, •carbocyclyloxy, •carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from ••halogen, ••nitro,
••carbocyclic aryl, ••carbocyclic aryl substituted by Ci-C3 alkoxy, •• -Gi alkyl,
••C!-C alkyl substituted by substituent(s) independently selected from
•••oxo,
•••mono- or di-Cι-C alkylamino,
•••mono- or di-CrC3 alkylamino substituted by carbocyclic aryl,
•••mono- or di-Cι-C3 alkylamino substituted by halogenated carbocyclic aryl,
•••carbocyclic arylcarbonylamino,
•••halogenated carbocyclic arylcarbonylamino,
•heterocyclyloxy,
•heterocyclyloxy substituted by Cι-C3 alkyl,
•substituted heterocyclyl-ethylideneaminooxy,
•Cι-C3 alkoxycarbonyl,
•Ci-C3 alkoxycarbonyl substituted by carbocyclic aryl,
•mono- or di-Cι-C3 alkylaminocarbonyl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-Cι-C alkylamino substituted by substituent(s) independently selected from
••cyano,
••carbocyclic aryl,
••heterocyclyl,
•mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
••hydroxy,
••C1-C3 alkyl,
•Ci-C3 alkylcalbonylamino,
•CrC3 alkylcalbonylamino substituted by substituent(s) independently selected from
••Cι-C3 alkylcalbonylamino,
••carbocyclic arylcalbonylamino,
••heterocyclyl,
•C C4 alkoxycalbonylamino,
•heterocyclyl calbonylamino,
•carbocyclic arylsulfonylamino, •carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-Cι-C3 alkylamino,
•C1-C3 alkylthio,
•Cι-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylaminocarbonyl,
••halogenated mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•heterocyclylthio substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
•C3-C6 cycloalkyl,
•C3-C6 cycloalkyl substituted by -C3 alkyl,
•C3-C6 cycloalkenyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C1-C3 alkoxy, ••C2-C3 alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted -C3 alkylsulfinyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C C4 alkyl,
••CrC alkyl substituted by substituent(s) independently selected from
•••halogen,
•••hydroxy,
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
•••mono- or di-carbocyclic arylamino,
•••mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
••••halogen,
••••nitro,
••••Ci-C3 alkyl,
••••Ci-C3 alkoxy,
••••halogenated -C3 alkoxy,
••Cι-C4 alkoxy,
••Cι-C alkoxy substituted by substituent(s) independently selected from
•••halogen,
•••carbocyclic aryl,
••carbocyclic aryloxy,
••C1-C3 alkoxycarbonyl,
••Cι-C3 alkylcarbonyloxy,
••mono- or di-CrC3 alkylamino,
••mono- or di-carbocyclic arylamino, ••halogenated mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
•••C1-C3 alkyl,
•••C1-C3 alkoxy,
•••halogenated -Cs alkoxy,
••mercapto,
••CrC3 alkylthio,
••halogenated C1-C3 alkylthio,
••CrC3 alkylsulfonyl,
••C3-C6 cycloalkyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••C C3 alkyl,
••C Cs alkyl substituted by carbocyclic aryl,
••C1-C3 alkoxy,
••Cι-C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C8 alkenyl,
C2-C8 alkenyl substituted by substituent(s) independently selected from
•halogen,
•oxo,
•CrC3 alkoxy,
•CrC3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C3 alkyl,
••halogenated C1-C3 alkyl,
••C1-C3 alkoxy,
••halogenated C1-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••nitro,
••C1-C3 alkyl,
••C C3 alkoxy,
(iii) C2-C4 alkynyl,
C2-C4 alkynyl substituted by carbocyclic aryl,
(iv) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•Ci-C3 alkyl substituted by substituent(s) independently selected from
••hydroxy,
••oxo,
••carbocyclic aryl,
•mono- or di-Cχ-C3 alkylamino,
•mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl,
•carbocyclic arylcarbonylamino,
•carbocyclic aryl,
(v) C3-C6 cycloalkeyl,
C3-C6 cycloalkeyl substituted by C1-C3 alkyl,
(vi) carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from
•hydroxy, •nitro,
(vii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, cyano, nitro,
C1-C9 alkyl,
C C9 alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•Cj-C alkoxy, •carbocyclic aryloxy, •mono- or di-Cχ-C3 alkylamino-N-oxy, •mono- or di-Cι-C3 alkylamino,
•mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl, •mono- or di-carbocyclic arylamino, •carbocyclylimino,
•carbocyclylimino substituted by carbocyclic aryl, •mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by Cι-C3 alkoxy, •mono- or di-carbocyclic arylaminocarbonyl,
•mono- or di-carbocyclic arylaminocarbonyl substituted by C C3 alkoxy, •carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from halogen,
C1-C3 alkyl, ••halogenated Ci-C3 alkyl, •heterocyclyl,
•heterocyclyl substituted by Ci-C3 alkyl, C2-C3 alkenyl, C2-C alkenyl substituted by carbocyclic aryl,
C1-C9 alkoxy,
C1-C9 alkoxy substituted by substituent(s) independently selected from
•hydroxy,
•halogen,
•carboxy,
•mono- or di-Cι-C3 alkylamino,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••halogen,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkyl,
•••halogenated C1-C3 alkyl,
C2-C3 alkenyloxy,
CrC3 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•halogenated C1-C4 alkyl,
• -C3 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•halogenated C1-C3 alkyl,
(carbocyclic aryl)S(O)2O, carboxy,
C1-C3 alkoxycarbonyl, mono- or di-C Cs alkylaminocarbonyl, mono- or di-Cι-C3 alkylaminocarbonyl substituted by carbocyclic aryl, mono- or di-carbocyclic arylaminocarbonyl, mono- or di-carbocyclic arylaminocarbonyl substituted by C C3 alkyl, amino, mono- or di-Ci-C4 alkylamino, mono- or di-Cι-C alkylamino substituted by cyano, mono- or di-carbocyclic arylamino,
C1-C3 alkynylcarbonylamino,
C1-C3 alkynylcarbonylamino substituted by carbocyclic aryl, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by Cι-C3 alkyl,
(carbocyclic aryl)NHC(O)NH,
(carbocyclic aryl)NHC(O)NH substituted by Cι-C3 alkoxy,
(carbocyclic aryl)NHC(O)NH substituted by haloganated Ci-C3 alkoxy, carbocyclic aryl diazo, carbocyclic aryl diazo substituted by mono- or di- Ci-C3 alkylamino,
C1-C3 alkylthio, halogenated Ci-C3 alkylthio, carbocyclic arylthio, carbocyclic arylthio substituted by substituent(s) independently selected from
•halogen,
•cyano,
•C1-C3 alkyl, heterocyclylthio,
C1-C3 alkylsulfonyl, mono- or di-C C3 alkylaminosulfonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•C1-C7 alkyl, ••halogenated C C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(viii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••Ci-C3 alkylcarbonyloxy,
••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino,
••C1-C3 alkoxycarbonyl,
•• -C3 alkylthio,
••C1-C3 alkylthio substituted by carbocyclic aryl,
••Ci-C3 alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkyl, •••halogenated C1-C3 alkyl,
•C1-C3 alkoxy,
•C1-C3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•mono- or di-Cι-C3 alkylamino,
•Cι-C alkylcarbonylamino,
•Ci-C3 alkylthio,
•Ci-C3 alkenylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by Cι-C3 alkoxycarbonyl,
•heterocyclylthio,
•heterocyclylthio substituted by C1-C3 alkyl,
•CrC3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by Cι-C4 alkyl,
•C1-C3 alkoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••halogenated C1-C3 alkyl,
••C1-C3 alkoxy,
••halogenated Cι-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••halogen, ••CrC3 alkyl, ••halogenated C1-C3 alkyl, ••Cι-C3 alkoxy, ••C1-C3 alkoxycarbonyl;
R2 is -NHNH2, -NHNHBoc, -N(R2a)(R2b), morpholino, 4-acetyl-piperazyl, or 4- phenyl-piperazyl; wherein R2a is H or Cι-C3 alkyl; R2b is Cι-C4 alkyl, C1-C4 alkyl substituted by substituent(s) independently selected from hydroxy,
Cι-C3 alkoxy, amino,
-NHBoc,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•C1-C3 alkoxy,
•-SO2NH2, heterocyclyl,
C3-C6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•Ci-C3 alkoxy, or a group of Formula IV;
wherein Boc is carbamic acid tert-butyl ester and R3 is C1-C3 alkyl or C1-C3 alkyl substituted by substituent(s) independently selected from •carbocyclic aryl, •halogenated carbocyclic aryl, •carbocyclic aryl substituted by C1-C3 alkoxy; L is selected from Formula V - XLX;
VI Via Vlb
R4 R4 R4
VIII Villa Vlllb
R4 4 4
IX IXa IXb
XIV XV XVI
XVII XVIII XIX
wherein 4 is H or C C3 alkyl;
R5 is H, C1-C3 alkyl, or C1-C3 alkyl substituted by a substituted carbocyclic aryl;
Y is -S(O)2-, -C(O)-, or -(CH2)m; m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, biphenyl, or phenanthryl; carbocyclyl is 10,l l-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7- dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2. l]hepteny; heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, IH- indolyl, lH-pyrrolo[2,3-c]pyridyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,2',5',2"- terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro- benzo[ 1,4] dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[l ,4]oxazinyl, 3,4-dihydro-2H- benzo[b][ 1,4] dioxepinyl, 4H-benzo[ 1,3] dioxinyl, 4H-benzopyranyl, 4-oxo-l,5,6,7- tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo- thioxanthenyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,l-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3- dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
2. A compound according to claim 1, wherein Q is Fomura II;
Ri represents (i) d-Cio alkyl,
CrCio alkyl substituted by substituent(s) independently selected from •halogen, •oxo,
•Ci-C3 alkoxy,
•C C3 alkoxy substituted by carbocyclic aryl, •C1-C3 alkylcarbonyloxy, •carbocyclyloxy, •carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from ••halogen, ••nitro, ••C1-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from •••oxo,
•••carbocyclic arylcarbonylamino, •••halogenated carbocyclic arylcarbonylamino, •heterocyclyloxy,
•heterocyclyloxy substituted by C1-C3 alkyl, •substituted heterocyclyl-ethylideneaminooxy, •C1-C3 alkoxycarbonyl,
•C C3 alkoxycarbonyl substituted by carbocyclic aryl, •mono- or di- - alkylaminocarbonyl, •mono- or di-carbocyclic arylamino, •mono- or di-carbocyclic arylamino substituted by hydroxy, •CrC3 alkylcalbonylamino, •C1-C3 alkylcalbonylamino substituted by substituent(s) independently selected from
••C1-C3 alkylcalbonylamino,
••carbocyclic arylcalbonylamino,
••heterocyclyl,
•Ci-C4 alkoxycalbonylamino,
•heterocyclyl calbonylamino,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-Ci-C3 alkylamino,
•C1-C3 alkylthio,
•C1-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylaminocarbonyl,
••halogenated mono- or di-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•heterocyclylthio substituted by substituent(s) independently selected from
••nitro,
••C C3 alkyl,
•C3-C6 cycloalkyl,
•C3-C6 cycloalkyl substituted by C1-C3 alkyl,
•C3-C6 cycloalkenyl, •carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••C1-C3 alkoxy,
••C2-C3 alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted -C3 alkylsulfinyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••Cι-C4 alkyl,
••C].-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••C1-C4 alkoxy,
••C1-C4 alkoxy substituted by substituent(s) independently selected from
•••halogen,
•••carbocyclic aryl,
••carbocyclic aryloxy,
••C1-C3 alkylcarbonyloxy,
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
•••halogen,
•••nitro,
•••CrC3 alkyl, •••C1-C3 alkoxy,
•••halogenated C1-C3 alkoxy,
••mercapto,
••C1-C3 alkylthio,
••halogenated Cι-C3 alkylthio,
••CrC3 alkylsulfonyl,
••C3-C6 cycloalkyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••hydroxy,
••C1-C3 alkyl,
••C].-C3 alkyl substituted by carbocyclic aryl,
••Ci-C3 alkoxy,
••C1-C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C6 alkenyl,
C2-C6 alkenyl substituted by substituent(s) independently selected from
•oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••halogenated C1-C3 alkyl,
••C1-C3 alkoxy,
••halogenated Ci-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
•• hydroxy, ••C1-C3 alkyl,
••C1-C3 alkoxy,
(iii) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•C1-C3 alkyl substituted by substituent(s) independently selected from
••oxo,
••carbocyclic aryl,
•carbocyclic arylcarbonylamino,
•carbocyclic aryl,
(iv) carbocyclyl, carbocyclyl substituted by nitro,
(v) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•Ci-C alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryloxy,
••carbocyclylimino,
••carbocyclylimino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylaminocarbonyl,
••mono- or di-carbocyclic arylaminocarbonyl substituted by C1-C3 alkoxy,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
—C1-C3 alkyl,
•••halogenated Cι-C3 alkyl, ••heterocyclyl,
••heterocyclyl substituted by C1-C3 alkyl,
•Cι-C7 alkoxy,
•Cι-C7 alkoxy substituted by substituent(s) independently selected from
••halogen,
••carbocyclic aryl,
•C1-C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by C1-C3 alkoxy,
•Q-C3 alkoxycarbonyl,
•mono- or di-Cι-C3 alkylaminocarbonyl,
•mono- or di-Cι-C3 alkylaminocarbonyl substituted by carbocyclic aryl,
•mono- or di-carbocyclic arylaminocarbonyl,
•mono- or di-carbocyclic arylaminocarbonyl substituted by Ct-03 alkyl,
•amino,
•mono- or di- -Cs alkylamino,
•Cι-C3 alkynylcarbonylamino,
•C Q alkynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by C1-C3 alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by Ci-C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated C1-C3 alkoxy,
•C1-C3 alkylthio,
•halogenated -C3 alkylthio,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by cyano,
•C1-C3 alkylsulfonyl,
•mono- or di-Cι-C3 alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
-C1-C7 alkyl, ••halogenated C1-C alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••CrC3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(vi) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C1-C4 alkyl,
•Cι-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••C1-C3 alkylthio,
••C1-C3 alkylthio substituted by carbocyclic aryl,
••Cι-C3 alkylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•Cι-C3 alkoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) mdependently selected from
••halogen,
••C1-C3 alkyl,
•C1-C3 alkylthio,
•C1-C3 alkenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by Ci-C4 alkyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••C1-C3 alkyl,
••Cι-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C C3 alkyl,
••halogenated C C3 alkyl;
Y is -C(O)-; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; carbocyclyl is 10,l l-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 9H- fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxo-isoindolyl, IH-indolyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,3-dihydro- benzo[ 1,4] dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H- benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H- benzo[b][ 1,4] dioxepinyl, 4-oxo-l, 5, 6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, cinnolyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
3. A compound according to claim 2, wherein
Ri represents (i) Ci- o alkyl, C1-C10 alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl,
•methoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•halogenated carbocyclic aryloxy,
•carbocyclic aryloxy substituted by nitro,
•heterocyclyloxy substituted by methyl,
•substituted heterocyclyl-ethylideneaminooxy,
•tert-butoxycarbonylamino,
•carbocyclic arylcarbonylamino,
•CrC2 alkylthio,
•Cι-C2 alkylthio substituted by substituent(s) independently selected from
••halogenated carbocyclic aryl,
••carbocyclic aryl substituted by methoxy,
•carbocyclic arylthio,
•hetrocyclylthio substituted by nitro,
•hetrocyclylthio substituted by methyl,
•C5-C6 cycloalkyl,
•C5-C6 cycloalkenyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••methyl,
••methoxy,
••ethenyl substituted by carbocyclic aryl substituted methylsulfϊnyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from •••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••Cι-C4 alkoxy,
••halogenated Cι-C alkoxy,
••CrC4 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C2 alkyl,
•• Cι-C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) C3-C5 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl,
(iv) carbocyclyl,
(v) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy, •cyano,
•nitro,
•C1-C9 alkyl,
•C Cg alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryl,
••carbocyclic aryl substituted by methyl,
••carbocyclic aryloxy,
•C1-C7 alkoxy,
•halogenated C C7 alkoxy,
•Cχ-C7 alkoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methoxy,
•amino,
•di-methylamino,
•propargynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino substituted by methyl,
•(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
•halogenated methylthio,
•carbocyclic arylthio substituted by cyano,
•di-propylamino sulfonyl,
•mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C C4 alkyl, •C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••methylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•C1-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl substituted by C1-C4 alkyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula Na, Villa, or IXa; wherein R4 and R5 are independently selected from H or C C3 alkyl; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren- 9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxo-isoindolyl, IH-indolyl, IH-pyrrolyl, l-oxo-3H-isobenzofuranyl, 2,3-dihydro- benzo[ 1,4] dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b] [1 ,4] dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo- benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3- dihydro-benzofuryl, 2-oxo-pyrrolidinyl, 4-oxo-l, 5,6,7-tetrahydro-indolyl, cinnolyl, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
4. A compound according to claim 3, wherein
Ri represents (i) Ci-Cio alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl, •methoxy substituted by carbocyclic aryl, •methylcarbonyloxy, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •carbocyclic aryloxy substituted by nitro, •heterocyclyloxy substituted by methyl, •substituted heterocyclyl-ethylideneaminooxy, •tert-butoxycarbonylamino, •carbocyclic arylcarbonylamino, •C1-C2 alkylthio,
•Ci-C2 alkylthio substituted by substituent(s) independently selected from ••halogenated carbocyclic aryl, ••carbocyclic aryl substituted by methoxy, •carbocyclic arylthio, •hetrocyclylthio substituted by nitro, •hetrocyclylthio substituted by methyl, •C5-C6 cycloalkenyl,
•carbocyclyl substituted by substituent(s) independently selected from ••halogen, ••methyl, ••methoxy, ••ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
••C1-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••CrC alkoxy,
••halogenated C1-C4 alkoxy,
••C].-C alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C2 alkyl,
•• C1-C2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by nitro,
(iii) C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•methyl substituted by oxo,
•methyl substituted by carbocyclic aryl,
•carbocyclic aryl, (iv) carbocyclyl,
(v) carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•C1-C9 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic aryl,
••carbocyclic aryl substituted by methyl,
••carbocyclic aryloxy,
•Cι-C7 alkoxy,
•halogenated Ci-C7 alkoxy,
•C1-O7 alkoxy substituted by carbocyclic aryl,
•methylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methoxy,
•amino,
•di-methylamino,
•propargynylcarbonylamino substituted by carbocyclic aryl,
•carbocyclic arylsulfonylamino substituted by methyl,
•(carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
•halogenated methylthio,
•carbocyclic arylthio substituted by cyano,
•di-propylamino sulfonyl,
•mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) or heterocyclyl substituted by substituent(s) independently selected from •halogen,
•nitro,
•C1-C4 alkyl,
•C1-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••methylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•Cι-C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•Ci-Cs alkylsulfonyl,
•carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by C11-C4 alkyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl;
L is selected from Formula XX - XXII;
wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren- 9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, IH- indolyl, IH-pyrrolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 4-oxo-benzopyranyl, azetidinyl, benzo[b]thienyl, furyl, isoxazolyl, morpholinyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-l, 5,6,7-tetrahydro- indolyl, 9H-xanthenyl, cinnolyl, imidazolyl, morpholino, pyrimidyl, pyrrolidyl, tetrahydro- thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
5. A compound according to claim 4, wherein
Ri represents (i) C1-C5 alkyl substituted by substituent(s) independently selected from •oxo,
•di-propylaminocarbonyl, •methoxy substituted by carbocyclic aryl, •methylcarbonyloxy, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •carbocyclic aryloxy substituted by nitro, •heterocyclyloxy substituted by methyl, •substituted heterocyclyl-ethylideneaminooxy, •tert-butoxycarbonylamino, •carbocyclic arylcarbonylamino, •C1-C2 alkylthio,
•C1-C2 alkylthio substituted by substituent(s) independently selected from ••halogenated carbocyclic aryl, ••carbocyclic aryl substituted by methoxy, •carbocyclic arylthio, •hetrocyclylthio substituted by nitro, •hetrocyclylthio substituted by methyl, •cyclohexenyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••methyl,
••methoxy,
••ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••nitro,
•• C1-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from
•••oxo,
•••carbocyclic aryl,
•••heterocyclyl,
••C1-C2 alkoxy,
••halogenated Cι-C2 alkoxy,
••Cι-C2 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryloxy,
••halogenated mono-carbocyclic arylaminocarbonyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C2 alkyl,
•• CrC2 substituted by carbocyclic aryl,
••methoxy,
••methoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C3 alkenyl substituted by substituent(s) independently selected from
•carbocyclic aryl,
•halogenated carbocyclic aryl, •carbocyclic aryl substituted by nitro,
(iii) C3-C6 cycloalkyl substituted by substituent(s) independently selected from •methyl substituted by oxo, •methyl substituted by carbocyclic aryl, •carbocyclic aryl, (iv) carbocyclyl,
(v) carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, cyano, nitro,
C1-C4 alkyl, -C2 alkyl substituted by substituent(s) independently selected from •halogen, •oxo,
•carbocyclic aryl,
•carbocyclic aryl substituted by methyl, •carbocyclic aryloxy, C1-C2 alkoxy, halogenated Cι-C2 alkoxy, C1-C2 alkoxy substituted by carbocyclic aryl, methylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by methoxy, amino, di-methylamino, propargynylcarbonylamino substituted by carbocyclic aryl, carbocyclic arylsulfonylamino substituted by methyl, (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy, halogenated methylthio, carbocyclic arylthio substituted by cyano, di-propylamino sulfonyl, •mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
•carbocyclic aryl,
•heterocyclyl substituted by methyl,
•heterocyclyl substituted by halogenated carbocyclic aryl,
(vi) or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•nitro,
•C C4 alkyl,
•Cι-C4 alkyl substituted by substituent(s) independently selected from
••halogen,
••methylthio substituted by halogenated carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
•methoxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by methyl,
•C C3 alkylthio,
•propenylthio,
•carbocyclic arylthio,
•C1-C3 alkylsulfonyl,
•carbocyclic arylsulfonyl,
•carbocyclic arylsulfonyl substituted by methyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•carbocyclic aryl substituted by methyl,
•carbocyclic aryl substituted by nitro,
•heterocyclyl; wherein carbocyclic aryl is phenyl , naphthyl, or biphenyl; carbocyclyl is 1-oxo-indanyl, indenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny; heterocyclyl is IH-indolyl, 2,4-dihydro-3-oxo-pyrazolyl, furyl, pyrazolyl, pyridyl, thienyl, 1,2,3-triazolyl, IH-pyrrolyl, 2,3-dihydro-l-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-l, 5,6,7-tetrahydro-indolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, pyrazolyl, pyrimidyl, quinolyl, thiazolyl, tetrahydro- thienyl, benzofuranyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
6. A compound according to claim 5 of Formua I selected from the group consisting of
cώ cr ?
CXAXXVXQX1
cPx A
or, in case of, a salt thereof.
7. A compound according to claim 3, wherein Ri represents
(i) Ci-C1() alkyl, alkyl substituted by substituent(s) independently selected from
•C5-C6 cycloalkyl,
•carbocyclic aryl,
•heterocyclyl,
(ii) C3-C6 cycloalkyl,
(iii) carbocyclic aryl,
(iv) or heterocyclyl;
L is selected from Formula XX - XXII; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; heterocyclyl is 1,3-dioxo-isoindolyl, IH-indolyl, l-oxo-3H-isobenzofuranyl, 2,3- dihydro-benzo [1,4] dioxinyl, 3 ,4-dihydro-2H-benzo [b] [1,4] dioxepinyl, 4-oxo-3 ,4-dihydro- phthalazinyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, oxolanyl, piperidyl, pyridyl, quinoxalyl, thienyl, quinolyl, or benzothiazolyl; or a salt thereof.
8. A compound according to claim 7, wherein Ri represents
(i) CrC4 alkyl,
C1-C alkyl substituted by substituent(s) independently selected from
•cyclopentyl,
•carbocyclic aryl,
•heterocyclyl,
(ii) carbocyclic aryl,
(iii) or heterocyclyl; wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl; heterocyclyl is 9H-xanthenyl, benzo[l,3]dioxolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, thienyl, IH-indolyl, quinoxalyl, quinolyl, or benzothiazolyl; or a salt thereof.
9. A compound according to claim 8 of Formua I thereof selected from the group consisting of
P x O
or, in case of, a salt thereof.
10. A compound according to claim 1, wherein Q is Fomura II;
Ri represents (i) d-Cio alkyl,
Ci-Cio alkyl substituted by substituent(s) independently selected from •halogen, •hydroxy, •oxo,
•CrC3 alkoxy,
•C C3 alkoxy substituted by substituent(s) independently selected from ••carbocyclic aryl, ••heterocyclyl,
••heterocyclyl substituted by Ci-C3 alkyl, •carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from ••halogen, ••nitro,
••carbocyclic aryl,
••carbocyclic aryl substituted by C C3 alkoxy, ••C1-C4 alkyl,
••CrC4 alkyl substituted by substituent(s) independently selected from •••mono- or di-Cι-C3 alkylamino,
•••mono- or di-Cι-C alkylamino substituted by carbocyclic aryl, •••mono- or di-Cι-C3 alkylammo substituted by halogenated carbocyclic aryl, •mono- or di-CrC3 alkylamino,
•mono- or di-Ci-C3 alkylamino substituted by substituent(s) independently selected from ••cyano,
••carbocyclic aryl, ••heterocyclyl,
•mono- or di-carbocyclic arylamino,
•mono- or di-carbocyclic arylamino substituted by Cj-C alkyl, •Cj-C3 alkylcalbonylamino, •Cι-C4 alkoxycalbonylamino, •carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
••nitro,
••C1-C3 alkyl,
••mono- or di-CrC3 alkylamino,
•C1-C3 alkylthio,
•Cι-C3 alkylthio substituted by substituent(s) independently selected from
••mono- or di-carbocyclic arylamino,
••halogenated mono- or di-carbocyclic arylamino,
••carbocyclic aryl,
••carbocyclic aryl substituted by substituent(s) independently selected from
•••halogen,
•••Cι-C alkoxy,
•carbocyclic arylthio,
•carbocyclic arylthio substituted by substituent(s) independently selected from
••halogen,
••C C3 alkyl,
•carbocyclic arylsulfonyl,
•halogenated carbocyclic arylsulfonyl,
•heterocyclylthio,
•C3-C6 cycloalkyl,
•C3-C6 cycloalkyl substituted by Ci-C3 alkyl,
•carbocyclyl,
•carbocyclyl substituted by substituent(s) independently selected from
••halogen,
••C C3 alkyl,
••C2-C alkenyl,
••C2-C3 alkenyl substituted by carbocyclic aryl,
••C2-C3 alkenyl substituted by carbocyclic aryl substituted Cι-C3 alkylsulfmyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen, ••hydroxy,
••nitro,
••Cι-C4 alkyl,
••C1-C4 alkyl substituted by substituent(s) independently selected from
•••halogen,
•••hydroxy,
•••carbocyclic aryl,
•••mono- or di-carbocyclic arylamino,
•••mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected
••••halogen,
••••nitro,
••••Cι-C3 alkyl,
••••C1-C3 alkoxy,
••••halogenated Cι-C3 alkoxy,
••Cι-C alkoxy,
••C1-C3 alkoxy substituted by substituent(s) independently selected from
•••halogen,
•••carbocyclic aryl,
••carbocyclic aryloxy,
••Cι-C3 alkoxycarbonyl,
••mono- or di-CrC3 alkylamino,
••C C3 alkylthio,
••halogenated Cι-C3 alkylthio,
••C1-C3 alkylsulfonyl,
••C3-C6 cycloalkyl,
••carbocyclic aryl,
••heterocyclyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••C1-C3 alkoxy, ••C1-C3 alkoxy substituted by carbocyclic aryl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(ii) C2-C8 alkenyl,
C2-C8 alkenyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkoxy,
•CrC3 alkoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••C1-C3 alkoxy,
••halogenated C1-C3 alkoxy,
•heterocyclyl,
•heterocyclyl substituted by nitro,
(iii) C2-C4 alkynyl,
C2-C4 alkynyl substituted by carbocyclic aryl,
(iv) C3-C6 cycloalkyl,
C3-C6 cycloalkyl substituted by substituent(s) independently selected from
•C1-C3 alkyl,
•Ci-C3 alkyl substituted by substituent(s) independently selected from
••hydroxy,
••oxo,
••carbocyclic aryl,
•mono- or di-Cι-C3 alkylamino,
•mono- or di-Cι-C alkylamino substituted by carbocyclic aryl,
•carbocyclic aryl,
(v) C3-C6 cycloalkeyl,
C3-C6 cycloalkeyl substituted by C C3 alkyl,
(vi) carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from •hydroxy,
•nitro,
(vii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C9 alkyl,
•C1-C9 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy,
••oxo,
••C1-C3 alkoxy,
••carbocyclic aryloxy,
••mono- or di-Cι-C3 alkylamino-N-oxy,
••mono- or di-C C3 alkylamino,
••mono- or di-Cι-C3 alkylamino substituted by carbocyclic aryl,
••mono- or di-carbocyclic arylamino,
••mono- or di-carbocyclic arylamino substituted by C1-C3 alkoxy,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by C C3 alkyl,
•C2-C3 alkenyl,
•Q2-C3 alkenyl substituted by carbocyclic aryl,
•Cι-C9 alkoxy,
•C1-C9 alkoxy substituted by substituent(s) independently selected from
••hydroxy,
••halogen,
••carboxy,
••mono- or di-d-03 alkylamino, ••carbocyclic aryl,
••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••heterocyclyl,
•••heterocyclyl substituted by substituent(s) independently selected from
••••halogen,
•— C1-C3 alkyl,
••••halogenated C C3 alkyl,
•C2-C3 alkenyloxy,
•Ci-C3 alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C4 alkyl,
••halogenated Ci-C alkyl,
••C1-C3 alkoxy,
•heterocyclyloxy,
•heterocyclyloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated d-03 alkyl,
•(carbocyclic aryl)S(O)2O,
•carboxy,
•C1-C3 alkoxycarbonyl,
•mono- or di-C C3 alkylaminocarbonyl,
•mono- or di-Cι-C3 alkylaminocarbonyl substituted by carbocyclic aryl,
•amino,
•mono- or di-C1-C4 alkylamino,
•mono- or di-Cι-C4 alkylamino substituted by cyano,
•mono- or di-carbocyclic arylamino,
•C1-C3 alkylcarbonylamino, •carbocyclic arylsulfonylamino,
•carbocyclic arylsulfonylamino substituted by d-Cs alkyl,
•(carbocyclic aryl)NHC(O)NH,
•(carbocyclic aryl)NHC(O)NH substituted by C C3 alkoxy,
•(carbocyclic aryl)NHC(O)NH substituted by haloganated C1-C3 alkoxy,
•C1-C3 alkylthio,
•halogenated Q-C3 alkylthio,
•carbocyclic arylthio,
•halogenated carbocyclic arylthio,
•carbocyclic arylthio substituted by C1-C3 alkyl,
•heterocyclylthio,
•d-03 alkylsulfonyl,
•mono- or di-Q-Cs alkylaminosulfonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••C1-C7 alkyl,
••halogenated C C7 alkyl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••C1-C3 alkyl,
••carbocyclic aryl,
••halogenated carbocyclic aryl,
(viii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•nitro,
•C1-C4 alkyl,
•CrC4 alkyl substituted by substituent(s) independently selected from
••halogen,
••hydroxy, oxo,
C1-C3 alkylcarbonyloxy,
Q-C3 alkoxycarbonyl,
C1-C3 alkylthio,
CrC3 alkylthio substituted by carbocyclic aryl,
C1-C3 alkylthio substituted by halogenated carbocyclic aryl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro, •heterocyclyl, C1-C3 alkoxy,
Cχ-C3 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by Ci-C3 alkyl, mono- or di-Cι-C3 alkylamino, C1-C4 alkylcarbonylamino, C1-C3 alkylthio, carbocyclic arylthio, halogenated carbocyclic arylthio, carbocyclic arylthio substituted by CrC3 alkoxycarbonyl, heterocyclylthio, heterocyclylthio substituted by C1-C3 alkyl, CrC3 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C C alkyl, Cχ-C3 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •nitro, .C1-C3 alkyl, ••halogenated d-C3 alkyl,
••C C3 alkoxy,
••halogenated d-d alkoxy,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) independently selected from
••d-C3 alkyl,
••halogenated d-d alkyl,
••d-d alkoxy,
••C1-C3 alkoxycarbonyl;
Y is -(CH2)m, m is 0 or 1 ; wherein carbocyclic aryl is phenyl, naphthyl, biphenyl, or phenanthryl; carbocyclyl is 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, indanyl, or indenyl; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, IH-indolyl, lH-pyrrolo[2,3- c]pyridyl, IH-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-l-oxo- isoindolyl, 2,3 -dihydro-benzo[ 1,4] dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo- pyrazolyl, 2H-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 3,4- dihydro-2H-benzo[b][ 1,4] dioxepinyl, 4H-benzo[ 1,3] dioxinyl, 4H-benzopyranyl, 4-oxo- 1, 5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,l-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperazyl, piperidyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, or thiolanyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
11. A compound according to claim 10, wherein
Ri represents (i) d-Cio alkyl substituted by substituent(s) independently selected from •methoxy, •methoxy substituted by carbocyclic aryl, •carbocyclic aryloxy,
•halogenated carbocyclic aryloxy,
•mono-Cι-C2 alkylamino substituted by cyano,
•mono- or di-Cι-C2 alkylamino substituted by carbocyclic aryl,
•mono-carbocyclic arylamino,
•mono-carbocyclic arylamino substituted by methyl,
•carbocyclic arylsulfonylamino substituted by methyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••nitro,
••d-C4 alkyl,
•• -d alkyl substituted by carbocyclic aryl,
"d-C4 alkyl substituted by hydroxy,
"Cι-C2 alkoxy,
••halogenated Cι-C2 alkoxy,
•heterocyclyl substituted by carbocyclic aryl,
(ii) C2-C8 alkenyl substituted by substituent(s) independently selected from
•methoxy substituted by carbocyclic aryl,
•carbocyclic aryl,
•carbocyclic aryl substituted by methoxy,
(iii) C2-C alkynyl substituted by carbocyclic aryl,
(iv) cyclohexyl substituted by carbocyclic arylmethyl,
(v) carbocyclyl,
(vi) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
•halogen,
•hydroxy,
•cyano,
•amino,
•Ci-Q, alkyl,
•halogenated d-C9 alkyl, •C1-C9 alkoxy,
•C1-C9 alkoxy substituted by substituent(s) independently selected from
••halogen,
••halogenated carbocyclic aryl,
•propenyloxy,
•methylamino,
•di-Cι-C2 alkylamino,
•di-Ci-C alkylamino substituted by cyano,
•methylthio,
•halogenated methylthio,
(vii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•Ci-d alkyl,
•d-C4 alkyl substituted by hydroxy,
•Ci-C4 alkyl substituted by carbocyclic aryl,
•methoxy,
•d-C2 alkoxycarbonyl,
•carbocyclic arylthio substituted by methoxycarbonyl,
•carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from
••halogen,
••halogenated methyl,
•heterocyclyl;
R2 is methylamino or dimethylamino;
L is selected from Formula Na, Villa, or IXa; wherein carbocyclic aryl is phenyl, naphthyl, biphenyl, or phenanthryl; carbocyclyl is 9H-fluorenyl, acenaphthyl, or anthraquinonyl; heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, l,2-dihydro-3-oxo-pyrazolyl, 1,3- dioxolanyl, IH-indolyl, IH-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3- dihydro-benzo[l,4]dioxinyl, 3,4-dihydro-2H-benzo[l,4]oxazinyl, 4-oxo-benzopyranyl, 9H- carbazolyl, 9H-xanthenyl, benzimidazolyl, benzo[l,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, oxolanyl, pyrazolo[5,l-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, 2H-benzopyranyl, 4H-benzo[l,3]dioxinyl, azetidinyl, imidazo[2,l-b]thiazolyl, morpholinyl, or 2,3-dihydro- benzofuryl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
12. A compound according to claim 11, wherein
Ri represents (i) Cι-C7 alkyl substituted by substituent(s) independently selected from •methoxy,
•methoxy substituted by carbocyclic aryl, •carbocyclic aryloxy, •halogenated carbocyclic aryloxy, •mono-ethylamino substituted by cyano, •di-methylamino substituted by carbocyclic aryl, •mono-carbocyclic arylamino, •mono-carbocyclic arylamino substituted by methyl, •carbocyclic arylsulfonylamino substituted by methyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro,
••Ci-d alkyl,
"Cι-C4 alkyl substituted by carbocyclic aryl, "d-C4 alkyl substituted by hydroxy, ••metoxy,
"halogenated methoxy, •heterocyclyl substituted by carbocyclic aryl,
(ii) C2-C7 alkenyl substituted by substituent(s) independently selected from •methoxy substituted by carbocyclic aryl, •carbocyclic aryl, •carbocyclic aryl substituted by methoxy,
(iii) butynyl substituted by carbocyclic aryl,
(iv) cyclohexyl substituted by carbocyclic arylmethyl,
(v) carbocyclyl,
(vi) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from halogen, hydroxy, cyano, amino, d-C2 alkyl, halogenated methyl,
Cι-C3 alkoxy, d-C3 alkoxy substituted by substituent(s) independently selected from
•halogen,
•halogenated carbocyclic aryl, propenyloxy, di-d-C2 alkylamino, di-Cι-C2 alkylamino substituted by cyano, methylthio, halogenated methylthio, (vii) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from •halogen, •d-d alkyl,
•Cι-C3 alkyl substituted by hydroxy, •Cι-C3 alkyl substituted by carbocyclic aryl, •methoxy, •ethoxycarbonyl,
•carbocyclic arylthio substituted by methoxycarbonyl, •carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from ••halogen,
••halogenated methyl, •heterocyclyl;
L is selected from Formula XX - XXII; wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is acenaphthyl; heterocyclyl is IH-indolyl, IH-pyrrolyl, 2,3-dihydro-benzo[l,4]dioxinyl, 9H- carbazolyl, benzo[l,3]dioxolyl, furyl, pyrazolyl, thienyl, 4-oxo-benzopyranyl, azetidinyl, imidazo[2,l-b]tbiazolyl, pyridyl, imidazolyl, 2,3-dihydro-benzofuryl, or benzo[b]thienyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
13. A compound according to claim 12 of Formua I selected from the group consisting of
oiKcr*
Apftcr α"
H TOC ,
or, in case of, a salt thereof.
14. A compound according to claim 1, wherein Q is Fomura II;
Ri represents (i) CrCi6 alkyl,
Ci-Ciβ alkyl substituted by substituent(s) independently selected from •halogen, •carbocyclyl, •carbocyclic aryl,
•carbocyclic aryl substituted by substituent(s) independently selected from ••halogen, ••nitro, ••C1-C3 alkyl, ••halogenated CrC3 alkyl, •• -C3 alkoxy, ••halogenated Cι-C3 alkoxy, (ii) C2-C3 alkenyl,
C2-C3 alkenyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from •halogen, •cyano, •nitro,
•C1-C5 alkyl,
•C1-C5 alkyl substituted by substituent(s) independently selected from ••halogen, ••oxo,
•C2-C3 alkenyl, •Cι-C alkoxy,
•Cι-C4 alkoxy substituted by substituent(s) independently selected from ••halogen, ••heterocyclyl, ••halogenated heterocyclyl, •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected from
••halogen,
••nitro,
•heterocyclyloxy,
•heterocyclyloxy substituted by substituent(s) independently selected from
••halogen,
••C1-C3 alkyl,
••halogenated -C3 alkyl,
•C1-C3 alkoxycarbonyl,
•mono- or di-CrC4 alkylamino,
•C1-C3 alkylcarbonylamino,
•carbocyclic aryl diazo,
•carbocyclic aryl diazo substituted by mono- or di- Ci-C3 alkylamino,
•C1-C3 alkylsulfonyl,
•carbocyclic aryl,
(iv) heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from
•halogen,
•C1-C3 alkyl,
•Cχ-C3 alkyl substituted by substituent(s) independently selected from
••halogen,
••oxo,
••carbocyclic arylcarbonylamino,
••halogenated carbocyclic arylcarbonylamino,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently selected from
•••halogen,
•••C1-C3 alkyl,
•••halogenated C1-C3 alkyl,
•C1-C3 alkoxy,
•C1-C3 alkylcarbonylamino,
•carbocyclic arylsulfonyl, •Ci-Cs alkoxycarbonyl,
•carbocyclic aryl,
•halogenated carbocyclic aryl,
•heterocyclyl,
•heterocyclyl substituted by substituent(s) mdependently selected from
••halogen,
••d-C3 alkyl,
••halogenated -C3 alkyl;
Y is -S(O)2-; wherein carbocyclic aryl is phenyl , biphenyl, or naphthyl; carbocyclyl is 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl; heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, IH-pyrrolyl, benzo[2,l,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, quinolyl, thiazolyl, or thienyl; halogen is fluoro, chloro, bromo, or iodo; or a salt thereof.
15. A compound according to claim 14 of Formua I selected from the group consisting of
; or, in case of, a salt thereof.
16. A compound according to claim 1, wherein Q is Fomura II; Rt is selected from H, -CO2'Bu, or -CO Bn (Bn is a benzyl group); R is methylamino or dimethylamino;
L is selected from Formula XX - XXII; Y is a single bond; or a salt thereof.
17. A method for modulating the G-protein receptor, SLC-1, comprising the step of contacting said SLC-1 with a MCH receptor antagonist.
18. A method for modulating the G-protein receptor, SLC-1, comprising the step of contacting said SLC-1 with a compound of claims 1-16.
19. The method of prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression in mammals in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound having the composition of any of claims 1-16.
20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the composition of any of claims 1-16.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32646301P | 2001-10-01 | 2001-10-01 | |
| US60/326,463 | 2001-10-01 | ||
| US32675801P | 2001-10-02 | 2001-10-02 | |
| US60/326,758 | 2001-10-02 | ||
| PCT/US2002/031059 WO2003028641A2 (en) | 2001-10-01 | 2002-09-30 | Mch receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002334733A1 true AU2002334733A1 (en) | 2003-06-26 |
| AU2002334733B2 AU2002334733B2 (en) | 2006-11-23 |
Family
ID=26985418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002334733A Ceased AU2002334733B2 (en) | 2001-10-01 | 2002-09-30 | MCH receptors antagonists |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7544690B2 (en) |
| EP (1) | EP1432693A2 (en) |
| JP (1) | JP2005523237A (en) |
| KR (1) | KR20040058191A (en) |
| CN (1) | CN1582281A (en) |
| AU (1) | AU2002334733B2 (en) |
| CA (1) | CA2460594A1 (en) |
| WO (1) | WO2003028641A2 (en) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| JP4561698B2 (en) * | 2002-02-19 | 2010-10-13 | 小野薬品工業株式会社 | Fused pyridazine derivative compound and drug containing the compound as an active ingredient |
| KR20040101520A (en) | 2002-04-16 | 2004-12-02 | 데이진 가부시키가이샤 | Piperidine derivatives having ccr3 antagonism |
| WO2003091245A1 (en) * | 2002-04-25 | 2003-11-06 | Teijin Limited | 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| GB0225938D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| JP4896518B2 (en) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | Nicotinamide kinase inhibitor |
| US7589207B2 (en) | 2002-12-13 | 2009-09-15 | Smithkline Beecham Corporation | Cyclohexyl compounds as CCR5 antagonists |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JPWO2004069798A1 (en) | 2003-02-10 | 2006-05-25 | 萬有製薬株式会社 | Melanin-concentrating hormone receptor antagonist containing piperidine derivative as active ingredient |
| CN100451004C (en) * | 2003-03-31 | 2009-01-14 | 大正制药株式会社 | Novel quinoline,Tetrahydroquinazoline,And pyrimidine derivatives and methods of treatment related to the use thereof |
| JP2006522109A (en) * | 2003-03-31 | 2006-09-28 | 大正製薬株式会社 | Novel quinazoline derivatives and therapeutic methods related to their use |
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
| BRPI0415051A (en) | 2003-10-01 | 2006-11-28 | Procter & Gamble | melanin-concentrating hormone antagonist compounds and their pharmaceutical compositions |
| GB0400193D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| WO2005095357A2 (en) * | 2004-03-30 | 2005-10-13 | Taisho Pharmaceutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| WO2006036024A1 (en) * | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| SE0402635D0 (en) * | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
| AR051802A1 (en) * | 2004-12-21 | 2007-02-07 | Astrazeneca Ab | MCHR1 ANTAGONIST HETEROCICLES |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| US7180447B1 (en) | 2005-04-29 | 2007-02-20 | Lockhead Martin Corporation | Shared phased array beamformer |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| NZ564222A (en) | 2005-06-14 | 2011-10-28 | Taigen Biotechnology Co Ltd | Pyrimidine compounds |
| EP1919865B1 (en) | 2005-08-30 | 2011-04-06 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
| JP2007091649A (en) * | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | Pyrimidine derivative and treatment method associated with its use |
| FR2891829A1 (en) * | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| HUE026011T2 (en) | 2006-03-22 | 2016-05-30 | Hoffmann La Roche | Pyrazoles as 11-beta-hsd-1 |
| US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| US20090170898A1 (en) * | 2006-03-31 | 2009-07-02 | Malena Bengtsson | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor |
| US8044068B2 (en) | 2006-04-04 | 2011-10-25 | Taisho Pharmaceutical Co., Ltd | Aminopyrrolidine compound |
| WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| JP5642963B2 (en) * | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ，インコーポレイティド | Pyridinonyl PDK1 inhibitor |
| TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| JP2010120852A (en) * | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | New diamide derivative |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20100286021A1 (en) * | 2007-09-25 | 2010-11-11 | Qun-Yong Zhou | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| EP2268635B1 (en) | 2008-04-21 | 2015-06-10 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
| SA109300309B1 (en) | 2008-05-20 | 2013-01-22 | باير شيرنج فارما ايه جي | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives |
| US20090298834A1 (en) * | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| EA019741B1 (en) | 2008-08-27 | 2014-05-30 | Такеда Фармасьютикал Компани Лимитед | Pyrrole compounds |
| UA105187C2 (en) * | 2008-10-02 | 2014-04-25 | Таісо Фармас'Ютікел Ко., Лтд. | 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| MX2011004258A (en) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Novel cyclic benzimidazole derivatives useful anti-diabetic agents. |
| JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
| WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| JP5642661B2 (en) | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having NPYY5 receptor antagonistic activity |
| JP5685181B2 (en) | 2009-03-05 | 2015-03-18 | 塩野義製薬株式会社 | Cyclohexane derivative having NPYY5 receptor antagonistic action |
| EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
| MX2012014273A (en) | 2010-06-07 | 2013-03-22 | Novomedix Llc | Furanyl compounds and the use thereof. |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| KR20150075120A (en) | 2011-02-25 | 2015-07-02 | 머크 샤프 앤드 돔 코포레이션 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| JP2014517813A (en) * | 2011-04-01 | 2014-07-24 | サザン リサーチ インスティテュート | Sulindac derivatives, their use and their preparation |
| EP2739143B1 (en) * | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| RU2015106909A (en) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC TRICYCLIC COMPOUNDS |
| KR20150118158A (en) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | Antidiabetic bicyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
| TW201536767A (en) | 2013-07-09 | 2015-10-01 | Takeda Pharmaceutical | Heterocyclic compound |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CA2990028A1 (en) | 2014-06-26 | 2015-12-30 | Monash University | Enzyme interacting agents |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
| JP2022536901A (en) * | 2019-06-12 | 2022-08-22 | プラクシス バイオテック エルエルシー | Inhibitors of integrated stress response pathways |
| CN114340670A (en) | 2019-07-11 | 2022-04-12 | 普拉克西斯精密药物股份有限公司 | Formulations of T-type calcium channel modulators and methods of use thereof |
| US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
| CN116492334A (en) * | 2023-03-01 | 2023-07-28 | 山东大学 | Application of 2,2':5',2' -trithiophene-5-carboxylic acid in preparation of lipid-lowering and weight-losing medicines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE124694T1 (en) | 1990-11-06 | 1995-07-15 | Pfizer | CHINAZOLINE DERIVATIVES TO IMPROVE THE ANTITUMOR EFFECT. |
| AU7692896A (en) * | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
| AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
-
2002
- 2002-09-30 CA CA002460594A patent/CA2460594A1/en not_active Abandoned
- 2002-09-30 CN CNA028239407A patent/CN1582281A/en active Pending
- 2002-09-30 US US10/490,996 patent/US7544690B2/en not_active Expired - Fee Related
- 2002-09-30 EP EP02800388A patent/EP1432693A2/en not_active Withdrawn
- 2002-09-30 JP JP2003531977A patent/JP2005523237A/en active Pending
- 2002-09-30 WO PCT/US2002/031059 patent/WO2003028641A2/en active Application Filing
- 2002-09-30 KR KR10-2004-7004782A patent/KR20040058191A/en not_active Application Discontinuation
- 2002-09-30 AU AU2002334733A patent/AU2002334733B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002334733A1 (en) | MCH receptors antagonists | |
| EP1432693A2 (en) | Mch receptor antagonists | |
| JP2004315511A (en) | Mch receptor antagonist | |
| WO2006035967A1 (en) | Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor | |
| AU695957B2 (en) | Benzimidazole compounds and their use as modulators of the GABA A receptor complex | |
| US6291476B1 (en) | Pyrazole carboxamides useful for the treatment of obesity and other disorders | |
| US20070010671A1 (en) | Novel quinazoline derivatives and methods of treatment related to the use thereof | |
| JP2007530445A (en) | Pyrimidine derivatives and methods of treatment related to their use | |
| JP2007091649A (en) | Pyrimidine derivative and treatment method associated with its use | |
| US20050197350A1 (en) | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | |
| MXPA03011886A (en) | Composite dosage forms having an inlaid portion. | |
| JP2006124387A (en) | New quinoline, tetrahydroquinazoline, and pyrimidine derivative, and treating method associated with their use | |
| CN104364238A (en) | Branched chain alkyl heteroaromatic ring derivative | |
| KR20140000703A (en) | Pyrazole derivative | |
| WO2012153729A1 (en) | Heteroaromatic ring derivative | |
| SE466309B (en) | 1-PYRIMIDINYLOXI-3-HETARYLALKYLAMINO-2-PROPANOLS, PHARMACEUTICAL COMPOSITION AND PREPARATION OF THEREOF | |
| CA2609161A1 (en) | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | |
| JP2007291087A (en) | Pyridine derivative and treatment method relating to use of the same | |
| JP2014111586A (en) | Pharmaceutical containing heteroaromatic ring derivative |